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ABSTRACT 
  
Malignant gliomas represent one of the most aggressive forms of Central Nervous System 
(CNS) tumors. According to the WHO classification of brain tumors, astrocytomas have been 
categorized into four grades, determined by the underlying pathology. Malignant (or high-
grade) gliomas include anaplastic glioma (WHO grade III) as well as glioblastoma multiforme 
(GBM; WHO grade IV). These are the most aggressive brain tumors with the worst prognosis 
(1). The therapeutic management of CNS tumors is based on surgery, radiotherapy and 
chemotherapy, depending on the characteristics of the tumor, the clinical stage and age (2), 
(3), however none of the standard treatments is completely safe and compatible with an 
acceptable quality of life (3), (4). Chemotherapy is the first choice in disseminated tumors, 
like invasive glioblastoma, high-risk medulloblastoma or multiple metastasis, but the 
prognosis in these patients is very poor (2),(3). New targeted therapies (2), anti-angiogenic 
therapies (3), (4) or gene therapies show a real benefit only in limited groups of patients with 
known specific molecular defects (4). Thereby, the development of new pharmacological 
therapies for brain tumors is mandatory. Malignant gliomas are frequently chemoresistant 
and this resistance seems to depend on at least two mechanisms: first, the poor penetration 
of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid 
barrier (BCSFB) and the blood-tumor barrier (BTB), due to their interaction with several 
ATP-binding cassette (ABC) drug efflux transporters that are overexpressed by the 
endothelial or epithelial cells of these barriers. Second, ABC drug efflux transporters in tumor 
cells confer multidrug resistance (MDR) on several other solid tumors; they are present on 
CNS tumors too and their role in gliomas is under investigation (5). Drug delivery across the 
blood-brain barrier (BBB) is one of the vital problems in targeted therapy treatments. Recent 
studies have shown that some small molecules used in these therapies are substrates of P-
glycoprotein (Pgp), as well as other efflux pumps like multidrug resistance-related proteins 
(MRPs) and breast-cancer resistance related protein (BCRP), which extrude several 
anticancer drugs and will not allow drugs to reach the tumor (1). 
 
DOXOrubicin (DOXO), a drug widely used in anti-cancer therapy, is a substrate of Pgp and 
BCRP, and it is very effective to attack the vitro brain tumor cells, but has a limited clinical use 
for its low delivery across BBB and the resistance of tumors. On the other hand BBB cells and 
brain tumor cells also have surface proteins, such as Low Density Lipoprotein Receptor 
(LDLR), which could be used as a therapeutic target. The importance of this study is based on 
the generation of therapeutical strategies to promote the passage of drugs through the BBB 
and the intratumoral accumulation, and at the same time, on the analysis of cellular 
mechanisms that induce increased expression of ABC transporters, to be used as therapeutic 
targets. 
 
 
In this work we demonstrated that the use of a new strategy based on the "Trojan horse", 
which combines DOXOrubicin introduced into a liposome, could safeguards the drug to 
prevent its recognition by the ABC transporters in both the BBB and the tumor cells. The 
construction of liposome allowed using the LDLR receptor cells as docking receptor, ensuring 
the entrance through the BBB and into the tumor cells through a process of endocytosis. This 
mechanism was associated with the use of statins, anti-cholesterol drugs which favoured the 
expression of LDLR and decreased the activity of ABC transporters, increasing the efficiency 
of our Trojan horse. Accordingly, I demonstrated that the use of a new DOXOrubicin 
liposomal formulation mimicking LDLs, called ApolipoDOXO, further favors drug delivery 
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through the BBB, overcoming the resistance of tumor and reducing the side effects of 
DOXOrubicin dose. In addition this strategy can be considered as a new strategy to increase 
the effectiveness of different drugs in several brain tumors and ensures high efficiency even 
in a hypoxic environment, characteristic of cancer cells, where the expression of Pgp 
transporter was increased.  
 
Taking advantage of another signaling pathway recognized as a modulator of Pgp activity this 
study presents not only the strategy of the Trojan horse, but also a second therapeutic 
proposal related to the use of Temozolomide plus DOXOrubicin. This strategy showed that 
temozolomide (TMZ) penetrated the BBB in a way involved the Wnt/GSK3/β-catenin 
signaling pathway, which modulates the expression of Pgp transporter. It was demonstrated 
that the TMZ reduces Wnt3 protein and mRNA allowing raising the hypothesis that this drug 
decreases Wnt3 gene transcription in BBB cells, decreasing β-catenin pathway activation by 
its phosphorylation, reducing β-catenin nuclear translocation and binding to the promoter of 
the mdr1 gene. Taking together the results of this study allowed the recognition of three basic 
mechanisms related to the down-regulation of Pgp and associated strategies: the first was the 
use of statins, which led to the transporter nitration decreasing its activity by NFκB pathway; 
the second one was based on the use of temozolomide, which by methylating Wnt3 gene 
reduces the activity of the β-catenin signaling pathway, decreasing the expression of Pgp 
transporter; the third one consisted on the cross-talk between the Wnt/GSK3/β-catenin axis 
and the Wnt/RhoA/RhoA kinase as a modulator of mdr1 transcription: we demonstrated that 
RhoA protein kinase promoted the activation of the protein PTB1, which by phosphorylating 
GSK3 induced phosphorylation of β-catenin, priming it for destruction by the proteasome, 
avoiding the binding to the promoter of the mdr1 gene and therefore reducing Pgp 
expression. In conclusion, the therapeutic startegies proposed in this work increased the 
cytotoxicity of tumour cells by increasing permeability not only in the BBB, but also in tumor 
barrier. Also, the "Trojan horse" strategy could be useful for the therapy of other diseases 
associated with the central nervous system.   On the other hand, these studies indicate that 
recognition of mechanisms associated with the expression of ABC transporters could be a key 
tool in the development of new anti-cancer therapies. 
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ABSTRACT 
Il glioma maligno rappresenta una delle forme più aggressive di tumore del sistema nervoso 
centrale (SNC). In base alla classificazione WHO dei tumori cerebrali, gli astrocitomi sono 
stati suddivisi in quattro gradi, in base ai loro caratteri patologici. I gliomi maligni o di altro 
grado comprendono il glioma anaplastico (grado III WHO) ed il glioblastoma multiforme 
(GBM; gradi IV WHO). Questi sono i tumori più aggressivi e dalla prognosi peggiore (1). Il 
trattamento terapeutico dei tumori del SNC è basato su chirurgia, radioterapia e 
chemioterapia, in base alle caratteristiche del tumore, allo stadio clinico ed all’età (2), (3), 
tuttavia nessuno di questi trattamenti standard è sicuro e compatibile con una qualità di vita 
accettabile (3), (4). La chemioterapia è la prima scelta terapeutica nei tumori disseminati, 
come il glioblastoma invasivo, il medulloblastoma ad alto rischio o le metastasi multiple, ma 
la prognosi di questi pazienti è molto scadente (2), (3). Le nuove “targeted therapies” (2), le 
terapie anti-angiogeniche (3), (4) o le terapie geniche mostrano un reale beneficio solo in un 
gruppo limitato di pazienti con specifici difetti molecolari (4). Pertanto, è necessario 
sviluppare nuove strategie farmacologiche per i tumori cerebrali. I gliomi maligni sono 
spesso chemioresistenti e tale resistenza è dovuta a due fattori: primo, la bassa penetrazione 
di molti farmaci antitumorali attraverso la barriera ematoencefalica (BEE), la barriera emato-
cerebrospinale (BECS) e la barriera emato-tumorale (BET), a causa della loro interazione con 
numerosi trasportatori di efflusso ATP Binding Cassette (ABC), che sono iperespressi nelle 
cellule endoteliali o epiteliali di queste barriere. In secondo luogo, i trasportatori di efflusso 
ABC conferiscono un fenotipo multidrug resistance (MDR) a molti tumori solidi; essi sono 
presenti anche nei tumori del SNC e la loro funzione nei gliomi è oggetto di studio (5). Il 
delivery di farmaci attraverso la BBB è uno dei problemi critici nelle “targeted therapies”. 
Studi recenti hanno mostrato che molte molecole usate in tali terapie sono substrati della 
glicoproteina P (Pgp) e di altre pompe di efflusso, come le MDR-related proteins (MRP) e la 
breast-cancer resistance related protein (BCRP), che estrudono numerosi farmaci 
antitumorali impedendo loro di raggiungere il tumore (1). 
 
La DOXOrubicina (DOXO), un farmaco ampiamente usato nella terapia antitumorale, è 
substrato di Pgp e BCRP; è molto efficiente in vitro contro le cellule derivate da tumori 
cerebrali, ma ha un uso clinico limitato a causa del suo basso passaggio attraverso la BBB e 
della resistenza tumorale. D’altra parte, le cellule di BBB e dei tumori cerebrali hanno anche 
proteine di superficie, come il recettore per le lipoproteine a bassa densità (RLDL) che può 
essere usato come bersaglio terapeutico. Questo studio è stato incentrato sulla creazione di 
strategie terapeutiche che incrementino il passaggio dei farmaci attraverso la BEE ed il loro 
accumulo intratumorale e sull’ analisi dei meccanismi molecolari che inducono l’aumentata 
espressione dei trasportatori ABC, al fine di sfruttarli come bersagli terapeutici. 
 
In questo lavoro ho dimostrato che l’uso di una nuova strategia “cavallo di Troia”, basata sulla 
DOXO liposomiale, può evitare che il farmaco sia estruso dai trasportatori ABC presenti sia 
sulla BEE sia sulle cellule tumorali. La formulazione liposomiale ha permesso di sfruttare il 
RLDL come punto di attracco, per garantire l’entrata nella BEE e nelle cellule tumorali 
mediante endocitosi.  Tale approccio è stato combinato con l’uso di statine, farmaci anti-
colesterolemici che hanno favorito l’espressione del RLDL e diminuito l’attività dei 
trasportatori ABC, aumentando ulteriormente l’efficacia del mio approccio. In linea con 
questo, ho dimostrato che l’uso di una nuova DOXO liposomiale mimante le LDL, chiamata 
ApolipoDOXO, aumenta ulteriormente il passaggio del farmaco attraverso la BEE, bypassa la 
resistenza delle cellule tumorali e riduce gli effetti collaterali legati alla DOXO. Questa 
strategia può essere usata per aumentare l’efficacia di diversi farmaci nei tumori cerebrali e 
A “Trojan Horse” strategy to reverse drug-resistance in brain tumors 
 
 
 
5 
 
per garantire una buona efficienza anche in ambienti ipossici, caratteristici dei tumori, dove 
l’espressione della Pgp è aumentata. 
 
Sfruttando un’altra via di segnale riconosciuta come modulatrice dell’attività di Pgp, il mio 
lavoro presenta anche un secondo approccio terapeutico basato sulla combinazione di 
temozolomide (TMZ) e DOXO. Tale studio ha mostrato che la TMZ può modulare sulla BEE la 
via di segnale Wnt/GSK3/β-catenina, che regola l’espressione della Pgp. Ho dimostrato che la 
TMZ riduce sia il mRNA che la proteina Wnt3, lasciando ipotizzare che tale farmaco riduca la 
trascrizione di Wnt3 nelle cellule di BEE, diminuendo di conseguenza l’attivazione della β-
catenina tramite fosforilazione, la sua traslocazione nucleare ed il suo legame sul promotore 
del gene mdr1.  
 
Nell’insieme lo studio ha permesso di identificare tre meccanismi che possono ridurre la 
quantità di Pgp e possono essere usati come strategie terapeutiche: primo, l’uso di statine, 
che inducono nitrazione di Pgp e diminuzione della sua attività, tramite la via di NFkB; 
secondo, l’uso della TMZ, che metilando il gene Wnt3, riduce l’attività della β-catenina e 
l’espressione della Pgp. Il terzo si basa sul cross-talk tra la via Wnt/GSK3/β-catenina e la via 
Wnt/RhoA/RhoA cinasi, come modulatore della trascrizione del gene mdr1: ho dimostrato 
che RhoA cinasi attiva la proteina PTPB1; quest’ultima – tramite defosforilazione di GSK3 – 
promuove la fosforilazione di β-catenina, indirizzandola alla degradazione proteasomiale, 
impedendone il legame sul promotore del gene mdr1 e riducendo così l’espressione di Pgp.  
 
In conclusione, le strategie terapeutiche proposte in questo lavoro hanno aumentato la 
citotossicità da chemioterapici nelle cellule tumorali aumentando la permeabilità non solo 
della BEE, ma anche del tumore. La strategia “cavallo di Troia” proposta può essere utile per 
la terapia anche di altre patologie del SNC. Inoltre, questo studio suggerisce che la conoscenza 
dei meccanismi che regolano l’espressione dei trasportatori ABC può essere un utile 
strumento per sviluppare nuove terapie anti-tumorali.   
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RESUMEN 
  
Los gliomas malignos representan una de las formas más agresivas de los tumores del 
sistema nervioso central (SNC).  De acuerdo con la clasificación de los tumores cerebrales de 
la Organización Mundial de la Salud (OMS), los astrocitomas han sido categorizados en cuatro 
grados, determinados por la patología subyacente. Es así como los gliomas malignos (o de 
alto grado) incluyen el glioma anaplásico  (grado III) así como el glioblastoma multiforme 
(GBM, grado IV),estos últimos los más agresivos con el peor pronóstico  (1). El manejo 
terapéutico de los tumores del SNC se basa en la cirugía, la radioterapia y la quimioterapia, 
dependiendo de las características del tumor, el estadio clínico y la edad (2),(3), sin embargo 
ninguno de los tratamientos estándar es completamente seguro y compatible con una calidad 
de vida aceptable (3), (4).   En general, la quimioterapia es la primera opción en los tumores 
diseminados, como el glioblastoma invasivo y el meduloblastoma de alto riesgo o con 
metástasis múltiple, pero el pronóstico en estos pacientes es muy pobre (2),(3). Solamente 
nuevas terapias dirigidas  (2) como las terapias anti-angiogénicas (4); o terapias génicas 
muestran un beneficio real en grupos limitados de pacientes con defectos moleculares 
específicos conocidos (4).  De este modo, se hace necesario el desarrollo de nuevas terapias 
farmacológicas para atacar los tumores cerebrales.   Frente a las terapias los gliomas 
malignos son con frecuencia quimioresistentes, y esta resistencia parece depender de al 
menos dos mecanismos: en primer lugar, la pobre penetración de muchas drogas anticáncer a 
través de la barrera hematoencefálica  (BBB: Blood Brain Barrier), la barrera del fluido 
sangre-cerebroespinal (BCSFB: Blood-cerebrospinal fluid barrier) y la barrera sangre-tumor 
(BTB: blood-tumor barrier).  Dicha resistencia se debe a la interacción de la droga con varios 
transportadores o bombas de eflujo de droga ABC (ABC: ATP-binding cassette) que se sobre 
expresan en las células endoteliales o epiteliales de estas barreras. En segundo lugar, estos 
transportadores de eflujo de drogas ABC propios de las células tumorales confieren un 
fenotipo conocido como resistencia a multidrogas (MDR: multidrug resistance), el cual es 
característico de varios tumores sólidos.  Este fenotipo también está presente en los tumores 
del SNC y su papel en gliomas es objeto de investigación  (5).   Por consiguiente el suministro 
de medicamentos a través de la BBB es uno de los problemas vitales en los tratamientos de 
terapia dirigida.  Estudios recientes han demostrado que algunas moléculas pequeñas 
utilizadas en estas terapias son sustratos de la glicoproteína P (Pgp: P-gycoprotein), así como 
también de otras bombas de eflujo como las proteínas relacionadas con la resistencia a 
multidrogas (MRPs: multidrug resistance-related proteins (MRPs) o la proteína relacionada 
con cáncer de seno (BCRP: breast-cancer resistance related protein)) que no permiten que las 
drogas de este tipo alcancen el tumor (1).   Un sustrato de Pgp y BCRP es la DOXOrubicina 
(DOXO), un fármaco utilizado en la terapia anti cáncer, el cual es muy eficaz para atacar las 
células del tumor cerebral in vitro, pero con un uso clínico  limitado por la poca entrega a 
través de la barrera hematoencefálica (BBB) y por la resistencia propia de los tumores. Por 
otra parte las células de BBB y las células del tumor cerebral tienen también proteínas 
superficiales, como el receptor de la lipoproteína de baja densidad (LDLR), que podría 
utilizarse como blanco terapéutico en BBB y tumores cerebrales.   Es asi como la importancia 
de este estudio se basa en la generación de estrategias terapéuticas que promuevan el paso 
de las drogas a través de la barrera hematoencefalica y tumoral, y a su vez, se reconozcan 
mecanismos celulares que induzcan el incremento en la expresión de los transportadores 
ABC, de manera que puedan ser utilizados como blancos terapéuticos.   
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Este estudio demostró que el uso de una nueva estrategia basada en el “Caballo de Troya”, 
donde se combina la droga DOXOrubicina, la cual es introducida dentro de un liposoma, 
salvaguarda la droga de manera que se evita su reconocimiento por parte de los 
transportadores ABC tanto de la BBB como de las células del tumor.  La construcción del 
liposoma permitió utilizar el receptor LDLR de las células asegurando la entrada a través de 
la BBB y hacia las células tumorales a través de un proceso de endocitosis.  Este mecanismo 
fue asociado al uso de estatinas o drogas anticolesterol las cuales favorecieron la expresión de 
LDLR y disminuyeron la actividad de los transportadores ABC por nitración de los mismos, 
incrementando la eficiencia de nuestro Caballo de Troya.  Por consiguiente demostramos que 
el uso de una nueva estrategia o formulación denominada ApolipoDOXO más el uso de 
estatinas favorece la administración de fármacos a través de la BBB, venciendo la resistencia 
del tumor y reduciendo los efectos colaterales dosis dependiente de la DOXOrubicina.  
Además esta estrategia del "Caballo de Troya", es un nuevo enfoque terapéutico que puede 
ser considerado como una nueva estrategia para aumentar la eficacia de diferentes fármacos 
en varios tumores cerebrales y garantiza una alta eficiencia incluso en un medio hipóxico, 
característico de las células cancerosas, donde la expresión del transportador Pgp se vió 
aumentada.   Teniendo en cuenta la relación entre algunas vías de señalización reconocidas 
como moduladores de la actividad de Pgp, este estudio presenta no solo la estrategia del 
Caballo de Troya, sino también otra propuesta terapéutica relacionada con el uso de 
Temozolomide más DOXOrubicina.  Esta estrategia demostró que el temozolomide logra 
penetrar la BBB por que interviene en la via de señalización de la Wnt/GSK3/β-catenina, la 
cual modula la expresión del transportador Pgp.  Se demostró que el TMZ disminuye la 
proteína y el mRNA de Wnt3 permitiendo plantear la hipótesis de que la droga al disminuir la 
transcripción del gen Wnt3 en células de BBB,  incrementa la activación de la vía fosforilando 
la β-catenina y conduciendo a disminuir la β-catenina nuclear y por tanto su unión al 
promotor del gen mdr1.  Con base en los resultados este estudio permitió el reconocimiento 
de tres mecanismos básicos relacionados con la expresión de los transportadores ABC y 
asociados a las estrategias empleadas: el primero fue el uso de las estatinas, el cual condujo a 
la nitración de los transportadores disminuyendo su actividad por la via del factor de 
transcripción NFκB; el segundo a partir del uso del temozolomide, el cual metila el gen de 
Wnt3 reduciendo la actividad de la via de señalización de la la β-catenina, disminuyendo la 
expresión del transportador Pgp.  El tercero consistió en la determinación de la relación entre 
el eje RhoA/RhoA quinasa como un modulador de la via (no canónica) GSK3/β-catenina.  Se 
demostró que la proteína quinasa RhoA promovió la activación de la proteína PTB1, la cual al 
fosforilar a GSK3 indujo la fosforilación de la β-catenina, lo cual dio lugar a su destrucción por 
el proteosoma, evitando su unión al promotor del gen mdr1 y por tanto reduciendo su 
expresión.  En conclusión las estrategias propuestas en este trabajo incrementaron la 
citotoxicidad de las células tumorales al aumentar la permeabilidad no solo de la barrera 
hematoencefálica, sino también de la propia barrera tumoral.  Igualmente, la estrategia del 
“Caballo de Troya” podría ser útil para la terapia de otras enfermedades asociadas al sistema 
nervioso central.   Por otra parte estos estudios indican que el reconocimiento de 
mecanismos asociados a la expresión de los transportadores ABC podría constituir una 
herramienta clave en el desarrollo de nuevas terapias anticáncer. 
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ATP ADENOSIN TRIPHOSPHATE 
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BCSF BLOOD CEREBRO-SPINAL FLUID  
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DOXO DOXORUBICIN 
DNA DEOXIRIBONUCLEIC ACID  
FPP FARNESYL PIROPHOSPHATE  
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NOS NITRIC OXIDE SYNTHASE  
NP NANOPARTICLES  
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1. Justification 
 
It is estimated that each year more than 11 million new cases of cancer, of which about 80% 
occur in developing countries are present in the world. In Colombia cancer is the third 
leading cause of death, after cardiovascular diseases and violence, so as in 2010, there were 
33.450 deaths by cancer, which accounted for 16.9% of all deaths: 16.381 were men and 
17.069 women, with a crude rate of 72.9 per 100,000 and 74.1 per 100,000 cancer mortality 
respectively, according to documents reported in the ten-year plan for the control of cancer 
of Colombia describe in the period of 2012-2021 
(http://www.cancer.gov.co/documentos/Plandecenalparaelcontroldelcancer).  Worldwide, 
deaths caused by tumors account for almost 15% of the total (rate of 65/100,000 people (1).  
This incidence depends on different factors: the zone, the age, among other epidemiological 
characteristics.  It is the case of leukemia and tumors of the central nervous system which are 
the main causes of death from cancer among the population under the age of 30 (2, 3). This 
incidence in young people is characteristic of brain tumors, i.e. 1 per 1300 in habitants 
develops brain cancer before the age of 20. In young people, 25% of cancer mortality is 
secondary to a tumor of the central nervous system (6, 7). On the other hand the 23% of 
pediatric cancers are brain where medulloblastoma is the most common cause of death 
related to cancer in children (8). Taking into account the adult population, 7 cases of 
malignant brain cancer per 100 thousand people are diagnosed every year and this rate is 
among the 10 leading causes of death due to cancer. (9). 
 
Whitin the 5 fundamental kinds of tumors of the CNS (neuronal tumors, poorly differentiated 
neoplasms, meningiomas, gliomas and metastasis), it has been shown that aggressive 
glioblastoma, and low and high grade gliomas account for 78% of primary brain tumors 
among adults (5), while brain metastasis of solid tumors are also frequent and occur in 
approximately 25% of patients with cancer (10). 
 
In addition, the analysis of the demographic characteristics of these lesions has been studied 
in Colombia and it is very similar to the world.  Each tumor set occurs in a specific 
demographic group. Meningiomas and schwannomas appear most commonly in women as 
astrocytomas are more frequent in men. Germ cell tumors and astrocytomas are diagnosed 
more in children and teens while meningiomas, adenomas and glioblastomas are detected 
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more in adults (2). Regarding patient’s sex, it has been shown that gliomas occur in men 40% 
more than women (11) and the average age of presentation is 45 years old. 
 
Taking the above data, it is estimated that the high levels of incidence/mortality for cancer of 
the central nervous system and especially gliomas, indicate a poor prognosis, which could be 
attributed to very advanced stages at the time of diagnosis or to the lack of efficacy in the 
treatment. From these observations, it is important to understand that the high prevalence of 
this disease is not only due to the aggressiveness of the tumor but also to deficiency in 
therapies that can control it. This limitation can be explained from the presence of a natural 
mechanism- the blood brain barrier (BBB) - that the brain uses to regulate the entry of 
substances, including anti cancer therapies. In this way the BBB acts as a neuroprotective 
shield in order to protect the brain from most substances, maintaining a balanced supply of 
nutrients to the brain tissues and filtering the harmful compounds from the brain to the 
blood stream (11). Anti cancer drugs such as anthracyclines, used for a long time, do not 
show a high effectiveness and the resistance to these agents has become a failure of 
chemotherapy, promoting a low prognosis. One of the mechanisms that are postulated as 
possible cause of this failure relies on the multidrug resistance (MDR) phenotype, which 
leads to a low citiotoxicity by anticancer agents; because they can not cross the BBB and can 
not accumulate in tumor.  Studies based on cells in vitro and clinical studies have shown that 
MDR occurs in central nervous system (CNS) (12) cancer cells.  In addition it has been 
recognized that the key mechanism of the MDR is based on the overexpression of human 
tumors membrane transporters, such as: the P-glycoprotein (Pgp) and the related MDR 
(MRPs), known as ABC transporters proteins (ABC: ATP binding cassette), which function as 
ATP-dependent pumps that bind to anti cancer drugs and pump them outside the BBB or 
tumor. The CNS tumors have a MDR phenotype, due to overexpression of Pgp and MRPs, 
which may be constitutive or induced by own chemotherapy (4). Therefore, this phenotype is 
a strong barrier to the diffusion of chemotherapeutic drugs.  This study contributes to 
increase the efficiency of anti cancer drugs using the association between ApolipoDOXO and 
Statins to improve administration of drugs through BBB, in order to overcome the resistance 
of the tumor and reduce the dose-dependent side effects of DOXO in vitro.  Additionally this 
work serves as basis to contribute to the decrease in deaths from brain cancer affecting a 
large percentage of the Colombian and world population. 
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2.  Theorical framework 
 
2.1. Brain tumors 
 
Brain tumors or Gliomas are named in different ways depending on histological features 
observed and compared with mature glial cells. Brain tumors with cells resembling 
astrocytes were termed astrocytomas; the tumor cells of ependymoma shared an appearance 
with ependymal cells; pinealoma was composed of tumor cells resembling those of the pineal 
gland. The names of several tumor entities related to cell types are no longer recognized 
today.  Examples are spongioblastoma to the spongioblast (or by other authors glioblastoma 
referring to the glioblast) and medulloblastoma to the medulloblast. It is noteworthy that this 
first comprehensive classification system already outlined the concept of tumors arising from 
immature precursor cells or from neuroectodermal stem cells (6).  Low grade  gliomas, 
mostly  astrocytomas  (World Health Organization (WHO) grade II) are progressively 
transforming  into malignant  gliomas,  that  is,  anaplastic tumors (WHO grade III) and 
glioblastoma multiforme  (GBM; WHO  grade  IV).  However, most GBM are diagnosed without 
any prior record of a tumor of lower grade (7). GBM is a complex mixture of cell types that 
includes astrocyte-like and stem-like cells, characterized by rapid growth and diffuse 
invasiveness into adjacent brain parenchyma. Resection possibility depends on tumor 
location and only the nodular component can be surgically controlled. The infiltrative 
component of the tumor, however, is left to chemotherapy and radiotherapy that can impede 
tumor progression for a limited time only. GBM patient survival is less than 1 year (8).  GBM 
has a severe mutated phenotype that consists of large chromosomal alterations; at the 
genetic level, the most frequent mutations affect genes involved in the control of cell cycle, 
growth, apoptosis, invasion and neovascularization (9).  Glioblastoma multiforme refers to a 
malignant neoplasm with abundant glial pleomorphism, numerous mitotic figures and giant 
cells, vascular hyperplasia, and focal areas of necrosis. It grows as an irregular mass in the 
white matter and infiltrates the surrounding parenchyma by coursing along white matter 
tracts, frequently involving the corpus callosum and crossing the midline to produce the 
characteristic ‘‘butterfly’’ appearance (10).   Of the estimated 17,000 primary brain tumors 
diagnosed in the United States each year, approximately 60% are gliomas (11).  GBM 
accounts for approximately half of all newly diagnosed primary brain tumors with an 
incidence of 2–3 cases per 100,000 people each year (8). It is the most frequent primary brain 
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tumor, accounting for approximately 12–15% of all intracranial neoplasms and 50–60% of all 
astrocytic tumors (12).  
  
Malignant Gliomas are the most common and deadly tumors, however, the survival of 
patients with GBM, although it varies individually, has improved from an average of 10 
months to 14 months after the diagnosis in the past 5 years since it has improved the level of 
care (13).   It has been recognized that the origin of brain cancers can be directly in the brain 
or outside the CNS in other parts of the body and spread to the brain such as metastasis (14). 
Approximately 25% of cancer patients develop brain metastases, and although usually 
appear late in the course of the disease, a brain metastasis may cause early symptoms, until 
the primary cancer has been identified.  In this way the diagnostic and therapeutic 
management approach depends on the quantity and location of brain injury and the stage of 
the cancer. Patients with brain cancer metastases are rarely cured (15) and this may be due 
to the role played by the tumor barrier and the BBB to obstruct the chemotherapeutic 
treatment with agents such as paclitaxel and DOXOrubicin (DOXO) .  Given the failure of many 
chemotherapy drugs that do not permeate the BBB, a new class of agents that have a good 
chemotherapeutic activity against metastases in the brain is required. These agents must be 
not only BBB permeable and active against metastatic cancer cells, but also non-toxic to the 
cells of the CNS (14).  
 
In general, the brain tumors derived from the cells glial respond differentially to treatment 
with surgery and radiotherapy or radiotherapy alone, combined with or without 
chemotherapy (7). The treatment of malignant brain tumors with conventional approaches is 
usually unsuccessful since curative doses generally lead to excessive toxicity in normal cells 
of the brain (10). 
 
2.2. Blood Brain Barrier  
 
BBB is constituted by the brain endothelial cells which form the anatomical substrate called 
cerebral microvascular endothelium (16).  BBB regulates the transport of solutes and other 
substances including drugs in and out of the brain, controls leukocyte migration, and 
maintains the homeostasis of the brain microenvironment, which is crucial for neuronal 
activity and proper functioning of CNS. The cerebral microvascular endothelium, together 
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with astrocytes, pericytes, neurons, and extracellular matrix, constitute a “neurovascular 
unit” that is essential for the health and function of the CNS (17). The transport of solutes and 
other substances across BBB is strictly constrained through both physical tight junctions 
(TJs) and adherent’s junctions (AJs) and metabolic barriers (enzymes, diverse transport 
systems) and excludes also very small, electrically neutral and lipid soluble molecules. Thus, 
conventional pharmacological drugs or chemotherapeutic agents are unable to pass through 
the barrier (17). 
  
The main structural differences between the endothelium of brain capillaries and other 
capillary endothelium are the TJs between adjacent endothelial cells (18), the lack of hollow 
fenestrations and pinocitotic vesicles (19).  The TJs are multiproteic complex located on the 
lateral surface of the brain endothelial cells, they are composed of transmembrane proteins, 
as claudin-3, occludin, adhesion molecules and cytosolic proteins, such as zonula occludens-
1/2/3, AF6, 7 H 6, cingulin, claudin-5.   In the BBB the presence of TJs and the absence of 
fenestrations prevent paracellular molecules delivery (20). The AJs, other complexes of 
basolateral membranes composed of vascular endothelial cadherin, p120 and complex α-/ β-
catenin, contribute to strong cellular adhesion and are required for the assembly of the TJs 
(20).  They further decrease the paracellular permeability of many substances.  Finally, the 
absence of pinocitotic vesicles increases the strict control over the processes of transcytosis 
through BBB.  In general, both the luminal (into the blood) surfaces and the basolateral (to 
the brain), contribute to the function of "barrier" of the brain microvascular endothelium 
(Figure 1).   
 
Several mentioned features are induced in the endothelial cells by the close proximity and 
multiple contacts with pericytes, astrocytes and neurons;  also, the simultaneous presence of 
endothelial cells, extracellular matrix and cells of the CNS form a physiologically competent 
BBB (17). 
 
In addition to the BBB, other crucial barriers to maintain the homeostasis of the brain 
parenchyma are the barrier blood - cerebrospinal fluid (BSCF), which is formed by the 
epithelial cells of the choroid plexus and regulates the transport of molecules between the 
CNS and cerebrospinal fluid (21) and the blood-retina barrier (22). In all these barriers, the 
mechanisms of passive diffusion, facilitated diffusion and active transport of substrates are 
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strictly regulated.  Here ABC transporters are crucial in the process of active transport 
through the cells of the BBB.  
 
 
 
Figure No. 1. Schematic representation of the blood-brain barrier (BBB). BBB is a 
structural-functional unit composed by peculiar brain microvascular endothelial cells, 
devoid of fenestrations, rich of tight junctions (TJs) and adherent junctions (AJs) on 
lateral surface, and ABC transporters, such as Pgp, MRP1-6, BCRP, on luminal and 
basolateral side. Most of these features, which determine a tight control on the bi-
directional transport of metabolites and xenobiotics, are maintained by the close 
proximity and multiple contacts between endothelial cells and CNS cells, such as 
astrocytes and neurons (23). 
 
2.3. Multidrug resistance genes and ABC transporters 
 
The multidrug resistance (MDR), which is the cross resistance toward chemotherapeutic 
drugs unrelated for chemical structure and mechanism of action, is the main cause of failure 
of the pharmacological therapy in human cancers. Tumors of CNS have often a MDR 
phenotype, due to the overexpression of Pgp and MRPs, which can be constitutive or induced 
by the chemotherapy itself. Moreover CNS is surrounded by brain-blood barrier (BBB), which 
is reach of both Pgp and MRPs. This abundance is a further obstacle to the diffusion of 
chemotherapeutic drugs toward brain tumors (24).  The MDR gene product Pgp is a 170-kDa 
transmembrane protein associated with tumor resistance to chemotherapeutic drugs such as 
DOXO. The Pgp drug efflux pump serves to lower intracellular concentrations of drugs to sub-
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lethal levels by actively transporting them out of the cells.   Currently, the ABC transporters 
family includes more than 200 prokaryotes and eukaryotes proteins, and many of them are 
still unknown. The function of ABC transporters is not limited to drug transport, and many 
important human ABC transporters are involved in transport and/or regulation of ions or 
other substances (25, 26) (Table No.1).    Initially discovered in the 1970s as a prototypic 
transporter involved in multidrug resistance (MDR) of cancer cells (27), Pgp was also the first 
ABC transporter that was detected in endothelial cells of the human BBB in 1989 (24), (28). 
Subsequently Pgp was localized in brain capillary endothelial cells of several species, 
including monkeys, rats, mice, cattle, and pigs, suggesting that Pgp may serve as general 
defense mechanism in the mammalian BBB, protecting the brain from intoxication by 
potentially harmful lipophilic compounds from natural sources and other lipophilic 
xenobiotics which otherwise could penetrate the BBB by simple diffusion without any 
limitation (29). The exact localization of Pgp in the BBB has been the object of numerous 
investigations using various experimental approaches such as in situ hybridization and 
immunohistochemistry. In the absence of Pgp in the BBB in mdr1a knockout mice, the brain 
penetration of Pgp substrate drugs can increase up to 10- to 100-fold (30).  
 
Furthermore, blockade of BBB Pgp by cerebral application of Pgp inhibitors significantly 
increases the brain concentration of various drugs, again being in line with Pgp functioning as 
an efflux transporter in the BBB. Expression of Pgp confers drug resistance to numerous 
antitumor agents, including DOXOrubicin, daunorubicin, actinomycin D, etoposide, 
teniposide, colchicine, taxol, vincristine, and vinblastine (31). In contrast to Pgp, details about 
other BBB ABC transporters are much more limited (32). The ABCC family (with the first 
member, MRP1, discovered in cancer cells in 1992) currently has 12 members (including 
MRP1-9), which act as organic anion transporters, but can also transport neutral organic 
drugs (33).  As a consequence, Pgp and MRPs have overlapping substrate specificity, so that 
several drugs are substrates for both transporter families (34). 
 
Like Pgp, MRPs are located in several normal tissues, including the BBB and BCSFB. 
Resistance to numerous anticancer agents is associated with overexpression of the 170-kDa 
Pgp or the 190-kDa MRPs.  The role of MRPs in BBB permeability has been demonstrated by 
experiments in which inhibitors of MRPs, such as probenecid or MK-571, were shown to 
enhance drug penetration into the brain or to inhibit drug efflux from isolated brain 
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endothelial cells (35). It is of great importance also the expression of BCRP (Breast Cancer 
Related Protein) transporter in BBB and tumor cells.  BCRP was first discovered in a 
chemotherapy-resistant breast cancer cell line, but there is no indication that its expression is 
specific for breast cancer cells or that BCRP should play a significant role only in 
chemotherapy resistance in breast cancer.   
 
Table 1. Substrates of ATP-binding cassette (ABC) transporters  
present in blood-brain barrier (BBB) 
  
 
The tissue distribution of BCRP shows extensive overlap with that of Pgp, suggesting that 
both transporters similarly confer protection from potentially harmful xenobiotics in various 
tissues (26).   In the brain, BCRP has been detected in capillary endothelial cells of humans 
mainly at the luminal surface (36). Based on mRNA analysis, BCRP was more strongly 
expressed on BBB than Pgp or MRP1 (33).  The role of BCRP in brain uptake was recently 
demonstrated by using mdr1a knockout mice, in which BCRP was inhibited by GF120918, 
resulting in reduced brain uptake of prazosin and mitoxantrone. Interestingly, mdr1a 
knockout mice had about three times more BCRP in the brain microvessels than normal mice, 
indicating an up regulation of BCRP to compensate for the lack of Pgp in the BBB (37).   ABC 
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transporters also share a low specificity for substrates, i.e. each transporter can recognize 
different molecules and the same substrate can be extracted by different transporters (38) 
(Table 1).  The vast majority of ABC transporters involved in multidrug resistance or their 
mRNAs have been identified in cells of the BBB and BSCF; the relative abundance in these 
barriers and the prevalent location luminal or basolateral membrane, is unknown for all 
transporters (23). Cells overexpressing ABC transporters have a different intracellular drug 
distribution and the reasons of this are not so clear. There are several possibilities involving 
both direct and indirect effects. First, the transporter may be expressed not only on the 
plasma membrane, but also on the vesicular membranes, where it actively contributes to 
drug transport from the cytoplasm into the vesicles.  Another explanation is suggested by the 
observation that vesicular sequestration is a saturable process strongly dependent on the 
cytoplasmic drug concentration (39).   
 
There are a limited number of studies on high-grade brain tumors identifying subtypes of 
MDR, the level of expression of these transporters, whit a lacking functional detailed and 
pharmacological analysis. This lack of knowledge has contributed in large part to the poor 
effectiveness of therapies targeting cancer in the CNS. Recently some factors associated with 
the expression of ABC transporterst have been identified, among which are: 1) hypoxia; 2) 
oxidative stress, 3) the use of chemotherapy; (4) the use of radiotherapy. In some cases the 
combination of these effects leads to an increase in the MDR (40). 
 
2.4. ABC transporters and hipoxia 
 
Many reports have demonstrated an increased chemoresistance  and radioresistance  in 
hypoxic cancer cells by activation of the Hypoxia-Inducible Factor-1 α (HIF-1α) mediated 
pathway (40) HIF-1α is composed of two subunits: β, which is constitutively expressed, and 
α, which is rapidly degraded under normal conditions but becomes stable when the oxygen or 
iron supply decreases, leading to a net increase in Hypoxia inducible factor alfa. This factor is 
constitutively high in the hypoxic areas of tumours.  When active, HIF-1α up regulates several 
genes involved in processes such as cellular growth, glucose and iron metabolism, pH control, 
angiogenesis, matrix remodelling and drug resistance. Since HIF-1α promotes cellular 
proliferation, inhibition of apoptosis, invasion and MDR, its expression in tumours is related 
to poor prognosis (41).   
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Thus, different therapeutic approaches have been attempted in order to reduce HIF-1α 
expression. In the lung, most cell types, including bronchial and alveolar epithelium, smooth 
muscle and vascular endothelium, overexpress HIF-1α under hypoxic conditions. High levels 
of HIF-1α have been described in mesothelioma biopsies of patients, one of the most highly 
chemoresistant and aggressive tumor, whereas mesothelial cells contain low amounts of HIF-
1α (41). HIF-1α is associated with multidrug resistance because could regulate transcription 
of ABC transporter genes in cancer cells and promote overexpression of Pgp and MRPs in 
cancer tissues.  These facts have been demonstrated to efflux the intracellular anticancer 
drugs outside the cancer cells, resulting in promotion of chemoresistance to taxanes 
(paclitaxel or docetaxel) and anthracyclines (DOXO or daunorubicin) (42). 
 
2.5. Therapeutic approach to brain cancer, the use of nanoparticles and liposomes 
(Article II)  
 
The antineoplastic drugs have been one of the major successes of cancer medicine.  Their use 
has helped to increase life, in childhood cancer has increased from  more than 30% in the 
1960s to 70 and 80% today (43), (44).   The first two anthracyclines, daunorubicin (also 
known as daunomycin and rubidomycin) and DOXOrubicin (DOXO, also known as 
Adriamycin), were isolated in the 1960s from Streptomyces peucetius, a species of 
actinobacteria. While DAU has been shown to be highly effective against acute lymphoblastic 
and myeloblastic leukemias, DOXO has been found to have a much broader anticancer 
spectrum, which includes numerous solid tumors in addition to hematological malignancies. 
Although more than 40 years old, anthracyclines  are still frequently used in clinical practice, 
and DOXO in particular, remains as an important component of many current chemotherapy 
protocols for treating breast cancer, sarcomas, childhood solid tumors (e.g., Wilms’ tumor), 
leukemias, Hodgkin’s disease, non-Hodgkin’s lymphomas, and many other cancers. 
Interestingly, rather than being replaced with novel progressive “targeted” agents, current 
clinical practice tends to combine them with the novel therapeutics to maximize the 
therapeutic response (45). Despite their extensive use, the mechanism of anthracyclines 
antineoplastic action is still a subject of debate and apparently it is a combination of several 
different mechanisms, which accounts for the high efficiency of this class of anticancer drugs 
(46), (47), (48).  
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Mechanism of action of anthracyclines is attributed to their intercalation between base pairs 
of the DNA strands, which prevents replication of rapidly growing cancer cells. However, 
more recent studies have shown that at clinically relevant concentrations, intercalation is 
unlikely to play a major role. Anthracyclines are called “topoisomerase poisons” because they 
act by stabilizing a reaction intermediate in which DNA strands are cut and covalently linked 
to topoisomerase II- tyrosine residues, which blocks subsequent DNA resealing. Failure to 
relax the supercoiled DNA blocks DNA replication and transcription. Furthermore, breaking 
DNA strands may trigger apoptosis of cancer cells, apparently via the p53-dependent 
pathway.  Some studies have also suggested that reactive oxygen species (ROS) formation  
and lipid peroxidation participate in the anticancer effects of anthracyclines (45). 
 
According with their structure DOXO differs from daunorubicin only by a single hydroxyl 
group. This fact has spurred researchers worldwide to find analogs of DOXO that have less 
acute toxicity, e.g. causing less cardiomyopathy, and can be administered orally, and/or have 
different, or greater antitumor efficacy. None of these analogs have stronger antitumor 
efficacy than the original two anthracyclines, but there are some differences in toxicity. 
Methods have been fashioned to keep the peak plasma level of DOXO muted to minimize 
cardiotoxicity, but the only apparently effective method available so far (prolonged drug 
infusion) is cumbersome. The bisoxopiperazine class of drugs (especially dexrazoxane) 
provides protection against anthracycline-induced cardiomyopathy and has much promise 
for helping mitigate this major obstacle to prolonged use of the anthracyclines. The DOXO 
analogs being evaluated in the 1990s have been selected for their ability to overcome 
multidrug resistance in cancer cells. Thirty years after discovery of the anticancer activity of 
the first anthracycline, some means of reducing anthracycline toxicity have been devised. 
Current studies are evaluating increased doses of epirubicin to improve anthracycline 
cytotoxicity, while limiting cardiotoxicity, but at present DOXO still remains in this drug class 
as the one having the most proven anticancer effect (49). 
 
Different methods have been developed in order to maintain an effective amount of DOXO 
which minimizes the cardiotoxicity; it has been developed derivatives of the drug, to prevent 
this and other effects in plasma.  Some systems can protect DOXO by macrophages 
phagocytosis and favor the entrance in the tumor cells to evade the presence of ABC 
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transporters  (47), (48). Some DOXO analogues have been evaluated in recent years and have 
proven to be effective to prevent resistance to drugs in cancer cells.  This is how many 
strategies offer a promising alternative therapy for brain cancers (13) (50).  Within these 
include nanoparticles or liposomes as key elements that used to allow access to the drug to 
the brain. 
 
In recent years the nanoparticles (NPs), emerged as a very efficient way of transporting the 
drug, due to small size, high solubility and multifunctionality (51).  Size ranges between 10 
and 1000 nm; they are made with a variety of materials, including carbohydrates like malto-
dextrins or chitosan derivatives (52); fatty acids as beenic and palmitic acid are assembled in 
the solid lipid NPs (SLNs)(53); proteins such as human albumin (HA)(54), among others, are 
also conjugated. Some of them are amphiphilic molecules micelles with their oriented 
towards the external surface hydrophilic and hydrophobic towards the inner center groups. 
Tumor specific drug delivery has become increasingly interesting in cancer therapy, as the 
use of chemotherapeutics is often limited due to severe side effects. Conventional drug 
delivery systems have shown low efficiency and a continuous search for more advanced drug 
delivery principles is therefore of great importance (50).  
 
Liposomes were suggested as drug transporters in cancer chemotherapy by Gregoriadis et al. 
in 1974. Since then, the interest in liposomes has increased and liposome systems are now 
being extensively studied as drug transporters. Three basic requirements need to be fulfilled 
if liposomes are to be successful in delivering drugs specifically to cancerous tissue: (i) 
prolonged blood circulation, (ii) sufficient tumor accumulation, (iii) controlled drug release 
and uptake by tumor cells with a release profile matching the pharmacodynamics of the drug.  
This system is part of the called nanoparticles. In nano aqueous polymeric particles made of 
natural or artificial polymers ranging in size between about 10 and 1000 nm, drugs may be 
adsorbed to the surface or chemically attached. Drug delivery systems such as microspheres, 
liposomes or polymeric NPs may improve the effectiveness and decrease the side effects of 
cancer chemotherapy.   Some of these transporters possess moderate MDR reversal activity 
on their own. To further enhance chemotherapy of drug-resistant malignancies, some 
investigators have integrated the approach of encapsulation with the combination of 
cytotoxic drugs and chemosensitizer (13).  The exact strategy implemented, however, has 
varied among studies. In some cases, only the chemosensitizer was encapsulated (55), 
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whereas in other studies, encapsulated cytotoxic drug was administered with free 
chemosensitizer (55). Co-encapsulation of anticancer drugs and chemosensitizers by 
polymeric particles has been reported to have good efficacy (56). Moreover, lower normal 
tissue drug toxicity and fewer drug-drug interactions have generally been observed in the 
combination treatments. However, so far, there has been no consensus regarding which 
strategy provides the optimal treatment outcome (57).  
 
There have been used many ways to present drug to BBB, especially focusing on DOXO for its 
low penetration across BBB.  One strategy is the pegylated liposomal DOXO developed to 
maintain or enhance the demonstrated antineoplastic effects of DOXO, while improving the 
toxicity profile associated with this important cytotoxic agent. Accumulating clinical data 
have confirmed the activity of pegylated liposomal DOXO in cancers of the breast and ovary 
(49).  
  
Figure No. 2. Nanoparticles- and liposomes-loaded drugs are more easily delivered 
across blood-brain barrier (BBB) than free drugs with at least three mechanisms: 1) 
they are favored to enter cells by simple diffusion; 2) they are uptaken by a receptor-
triggered endocytosis, if conjugated with specific ligands; 3) they are less effluxed by 
ABC transporters: indeed nanoparticles and liposomes can directly inhibit the catalytic 
cycle of ABC transporters and alter the optimal physico-chemical properties of the 
plasma membrane in which the transporters work. Overall, the drugs loaded on these 
delivery systems can pass through the BBB and reach the brain parenchyma at 
therapeutically relevant concentrations (23). 
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The abundance of ABC transporters in endothelial cells of brain capillaries of bovine, murine 
and human origin may help to clarify by which mechanisms NPs and liposomes protect drugs 
from the ABC transporters-mediated efflux (Figure 2). This information could be then 
translated into the design of NPs/liposomes with specific physico-chemical properties, useful 
not only to increase the delivery across BBB, but to increase the pharmacological efficacy in 
every condition for which the ABC transporters represent an obstacle. 
 
The major advantage of using NPs/liposomes-based strategies is their great versatility: once 
synthesized a specific carrier formulation, the cargo can be easily varied and can include 
drugs, siRNA, gene-delivering systems, and radiotracers. Such versatility enlarges the number 
of applications, from the therapeutic use of drug-delivery systems in diseases such as cancer, 
epilepsy, infective or neurodegenerative disorders, to the diagnostic use and to theranostic 
applications, which couples diagnosis and therapy. If these are the benefits of NPs- and 
liposome-based strategies, there are also many unsolved issues, such as the lack of consistent 
information about their long term toxicity or the lack of effective strategies assuring a strong 
tropism for BBB or CNS cells. These gaps have to be considered as challenges, which will give 
the opportunity to continue developing new drug delivery systems, progressively more 
effective and selective  (58, 59).   
 
2.5.1. Statins and mechanism of action 
 
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, which catalyzes the rate limiting step in cholesterol synthesis. Therefore, statins 
dramatically decrease both cholesterol and isoprenoid intermediates, impairing the 
isoprenylation and activity of different enzymes, such as the small G-protein families Ras and 
Rho (60). Farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) serve as 
important lipid attachments for the posttranslational modification of heterotrimeric G-
proteins and small GTP binding proteins (61).  Isoprenylation converts small GTPases from a 
cytosolic (inactive) state to a membrane-bound (active) state.  Statins reduce the risk of 
myocardial infarction and stroke. Increasing evidence suggests that protection conferred by 
statins relates not only to cholesterol-lowering but rather to direct effects on endothelium 
function as well as antithrombotic and antiinflammatory effects. In humans, improvement of 
Martha Leonor Pinzón Daza 
 
 
 
26 
 
endothelium function is one the earliest clinical effects after initiation of statin treatment 
(62).   
  
Most statins are given in the active α-hydroxy acid form except for lovastatin and simvastatin, 
which are administered as inactive lactone prodrugs. Both lactone and acid forms were 
observed in the systemic circulation after oral administration of atorvastatin, lovastatin, 
simvastatin, and cerivastatin in humans and/or animals, indicating that interconversion 
occurs between the lactone and acid forms of these statins.  The 2 forms of these statins are 
substrates for Pgp transporter (63). To date, there are several lines of preclinical and 
epidemiologic evidences to support the anticancer potential of statins.  (64). Some 
epidemiologic analyses have demonstrated up to a 50% reduction in cancer risk among statin 
users and partial or complete responses have been observed in some, but not all, patients 
undergoing early phase 1/2 trials.  These mixed responses underscore the importance of 
reliably identifying the appropriate subset of patients who stand to benefit most from statin-
based anticancer therapy. To ultimately advance statins as anticancer agents, it is therefore 
crucial to understand the molecular mechanisms involved in their anticancer activity and to 
delineate markers that distinguish the subset of tumors that are sensitive to statin-induced 
apoptosis. Statin-induced apoptosis results directly from inhibiting HMGCoA reductase (64), 
Once statins have blocked it and depleted the intracellular end-products of the mevalonate 
pathway, cytoplasmic transcription factors known as sterol regulatory element-binding 
proteins are activated. These transcription factors translocate to the nucleus, bind DNA at 
promoter regions containing sterol response elements (SREs), and induce the transcription of 
several key target genes, including HMGCR and the low-density lipoprotein receptor (LDLR). 
Up-regulated LDLR on the cell surface then binds and internalizes extracellular LDL-loaded 
cholesterol, thus reducing plasma cholesterol. It is this extraordinary feedback mechanism 
that has been successfully exploited to control hypercholesterolemia with statins  (63). 
  
A well-characterized pleiotropic effect of statins is the upregulation and activation of 
endothelial nitric oxide sinthase (eNOS), one of the three NOS isoforms that catalyze the 
conversion of L-arginine to L-citrulline and nitric oxide (NO) with a 1:1 stoichiometry (62). 
Statins regulate eNOS via inhibition of geranylgeranylation of the small G-protein Rho (65).  
Translocation of inactive Rho from the cytosol to the membrane depends on 
geranylgeranylation. Activated Rho binds and activates Rho-associated kinases, which in turn 
A “Trojan Horse” strategy to reverse drug-resistance in brain tumors 
 
 
 
27 
 
leads to phosphorylation of myosin light chains required for the formation of actin stress 
fibers and focal adhesion complexes. Anchoring of mRNAs to the actin cytoskeleton is 
necessary for their stability and translational expression (66).  Consequently, Rho-mediated 
reorganization of the actin cytoskeleton may regulate the trafficking and subcellular 
localization of specific mRNAs.    
 
Rho GTPases play a key role in the regulation of tumor growth, migration, and sensitivity to 
anticancer drugs. Some of these functions are dependent on the activity of the transcription 
factor nuclear factor-κB (NFκB)  (67), (68) or Wnt3a /β-catenin (non canonical) signaling 
pathway (69).  NF-κB is composed of protein dimers, such as the heterodimer p50/p65, and 
regulates the expression of genes involved in inflammation, cellular proliferation, and 
apoptosis (70).  In resting cells, members of the inhibitory IκB family proteins, like IκBα, bind 
directly to NF-κB dimer in the cytoplasm, preventing its nuclear localization. NF-κB is free to 
translocate and bind to DNA on the target genes when IκBα is phosphorylated by the IκB 
kinase (IKK) complex, ubiquitinated, and degraded by S26 proteasome (71). Statins, by 
inhibiting RhoA and its effector Rho kinase, can activate the IKK/NF-κB pathway (72).  In 
addition, DOXO can induce NF-κB translocation in cancer cells via different mechanisms (73). 
By activating NF-κB, statins and DOXO may enhance the transcription of the inducible nitric-
oxide synthase (iNOS) (70). NO is a signaling molecule involved in the control of cellular 
growth, differentiation, and apoptosis (70). In previous studies Riganti et al. suggested that 
NO is implicated in the DOXO cytotoxicity in HT29 cells and reverts DOXO resistance via the 
tyrosine nitration of Pgp and MRP3, two ATP-binding cassette transporters that recognize 
DOXO as a substrate. Such a nitration reduces the drug efflux in DOXO-resistant cells (74). 
  
2.6. ABC transporters and signaling pathway 
 
Statins have been recognized as regulators of iNOS expression, nitration and modulation of 
the activity of ABC transporters, via RhoA protein and NF-κB transcription factor (74). 
However it is necessary to study other pathways that may be involved in the expression 
and/or activity of ABC transporters modulation, in order to find therapeutic targets 
associated with the use of new therapies (systems of nanoparticles or liposomes) to increase 
their effectiveness. In this way it has been considered the activity of the protein Rho as a 
modulator of Wnt3/β-catenin signaling pathway.   Activation of signaling pathways by the 
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Wnt family secreted glycoproteins is central to a wide array of developmental events across 
all animal taxa, including cell proliferation, migration, establishment of cell polarity, and 
specification of cell fate (75).  Dysregulation of Wnt signaling is known to result in human 
disease, and aberrant Wnt activation is a critical step in oncogenesis in many human tumors 
(76).  Furthermore it has been shown a correlation between Wnt/β-catenin signaling 
activation and ABC transporters expression (77) which induce multidrug resistance. Wnt 
ligands bind to cellular receptors to activate diverse signaling events, including β-catenin-
dependent transcriptional induction (the canonical pathway), stimulated release of 
intracellular calcium (the Wnt–Ca2+ pathway), and initiation of the planar cell 
polarity/convergent extension pathway (the PCP pathway) (76) (72).   There are ~20 
members of the Wnt family in mammals that can be divided into two major categories: 
transforming and non-transforming factors.  Transforming Wnts possess the ability to 
transform mammary epithelial cells and can induce secondary axis formation in Xenopus. 
Transforming Wnts generally activate the canonical, β-catenin-dependent signaling wherein 
Wnt stimulation regulates cellular β-catenin to ultimately induce transcription of target genes 
(78). Cytosolic β-catenin is continuously degraded in unstimulated cells via phosphorylation– 
ubiquitination-coupled proteasomal degradation. Receptor binding of canonical Wnts inhibits 
this degradation resulting in the accumulation of stabilized β-catenin, which can then shuttle 
into the nucleus. Nuclear β-catenin interacts with members of the T-cell factor 
(TCF)/lymphoid enhancing factor (LEF) family of HMG-box transcription factors to induce 
expression of Wnt target genes  (79). Non-transforming Wnts neither transform cells nor 
induce secondary axis formation and are associated with the non-canonical Wnt–Ca2+ and 
PCP pathways. Wnt signaling in these pathways is β-catenin-independent. Non-transforming 
Wnts control cytoskeletal changes to affect movement and polarity and do so in part by 
promoting the activation of the Rho family of GTPases, including Rho and Rac, which are 
important regulators of cytoarchitecture, cell adhesion, transcriptional events, and cell cycle 
progression (78). Wnt-induced activation of Rho GTPases is not restricted to non 
transforming Wnts, however. The canonical Wnt1 in Xenopus was shown to trigger the 
activation of both Rho and Rac, and, in several studies, Wnt3A was reported to promote both 
canonical β-catenin dependent signaling as well as the activation of RhoA  (69). While the 
importance of Wnt-triggered Rho activation of non-canonical signaling is well appreciated, its 
contribution to canonical signaling has not been examined.  For that reason it is important to 
verify this pathway as a critical actor of β-catenin-induced transcription of target genes like 
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ABC transporters.  In addition a possible modulator of canonical signaling pathway could be 
the statins which are important Rho activity regulators.   
 
3. Hypothesis 
 
BBB is the first obstacle for access of drugs targeting cancer cells in the brain.  This 
impediment is represented by the expression of ABC transporters, which recognize and 
extrude the drugs out of the cells, decreasing the effectiveness of the chemotherapy.   Taking 
as a basis the liposome structure, which accommodates the anti-cancer drug DOXO, it is 
possible to create a "Trojan horse".  The liposome marked with a human peptide from 
APOB100, allows the recognition of the LDL (LDL-R) receptor, which is expressed in the cells 
of the BBB.  This leads the liposome to cross the BBB, due to its low polarity by a process of 
simple diffusion or by endocytosis via LDL-R.  In addition, the simultaneous use of statins, 
anti-cholesterol drugs, allows a greater expression of LDL-R and also induces a decrease in 
the activity of ABC transporters.  Statins reduce the Rho GTPase activity and increase the 
activation of NOS, induce the synthesis of not favoring the nitration of ABC transporters.    
This combination increases the permeability of the "Trojan horse" allowing greater 
accumulation and toxicity of drugs in cancer cells.  In hypoxia conditions there is an 
increasing Pgp expression however our strategy could be useful to reduce ABC transporters 
activity and could induce citotoxicity in cancer cells. 
In addition to recognize that Temozolomide crosses the BBB, the combined use of this drug 
associated with DOXO arised as an alternative therapy.  Temozolomide is not substrate of 
ABC transporters or evades its action, it is a modulator of GSκ3/β-catenin signalling, which is 
involved in the expression of Pgp transporter. This study contributes to clarify how 
Temozolomide reduces the activity of the GSκ3/β-catenin pathway, lowers the expression of 
Pgp transporter and therefore facilitates the entrance of DOXO.  By associating 
Temozolomide with the DOXO the permebeality of the latter can be increased through the 
BBB, increasing the cytotoxicity of cancer cells. 
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4. General Objective 
 
The objective of this work was to reverse the MDR phenotype in CNS tumors starting from 
the creation and use of a therapeutic strategy that improves the permeability of DOXO 
through the BBB, its accumulation and cytotoxic effect in tumors. 
 
 
4.1. Specific Objectives 
 
A. Generate a tool based on liposomes therapy that improves the permeability of DOXO 
through the BBB and reversed the MDR phenotype. 
B. Verify that the LDL-mimicking liposome, ApolipoDOXO, binds the LDL receptor, 
reversed the MDR phenotype, i.e.: 
1. crosses in vitro the BBB 
2. accumulates in tumor cells  
3. exerts a strong cytotoxic effect. 
C. Evaluate the use of combination therapies with DOXO or ApolipoDOXO, in the reversal 
of the MDR phenotype, associated with the use of: 
1. Statins 
2. Temozolomide   
D. Evaluate the behavior of the ApolipoDOXO system in the tumor microenvironment 
under hypoxic conditions. 
E. Determine molecular mechanisms associated with the expression of the MDR 
phenotype caused by overexpression of ABC transporters. 
 
5. General discussion  
 
Malignant gliomas, the most common brain tumors known as high-grade tumors, and 
systemic metastatic tumors, have high levels of ABC transporters or molecules responsible 
for the efflux of drugs used in chemotherapy treatments.  These tumors response to 
chemotherapy is poor, since many anticancer drugs (DOXO, daunorubicin, etoposide, 
teniposide, paclitaxel, docetaxel, vincristine, vinblastine, cisplatin, methotrexate) have a 
permeability limited through the BBB and tumor cell membrane, and drugs able to enter the 
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cell are immediately removed by ABC transporters (1).  (80). This barrier and tumor cell 
defense system bring as consequence that approximately 10% of patients with CNS tumours 
develop metastases and chemoresistance maintaining an intact BBB (15).  Currently there are 
new strategies aimed at improving the effectiveness of primary brain tumors and metastatic 
conventional chemotherapies, maintaining unaltered the other cells of the CNS (14). The little 
possibility that drugs move through the BBB and the little accumulation in tumor cells are the 
main factors to consider in deficiency of therapies, which may be due to the molecular 
properties of the BBB, with few fenestrations, many strong unions as the tight junctions, and 
high levels of expression of pumps or ABC transporters (1, 5).    This expression has been 
identified in CNS tumours (81), where they contribute to the chemoresistance.  Therefore, a 
pharmacological therapy indicated for CNS tumors should be focused on mechanisms to 
evade the action of these transporters and/or recognize pathways that can promote the 
expression of them.  In this context, my work suggests two approaches: First, it proposes 
strategies that evade the response of transporters in the cells of the BBB or tumor cells and 
second, it analyses cellular mechanisms that induce the expression of ABC transporters and 
that can be considered therapeutic targets.  
 
The first approach use in this study suggests (Article I) a new combination, based on the 
association of statins plus DOXO encapsulated in liposomes marked with the binding peptide 
of LDL-R from APOB100 (ApolipoDOXO) taking into account two considerations: (a) 
liposomal drugs and statins have chemosensitive properties in solid tumors; (b) liposomal 
drugs cross the BBB more easily than free drugs.  Some authors have proposed that the use of 
liposomes is safer than the use of nanoparticles (82),  however, there are few studies based 
on the use of liposomes as transporters of drugs in the CNS  (83).   On the other hand, the 
liposomes are less toxic than other nanoparticles, since the former are constructed of 
substances such as phospholipids and cholesterol which are physiologically embedded in the 
cell membrane and subsequently degraded.   Some studies have shown that the anti-cancer 
drugs loaded in liposomes are a successful alternative cancer treatment therapies and it is 
suggested that liposomal formulations may overcome the effect of ABC transporters.  This is 
how it has been shown that in addition to staying a long time in tumor cells  (83). Moreover 
liposomal drugs are not promoters of the expression of transporters as Pgp, unlike some 
drugs (84). 
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Previously it was shown the use of membrane receptors as a target for the recognition of 
liposomes: transferrin (Tf), lactoferrin, insulin, among others are some examples used in 
liposomes directed toward the cerebral parenchyma  (83).  This strategy has been recognized 
because it allows masking drug to enter the endothelial cells of the capillaries of the brain. 
Many liposomes enter mechanisms associated to a receiver via endocytosis.  It is the case of 
PEG-liposome conjugated with Tf which more easily traversed BBB cells than non-conjugated 
liposomes.  In adittion  the use of the boron 10-loaded liposomes in co-culture models, 
increased the cytotoxicity of cells of glioblastoma U87 (85).  In the present study the strategy 
named Trojan horse, demonstrated that the use of liposomes associated with LDL, 
ApolipoDOXO, can be advantageous since they can be recognized, through peptide from 
ApoB100, not only by the endothelial cells of the BBB, but also by the tumor cells.  Likewise 
combined administration with statins favors the increase in expression of the LDL receptor, 
which is consistent with the use of LDLR-associated liposomes.  On the other hand 
ApolipoDOXO crossed through the cells of the BBB and it also induced cytotoxicity in tumor 
cells in co-culture. 
 
The Trojan horse liposome system proposed in this paper, differs from other studies using 
nanoparticles that penetrate the BBB since this is a more "physiological" system: it takes 
advantage from the usual metabolic effects of statins which, by reducing the amount of 
cholesterol, promote the increase in LDL receptors and the synthesis of NO (favoring the 
nitration and inactivation of ABC transporters). On the other hand, it takes advantage also 
from the properties of the liposomes, which cross the BBB by diffusion or by endocytosis.   
The union of these two factors promotes the effectiveness against drug-resistant tumors.  
This final effect was demonstrated not only in conditions of normoxia, but also in hypoxic 
conditions, in which drug resistance is increased, since HIF-1α hypoxia modulates the 
expression of transporters as Pgp (Article III) (86, 87).   HIF-1α presents a double action on 
the cells of the BBB; first it increases the expression of Pgp transporter, which limits the use 
of DOXOrubicin, reducing its permeability, and second it increases the expression of LDL 
receptor in the cells, therefore it favours the use of the ApolipoDOXO to be better recognized 
and allow their passage by endothelial cells. 
 
In this part of the study (Article III) it was evaluated the passage of drugs such as DOXO and 
vinblastine, substrates of Pgp, under conditions of normoxia and hypoxia.   Cells of 
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endothelial barrier have different behavior depending on the species which come from: cells 
murine bEND3 decrease their permeability while hCMEC/D3 human cells do not change it in 
hypoxia.  This difference lies in the expression of Pgp, which occurs under conditions of 
normoxia in human cells but not in murine cells, which confirms findings of other researchers 
(88).  However, this study demonstrated how hypoxia could modulate the activity of Pgp 
transporter in murine cells, while in the human cells hCMEC/D3 HIF-1α is stabilized also in 
normoxia. There is a transporters-specific regulation under hypoxia; indeed other 
transporters such as MRP 1 and 6 could be invariant under these conditions. In this study it 
was found that HIF-1α and SREBP-2 co-immunoprecipitated, HIF-1α favored the nuclear 
translocation of SREBP-2 and the transcription of HMGCoAR.  The activation of HIF-
1α/SREBP-2 axis determined the rate of cholesterol synthesis.  Currently there are no known 
reports that show this dependence on cholesterol synthesis of the activity of HIF-1α in cells of 
the BBB.  Thus the study proposes that the SREBP-2 transcription factor activation dependent 
on HIF-1α positively modulates the expression of LDLR receptor cells BBB.  This effect also 
favoured an increased ApolipoDOXO permeability associated with the use of statins in 
hypoxic conditions in both BBB cells and glioblastoma cells. 
 
Therapies associated with nanoparticles or liposomes have improve the entry of drugs such 
as DOXO in cancer cells seeking to improve therapies and decreasing the isolated drug (13) 
cardiotoxic effect.  However other efforts have led to improved therapies which in principle 
have shown a great effectiveness not being dependent on the ABC transporters.  It is the case 
of temozolomide (TMZ), which, despite the use of different doses, does not show sufficient 
efficacy to control GBM disease  (18).  In this study it was demonstrated that the TMZ, in 
similar doses to those found in blood (89), increased the permeability of the cells of the BBB 
to DOXO, seen by the increase in coefficients of permeability, and decreased the expression of 
the transporter Pgp (Article IV).  In the systemic circulation the TMZ is quickly converted into 
its form active 3-methyl-(triazen-1-il) imidazole-4-carboxamide, so that it could be 
considered the latter as the reducer of Pgp expression. 
 
Previous studies have reported that Pgp is under the transcriptional control of the β-catenin, 
whose activity is regulated by Wnt/GSK3/β-catenin signalling in hCMEC/D3 cells (77), an 
effect that I confirmed in my study (Article V).  TMZ-treated cells showed an increase in the 
activity of GSK3 and an increase in the amount of phosphorylated β-catenin, leading to the 
Martha Leonor Pinzón Daza 
 
 
 
34 
 
decline of the nuclear β-catenin and binding to the promoter of mdr1.  The activity of 
GSK3/β-catenin signaling pathway depends on the combination of factors as Wnts to LRP5/6 
or Frizzled receptors (77), in this way it was evaluated the action that could have the TMZ on 
this axis.  It was found that the TMZ decreased protein and mRNA Wnt3 allowing raising the 
hypothesis that the drug decreases the Wnt3 gene transcription in cells of the BBB, increases 
the phosphorylation of the β-catenin and reduces nuclear and binding to the promoter of the 
mdr1 gene.  It is known that TMZ, an alkylating agent, mehtylates a guanine at position O6 
and induces the double-stranded DNA breaks. Primary cytotoxic lesions of the O6 
methylguanine can be removed by a direct repair mechanism by the methyltransferase 
(MGMT)-methylguanine in tumors expressing it, or tolerated in tumors with mismatch 
repair-deficient (MMR-). MGMT or deficiency in MMR confers resistance to treatments with 
TMZ.  However, most of the methylations caused by the TMZ are methylations of another type 
usually non-cytotoxic (90). The consequences of these methylations have not been studied.  It 
was found that TMZ methylates Wnt3 gene promoter in untreated BBB cells that express a 
promoter fully demethylated, which is consistent with the constitutive transcription of Wnt3: 
Thus the methylation of promoter induced by the TMZ could explain the decrease in the 
Wnt3, suggesting that the TMZ is an epigenetic regulator of the Wnt3 gene.  This deregulation 
is not only noted on BBB endothelial cells, but also in cells of glioblastoma (91). 
 
The combination of TMZ with DOXO proved to be effective to increase the permeability of 
DOXO in cells of the BBB by decreasing the expression of the Pgp transporter by methylation 
of Wnt3, which affects the GSK3/β-catenin pathway and the expression of the transporter 
Pgp.  Likewise it was increased the cytotoxicity of GBM cells maintained in coculture with 
BBB cells. 
 
In this work, beside identifing potential strategies that facilitate the movement of drugs 
through the blood-brain barrier, we identified specific molecular mechanisms associated with 
the expression of Pgp transporter in human cells of BBB, which are quoted below: 
 
1. Use statins produced NOS expression through a NFκB-dependent mechanism (Article 
I) and leads to the synthesis of NO; NO nitrates ABC transporters and decresased 
ATPase activity.  This mechanism had been previously evaluated in colon cancer cells 
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HT29 (73) and it was evidenced as a modulator mechanism of the activity of Pgp and 
BCRP transporters in cells of the BBB. 
2. Another key mechanism presented in this study, corresponds to the modulation of the 
TMZ in the methylation of the gene Wnt3 (Article IV) that reduces the activity of 
GSK3/β-catenin signaling pathway and therefore reduces the expression of Pgp 
transporter. 
3. The last mechanism corresponds to the action of the axis of the RhoA/RhoA kinase as 
a key element in the activity of the GSK3/β-catenin (non-canonical) pathway, 
demonstrating that this pathway associated with the activity of RhoA and RhoA 
protein expression kinase is an important factor that favors the Pgp transporter 
expression (Article V).   Previous studies had shown that PTP1B tyrosine phosphatase 
reduces the activity of GSK3 by 216 tyrosine dephosphorylation, which is critical to 
the activity of GSK3 (92).  PTP1B is activated by phosphorylation of serine 50 (93).  In 
this study it was demonstrated that RhoA kinase phosphorylated PTP1B in serine 50, 
and decreased the GSK3 phosphorylation on tyrosine 216.  Reducing the 
phosphorylation of GSK3 decreases phosphorylation of β-catenin favoring its 
accumulation at the nuclear level and therefore promoting its binding to mdr1 gene 
promoter. 
 
All these mechanisms contributing to modulate the expression of Pgp are of great interest 
considering that this transporter is the main generator of resistance to drugs in the BBB and 
in glioblastoma cells.  Therefore, this study provides knowledge in two ways: one, in the 
improvement of the presentation of the drug anticancer; two, in the knowledge of 
mechanisms of action that promote the MDR phenotype.  Our strategies can be considered 
not only in the modulation of brain cancer but also in the management of diseases associated 
with the CNS. 
 
6. Conclusions and Perspectives  
 
The study presented in this thesis allows concluding that the use of combined chemotherapy 
of glioblastomas would be helpful to increase the effectiveness of the drugs by circumventing 
ABC transporters.  Thus the strategy of the "Trojan horse", based on the administration of 
statins over the use of DOXO encapsulated in liposomes associated to the LDL receptor, could 
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have potential applications in therapy not only of brain cancer, but also of different diseases 
in which the BBB represents an obstacle.  On the other hand, these results suggest that TMZ 
increases the permeability of drugs in the BBB, which are substrate of Pgp transporter. 
Therefore association of TMZ with DOXO could be a new combined therapy approach for 
glioblastoma. 
 
Additionally it was shown evidence for apparent metabolic changes occurring in the cells of 
the BBB during hypoxia, which allowed posing an effective strategy that improves the 
permeability of the drug in BBB cells exposed to a hypoxic environment and/or with an active 
HIF-1α.   This strategy is flexible, as different drugs could be encapsulated in liposomes 
associated to the LDL receptor. 
 
The understanding of new mechanisms associated with the expression of the MDR phenotype 
caused by overexpression of ABC transporters, was evident in this work.  It was possible to 
demonstrate that statins reduce the activity of transporters through a process of nitration.  
On the other hand the use of Temozolomide favored the methylation of the gene Wnt3 
promoting the inactivation of the GSK3/β-catenin pathway and the decrease of expression of 
Pgp transporter.  It was shown that the expression of P-glycoprotein is controlled by a 
crossover between the canonical and non-canonical Wnt/β-catenin pathway.  Alteration of 
this crosstalk by inhibition of RhoA/RhoA kinase could represent a strategy to decrease the 
expression of Pgp and increase the passage of substrates of this transporter through the BBB. 
 
The effects of a new therapeutic strategy associated with the knowledge of mechanisms that 
regulate the MDR phenotype are presented in this study as an effective alternative that 
promotes the use of new approaches in the fight against Glioblastoma and which could be 
useful in the control of other diseases of the Central Nervous System. 
 
The next phase of this work will consist of assessing mechanisms associated with resistance 
to drugs caused by stress.  It has been recognized the reactive species of oxygen (ROS) that 
arise due to the use of drugs or the environment hypoxic tumor could increase the Multidrug 
resistance phenotype by increasing the expression of ABC transporters.  The next goal will be 
to analyze these events and develop new therapies based on specific targets. 
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BACKGROUND AND PURPOSE
The passage of drugs across the blood–brain barrier (BBB) limits the efficacy of chemotherapy in brain tumours. For instance,
the anticancer drug doxorubicin, which is effective against glioblastoma in vitro, has poor efficacy in vivo, because it is
extruded by P-glycoprotein (Pgp/ABCB1), multidrug resistance-related proteins and breast cancer resistance protein
(BCRP/ABCG2) in BBB cells. The aim of this study was to convert poorly permeant drugs like doxorubicin into drugs able to
cross the BBB.
EXPERIMENTAL APPROACH
Experiments were performed on primary human cerebral microvascular endothelial hCMEC/D3 cells, alone and co-cultured
with human brain and epithelial tumour cells.
KEY RESULTS
Statins reduced the efflux activity of Pgp/ABCB1 and BCRP/ABCG2 in hCMEC/D3 cells by increasing the synthesis of NO,
which elicits the nitration of critical tyrosine residues on these transporters. Statins also increased the number of low-density
lipoprotein (LDL) receptors exposed on the surface of BBB cells, as well as on tumour cells like human glioblastoma. We
showed that the association of statins plus drug-loaded nanoparticles engineered as LDLs was effective as a vehicle for
non-permeant drugs like doxorubicin to cross the BBB, allowing its delivery into primary and metastatic brain tumour cells
and to achieve significant anti-tumour cytotoxicity.
CONCLUSIONS AND IMPLICATIONS
We suggest that our ‘Trojan horse’ approach, based on the administration of statins plus a LDL receptor-targeted liposomal
drug, might have potential applications in the pharmacological therapy of different brain diseases for which the BBB
represents an obstacle.
BJP British Journal ofPharmacology
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Abbreviations
ABC, ATP-binding cassette; AMC, amino-4-methylcumarine; BBB, blood–brain barrier; BCRP/ABCG2, breast cancer
resistance protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GGPP, geranylgeranyl pyrophosphate; LDL,
low-density lipoprotein; MRPs/ABCCs, multidrug resistance-related proteins; PEG, polyethylene glycol; Pgp/ABCB1,
P-glycoprotein; PTIO, phenyl-4,4,5,5,tetramethylimidazoline-1-oxyl 3-oxide; TBS, Tris-buffered saline
Introduction
Primary CNS tumours, like glioblastoma, and CNS metastasis
of solid tumours are poorly responsive to chemotherapy, as a
consequence of the intrinsic tumour resistance and of the low
penetration of many anticancer drugs across the blood–brain
barrier (BBB). Both tumour cells and BBB endothelial cells
are rich in ATP-binding cassette (ABC) transporters, like
P-glycoprotein (Pgp/ABCB1), multidrug resistance-related
proteins (MRPs/ABCCs) and breast cancer resistance protein
(BCRP/ABCG2) that extrude drugs from the luminal side of
endothelial cells back into the blood and out of the tumour
cells (Declèves et al., 2006; Mercer et al., 2009; Robey et al.,
2010). Doxorubicin, for instance, is a very effective anticancer
drug against glioblastoma cells in vitro, but since it is a sub-
strate of Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2, its
delivery across the BBB is hampered and it is ineffective
clinically at treating this tumour.
The effects of a pegylated liposomal doxorubicin (Doxil or
Caelyx) have recently been investigated in glioblastoma, but
the results obtained are unconvincing (Glas et al., 2007; Beier
et al., 2009; Ananda et al., 2011). As alternative strategy,
liposome-encapsulated drugs that have shown selective intra-
tumour drug delivery, lower side effects and particular effi-
cacy against aggressive and chemoresistant tumours (Jabr-
Milane et al., 2008; Riganti et al., 2011), have been proposed
as vehicles able to cross the BBB (through a diffusion process
or a receptor-mediated endocytosis) and deliver their cargo
into the CNS (Deelen and Loscher, 2007). Certain types of
drug-containing nanoparticles adsorb apoB-100 and apo-E
proteins from human low-density lipoprotein (LDLs; Kim
et al., 2007), are recognized by the LDL receptor and achieve
an efficient drug delivery into brain parenchyma (Michaelis
et al., 2006; Nikanjam et al., 2007) because both neurons and
glial cells express LDL receptors (Ambruosi et al., 2006).
In addition to increasing the delivery across the BBB, an
‘ideal’ chemotherapy for primary and metastatic tumours of
CNS must simultaneously overcome the ABC transporters-
dependent drug resistance of tumour cells. To meet these two
requisites, in the present study we have investigated a
nanoparticle-based approach – that is, the association of
cholesterol-lowering drugs like statin plus a LDL receptor-
targeting liposomal doxorubicin (termed ‘apo-Lipodox’;
Kopecka et al., 2011).
Previous works from our group has shown that statins
have chemosensitizing properties in epithelial tumours
(Riganti et al., 2005; Riganti et al., 2006; Kopecka et al., 2011).
Moreover statins are reported to exert cytotoxic effects
against CNS tumour cells (Bababeygy et al., 2009; Yanae et al.,
2011). To our knowledge, no data exist on the effects of
statins on the metabolism and permeability of BBB cells. In
this study, we investigated whether the association of statin
with LDL receptor-targeted liposome-encapsulated doxoru-
bicin simultaneously increases the drug permeability across
the BBB and the cytotoxicity against CNS tumour cells, which
would meet the two requisites of an optimal chemotherapy
for brain tumours.
Methods
Chemicals
Plasticware for cell cultures was from Falcon (Becton Dickin-
son, Franklin Lakes, NJ, USA). Mevastatin, simvastatin, rhod-
amine 123 and Hoechst 33342 were purchased from
Calbiochem (San Diego, CA, USA). Electrophoresis reagents
were obtained from Bio-Rad Laboratories (Hercules, CA, USA);
the protein content of cell monolayers and lysates was
assessed with the BCA kit from Sigma Chemical Co (St. Louis,
MO, USA). When not otherwise specified, all the other rea-
gents were purchased from Sigma Chemical Co.
Cell lines
The hCMEC/D3 cells, a human brain microvascular endothe-
lial cell line, were cultured as previously described (Weksler
et al., 2005). Human glioblastoma U87-MG cells were cultured
in DMEM medium, human neuroblastoma SJKNP cells and
human breast cancer MDA-MB-231 cells were grown in RPMI-
1640 medium, human lung cancer A549 cells were grown in
Ham’s F12 medium. These cell lines (purchased from Ameri-
can Type Cells Collection) were maintained with 1% v v-1
penicillin-streptomycin and 10% v v-1 FBS, at 37°C and 5% CO2
and were preliminarily characterized for the amount of Pgp,
MRP1, BCRP and LDL receptor and for drug-resistance param-
eters (intracellular doxorubicin accumulation, extracellular
release of lactate dehydrogenase, LDH) as reported below.
Cholesterol and geranylgeranyl pyrophosphate
de novo synthesis
Cells grown to confluence in 35-mm diameter Petri dishes,
incubated as reported in the Results section, were labelled for
24 h with 1 mCi·mL-1 [3H]-acetate (3600 mCi·mmol-1; Amer-
sham Bioscience, Piscataway, NJ, USA), then washed and sub-
jected to lipid extraction with the methanol/hexane method
(Kopecka et al., 2011). Samples were resuspended in 30 mL
chloroform and separated by TLC, using 1:1 v v-1 ether/
hexane as the mobile phase. Solutions of 10 mg·mL-1 choles-
terol and 10 mg·mL-1 geranylgeranyl pyrophosphate (GGPP)
were used as standards. After exposure for 1 h to an iodine-
saturated atmosphere, the migrated spots were cut out and
their radioactivity was measured by liquid scintillation, using
a Tri-Carb Liquid Scintillation Analyzer (PerkinElmer,
Waltham, MA, USA). Cholesterol and GGPP synthesis were
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expressed as pmol [3H]-cholesterol per 106 cells or [3H]-GGPP
per 106 cells, according to the corresponding calibration
curve.
Spectrophotometric measurement of
membrane cholesterol
Cells were rinsed with 0.5 mL PBS, sonicated on ice with two
bursts of 10 s and centrifuged at 100 000¥ g for 1 h at 4°C.
The pellets (cell membrane fractions) were resuspended in
0.25 mL PBS and the cholesterol concentration was measured
with an enzymatic colorimetric assay kit (OSR6516, Olympus
System Reagent, Olympus Europe Holding GmbH, Hamburg,
Germany), following the manufacturer’s instructions. The
absorbance was measured at 540/600 nm by an Olympus
Analyzers spectrophotometer (Olympus Europe Holding
GmbH). b-Methyl-cyclodextrin (10 mmol·L-1 for 3 h) was
used as a cholesterol chelator (Kopecka et al., 2011). A 50 mL
aliquot was used to determine the protein content with the
BCA kit. The results are expressed in mg cholesterol·mg-1
membrane proteins, according to a previously prepared titra-
tion curve.
RhoA and RhoA kinase activity
To evaluate RhoA activity, the GTP-bound fraction, taken as
an index of monomeric G-proteins activation (Laufs and
Liao, 2000), was measured using the G-LISA™ RhoA Activa-
tion Assay Biochem Kit (Cytoskeleton Inc, Denver, CO, USA),
according to the manufacturer’s instructions. Absorbance was
read at 450 nm, using a Packard EL340 microplate reader
(Bio-Tek Instruments, Winooski, VT, USA). For each set of
experiments, a titration curve was prepared, using serial dilu-
tion of the Rho-GTP positive control of the kit. Data are
expressed as absorbance units·mg-1 cell proteins. RhoA kinase
activity was measured using the CycLex Rho Kinase Assay Kit
(CycLex Co, Nagano, Japan), following the manufacturer’s
instructions. The titration curve was prepared with serial dilu-
tions of recombinant RhoA kinase (Rock2, MBL Inc, Woburn,
MA, USA). Data are expressed as absorbance units·mg-1 cell
proteins.
NF-kB activity
Nuclear proteins were extracted using the Nuclear Extract Kit
(Active Motif, Rixensart, Belgium) and quantified. The activ-
ity of NF-kB was assessed by the TransAM™ Flexi NFkB Family
kit (Active Motif), by adding 1 pmol of the biotinylated probe
containing the NF-kB consensus site 5′-GGGACTTTCC-3′ to
10 mg of nuclear extract proteins. The absorbance at 450 nm
was measured with a Packard EL340 microplate reader (Bio-
Tek Instruments). For each set of experiments, a blank was
prepared with bi-distilled water, and its absorbance was sub-
tracted from that obtained in the presence of nuclear extracts.
Data are expressed as absorbance units·mg-1 cell proteins.
NOS activity and nitrite measurement
Cells were detached by trypsin/EDTA, resuspended in 0.3 mL
of assay buffer (20 mmol·L-1 HEPES, 0.5 mmol·L-1 EDTA, and
1 mmol·L-1 dithiothreitol DTT; pH 7.2) and sonicated. NOS
(EC 1.14.13.49) activity was measured in 100 mg of cell lysates
with the Ultrasensitive Colorimetric Assay for Nitric Oxide
Synthase kit (Oxford Biomedical Research, Oxford, MI, USA).
Results are expressed as nmol nitrite·min-1·mg-1 cell proteins.
Nitrite production was measured by adding 0.15 mL of cell
culture medium to 0.15 mL of Griess reagent in a 96-well
plate. After a 10 min incubation at 37°C in the dark, the
absorbance was detected at 540 nm with a Packard EL340
microplate reader. A blank was prepared for each experiment
in the absence of cells, and its absorbance was subtracted
from that obtained in the presence of cells. Nitrite concen-
tration was expressed as nmol nitrite·mg-1 cell protein.
Western blot analysis
Cells were rinsed with lysis buffer (50 mmol·L-1 Tris,
10 mmol·L-1 EDTA, 1% v v-1 Triton-X100), supplemented
with the protease inhibitor cocktail set III (80 mmol·L-1
aprotinin, 5 mmol·L-1 bestatin, 1.5 mmol·L-1 leupeptin,
1 mmol·L-1 pepstatin; Calbiochem), 2 mmol·L-1 phenylmeth-
ylsulfonyl fluoride (PMSF) and 1 mmol·L-1 sodium
orthovanadate, then sonicated and centrifuged at 13 000¥ g
for 10 min at 4°C. Extracts of protein, 20 mg, were subjected
to SDS-PAGE and probed with the following antibodies: anti-
phospho-Ser(176/180)-IKKa/b (Cell Signaling Technology
Inc, Danvers, MA, USA), anti-IKKa/b (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA), anti-IkB-a (Santa Cruz
Biotechnology Inc.), anti-neuronal NOS (nNOS/NOS I, Trans-
duction Laboratories, Lexington, KY, USA), anti-inducible
NOS (iNOS/NOS II, Transduction Laboratories), anti-
endothelial NOS (eNOS/NOS III, Transduction Laboratories),
anti-phospho-(Ser 1177) eNOS (Cell Signaling Technology
Inc), anti-Pgp/ABCB1 (Santa Cruz Biotechnology Inc.), anti-
MRP1/ABCC1 (Abcam, Cambridge, MA, USA), anti-BCRP/
ABCG2 (Santa Cruz Biotechnology Inc.), anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH, Santa Cruz Biotechnol-
ogy Inc.) This procedure was followed by exposure to a
peroxidase-conjugated secondary antibody (Bio-Rad). The
membranes were washed with Tris-buffered saline (TBS)-
Tween 0.1% v v-1, and proteins were detected by enhanced
chemiluminescence (PerkinElmer).
To assess the presence of nitrated proteins, the whole cell
extract was immunoprecipitated with a rabbit polyclonal
anti-nitrotyrosine antibody (Millipore, Billerica, MA, USA),
using the PureProteome Protein A and Protein G Magnetic
Beads (Millipore). Immunoprecipitated proteins were sepa-
rated by SDS-PAGE and probed with anti-Pgp/ABCB1, anti-
MRP1/ABCC1 or anti-BCRP/ABCG2 antibody. Whole cells
lysates, 30 mg, were probed with the same antibodies before
the immunoprecipitation step to check the total amount of
Pgp, MRP1 and BCRP.
ABC transporters activity
To measure the ATPase activity of Pgp/ABCB1, MRP1/ABCC1
and BCRP/ABCG2, cells were lysed in buffer A (50 mmol·L-1
HEPES, 750 mmol·L-1 KCl, 200 mmol·L-1 sucrose,
10 mmol·L-1 NaHCO3; pH 7.4), supplemented with protease
inhibitor cocktail set III, centrifuged at 13 000¥ g for 5 min,
then at 100 000¥ g for 1 h at 4°C. The pellet was resuspended
in 1 mL buffer B (20 mmol·L-1 HEPES, 160 mmol·L-1 KCl,
1 mmol·L-1 MgCl2, 1 mmol·L-1 CaCl2, 0.5% v v-1 Triton X-100;
pH 7.4). To obtain membrane fractions enriched in Pgp/
ABCB1, MRP1/ABCC1 and BCRP/ABCG2, 100 mg of mem-
brane proteins were immunoprecipitated overnight with the
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specific primary antibodies, then washed twice with 1 mL
buffer B, supplemented with 2 mmol·L-1 DTT; 50 mg of each
sample were mixed with 2 mmol·L-1 ATP, 2.5 mmol·L-1 phos-
phoenolpyruvate, 7.5 U pyruvate kinase and 8.0 U LDH to
check ATPase activity, as previously described (Doublier et al.,
2008). The reaction was started by adding 0.25 mmol·L-1
NADH and was followed for 10 min, measuring the absorb-
ance at 340 nm with a Packard EL340 microplate reader. The
reaction kinetics was linear throughout the time of measure-
ment. The NADH oxidation rate (expressed as mmol NADH
oxidized·min-1·mg-1 cell proteins) of each sample was sub-
tracted from the oxidation obtained in the absence of
immunoprecipitated proteins. The ATP hydrolysis rate was
calculated stoichiometrically and ATPase activity was
expressed as mmol ATP hydrolysed·min-1·mg-1 cell proteins.
The efflux of rhodamine 123, taken as an index of Pgp/
ABCB1 and MRP1/ABCC1 activity, and the intracellular accu-
mulation of Hoechst 33342, taken as an index of BCRP/
ABCG2 activity, were measured as reported previously
(Riganti et al., 2011).
LDL receptor expression
Total RNA was extracted and reverse transcribed using
the QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany). RT-PCR was carried out using IQ™ SYBR Green
Supermix (Bio-Rad), according to the manufacturer’s instruc-
tions. The same cDNA preparation was used for the quanti-
fication of LDL receptor and GAPDH, used as a housekeeping
gene. The sequences of LDL receptor primers were 5′-TG
AACTGGTGAGAGGACCAC-3′, 5′-TGTTCTTAAGCCGCCAG
TTGTT-3′; the sequences of the GAPDH primers were
5′-TGGTCACCAGGGCTGCTT-3′, 5′-AGCTTCCCGTTCTCAG
CCTT-3′. The relative quantification of each sample was
obtained by comparing the LDL receptor PCR product with
the GAPDH PCR product, with the Bio-Rad Software Gene
Expression Quantitation (Bio-Rad).
For flow cytometry detection of surface LDL receptors,
cells were washed with PBS, detached with Cell Dissociation
Solution (Sigma) and resuspended at 5 ¥ 105 cells·mL-1 in
1 mL RPMI medium containing 5% v v-1 FBS. Samples were
washed with 0.25% w v-1 BSA-PBS, incubated with the
primary antibody for LDL receptors (Abcam) for 45 min at
4°C, then washed twice and incubated with secondary FITC-
conjugated antibody for 30 min at 4°C. After washing and
fixation with paraformaldehyde 2% w v-1, the number of LDL
receptors expressed on the surface was detected on 100 000
cells by a FACSCalibur system (Becton Dickinson), using the
Cell Quest software (Becton Dickinson). Control experiments
included incubation of cells with non-immune isotypic
antibody, followed by the appropriate labelled secondary
antibody.
Synthesis of LDL receptor-targeted
liposome-encapsulated doxorubicin
LDL receptor-targeted liposome-encapsulated doxorubicin
was prepared using anionic pegylated liposomes
(COATSOME EL-01-PA, NOF Corporation, Tokyo, Japan) of
the following composition: 1,2 distearoyl-sn-3-glycero-3-
phosphoethanolamine conjugated with polyethylene
glycol (PEG), cholesterol, 1,2 dipalmitoyl-sn-glycero-3-
phosphocoline, 1,2 dipalmitoyl-sn-glycero-3-phosphogly-
cerol, at a molar ratio 4.2:11.4:15.2:11.4. For each prepara-
tion, 30 mg desiccated liposomes were incubated with
1.5 mmol·L-1 doxorubicin in sterile aqueous solution, accord-
ing to the manufacturer’s instructions. The residual non-
encapsulated drug was removed by gel filtration in a
Sephadex G-50 (Amersham Bioscience) column. The amount
of encapsulated doxorubicin was quantified by diluting 50 mL
of liposomal suspension in 0.5 mL of 1:1 v v-1 ethanol/HCl
0.3 N, sonicating the liposomes and measuring the fluores-
cence emitted by the drug with a LS-5 spectrofluorimeter
(PerkinElmer). Excitation and emission wavelengths were
475 nm and 553 nm respectively. The encapsulation effi-
ciency was calculated as described (Wong et al., 2004). The
liposomes with an encapsulation efficiency higher than 85%
(termed ‘Lipodox’) were collected, stored at a doxorubicin
concentration of 0.5 mmol·L-1 and used to produce apoB100-
conjugated doxorubicin-loaded liposomes (termed ‘apo-
Lipodox’). With this aim, the following recombinant peptide
from human apoB100 was used: DWLKAFYDKVAEKLKEA-
FRLTRKRGLKLA (LDL receptor-binding site is underlined;
GenScript, Piscataway, NJ, USA). An aqueous solution of the
peptide, 2.5 mmol·L-1, was added to liposomal doxorubicin,
vortexed and incubated for 30 min at room temperature,
with mild agitation. The unbound peptide was removed by
dialysis as described previously (Nikanjam et al., 2007). The
amount of peptide attached to the liposomes was detected by
the QuantiPro BCA Assay kit (Sigma).
To assess the role of PEG in the peptide attachment,
anionic non-pegylated liposomes (COATSOME EL01A,
NOF Corporation), with the following composition: 1,2
dipalmitoyl-sn-glycero-3-phosphocoline, cholesterol, 1,2
dipalmitoyl-sn-glycero-3-phosphoglycerol (molar ratio of
3:4:3), were used in control experiments. To investigate the
effects of liposomal shell alone, empty anionic pegylated
liposomes (COATSOME EL-01-PA series), conjugated or not
with the LDL receptor-targeted peptide, were used.
The size of the liposomes was evaluated by dynamic light
scattering: 10 mL of liposome suspension were diluted in 1 mL
of 120 mmol·L-1 NaCl solution and analysed with an ALV-
NIBS dynamic light scattering instrument (Langen, Germany)
provided with a Ne–He laser and an ALV-5000 multiple tau
digital correlator. The scattered light intensity was recorded
for 30 s on suspensions at 37°C. The hydrodynamic radius of
liposomes was evaluated by using both the cumulant method
and the CONTIN algorithm (Provencher, 1982). The mean
radius of each liposomal preparation is presented in Table 1.
The morphological analysis of apo-Lipodox was per-
formed on diluted samples (5 mg·mL-1 liposomes in
120 mmol·L-1 NaCl solution), using a Philips CM10 transmis-
sion electron microscope (TEM; Philips Amsterdam, The
Netherlands), at an acceleration voltage of 80 kV. For each
sample, a minimum of three microscopic fields was
examined.
Permeability coefficient across the BBB cells
The permeability to inulin, taken as a parameter of the integ-
rity of the tight junctions (Monnaert et al., 2004), was meas-
ured on hCMEC/D3 cells seeded at 50 000·cm-2 and grown
for 7 days up to confluence in 6-multiwell Transwell devices
(0.4 mm diameter pores-size, Corning Life Sciences, Chorges,
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France). Cells were incubated with or without mevastatin or
simvastatin (0.1 mmol·L-1 for 24 h) or b-methyl-ciclodextrin
(10 mmol·L-1 for 3 h), then the culture medium was replaced
in the upper and lower chambers and 2 mCi·mL-1 [14C]-inulin
(10 mCi·mmol-1; PerkinElmer) was added to the upper
chamber of Transwell. After 3 h, the medium in the lower
chamber was collected and the amount of [14C]-inulin was
measured using a Tri-Carb Liquid Scintillation Analyzer (Perk-
inElmer). Radioactivity was converted to nmol inulin·cm-2,
using a calibration curve prepared previously.
For doxorubicin permeability, hCMEC/D3 cells seeded as
reported above, were incubated with or without mevastatin
or simvastatin (0.1 mmol·L-1 for 24 o 48 h). After this period,
the culture medium was replaced in the upper and lower
chambers and 5 mmol·L-1 doxorubicin or apo-Lipodox were
added in the upper chamber of Transwell for 3 h, then the
medium in lower chamber was collected and the amount of
doxorubicin was measured fluorimetrically, using a LS-5 spec-
trofluorimeter (PerkinElmer). Excitation and emission wave-
lengths were 475 nm and 553 nm, respectively. Fluorescence
was converted in nmol doxorubicin·cm-2, using a calibration
curve previously set.
The permeability coefficients were calculated as described
previously (Siflinger-Birnboim et al., 1987).
Intratumour drug accumulation and toxicity
in co-culture models
The hCMEC/D3 cells (50 000·cm-2) were grown for 7 days up
to confluence in 6-multiwell Transwell devices (0.4 mm diam-
eter pores-size), whereas in the lower chamber, 500 000 cells
(U87-MG, SJKNP, A549 or MDA-MB-231 cells) were seeded at
day 4. At day 7, 0.1 mmol·L-1 simvastatin was added to the
upper chamber medium for 48 h, when indicated. During the
final 24 h, 5 mmol·L-1 doxorubicin or apo-Lipodox were added
into the upper chamber of Transwell, then the inserts were
removed and the extracellular medium of cells in the lower
chamber was checked for the LDH activity, taken as an index
of cytotoxicity and necrosis (Kopecka et al., 2011). Cells in
the lower chamber were detached, and divided into two aliq-
uots of 250 000 cells each: the first aliquot was lysed in
0.5 mL ethanol/HCl 0.3 N (1:1 v v-1) and analysed for the
intracellular content of doxorubicin, as reported above.
Results are expressed as nmol doxorubicin·mg-1 cell proteins.
The second aliquot was lysed in 0.5 mL of caspase lysis buffer
(20 mmol·L-1 HEPES/KOH, 10 mmol·L-1 KCl, 1.5 mmol·L-1
MgCl2, 1 mmol·L-1 EGTA, 1 mmol·L-1 EDTA, 1 mmol·L-1 DTT,
1 mmol·L-1 PMSF, 10 mg·mL-1 leupeptin; pH 7.5). Then 20 mg
cell lysates were incubated for 1 h at 37°C with 20 mmol·L-1
of the fluorogenic substrate of caspase 3, DEVD-7-amino-
4-methylcumarine (DEVD-AMC), in 0.25 mL caspase
assay buffer (25 mmol·L-1 HEPES, 0.1% w v-1 3-[(3-
cholamidopropyl ) dimethylammonio ] - 1 - propanesulfonate
CHAPS, 10% w v-1 sucrose, 10 mmol·L-1 DTT, 0.01% w v-1 egg
albumin; pH 7.5). The reaction was stopped by adding
0.75 mL ice-cold 0.1% w v-1 trichloroacetic acid and the fluo-
rescence of the AMC fragment released by active caspase-3
was read using a LS-5 spectrofluorimeter (PerkinElmer). Exci-
tation and emission wavelengths were 380 nm and 460 nm
respectively. Fluorescence was converted in pmol·mg-1 cell
protein using a calibration curve prepared previously with
standard solutions of AMC.
For fluorescence microscope analysis, tumour cells in the
lower chamber were seeded on sterile glass coverslips and
treated as reported above. At the end of the incubation time,
samples were rinsed with PBS, fixed with 4% w v-1 parafor-
maldehyde for 15 min, washed three times with PBS and
incubated with 4′,6-diamidino-2-phenylindole dihydrochlo-
ride (DAPI) for 3 min at room temperature in the dark. Cells
were washed three times with PBS and once with water, then
the slides were mounted with 4 mL of Gel Mount Aqueous
Mounting and examined with a Leica DC100 fluorescence
microscope (Leica Microsystems GmbH, Wetzlar, Germany).
For each experimental point, a minimum of five microscopic
fields were examined.
Statistical analysis
All data in the text and figures are presented as means  SD.
The results were analysed by a one-way ANOVA. A P < 0.05
was considered significant.
Results
Statins induce the synthesis of NO in human
primary BBB cells by a RhoA/RhoA
kinase/NF-kB-dependent mechanism
As inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase enzyme, statins decrease the synthesis of cholesterol
Table 1
Dynamic light scatter analysis of liposomes
Liposomesa Acronymb Doxorubicin PEG Peptide Radius (mean  SD) P.I.c
COATSOME EL01A – Yes No Yes 70.05 nm  22.45 nm 0.187
COATSOME EL-01-PA Lipodox Yes Yes No 70.63 nm  28.55 nm 0.183
COATSOME EL-01-PA apo-Lipodox Yes Yes Yes 72.05 nm  23.14 nm 0.180
COATSOME EL-01-PA EL No Yes No 69.57 nm  27.35 nm 0.171
COATSOME EL-01-PA apoEL No Yes Yes 71.77 nm  18.71 nm 0.177
aCommercial name (NOF Corporation).
bAcronyms used in text and figures.
cPolydispersity Index.
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and isoprenoids like farnesyl pyrophosphate and GGPP in
mammalian cells (Liao and Laufs, 2005). We observed in solid
tumours that a decrease in GGPP reduces the activity of small
GTPase of the RhoA family, activates the NF-kB transcription
factor and up-regulates the inducible NO synthase (iNOS/NOS
II) gene (Riganti et al., 2006; Riganti et al., 2008). The human
brain microvascular endothelial hCMEC/D3 cells were sensi-
tive to both mevastatin and simvastatin, two lipophilic statins
that reduced the endogenous synthesis of cholesterol and
GGPP in a dose- and time-dependent manner (Figure 1A). The
lowest concentration that significantly decreased cholesterol
and GGPP level after 24 h was 0.1 mmol·L-1 and this was
chosen for all the subsequent experiments. The cholesterol
chelator b-methyl-cyclodextrin significantly depleted the
cell membrane of cholesterol (Supporting information
Figure S1A) and in parallel disrupted the integrity of the tight
junctions in hCMEC/D3 cells, as demonstrated by the
increased permeability coefficient of inulin (Supporting infor-
mation Figure S1B). In the experimental conditions used in
this study, mevastatin and simvastatin reduced the amount of
cholesterol in the cell membrane by a lesser extent than
b-methyl-cyclodextrin (Supporting information Figure S1A)
and did not affect the permeability to inulin (Supporting
information Figure S1B).
In keeping with the decrease in GGPP, the activity of the
geranylgeranylated protein RhoA, measured as the amount of
active GTP-bound protein, was reduced by both statins,
resulting in a lower activation of the downstream effector
RhoA kinase (Figure 1B). In parallel, the amount of IKKa/b
complex phosphorylated on serine 176/180, which was
nearly undetectable in untreated hCMEC/D3 cells, was
increased by mevastatin and simvastatin, without significant
changes in the expression of IKKa/b protein (Figure 1C). Such
an increase was accompanied by a decrease in the inhibitory
protein Ik-Ba (Figure 1C) and by the activation of NF-kB,
measured as the ability of the transcription factor translo-
cated into the nucleus to bind its specific target sequence
(Figure 1D).
Differently from the constitutive NOS isoforms (neuronal
NOS/NOS I and endothelial NOS/NOS III), the inducible
iNOS/NOS II is usually absent in non-stimulated cells and is
up-regulated by different stimuli, like cytokines and bacterial
lipopolysaccharide that induce the activation of NF-kB (Pautz
et al., 2010). Statins increased the expression of NOS II; this
was undetectable in untreated hCMEC/D3 cells (Figure 1E).
The statins did not induce NOS I and did not change the
expression of NOS III, but a slight increase in the amount of
the active phospho-(Ser1177)-NOS III was detected following
statins treatment (Figure 1E). As a consequence of these
changes, the global enzymatic activity of NOS in cell lysates
and the synthesis of NO, measured as the amount of the
stable NO-derivative nitrite in culture supernatant, were sig-
nificantly increased in hCMEC/D3 cells treated with mevas-
tatin or simvastatin (Figure 1F).
Statins reduce the activity of Pgp and BCRP
and increase the permeability of doxorubicin
across the BBB cells by a NO-dependent
mechanism
hCMEC/D3 cells constitutively express several ABC transport-
ers (Carl et al., 2010), like Pgp/ABCB1, MRP1/ABCC1, BCRP/
ABCG2 (Figure 2A). The immunoprecipitation of membrane
extracts with an anti-nitrotyrosine antibody, followed by the
Western blot detection with the specific primary antibodies,
revealed that mevastatin and simvastatin promoted a nitra-
tion on tyrosine of Pgp/ABCB1 and BCRP/ABCG2, similar to
the one produced by the NO donor sodium nitroprusside
(Figure 2A). Both these transporters also showed a low level of
nitration in untreated cells, whereas no nitration was detect-
able on MRP1/ABCC1 in each experimental condition. In
parallel the ATPase activity of Pgp/ABCB1 and BCRP/ABCG2,
but not that MRP1/ABCC1, was decreased in the presence of
the statins (Figure 2B), suggesting that the nitration probably
impairs the catalytic cycle of the pumps. Indeed, the intrac-
ellular retention of rhodamine 123 (Figure 2C) that is
inversely related to the activity of Pgp/ABCB1, and the intra-
cellular retention of Hoechst 33342 (Figure 2D) that is
inversely related to the activity of BCRP/ABCG2, were both
increased by the statins. Although the tyrosine nitration and
the decrease in ATPase activity in Pgp/ABCB1 and BCRP/
ABCG2 were already detectable after 24 h of incubation with
mevastatin or simvastatin (Figure 2A and B) and were not lost
after 48 h (data not shown), the effects of these changes on
the activity of Pgp/ABCB1 and BCRP/ABCG2 were stronger
after 48 h (Figure 2C and D).
As doxorubicin is transported by Pgp/ABCB1, MRP1/
ABCC1 and BCRP/ABCG2, its ability to cross the BBB cells is
poor in vivo; also in hCMEC/D3 cells, the permeability coef-
ficient was low (Figure 2E). However, the treatment with
statins for 48 h significantly increased the permeability of
the drug. The presence of the NO scavenger 2-phenyl-
4,4,5,5,tetramethylimidazoline-1-oxyl 3-oxide (PTIO) pre-
vented the increase in permeability to doxorubicin
(Figure 2E), suggesting that NO levels play a crucial role in
regulating the activity of Pgp/ABCB1 and BCRP/ABCG2 in
hCMEC/D3 cells.
The association of statins plus a LDL
receptor-targeted liposome-encapsulated
doxorubicin further increases the drug
transport across BBB cells
By lowering the de novo synthesis of cholesterol, statins force
mammalian cells to expose the LDL receptor on their surface
(Liao and Laufs, 2005). In hCMEC/D3 cells treated with mev-
astatin and simvastatin, the mRNA level for LDL receptors
was significantly increased after 24 h (Figure 3A), a time point
at which the synthesis of cholesterol was decreased
(Figure 1A). The amount of LDL receptor protein on the cell
surface was further increased by statins after 48 h (Figure 3B).
We have previously shown that anionic pegylated lipo-
somes loaded with doxorubicin and conjugated with a syn-
thetic peptide containing the LDL receptor-binding site from
human apo-B100 (the so-called ‘apo-Lipodox’) was internal-
ized efficiently via a LDL receptor-mediated endocytosis and
was less extruded by Pgp/ABCB1 in solid tumour cells
(Kopecka et al., 2011). We thus applied apo-Lipodox that
appeared as round-shaped particles with electron-dense areas
due to the doxorubicin packed inside the liposomal shell
(Figure 3C), to hCMEC/D3 cells untreated or treated with
mevastatin and simvastatin for 48 h. In control cells, the
permeability coefficient of apo-Lipodox was higher than that
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Figure 1
Effects of statins on cholesterol and GGPP synthesis, RhoA/RhoA kinase activity, NF-kB pathway and NO synthesis in BBB cells. (A) Cholesterol and
GGPP synthesis. hCMEC/D3 cells were incubated in the absence (CTRL) or presence of different concentrations of 0.1, 1, 10 mmol·L-1 mevastatin
(MVS) and simvastatin (SIM) for 24 h (left panel), or in the presence of 0.1 mmol·L-1statin for 12, 24 or 48 h (right panel). In the subsequent 24 h,
the cells were labelled with [3H]-acetate, then cholesterol (open columns) and GGPP (hatched columns) synthesis was measured as reported under
Methods. Data are presented as means  SD (n = 3). Versus CTRL: *P < 0.05. For the subsequent experiments, 0.1 mmol·L-1MVS or SIM for 24 h
was used. (B) RhoA/RhoA kinase activity. Samples were subjected to ELISA assays to measure the amount of RhoA-GTP (open bars) and the activity
of RhoA kinase (hatched bars). The experiments were performed in duplicate, as described in the Methods section. Data are presented as means
 SD (n = 3). Versus CTRL: *P < 0.05. (C) Western blot detection of phospho-Ser(176/180)-IKK a/b, IKK a/b and IkB-a protein in extracts from
hCMEC/D3 cells. The expression of GAPDH was used to check the equal protein loading. The figure is representative of three experiments with
superimposable results. (D) NF-kB activity. The activity of NF-kB was detected in the nuclear extracts measuring the DNA-binding capacity of NF-kB
on its target sequence (see Methods). Measurements were performed in duplicate and data are presented as means  SD (n = 3). Versus CTRL:
*P < 0.05. (E) Western blot detection of NOS isoforms (nNOS/NOS I; iNOS/NOS II; eNOS/NOS III) and of phospho-(Ser 1177)eNOS/NOS III
protein in extracts from hCMEC/D3 cells. The expression of GAPDH was used to check the equal protein loading. The figure is representative of
three experiments with superimposable results. (F) NO synthesis. NOS activity in cell lysates and nitrite accumulation in the extracellular medium
were measured by use of spectrophotometric assays, as reported in Methods. Data are presented as means  SD (n = 3). Versus CTRL: *P < 0.05.
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Figure 2
Effects of statins on ABC transporters activity and doxorubicin permeability across BBB cells. The hCMEC/D3 cells were incubated in the absence
(CTRL) or presence of 0.1 mmol·L-1mevastatin (MVS) or simvastatin (SIM) for 24 h or 48 h, then subjected to the following investigations. (A)
Nitration of ABC transporters. After a 24 h incubation, cells were lysed and the whole cell extracts were immunoprecipitated with an anti-
nitrotyrosine polyclonal antibody. The immunoprecipitated proteins were subjected to Western blotting, using an anti-Pgp, an anti-MRP1 or an
anti-BCRP antibody (see Methods). The NO donor sodium nitroprusside (100 mmol·L-1 for 24 h, SNP) was used as a positive control of nitration.
The figure is representative of three experiments with similar results. (B) ATPase activity was measured spectrophotometrically after immunopre-
cipitation of Pgp, MRP1, BCRP from membrane fractions, as described in the Methods. Measurements were performed in duplicate and data are
presented as means  SD (n = 3). Versus CTRL: *P < 0.05. (C) Rhodamine assay. Cells were incubated for 20 min at 37°C with the fluorescent Pgp
substrate rhodamine 123. The intracellular fluorescence was assessed by flow cytometry analysis in untreated cells (grey peak) and in cells treated
with statins for 24 h (dotted line) or 48 h (continuous line). The figures shown here are representative of three similar experiments performed in
duplicate. (D) Hoechst 33342 assay. Cells were incubated for 15 min at 37°C with Hoechst 33342, lysed and analysed fluorimetrically for the
intracellular content of the dye. Measurements were performed in duplicate and data are presented as mean  SD (n = 3). Versus CTRL: *P < 0.05.
(E) Transport of doxorubicin across BBB monolayer. hCMEC/D3 cells were grown up to the confluence in Transwell insert, in fresh medium or in
the presence of statins for 48 h, alone or co-incubated with the NO scavenger PTIO (100 mmol·L-1). 5 mmol·L-1doxorubicin was then added in the
upper chamber. After 3 h, the medium was recovered by the lower chamber and the amount of doxorubicin was measured fluorimetrically.
Measurements were performed in duplicate and data are presented as means SD (n = 4). Versus CTRL: *P < 0.05; versus condition without PTIO:
°P < 0.001.
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Figure 3
Effects of statins on the expression of LDL receptors and on the permeability of LDL receptor-targeted liposomal doxorubicin across the BBB. The
hCMEC/D3 cells were incubated in the absence (CTRL) or presence of 0.1 mmol·L-1mevastatin (MVS) or simvastatin (SIM) for 24 h (A, B), 48 h (B,
D and E), then subjected to the following investigations. (A) RT-PCR of LDL receptors. Total RNA was extracted, reverse transcribed and amplified
by RT-PCR, as indicated in Methods. Measurements were performed in triplicate and data are presented as means  SD (n = 3). Versus CTRL:
*P < 0.005. (B) Flow cytometry analysis of surface LDL receptors in untreated cells (grey peak) or treated with MVS (continuous line) or SIM (dotted
line) for 48 h. The figures shown here are representative of 3 similar experiments, performed in triplicate. (C) Apo-Lipodox imaging by TEM. The
micrographs (28 500¥ magnification) are representative of three similar experiments. (D) Transport of apo-Lipodox across the BBB monolayer. The
hCMEC/D3 cells were grown to the confluence in Transwell insert, in fresh medium or in the presence of statins or of the NO scavenger PTIO
(100 mmol·L-1 for 48 h), then 5 mmol·L-1 apo-Lipodox was added in the upper chamber. After 3 h, the amount of the drug recovered by the lower
chamber medium was measured fluorimetrically. Measurements were performed in duplicate and data are presented as means  SD (n = 4).
Versus CTRL: *P < 0.005; versus condition without PTIO: °P < 0.001. (E) Transport of Lipodox and apo-Lipodox across the BBB monolayer. The
hCMEC/D3 cells were grown up to the confluence in Transwell insert, in fresh medium or in the presence of SIM, then 5 mmol·L-1 Lipodox or
apo-Lipodox was added in the upper chamber. When indicated, the free LDL receptor-targeted apoB100 peptide (the same that was conjugated
with apo-Lipodox), was co-incubated with the liposomes (100 mmol·L-1; B100). After 3 h, the amount of doxorubicin recovered by the lower
chamber medium was measured fluorimetrically. Measurements were performed in duplicate and data are presented as means  SD (n = 3).
Versus CTRL: *P < 0.005; versus SIM: °P < 0.05.
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of free doxorubicin (see Figures 2E and 3D; comparing these
data the significance of apo-Lipodox vs. doxorubicin was P <
0.005). The transport of apo-Lipodox across the BBB monol-
ayer was even higher than that of free doxorubicin in cells
exposed to statins (Figures 2E and 3D; significance of apo-
Lipodox vs. doxorubicin in statin-treated cells: P < 0.001).
Again, the addition of PTIO dramatically decreased the per-
meability of apo-Lipodox, suggesting that the NO levels – and
the consequent status of nitration on ABC transporters – are
also critical for the transport of apo-Lipodox in hCMEC/D3
cells.
In addition to the increased intracellular retention due to
the inhibition of ABC transporters, we also investigated
whether an increased uptake by LDL receptor-mediated endo-
cytosis was critical in determining the greater permeability of
apo-Lipodox. Apo-Lipodox exhibited a mean concentration
of LDL receptor-targeted peptide of 20  1.6 mg·mL-1, corre-
sponding to about 3 ¥ 1012 peptides·mL-1 (n = 3).
The permeabilities of Lipodox (liposomal doxorubicin
without the LDL receptor-targeted peptide) and apo-Lipodox
were similar in untreated hCMEC/D3 cells and were unaf-
fected by an excess of free LDL receptor-targeted peptide
under basal conditions (Figure 3E). However, apo-Lipodox
crossed the BBB monolayer at a significantly higher rate when
cells where pre-incubated with simvastatin, which increased
the amount of LDL receptors (Figure 3A and B); this transport
was dramatically decreased by the competing free LDL
receptor-targeted peptide (Figure 3E). In contrast, Lipodox
permeability was the same in the presence of simvastatin or
of the competing peptide (Figure 3E), suggesting that the
uptake of non-targeted liposomes was not dependent on the
LDL receptor-mediated endocytosis.
To assess whether the presence of PEG influences the
attachment of the LDL receptor-targeted peptide to the lipo-
somal shell and/or the binding to the LDL receptor, parallel
experiments were performed with anionic non-pegylated
liposomes. These particles did not significantly differ in their
radius (Table 1) or in the amount of peptide attached (22 
1.9 mg·mL-1; n = 3). The permeability of pegylated and non-
pegylated apo-Lipodox was superimposable in both untreated
and simvastatin-treated hCMEC/D3 cells (Supporting infor-
mation Figure S2), suggesting that the presence of PEG did
not interfere with the attachment of LDL receptor-targeted
peptide or with the liposome uptake, either by simple endo-
cytosis or LDL receptor-mediated endocytosis.
Empty liposomes may affect different intracellular path-
ways modulating the activity of Pgp/ABCB1 in epithelial cells
(Riganti et al., 2011). To clarify whether empty liposomes
affected the activation of NF-kB, the synthesis of nitrite, the
activity of NOS enzyme, the induction of necrosis or apop-
tosis, we measured these parameters (Supporting information
Figure S3A–C) in hCMEC/D3 cells, exposed to the same
empty anionic pegylated liposomes used for apo-Lipodox,
conjugated or not with the LDL receptor-targeted peptide.
None of the liposomal formulations modified the above
parameters compared to the untreated cells. Furthermore,
when we co-incubated free doxorubicin with empty lipo-
somes, with or without the LDL receptor-targeted peptide, in
hCMEC/D3 cells pretreated or not with simvastatin
(0.1 mmol·L-1 for 48 h), we did not detect a different perme-
ability compared with free doxorubicin alone (Supporting
information Figure S3D). We thus excluded a permeabilizing
effect exerted by the liposomal shell itself.
The association of statins plus LDL
receptor-targeted liposome-encapsulated
doxorubicin is effective at delivering
doxorubicin into tumour cells co-cultured
with BBB cells
The abundance of ABC transporters on primary CNS
tumours, on cerebral metastasis of epithelial solid tumours
and on BBB cells determines a poor response to chemo-
therapy. To clarify if the association of statins and apo-
Lipodox can overcome such resistance, we produced
co-culture models by growing hCMEC/D3 cells on Transwell
insert and tumour cells – that is, human glioblastoma multi-
forme U87-MG cells, human neuroblastoma SJKNP cells,
human invasive breast cancer MD-MBA-231 cells and human
non-small cells lung cancer A549 cells – in the lower chamber.
A preliminary characterization of these cell lines showed
that they all expressed at various levels Pgp/ABCB1, MRP1/
ABCC1 and BCRP/ABCG2 (Figure 4A), and that simvastatin
did not modify the amount of these transporters (Figure 4A)
but increased the surface LDL receptors (Figure 4B). Whereas
the intracellular content of free doxorubicin was low in all
the cell lines (giving a fluorescence similar to the autofluo-
rescence of untreated cells, Figure 4C) and not sufficient to
elicit cytotoxicity (Figure 4C), apo-Lipodox was accumulated
to higher extent, exerting significant cell damage, as revealed
by the release of LDH in the culture supernatant. The addi-
tion of simvastatin to free doxorubicin enhanced the drug
retention and the LDH release compared to doxorubicin
alone. For all the cell lines, the maximal increase in these
parameters was achieved by the combination of simvastatin
plus apo-Lipodox (Figure 4C).
When added to the upper chamber of the Transwell con-
taining confluent hCMEC/D3 cells on the insert and U87-MG
in the lower chamber, doxorubicin poorly entered glioblas-
toma cells, as shown by the low red fluorescence in U87-MG
cells recovered by the lower chamber (Figure 5A); the drug
delivery into tumour cells was improved by pretreating BBB
cells with simvastatin for 48 h followed by doxorubicin or
apo-Lipodox in the last 24 h. The strongest fluorescent signal
was achieved by the association of simvastatin (for 48 h) plus
apo-Lipodox (in the last 24 h; Figure 5A).
Quantitative fluorimetric analysis of intratumour doxoru-
bicin confirmed that the drug content was significantly
higher when simvastatin was combined with apo-Lipodox
rather than with doxorubicin in all the cell lines co-cultured
with hCMEC/D3 cells (Figure 5B). In keeping with these
results, doxorubicin alone did not exert any relevant cyto-
toxic effect in tumour cells, in terms of LDH release
(Figure 5B) and caspase-3 activation (Figure 5C). The associa-
tion of free doxorubicin plus statin or the use of apo-Lipodox,
two experimental conditions that increased the intracellular
amount of doxorubicin in the cell lines without a BBB mon-
olayer (Figure 4C), were significantly less effective in the pres-
ence of BBB monolayer (Figure 5B), although apo-Lipodox
increased the release of LDH in all the cell lines and induced
the activation of caspase-3 in A549 and SJKNP cells
(Figure 5C). Also in BBB-tumour cells co-cultures, the
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Figure 4
Characterization of different CNS- and non-CNS-derived tumour cells for ABC transporters expression, surface LDL receptors and resistance to
doxorubicin. Human glioblastoma U87-MG cells, human neuroblastoma SJKNP cells, human breast cancer MDA-MB-231, human lung cancer
A549 cells were grown in the absence (CTRL) or presence of simvastatin (0.1 mmol·L-1for 48 h; SIM). When indicated, 5 mmol·L-1doxorubicin
(DOXO) or apo-Lipodox (APOLIPO) were added in the last 24 h. (A) Western blot analysis of ABC transporters. The expression of Pgp, MRP1 and
BCRP on whole cells extracts was detected by Western blotting. The expression of GAPDH was used to check the equal protein loading. The figure
is representative of three experiments with superimposable results. (B) Flow cytometry analysis of surface LDL receptors in untreated cells (dotted
line) or SIM-treated cells (continuous line). Negative controls, with non-immune isotypic antibodies, are represented by the grey peak. The figures
shown here are representative of two similar experiments, each performed in duplicate. (C) Intracellular doxorubicin accumulation and toxicity.
Culture supernatant was checked for the extracellular activity of LDH; cells were detached and lysed to quantify the intracellular amount of
doxorubicin, as described in Methods. The hatched columns in the conditions ‘CTRL’ and ‘SIM’ refer to the cell autofluorescence, measured in
the absence of doxorubicin or apo-Lipodox administration. Measurements were performed in duplicate and data are presented as means  SD
(n = 3). Versus CTRL: *P < 0.05.
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Figure 5
Drug delivery and antitumour efficacy of statins plus LDL receptor-targeted liposomal doxorubicin in co-culture models. The hCMEC/D3 cells were
grown for 7 days up to confluence in Transwell inserts, whereas U87-MG, SJKNP, A549 or MDA-MB-231 cells were seeded at day 4 in the lower
chamber. At day 0, supernatant in the upper chamber was replaced with fresh medium without (CTRL) or with simvastatin (0.1 mmol·L-1for 48 h;
SIM). 5 mmol·L-1doxorubicin (DOXO) or apo-Lipodox (APOLIPO) were added in the upper chamber of Transwell in the last 24 h, then the following
investigations were performed. (A) Microscope analysis of doxorubicin accumulation. U87-MG cells were seeded on sterile glass coverslips, treated
as reported above, then analysed by fluorescence microscopy to detect the intracellular accumulation of doxorubicin. The cells were also
counterstained with the nuclear fluorescent probe DAPI. The micrographs are representative of three experiments with similar results. (B) Culture
supernatant of tumour cells was checked for the extracellular activity of LDH, cells were detached and lysed to quantify the intracellular amount of
doxorubicin, as described in Methods. The hatched columns of the conditions ‘CTRL’ and ‘SIM’ refer to the cell autofluorescence, measured in the
absence of doxorubicin or apo-Lipodox administration. Measurements were performed in duplicate and data are presented as means SD (n = 4).
Versus CTRL: *P < 0.05. (C) Apoptosis induction. The activation of caspase-3 in tumour cells lysates was measured fluorimetrically as described in the
Methods section. Measurements were performed in duplicate and data are presented as means  SD (n = 3). Versus CTRL: *P < 0.05.
BJP ML Pinzón-Daza et al.
1442 British Journal of Pharmacology (2012) 167 1431–1447
association of simvastatin plus apo-Lipodox was the most
effective at achieving a significant delivery of doxorubicin
(Figure 5B) and inducing cell death by both necrosis
(Figure 5B) and apoptosis (Figure 5C). Free doxorubicin
co-incubated with empty liposomes, with or without the LDL
receptor-targeted peptide, did not accumulate within
U87-MG cells more than doxorubicin alone, either in the
absence or in the presence of simvastatin (Supporting infor-
mation Figure S4A). Similarly, the death of glioblastoma cells,
measured as release of LDH and activation of caspase-3, was
not increased by the addition of free doxorubicin to empty
liposomes (Supporting information Figure S4B).
Discussion and conclusions
The therapeutic management of CNS tumours, currently
based on surgery, radiotherapy and chemotherapy, is not
completely safe and compatible with an acceptable quality of
life. Chemotherapy is the first choice in disseminated
tumours, such as invasive glioblastoma, high-risk medullob-
lastoma or multiple metastasis, but the percentage of success
remains low. New targeted therapies, anti-angiogenic thera-
pies or gene therapies show a real benefit only in limited
groups of patients with known specific molecular defects
(Sathornsumetee et al., 2007; Rossi et al., 2008). Thereby, the
development of new pharmacological therapies for CNS
tumours is still needed.
The low drug delivery across BBB and the low drug accu-
mulation within the tumour are among the main factors that
decrease the efficacy of chemotherapy in primary and meta-
static brain tumours. In addition, having no fenestrations
and many tight junctions, the brain microvascular endothe-
lium has high levels of drug efflux pumps of the ABC trans-
porter family (Declèves et al., 2006; Mercer et al., 2009; Robey
et al., 2010). The latter have also been identified in CNS
tumours (Nakagawa et al., 2009), where they contribute to
the frequently observed chemoresistance. Therefore, an effec-
tive pharmacological therapy for CNS malignancies should
overcome the extrusion of the drugs from both endothelial
and tumour cells. In this perspective, we suggest a new com-
bination approach, based on the association of statins plus
LDL receptor-targeting liposomal drug, starting from two
considerations: (i) both statins and liposomal drugs have
chemosensitizer properties in solid tumours; (ii) liposomal
drugs are delivered across the BBB more easily than free drugs.
We have previously observed that in cancer cells, statins
increase the synthesis of NO, which inhibits ABC transporters
efflux (Riganti et al., 2005; Riganti et al., 2006; Riganti et al.,
2008), and decrease the amount of membrane cholesterol,
which also lowers the activity of Pgp/ABCB1 (Kopecka et al.,
2011).
In the past few years, statins have been proposed as drugs
with potential benefits in cerebrovascular and neurodegen-
erative diseases, but to our knowledge, whether they have
effects on the transport functions of brain microvascular
endothelium has not been investigated. We found here that
in human BBB cells, the lipophilic statins mevastatin and
simvastatin decreased the synthesis of cholesterol and isopre-
noids and reduced the amount of cholesterol in plasma mem-
brane. This event has been previously linked to the loss of
integrity of tight junctions and to the increased paracellular
leakage of drugs across the BBB monolayer (Monnaert et al.,
2004). In our work, we observed that a strong decrease in
membrane cholesterol, caused by b-methyl-cyclodextrin,
actually impaired the integrity of tight junctions in
hCMEC/D3 cells, but the smaller variations of membrane
cholesterol produced by statins did not. According to these
data, it seems unlikely that statins – at least at the concen-
trations used in this study – increase the paracellular trans-
port across BBB. At low (micromolar) concentrations, that is,
in keeping with the Ki of statins for 3-hydroxy-3-
methylglutaryl coenzyme A reductase (Liao and Laufs, 2005),
mevastatin and simvastatin lowered the synthesis of isopre-
noids in hCMEC/D3 cells and decreased the activity of
RhoGTPase. In parallel, they increased the synthesis of NO,
by up-regulating the IKK/NF-kB-mediated expression of
iNOS/NOS II and by enhancing the phosphorylation on
serine 1177 of eNOS/NOS III. The effects exerted by RhoA
on NF-kB and NO synthesis are highly variable and depend
on cell type (Nakata et al., 2007; Ahn et al., 2008; 32: Ye et al.,
2008). Lovastatin has been reported to inhibit RhoA, stimu-
late the activity of IKK-a and NF-kB and enhance the expres-
sion of iNOS in rat glioma cells (33: Rattan et al., 2003); we
hypothesize that such a mechanism occurs also in our model.
It has been also shown that RhoA kinase reduces the stability
of eNOS mRNA and prevents the Akt-dependent phosphor-
ylation of eNOS (Rikitake and Liao, 2005). In accord with
these observations, we detected an increased phosphoryla-
tion of eNOS in BBB cells treated with statins that inhibited
RhoA kinase. This event, together with the up-regulation of
iNOS isoform, led to a significant increase in NO levels and
this suggests that this is the mechanism by which statins
reduce the vascular tone and increase cerebral flow, as inhibi-
tors of Rho kinase produce similar effects (Rikitake et al.,
2005).
A high blood flow usually ensures better delivery of anti-
cancer drugs within tumour areas and better tumour oxy-
genation enhances the cytotoxicity of many anticancer drugs
including doxorubicin. In addition to these theoretical ben-
efits, the increased production of NO elicited by the statins
reduced the activity of at least two proteins – Pgp/ABCB1 and
BCRP/ABCG2 – that are involved in the apical extrusion of
drugs in hCMEC/D3 cells (Tai et al., 2009) and in vivo
(Declèves et al., 2006; Mercer et al., 2009; Robey et al., 2010).
Activators of endogenous NO synthesis, such as lipopoly-
saccharide, TNF-a and endothelin-1, as well as the NO donor
SNP, are known to affect Pgp/ABCB1 in rat brain capillaries,
producing a decrease in the transporter expression and activ-
ity after a 3 h incubation (Bauer et al., 2007; Hartz et al., 2007)
followed by an increase at 6 h (Bauer et al., 2007). Since the
expression of Pgp/ABCB1 is subjected to rapid changes in BBB
cells (Bauer et al., 2007; Hawkins et al., 2010), we cannot
exclude the possibility that the NO synthesis induced by
statins produces a decrease in Pgp/ABCB1 expression at
earlier time points (e.g. less than 6 h), followed by a return to
a ‘steady state’ at 24 h. Furthermore, the effects of NO are
highly dependent on the species studied and on the amount
and rate of NO released (Huerta et al., 2008). This variability
may explain some apparently contrasting findings, that is, a
high concentration of exogenous NO for 6 h increased the
expression of Pgp/ABCB1 in rat endothelial cells (Bauer et al.,
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2007), whereas weak inducers of NOS II like statins did not
produce any change of Pgp/ABCB1 expression in human
hCMEC/D3 cells after 24 h (Figure 2A). Such low levels of
endogenous NO, however, were sufficient to elicit a detect-
able nitration of the transporter, which decreased its activity.
The reduction was even more pronounced after 48 h, indi-
cating that statins induce a persistent inhibition of Pgp/
ABCB1 activity after a longer time. As we considered the
prolonged half-life of Pgp/ABCB1 in low-serum mediums
(Zhang and Ling, 2000), the standard culture condition for
hCMEC/D3 cells, we expected the reduction in activity of the
ABC pumps to be higher at 48 h than at 24 h, although a
clear nitration of the pump was already detectable after 24 h.
The reversal of statins’ effects by the NO scavenger PTIO
suggests that the persistent inhibition of Pgp/ABCB1 and
BCRP/ABCG2 activity was due to a continuous synthesis of
NO by hCMEC/D3 cells.
Since in other models of BBB, the rate of drug efflux was
NO independent (Salkeni et al., 2009), we cannot exclude a
priori that statins also reduce the activity of ABC transporters
by other mechanisms, for example, by decreasing the Pgp/
ABCB1 expression and glycosylation (Sieczkowski et al.,
2010) or by reducing the amount of cholesterol in the plasma
membrane, an event that impairs the activity of Pgp/ABCB1
(Troost et al., 2004; Kopecka et al., 2011). Whatever the pleio-
tropic effects of statins on ABC transporters are, the final
result of treating BBB cells with statins was a dramatic
increase in the permeability of doxorubicin, a substrate of
both Pgp/ABCB1 and BCRP/ABCG2.
In all mammalian cells, statins also up-regulate the tran-
scription and surface exposure of LDL receptors, offering a
flexible method of designing specific, nanoparticle-based tar-
geted therapies. We have previously validated the efficacy of
an engineered LDL receptor-targeted liposome-encapsulated
doxorubicin (‘apo-Lipodox’) in solid tumours with high
expression of LDL receptors (Kopecka et al., 2011). Besides
being taken up more by LDL receptor-driven endocytosis
(Kopecka et al., 2011), liposomal particles alter the lipid com-
position of the plasma membrane microdomains (i.e. lipid
rafts) where Pgp/ABCB1 is active, interfere with ATP hydroly-
sis and substrate binding, and elicit a lower extrusion of
doxorubicin in Pgp-overexpressing cells (Riganti et al., 2011).
In untreated hCMEC/D3 cells, the permeability for apo-
Lipodox was significantly greater than that of free doxoru-
bicin, probably as a consequence of the decreased efflux via
Pgp/ABCB1 and of the increased uptake. Since both the non-
LDL receptor-targeted Lipodox and the LDL receptor-targeted
apo-Lipodox had a higher uptake than free doxorubicin in
the absence of statins, it is likely that liposomes have a facili-
tated entry within BBB cells by simple endocytosis. The
uptake of apo-Lipodox was unaffected by an excess of the free
LDL receptor-binding apoB100 peptide under basal condi-
tions, suggesting that the LDL receptors present on the
surface of untreated hCMEC/D3 cells were too few to play a
critical role in the liposome uptake. In contrast, the LDL
receptor became a helpful tool to increase the endocytosis of
targeted liposomes when its levels increased on the cells’
surface, that is, after exposure to statins. Simvastatin, which
forced BBB cells to expose more LDL receptors and simulta-
neously decreased the activity of Pgp/ABCB1, indeed
enhanced the apo-Lipodox uptake and reduced the apical
efflux of doxorubicin, increasing the trans-cellular transport
of the drug. Empty liposomal shells, which inhibited the
activity of Pgp/ABCB1 in chemoresistant tumours (Riganti
et al., 2011), did not exert any permeabilizing activity on the
delivery of doxorubicin across the BBB, suggesting that the
effects of the lipidic envelope alone may be tissue-dependent.
We show here that simvastatin enhanced the number of
LDL receptors exposed and induced chemosensitization in
different human tumour (glioblastoma, neuroblastoma, non-
small cell lung cancer, breast cancer) cells with constitutive
expression of Pgp/ABCB1, MRP1/ABCC1 and BCRP/ABCG2
and different degrees of resistance to doxorubicin. Pretreat-
ment of the tumour cells with simvastatin followed by the
apo-Lipodox showed the greatest cytotoxic efficacy not only
in primary CNS tumours like glioblastoma, but also in epi-
thelial tumours, such as lung and breast cancers cells, whose
metastasis within the CNS are often unresponsive to therapy.
In co-culture models, the application of free doxorubicin on
the luminal side of hCMEC/D3 monolayer did not yield any
strong drug delivery into the tumour cells growing under the
BBB. Apo-Lipodox alone or the combination of simvastatin
plus free doxorubicin increased drug delivery and toxicity.
However, the extent of this increase was variable, depending
on the different levels and activity of ABC transporters and
LDL receptors, and on the existence of other mechanisms of
resistance characterizing each cell line. The presence of spe-
cific tumour cells on the basal side of hCMEC/D3 cells may
also affect the permeability of the BBB differently, determin-
ing different rate and kinetics of drug delivery. Only the
pretreatment of the co-cultures with simvastatin followed by
apo-Lipodox elicited a clear increase in doxorubicin delivery
and toxicity, consisting of both necrotic and apoptotic death,
in all the models investigated, including the highly chemore-
sistant glioblastoma.
A direct anti-tumour activity of statins against glioblas-
toma cells has been reported previously (Bababeygy et al.,
2009; Yanae et al., 2011): for instance, in rat C6 glioma cells,
5 mmol·L-1 mevastatin and simvastatin induced apoptosis by
decreasing the intracellular availability of GGPP and the acti-
vation of ERK1/2 and Akt (Yanae et al., 2011), suggesting that
the effect could be mediated by a decrease in the activity of a
geranylgeranylated protein. We did not detect direct cyto-
toxic effects of statins in co-cultured glioblastoma cells,
perhaps because we used simvastatin at lower dose. It is
noteworthy, however, that statins, at concentrations that are
found in the blood of patients receiving anti-cholesterolemic
therapy, enhanced the efficacy of a chemotherapeutic drug
like doxorubicin against glioblastoma cells.
Phase I/II trials with pegylated liposomal doxorubicin
have shown that the drug has very few side effects and is well
tolerated, but does not offer a significant advantage in terms
of overall survival or progression-free survival in comparison
to the standard protocols based on radio-chemotherapy (Glas
et al., 2007; Beier et al., 2009; Ananda et al., 2011). For this
reason, chemical modifications and improvements of drug-
loaded nanoparticles are under intensive investigations
(Michaelis et al., 2006; Nikanjam et al., 2007; Guo et al., 2011;
Wohlfart et al., 2011). The approach proposed in our work
differs from the other studies on CNS-penetrating nanoparti-
cles because it is more ‘physiological’: it takes advantage of
the usual metabolic effects of therapeutic doses of statins –
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the increase in LDL receptors exposed and the synthesis of
NO – and from the properties of liposomes, that induce
permeability across the BBB and efficacy against drug-
resistant tumours. We are currently testing this association in
animal models bearing primary and metastatic CNS tumours,
in order to determine the pharmacokinetic profile, the
optimal administration regimen, the immunogenicity of
apoLipodox, the antitumour effect and the presence of side
effects. Testing our strategy in animals will add further impor-
tant details about the molecular mechanisms of apo-Lipodox,
inferred by these in vitro experiments, in order to validate the
feasibility and efficacy of the association proposed.
The problem of poor permeability across the BBB is not
limited to anticancer drugs, but also affects the delivery of
agents used in epilepsy and neurodegenerative diseases. In a
general perspective, our ‘Trojan horse’ approach, based on
the administration of statins followed by a LDL receptor-
targeting liposomal drug, might have potential applications
in the pharmacological therapy of different CNS diseases.
Acknowledgements
We thank Mr Costanzo Costamagna, Department of Genet-
ics, Biology and Biochemistry, University of Turin, for the
technical assistance and Mr Silvano Panero, Department of
Vegetal Biology, University of Turin, for the help with the
TEM analysis. We are grateful to Dr Marco Minella and Prof
Claudio Minero, Department of Analytical Chemistry, Uni-
versity of Turin, for having provided the dynamic light scat-
tering facility and for the valuable advices in the
interpretation of the data. We are indebted with Prof Davide
Schiffer, Neuro-Bio-Oncology Center, Vercelli, Italy, for the
helpful discussion and the critical revision of the manuscript.
This work has been supported by grants from Compagnia
di San Paolo, Italy (Neuroscience Program; grant 2008.1136)
and Italian Association for Cancer Research (AIRC; MFAG
11475) to CR. M L P-D is a recipient of an ERACOL Erasmus
Mundus fellowship.
Conflict of in interest
None.
References
Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008). Simvastatin,
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,
suppresses osteoclastogenesis induced by receptor activator of
nuclear factor-kB ligand through modulation of NF-kB pathway. Int
J Cancer 123: 1733–1740.
Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ,
Kreuter J (2006). Biodistribution of polysorbate 80-coated
doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles
after intravenous administration to glioblastoma-bearing rats. J
Drug Target 14: 97–105.
Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J et al.
(2011). Phase 2 trial of temozolomide and pegylated liposomal
doxorubicin in the treatment of patients with glioblastoma
multiforme following concurrent radiotherapy and chemotherapy.
J Clin Neurosci 18: 1444–1448.
Bababeygy SR, Polevaya NV, Youssef S, Sun A, Xiong A,
Prugpichailers T et al. (2009). HMG-CoA reductase inhibition causes
increased necrosis and apoptosis in an in vivo mouse glioblastoma
multiforme model. Anticancer Res 29: 4901–4908.
Bauer B, Hartz AMS, Miller DS (2007). Tumor necrosis factor a and
endothelin-1 increase P-glycoprotein expression and transport
activity at the blood-brain barrier. Mol Pharmacol 71: 667–675.
Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D,
Grauer O et al. (2009). RNOP-09: pegylated liposomal doxorubicine
and prolonged temozolomide in addition to radiotherapy in newly
diagnosed glioblastoma-a phase II study. BMC Cancer 9: 308–318.
Carl SM, Lindley DJ, Couraud PO, Weksler BB, Romero I,
Mowery SA et al. (2010). ABC and SLC transporter expression and
pot substrate characterization across the human CMEC/D3
blood-brain barrier cell line. Mol Pharm 7: 1057–1068.
Declèves X, Amiel A, Delattre JY, Scherrmann JM (2006). Role of
ABC transporters in the chemoresistance of human gliomas. Curr
Cancer Drug Targets 6: 433–445.
Deelen JF, Loscher W (2007). The blood-brain barrier and cancer:
transporters, treatment, and Trojan horses. Clin Cancer Res 13:
1663–1674.
Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E,
Pescarmona G et al. (2008). RhoA silencing reverts the resistance to
doxorubicin in human colon cancer cells. Mol Cancer Res 6:
1607–1620.
Glas M, Koch H, Hirschmann B, Jauch T, Steinbrecher A,
Herrlinger U et al. (2007). Pegylated liposomal doxorubicin in
recurrent malignant glioma: analysis of a case series. Oncology 72:
302–307.
Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J et al. (2011). TRAIL and
doxorubicin combination enhances anti-glioblastoma effect based
on passive tumor targeting of liposomes. J Control Release 154:
93–102.
Hartz AMS, Bauer B, Fricker G, Miller DS (2007). Rapid modulation
of P-glycoprotein-mediated transport at the blood-brain barrier by
tumor necrosis factor-a and lipopolysaccharide. Mol Pharmacol 69:
462–470.
Hawkins BT, Sykes DB, Miller DS (2010). Rapid, reversible
modulation of blood-brain barrier P-glycoprotein transport activity
by vascular endothelial growth factor. J Neurosci 30: 1417–1425.
Huerta S, Chilka S, Bonavida B (2008). Nitric oxide donors: novel
cancer therapeutics. Int J Oncol 33: 909–927.
Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM (2008).
Multi-functional nanocarriers to overcome tumour drug resistance.
Cancer Treat Rev 34: 592–602.
Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaele D
et al. (2007). Translocation of poly(ethylene
glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain
endothelial cells: role of apolipoproteins in receptor-mediated
endocytosis. Biomacromolecules 8: 793–799.
Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A
et al. (2011). A LDL-masked liposomal-doxorubicin reverses drug
resistance in human cancer cells. J Control Release 149: 196–205.
BJPNew strategy for drug delivery into brain tumours
British Journal of Pharmacology (2012) 167 1431–1447 1445
Laufs U, Liao JK (2000). Targeting Rho in cardiovascular disease.
Circ Res 87: 526–528.
Liao K, Laufs U (2005). Pleiotropic effects of statins. Annu Rev
Pharmacol Toxicol 45: 89–118.
Mercer RW, Tyler MA, Ulasov IV, Maciej S (2009). Targeted
therapies for malignant glioma. BioDrugs 23: 25–35.
Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN,
Michaelis M et al. (2006). Covalent linkage of apolipoprotein E to
albumin nanoparticles strongly enhances drug transport into the
brain. J Pharmacol Exp Ther 317: 1246–1253.
Monnaert V, Betbeder D, Fenart L, Bricout H, Lenfant AM,
Landry C et al. (2004). Effects of g- and hydroxypropyl- g
-cyclodextrins on the transport of doxorubicin across an in vitro
model of blood-brain barrier. J Pharmacol Exp Ther 311:
1115–1120.
Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T (2009).
Prognostic significance of the immunohistochemical expression of
O6-methylguanine-DNA methyltransferase, P-glycoprotein, and
multidrug resistance protein-1 in glioblastomas. Neuropathology
29: 379–388.
Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A,
Tasaki H et al. (2007). Statin treatment upregulates vascular
neuronal nitric oxide synthase through Akt/NF-kB pathway.
Arterioscler Thromb Vasc Biol 27: 92–98.
Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF,
Forte TM (2007). Synthetic nano-low density lipoprotein as targeted
drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:
86–94.
Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H (2010).
Regulation of the expression of inducible nitric oxide synthase.
Nitric Oxide 23: 75–93.
Provencher SW (1982). A constrained regularization method for
inverting data represented by linear algebraic or integral equations.
Comput Phys Commun 27: 213–227.
Rattan R, Giri S, Singh AK, Singh I (2003). RhoA negatively
regulates cytokine-mediated inducible nitric oxide synthase
expression in brain derived transformed cell lines: negative
regulation of IKKa. Free Radic Biol Med 39: 1037–1050.
Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G,
Ghigo D et al. (2005). Nitric oxide reverts the resistance to
doxorubicin in human colon cancer cells by inhibiting the drug
efflux. Cancer Res 65: 516–525.
Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A
(2006). Statins revert doxorubicin resistance via nitric oxide in
malignant mesothelioma. Int J Cancer 119: 17–27.
Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G,
Ghigo D et al. (2008). Activation of nuclear factor-kappa B pathway
by simvastatin and RhoA silencing increases doxorubicin
cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 74:
476–484.
Riganti C, Voena C, Kopecka J, Corsetto P, Montorfano G, Enrico E
et al. (2011). Liposome-encapsulated doxorubicin reverses
drug-resistance by inhibiting P-glycoprotein in human cancer cells.
Mol Pharm 8: 683–700.
Rikitake Y, Liao JK (2005). Rho GTPases, statins, and nitric oxide.
Circ Res 97: 1232–1235.
Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T et al.
(2005). Inhibition of Rho kinase (ROCK) leads to increased cerebral
blood flow and stroke protection. Stroke 36: 2251–2257.
Robey RW, Massey PR, Amiri-Kordestani L, Bates SE (2010). ABC
transporters: unvalidated therapeutic targets in cancer and the CNS.
Anticancer Agents Med Chem 10: 625–633.
Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008).
Medulloblastoma: from molecular pathology to therapy. Clin
Cancer Res 14: 971–976.
Salkeni MA, Lynch JL, Otamis-Price T, Banks WA (2009).
Lipopolysaccharide impairs blood–brain barrier P-glycoprotein
function in mice through prostaglandin- and nitric
oxide-independent pathways. J Neuroimmune Pharmacol 4:
276–282.
Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA,
Vredenburgh JJ, Rich JN (2007). Molecularly targeted therapy for
malignant glioma. Cancer 110: 13–24.
Sieczkowski E, Lehner C, Ambros PF, Hohenegger M (2010). Double
impact on pglycoprotein by statins enhances doxorubicin
cytotoxicity in human neuroblastoma cells. Int J Cancer 126:
2025–2035.
Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA,
Shepard JM, Malik AB (1987). Molecular sieving characteristics of
the cultured endothelial monolayer. J Cell Physiol 132: 111–117.
Tai LM, Loughlin AJ, Male DK, Romero IA (2009). P-glycoprotein
and breast cancer resistance protein restrict apical-to-basolateral
permeability of human brain endothelium to amyloid-b. J Cereb
Blood Flow Metab 29: 1079–1083.
Troost J, Lindenmaier H, Haefeli WE, Weiss J (2004). Modulation of
cellular cholesterol alters P-glycoprotein activity in
multidrug-resistant cells. Mol Pharmacol 66: 1329–1332.
Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K,
Leveque M et al. (2005). Blood-brain barrier-specific properties of a
human adult brain endothelial cell line. FASEB J 19: 1872–1874.
Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J (2011).
Kinetics of transport of doxorubicin bound to nanoparticles across
the blood–brain barrier. J Control Release 154: 103–107.
Wong HL, Bendayan R, Rauth AM, Wu XY (2004). Development of
solid lipid nanoparticles containing ionically complexed
chemotherapeutic drugs and chemosensitizers. J Pharm Sci 93:
1993–2008.
Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y et al.
(2011). Statin-induced apoptosis via the suppression of ERK1/2 and
Akt activation by inhibition of the geranylgeranyl-pyrophosphate
biosynthesis in glioblastoma. J Exp Clin Cancer Res 30: 74–82.
Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y
(2008). The role of eNOS, iNOS, and NF-kB in upregulation and
activation of cyclooxygenase-2 and infarct size reduction by
atorvastatin. Am J Physiol Heart Circ Physiol 295: H343–H351.
Zhang W, Ling V (2000). Cell-cycle–dependent turnover of
P-glycoprotein in multidrug-resistant cells. J Cell Physiol 184:
17–26.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Effects of statins on membrane cholesterol and
tight junctions integrity in hCMEC/D3 cells. (A) Cells were
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incubated in the absence (CTRL) or presence of 0.1 mmol·L-1
mevastatin (MVS) or simvastatin (SIM) for 24 h or
10 mmol·L-1 b-methyl cyclodextrin (MCD) for 3 h, then lysed
and subjected to cell membranes isolation. The cholesterol
content in membrane extracts was measured spectrophoto-
metrically as described in the Methods section. Measure-
ments were performed in duplicate and data are presented as
means  SD (n = 3). Vs CTRL: *P < 0.01. (B) Cells were seeded
on Transwell insert, grown up to confluence for 7 days and
incubated as reported in A; 2 mCi·mL-1 [14C]-inulin was then
added in the upper chamber. After 3 h the medium was recov-
ered by the lower chamber and the amount of [14C]-inulin
was measured by liquid scintillation. Measurements were per-
formed in duplicate and data are presented as means  SD
(n = 4). Vs CTRL: *P < 0.05.
Figure S2 Effects of pegylation on the permeability of LDL
receptor-targeted liposomal doxorubicin across the BBB. Cells
were grown up to the confluence for 7 days in Transwell
insert, then incubated in the absence (CTRL) or presence of
0.1 mmol·L-1 simvastatin (SIM) for 48 h. 5 mmol·L-1 apo-
Lipodox obtained from anionic non-pegylated liposomes
(COATSOME EL01A series; - PEG) or from anionic pegylated
liposomes (COATSOME EL-01-PA series; + PEG) was added in
the upper chamber and after 3 h the amount of the drug
recovered by the lower chamber medium was measured fluori-
metrically. Measurements were performed in duplicate and
data are presented as means SD (n = 3). Vs CTRL: * P < 0.005.
Figure S3 Effects of empty liposomes on NF-kB activity, NO
synthesis, cytotoxicity and permeability in hCMEC/D3 cells.
The hCMEC/D3 cells were incubated in the absence (CTRL) or
presence of 5 mmol·L-1 empty anionic pegylated liposomes
(EL) or empty anionic pegylated LDL receptor-targeted
conjugated-liposomes (apoEL) for 24 h, then subjected to the
following investigations. (A) NF-kB activity. The activity of
NF-kB was detected in the nuclear extracts measuring the
DNA-binding capacity of NF-kB on its target sequence (see
Methods). Measurements were performed in duplicate and
data are presented as means  SD (n = 3). (B) NO synthesis.
NOS activity in cell lysates (open bars) and nitrite accumula-
tion in the extracellular medium (hatched bars) were meas-
ured with spectrophotometric assays, as reported in the
Methods section. Data are presented as means SD (n = 3). (C)
Cytotoxicity. Culture supernatant of cells was checked for the
extracellular activity of LDH (open bars), cells were detached
and lysed to measure the activity of caspase-3 (hatched bars),
as described in the Methods section. Measurements were per-
formed in duplicate and data are presented as means  SD
(n = 3). (D) Transport of doxorubicin across BBB monolayer in
the presence of empty liposomes. The hCMEC/D3 cells were
grown up to the confluence for 7 days in Transwell insert, in
fresh medium or in the presence of simvastatin (5 mmol·L-1 for
48 h; SIM); then 5 mmol·L-1 doxorubicin (DOXO), alone or
co-incubated with 5 mmol·L-1 empty anionic pegylated lipo-
somes (EL) or empty anionic pegylated LDL receptor-targeted
conjugated-liposomes (apoEL), were added in the upper
chamber. After 3 h the amount of the drug recovered by the
lower chamber medium was measured fluorimetrically. Meas-
urements were performed in duplicate and data are presented
as means  SD (n = 3). Vs the corresponding condition
without SIM: * P < 0.005.
Figure S4 Effects of empty liposomes on the delivery and
cytotoxicity of free doxorubicin in co-culture models. The
hCMEC/D3 cells were grown for 7 days up to confluence in
Transwell inserts, whereas U87-MG cells were seeded at day 4
in the lower chamber. At day 0, supernatant in the upper
chamber was replaced with fresh medium without
(CTRL) or with simvastatin (0.1 mmol·L-1for 48 h; SIM).
5 mmol·L-1doxorubicin (DOXO), alone or co-incubated
with 5 mmol·L-1 empty anionic pegylated liposomes (EL) or
empty anionic pegylated LDL receptor-targeted conjugated-
liposomes (apoEL), were added in the upper chamber of Tran-
swell in the last 24 h, then the following investigations were
performed. (A) U87-MG cells were lysed in ethanol/HCl and
the intracellular amount of doxorubicin was measured fluori-
metrically (see Methods section). Measurements were per-
formed in duplicate and data are presented as means  SD
(n = 3). (B) The culture supernatant of tumor cells was
checked for the extracellular activity of LDH (open bars), cells
were detached and lysed to measure the activity of caspase-3
(hatched bars), as described in the Methods section. Measure-
ments were performed in duplicate and data are presented as
means  SD (n = 3).
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Supporting Figure 1. Effects of statins on membrane cholesterol and tight junctions integrity 
in hCMEC/D3 cells.  
A. Cells were incubated in the absence (CTRL) or presence of 0.1 µmol L-1 mevastatin (MVS) or 
simvastatin (SIM) for 24 h or 10 mmol L-1 β-methyl cyclodextrin (MCD) for 3 h, then lysed and 
subjected to cell membranes isolation. The cholesterol content in membrane extracts was measured 
spectrophotometrically as described in the Methods section. Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). Vs CTRL: * p < 0.01. B. Cells were seeded 
on Transwell insert, grown up to confluence for 7 days and incubated as reported in A; 2 µCi mL-1 
[14C]-inulin was then added in the upper chamber. After 3 h the medium was recovered by the lower 
chamber and the amount of [14C]-inulin was measured by liquid scintillation. Measurements were 
performed in duplicate and data are presented as means + SD (n = 4). Vs CTRL: * p < 0.05. 
Supporting Figure 2 
 
 
Supporting Figure 2. Effects of pegylation on the permeability of LDLR-targeted liposomal 
doxorubicin across the BBB. 
Cells were grown up to the confluence for 7 days in Transwell insert, then incubated in the absence 
(CTRL) or presence of 0.1 µmol L-1 simvastatin (SIM) for 48 h. 5 µmol L-1 apo-Lipodox obtained 
from anionic non-pegylated liposomes (COATSOME EL01A series; - PEG) or from anionic 
pegylated liposomes (COATSOME EL-01-PA series; + PEG) was added in the upper chamber and 
after 3 h the amount of the drug recovered by the lower chamber medium was measured 
fluorimetrically. Measurements were performed in duplicate and data are presented as means + SD 
(n = 3). Vs CTRL: * p < 0.005.  
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Supporting Figure 3. Effects of empty liposomes on NF-kB activity, NO synthesis, cytotoxicity 
and permeability in hCMEC/D3 cells. 
The hCMEC/D3 cells were incubated in the absence (CTRL) or presence of 5 µmol L-1 empty 
anionic pegylated liposomes (EL) or empty anionic pegylated LDLR-targeted conjugated-liposomes 
(apoEL) for 24 h, then subjected to the following investigations. 
A. NF-kB activity. The activity of NF-kB was detected in the nuclear extracts measuring the DNA-
binding capacity of NF-kB on its target sequence (see Methods). Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). B. NO synthesis. NOS activity in cell 
lysates (open bars) and nitrite accumulation in the extracellular medium (hatched bars) were 
measured with spectrophotometric assays, as reported in the Methods section. Data are presented as 
means + SD (n = 3). C. Cytotoxicity. Culture supernatant of tumor cells was checked for the 
extracellular activity of LDH (open bars), cells were detached and lysed to measure the activity of 
caspase-3 (hatched bars), as described in the Methods section. Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). D. Transport of doxorubicin across BBB 
monolayer in the presence of empty liposomes. The hCMEC/D3 cells were grown up to the 
confluence for 7 days in Transwell insert, in fresh medium or in the presence of simvastatin (5 µmol 
L-1 for 48 h; SIM); then 5 µmol L-1 doxorubicin (DOXO), alone or co-incubated with 5 µmol L-1 
empty anionic pegylated liposomes (EL) or empty anionic pegylated LDLR-targeted conjugated-
liposomes (apoEL), were added in the upper chamber. After 3 h the amount of the drug recovered 
by the lower chamber medium was measured fluorimetrically. Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). Vs the corresponding condition without 
SIM: * p < 0.005. 
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Supporting Figure 4. Effects of empty liposomes on the delivery and cytotoxicity of free 
doxorubicin in co-culture models. 
The hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts, whereas U87-
MG cells were seeded at day 4 in the lower chamber. At day 0, supernatant in the upper chamber 
was replaced with fresh medium without (CTRL) or with simvastatin (0.1 µmol L-1for 48 h; SIM). 5 
µmol L-1doxorubicin (DOXO), alone or co-incubated with 5 µmol L-1 empty anionic pegylated 
liposomes (EL) or empty anionic pegylated LDLR-targeted conjugated-liposomes (apoEL), were 
added in the upper chamber of Transwell in the last 24 hours, then the following investigations were 
performed.  
A. U87-MG cells were lysed in ethanol/HCl and the intracellular amount of doxorubicin was 
measured fluorimetrically (see Methods section). Measurements were performed in duplicate and 
data are presented as means + SD (n= 3). B. The culture supernatant of tumor cells was checked for 
the extracellular activity of LDH (open bars), cells were detached and lysed to measure the activity 
of caspase-3 (hatched bars), as described in the Methods section. Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). 
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Abstract: The blood-brain barrier (BBB), the unusual microvascular endothelial interface between the central nervous system (CNS) and 
the circulatory system, is a major hindrance to drug delivery in the brain parenchyma. Besides the absence of fenestrations and the abun-
dance of tight junctions, ATP-binding cassette (ABC) transporters critically reduce drug entry within the CNS, as they carry many drugs 
back into the bloodstream. Nanoparticle- and liposome-carried drugs, because of their increased cellular uptake and reduced efflux 
through ABC transporters, have been developed in recent times to circumvent the low drug permeability of the BBB. 
This review discusses the role of ABC transporters in controlling drug penetration into the brain parenchyma, the rationale for using 
nanoparticle- and liposome-based strategies to increase drug delivery across the BBB and new therapeutic strategies for using nanoparti-
cle- and liposome-carried drugs in different conditions, ranging from CNS tumors and neurodegenerative diseases to viral infections and 
epilepsy. 
Keywords: ATP-binding cassette transporters, blood-brain barrier, central nervous system, drug delivery, nanoparticles, liposomes.  
BLOOD-BRAIN BARRIER ANATOMY AND PHYSIOL-
OGY: AN OVERVIEW 
 The blood-brain barrier (BBB), the microvascular endothelial 
network within the capillaries of the central nervous system (CNS), 
maintains a constant microenvironment in the cerebral parenchyma 
[1]. It regulates the bi-directional transport of metabolites and 
xenobiotics, controls the migration of leukocytes, preserves salt 
homeostasis and allows toxic metabolites to be removed from the 
brain parenchyma and delivered back into the bloodstream [2]. 
Acting as a neuroprotective shield, the BBB defines the optimal 
conditions for neuronal and glial activity. The transport of metabo-
lites and drugs across the BBB is strictly regulated by the presence 
of tight junctions (TJs), adherent junctions (AJs) and functional 
“metabolic barriers”, such as catabolic enzymes and efflux transport 
systems. Only electrically neutral and hydrophobic molecules with 
low molecular weight can easily cross the BBB, while the vast ma-
jority of drugs (analgesics, antibiotics, antivirals, anti-epileptic and 
chemotherapeutic drugs) are excluded [3].  
 The main structural difference between the endothelium of the 
brain capillaries and the endothelium of other capillaries is the 
presence of TJs between adjacent endothelial cells [4] and the lack 
of fenestrations and pinocytotic vesicles [5]. TJs are multiprotein 
complexes localized in the lateral surface of the endothelial cells in 
the CNS. They are formed by transmembrane proteins, such as 
occludin, claudin-3, claudin-5, junctional adhesion molecule, and 
cytosolic proteins, such as zonula occludens-1/2/3, AF6, 7H6, and 
cingulin. In the physiologically competent BBB, the presence of 
TJs and the absence of fenestrations prevent the paracellular pas-
sage of molecules [6]. AJs, other basolateral junctions complexes 
made of vascular-endothelial cadherin, p120 and -/-catenin com-
plexes, contribute to the strong cell-cell adhesion and are required 
for the assembly of TJs [6], further decreasing the paracellular per-
meability of many substances. Finally, the lack of pinocytotic  
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vesicles increases even more the tight control of the transcytotic 
processes across the BBB. 
 Overall, both luminal and basolateral surfaces, facing blood and 
brain interstitial fluids respectively, contribute to the “barrier” role 
of the brain's microvascular endothelium (Fig. 1). Several of the 
functions described above in the endothelial cells are made possible 
by the close proximity and the multiple contacts with pericytes, 
astrocytes and neurons: it is the concurrent presence of endothelial 
cells, extracellular matrix and CNS cells that forms a physiologi-
cally competent BBB [7]. 
 Besides the BBB, other barriers crucial for the homeostasis of 
the brain parenchyma are the blood-cerebrospinal fluid barrier 
(BCSF), which is formed by the epithelial cells of the choroid 
plexus and regulates the transport of molecules between CNS and 
cerebrospinal fluid [8], and the blood-retina barrier [9]. In all of 
these barriers, the mechanisms of passive diffusion, facilitated dif-
fusion and active transport of substrates are tightly regulated.  
 The ATP-binding cassette (ABC) transporters are crucial play-
ers in the active transport processes across the BBB. 
THE ABC TRANSPORTERS SYSTEM AND THE BBB 
 It was originally believed that the transport of drugs across the 
BBB occurred through passive diffusion and depended on the spe-
cific physicochemical properties of the drug, such as lipophilicity, 
molecular weight and charge [3]. Yet, many lipophilic drugs do not 
get carried into the CNS. This observation highlights the role of the 
ABC transporters, as the main actors in the efflux of drugs expected 
to cross the BBB easily and instead showing very low level within 
the CNS [10]. 
 Both the BBB and the BCSF contain several members of the 
ABC transporter family, such as P-glycoprotein (Pgp/ABCB1), 
multidrug resistance related proteins (MRPs/ABCCs), breast cancer 
resistance protein (BCRP/ABCG2). They are all integral membrane 
transporters and share the mechanism of ATP hydrolysis as the 
driving force for transporting substrates against their concentration 
gradient. ABC transporters also share a low specificity for sub-
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strates, i.e. each transporter can recognize different molecules and 
the same substrate can be effluxed by more than one transporter 
[11] (Table 1). The vast majority of ABC transporters involved in 
drug resistance, or at least their mRNAs, have been identified in 
BBB and BCSF cells. The reason for the relative abundance of 
these transporters on the BBB and BCSF, as well as their prevalent 
localization on the luminal or basolateral cell membranes, have not 
yet been fully explained [12]. 
 Pgp was the first ABC transporter detected in human BBB cells 
[13, 14]. Subsequently Pgp was detected in brain capillary endothe-
lium of several species, including monkeys, rats, mice, cattle, and 
pigs. Its abundance across different species suggests that Pgp may 
represent a crucial defense mechanism in mammals, exerted by 
limiting the delivery of potentially dangerous lipophilic molecules, 
which otherwise would cross the BBB by passive diffusion [13, 
14]. 
 There are two types of human Pgp: type I (also termed 
“multidrug resistance-1/MDR1 Pgp”, encoded by the mdr1 gene), 
responsible for the multidrug resistant phenotype in tumor cells and 
actively involved in the drug efflux in BBB cells; type II (encoded 
by mdr2 gene), restricted to the canalicular plasma membrane of 
hepatocytes, where it works as a phosphatidylcholine translocase 
[13]. In the BBB, Pgp is located on the luminal membrane of endo-
thelial cells (Fig. 1) and dramatically decreases the accumulation of 
drugs within the CNS by pumping them back to the bloodstream 
[15]. Moreover, Pgp is involved in the basal-apical efflux of en-
dogenous metabolites produced by brain parenchyma, like amyloid 
 (A) peptides [16]. Therefore Pgp represents a crucial control 
step for the extrusion of both exogenous and endogenous com-
pounds. 
 The impact of Pgp on CNS homeostasis was shown by using 
mdr1a knockout mice, where CNS levels of Pgp substrates – such 
as anticancer drugs', analgesics', anti-epileptics', anti-retrovirals' or 
antibiotics' levels-increased 10-to-100-fold, causing serious toxicity 
[17]. Similar results were obtained when synthetic inhibitors of the 
transporter were used [18, 19, 20]. One major limitation of Pgp 
inhibitors is their low tissue specificity and subsequent high toxic-
ity. That notwithstanding, research on Pgp inhibitors with con-
trolled potency and higher selectivity continues in two directions. In 
one, drugs that exert the expected therapeutic effects on CNS cells 
and simultaneously inhibit Pgp are under development [21]. In the 
other, inhibitors of Pgp have been recently studied for diagnostic 
use. Marked with appropriate radiotracers in positron emission 
tomography (PET) or single-photon emission computed tomogra-
phy (SPECT) they help visualize the localization and functional 
activity of Pgp within the CNS [22, 23, 24]. Some neurodegenera-
tive diseases show reduction of Pgp in specific brain areas as an 
early sign of disease [25, 26]. Its detection might thus have wide 
applications in the early diagnosis of these conditions and could 
help identify those patients who might benefit from the therapeutic 
administration of Pgp modulators [27]. 
 The MRP transporter family currently has 12 members (includ-
ing MRP1-9), which are transporters of anionic and neutral organic 
molecules [28] (Table 1). Their spectrum of substrates overlaps 
with Pgp [11]. Like Pgp, MRPs are localized in the BBB, the BCSF 
and also in the blood-spinal cord barrier [29]. The role of MRPs as 
controllers of drug delivery across the BBB was demonstrated with 
pharmacological inhibitors, such as probenecid or MK-571, which 
enhance drug delivery within the CNS or decrease the drug efflux 
from isolated brain endothelial cells [30]. The contribution of 
MRPs to drug transport across the BBB, however, is not unidirec-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of the blood-brain barrier (BBB). BBB is a structural-functional unit composed by peculiar brain microvascular endothelial 
cells, devoid of fenestrations, rich of tight junctions (TJs) and adherent junctions (AJs) on lateral surface, and ABC transporters, such as Pgp, MRP1-6, BCRP, 
on luminal and basolateral side. Most of these features, which determine a tight control on the bi-directional transport of metabolites and xenobiotics, are 
maintained by the close proximity and multiple contacts between endothelial cells and central nervous system cells, such as astrocytes and neurons.  
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tional, as MRPs may have a luminal or a basolateral location (Fig. 
1). This characteristic, along with the close homology of the ABCC 
family members, makes the design of selective pharmacological 
inhibitors of MRPs problematic. 
 Greater efforts have also been made to find selective inhibitors 
of BCRP, which – like Pgp – is present on the luminal surface of 
the BBB cells [31] (Fig. 1). Based on mRNA analysis, BCRP is 
more expressed on the BBB than Pgp or MRP1. Interestingly, 
BCRP levels were three times as high in brain microvessels of 
mdr1a knockout mice than wild-type mice, suggesting a compensa-
tive up-regulation of BCRP and a possible cross-talk between Pgp 
and BCRP in BBB cells. Pgp and BCRP cooperate to reduce the 
brain accumulation of topotecan [32], lapatinib [33], dasatinib [34], 
sorafenib [35]. For this reason the simultaneous inhibition of Pgp 
and BCRP has been proposed as a powerful strategy to increase the 
transport of specific drugs: for instance, the inhibition of both 
transporters with clinically achievable doses of canertinib and er-
lotinib improved the delivery of pazopanib within the CNS [36], 
suggesting a synergistic effect of these inhibitors. The dual inhibi-
tors tariquidar and elacridar, that block both Pgp and BCRP in the 
BBB in vivo, have been intensively investigated as therapeutic tools 
[34, 37]. The chemical structure of tariquidar and elacridar has been 
proposed as a starting point for the synthesis of PET radiotracers, 
able to monitor the localization and activity of Pgp and BCRP 
within the CNS [23, 24].  
 Most of the studies on ABC transporter inhibitors were per-
formed in animals. It should be noted that species-specific differ-
ences exist between rodents and humans for Pgp localization and 
activity [38], making it difficult to translate some promising results 
obtained in animal models into clinical applications in humans. 
Furthermore the localization of ABC transporters in BBB cells is 
not limited to the plasma membrane. In solid tumors large amounts 
are found in cytoplasmic vesicles, where they promote intravesicu-
lar drug sequestration. Whether these intracellular ABC transporters 
can also be effectively blocked by the common pharmacological 
inhibitors, remains unclear.  
 Overall, the routine use of ABC transporter inhibitors to en-
hance the drug delivery across the BBB in vivo is still controversial. 
The efflux of drugs from BBB cells and their vesicular sequestra-
tion depend on their cytoplasmic concentration [39]: the higher the 
drug concentration within the BBB cells, the lower the percentage 
of the drug effluxed back into the bloodstream or sequestered. With 
this paradigm in mind, new strategies of drug delivery have been 
developed, to increase drug uptake by BBB cells and reduce back-
ward efflux. Common approaches have included the osmotic open-
ing of the TJs [40], regional drug delivery by local catheters, drug-
enriched wafers and conventionally-enhanced delivery devices [41], 
the use of carrier systems like antibody-conjugated drugs, nanopar-
ticle (NP)-carried drugs or liposome-carried drugs [40, 42, 43].  
NANOPARTICLES AND LIPOSOMES AS DRUG DELIV-
ERY SYSTEMS: AN OVERVIEW 
 Owing to their small size, customizable surface, good solubil-
ity, targeted drug delivery and multifunctionality, NPs have 
emerged in the last decades as useful drug carriers [44]. 
 NPs are commonly defined as carriers with a size between 10 
and 1000 nm, made with a broad spectrum of materials: sugar de-
rivatives such as malto-dextrins [45] or chitosan [46]; fatty acids 
such as beenic acid and palmitic acid that are assembled in the so-
called solid lipidic NPs (SLNs) [47]; proteins such as human albu-
min (HA) and type B gelatin [48]. Some NPs are micelles of am-
phiphilic molecules with the peculiar orientation of the hydrophilic 
groups on the outer surface and the hydrophobic groups in the in-
ternal core. This structure offers the advantage to carry both water-
soluble drugs, adsorbed on the hydrophilic moieties, and poorly 
Table 1. Substrates of ATP-binding cassette (ABC) transporters present in blood-brain barrier (BBB).  
ABC transporter Localization on BBB Endogenous substrates Xenobiotics  and drugs 
Pgp (ABCB1) luminal neutral/cationic organic compounds, 
amyloid  peptide 
doxorubicin, daunorubicin, vincristine, vinblastine, actino-
mycin-D, paclitaxel, docetaxel, etoposide, teniposide, topote-
can, mitoxantrone, methotrexate, imatinib, lapatinib, 
dasatinib, sorafenib, gefitinib, erlotinib, zidovudine, lami-
vudine, saquinavir, indinavir, nelfinavir, ketoconazole 
MRP1 (ABCC1) luminal GSH-conjugated and anionic organic 
compounds, leukotriene C4 
etoposide, teniposide, vincristine, vinblastine, paclitaxel, 
docetaxel, doxorubicin, daunorubicin, epirubicin, mitoxan-
trone, methotrexate, topotecan, irinotecan 
MRP2 (ABCC2) luminal anionic organic compounds cisplatin, methotrexate, doxorubicin, daunorubicin, etoposide, 
paclitaxel, docetaxel, toptecan, irinotecan 
MRP3 (ABCC3) basal glucuronic acid- and GSH-conjugated 
compounds, bile salts 
etoposide, teniposide, methotrexate, cisplatin, doxorubicin, 
vincristine 
MRP4 (ABCC4) luminal nucleotide derivatives, organic anionic 
compounds 
methotrexate, 6-mercaptopurine, 6-thioguanine, topotecan, 
cisplatin 
MRP5 (ABCC5) basal nucleotide derivatives, organic anionic 
compounds 
6-mercaptopurine, 6-thioguanine, gemcitabine 
MRP6 (ABCC6) basal anionic cyclic pentapeptide unknown 
BCRP (ABCG2) luminal hydrophobic and hydrophilic anionic 
compounds 
prazosin, mitoxantrone, doxorubicin, daunorubicin, topote-
can, 7-ethyl-10-hydroxycamptothecin (SN-38), methotrexate, 
imatinib, lapatinib, dasatinib, sorafenib, gefitinib, erlotinib 
Pgp: P-glycoprotein; MRP: multidrug resistance related protein; BCRP: breast cancer related protein; GSH: glutathione. 
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water-soluble drugs, hidden in the hydrophobic core, and makes 
amphiphilic micelles very versatile carriers [49]. 
 Amphiphilic polymers used for micelles - such as poly(lactic 
acid), poly(-hydroxybutyrate), poly(lactic-co-glycolic acid) 
(PLGA), poly(-caprolactone), polyalkylcyanoacrylate, poly(butyl 
2-cyanoacrylate) (PBCA), poly(isobutyl 2-cyanoacrylate), poly 
(methyl methacrylate), polystyrene - commanded a good deal of 
interest in the last few years, because they can self-assembly, are 
stable and have customizable features, as they can vary in length 
and composition of polymers [48]. These NPs are collectively 
termed polymersomes [50] and can be divided into nanospheres (if 
entirely made of solid components) and nanocapsules (if made of a 
solid shell surrounding a central cavity, containing hydrophilic or 
hydrophobic solvents). Polymeric micelles are usually larger than 
SLNs; despite their great versatility in transporting drugs, their size 
can sometimes limit the efficacy of drug delivery in particular tis-
sues. To be used in vivo, polymeric NPs must be biocompatible. To 
increase the biocompatibility of synthetic polymers, cholesterol is 
often included in NPs. Cholesterol also helps the self-assembly of 
NPs and is useful for actively targeting different types of choles-
terol receptors present in mammalian tissues [51].  
 Dendrimers, branched NPs with uniform and well-defined size 
and shape, and a highly controlled dendritic architecture (in terms 
of size, branching density, surface functionality), are another class 
of polymeric NPs, able to cross cell membranes and biological bar-
riers including the BBB [52]. The most common materials used for 
the synthesis of dendrimers are poly(amidoamine) (PAMAM), 
poly(propylene imine) or polyether-copolyester. Dendrimers can 
transport drugs, either encapsulated or chemically bound, and are 
often used as carriers of pro-drugs, which are then released as ac-
tive metabolites; the so-called “pH-sensitive” dendrimers are able 
to deliver drugs when exposed at specific pH (e.g. in the more 
acidic microenvironment of brain tumors). Such versatility makes 
dendrimers ideal carriers for the delivery of anticancer, anti-
inflammatory and antibiotic agents to the CNS [53]. 
 The main requisites that NPs must have when they are adminis-
tered systemically are: 1) the preservation of their structural integ-
rity in the bloodstream; 2) their escape from sequestration in re-
ticulo-endothelial cells (or “stealthness”); 3) the absence of “first-
passage” effect and hepatic catabolism and 4) the absence of impor-
tant urinary clearance [48]. Furthermore, NPs must not induce side-
effects, such as liver or kidney toxicity or abnormal immunoreactiv-
ity. Finally, the stability and the pharmacokinetic profile of each 
drug can widely differ, depending on its therapeutic use. Therefore 
NPs must be designed in such a versatile manner to prevent the 
early degradation/release of the drug, to allow drug delivery to the 
target tissue at the desired concentration and to provide a better 
pharmacokinetic profile than the free drug [54]. For instance the 
delivery of the anti-diarrheal drug loperamide with PLGA NPs 
conjugated with the peptide Gly-Phe-Thr-Gly-Phe-Leu-Ser-(O--D-
glucose)-CONH2 produced stronger and more prolonged pharma-
cological effects than the intraventricular injection of free lopera-
mide [55]. Similarly, the loading of paclitaxel into glutathione 
(GSH)-coated PLGA NPs not only lowered the drug efflux through 
the ABC transporters of the BBB, but also allowed a long-lasting 
and steady release of paclitaxel within RG2 glioma cells [56]. 
 Besides being manufactured as drug or pro-drug containing 
carriers, NPs containing metallic compounds, such as titanium di-
oxide (TiO2), gold and iron oxide derivatives [57, 58], have been 
synthesized. One specific property of these NPs is in their targeting, 
that can be increased by the application of appropriate magnetic 
fields [57], using the so-called magnetic resonance imaging (MRI) 
guided focused ultrasound technique [59]. 
 Liposomes are lipid vesicles with a wide range of sizes, e.g. 
from 20 nm to 1 m of diameter. They are made by one or multiple 
phospholipid bilayers with the typical structural organization of cell 
membranes. The only exception to this definition is niosomes, 
which share all functional properties with the classical liposomes 
but are non phospholipid-based vesicles, as they contain non-ionic 
surfactants and cholesterol [49]. Thanks to the variety of sizes and 
lamellar structures, liposomes are as versatile carriers as NPs: they 
can be loaded with hydrophobic, hydrophilic or amphipathic drugs, 
using relatively simple techniques. Drugs can be encapsulated 
within or adsorbed on the lipid shell, depending on their hydropho-
bicity, and can be released from the same type of liposome with 
different kinetics, achieving superior therapeutic efficacy than free 
drugs. Liposomes, like NPs, are subjected to the enhanced perme-
ability and retention (EPR) effect, i.e. they usually have low sys-
temic concentration and high tumor concentration. The EPR effect 
and the multiple mechanisms of drug delivery make it possible for 
instance to carry high amounts of chemotherapeutic drugs with 
relatively low side-effects. For this reason, liposomes have been 
used against tumors unresponsive to conventional chemotherapy 
since 1970s.  
 Until now, the most commonly used carriers for drug delivery 
within the CNS included polymeric NPs and liposomes [49]. This 
review discusses the physicochemical properties that make NPs and 
liposomes suitable carriers for drug delivery across the BBB, the 
role of surface coating, the different mechanisms of uptake by BBB 
cells, the current hypothesis on their ability to bypass the ABC 
transporter-mediated efflux and the potential clinical uses of NPs 
and liposomes in different conditions of the CNS. 
NANOPARTICLE-BASED STRATEGIES FOR DRUG DE-
LIVERY ACROSS THE BBB 
The Passive Targeting of NPs Across the BBB: Effects of Size, 
Charge Surface and Coating  
 Several experimental evidences have reported that NPs enhance 
delivery across the BBB, because of either passive targeting (non-
specific endocytosis) or active targeting (by binding to specific 
receptors of the luminal surface of BBB cells, followed by a recep-
tor-driven endocytosis). Confocal microscope analysis and cell 
fractioning studies on rat brain endothelial cells showed that indeed 
NPs were mostly associated with plasma membrane and vesicular 
compartments, and only a small fraction was associated with caveo-
lae. These data indicate a prevalent uptake of NPs via non-specific 
endocytosis [60]. In the case of passive targeting, the chemical 
structure and the physicochemical properties of the surface are 
critical to make NPs suitable for the uptake within the BBB cells. 
 The size of the synthesized NPs is crucial. NPs smaller than 20 
nm can pass through BBB endothelial cells by transcytosis and – in 
the case of active targeted NPs – they can easily interact with the 
target receptors present on the surface of the BBB cells [61].  
 It is generally recognized that the surface features of NPs, more 
than their core structure, are critical for the delivery through the 
BBB; changes in the surface charge and coating may influence the 
ability to cross biological barriers. Fenart and coworkers synthe-
sized NPs of cross-linked malto-dextrins, derivatized with phos-
phate-conjugated ligands (to obtain anionic NPs), quaternary am-
monium-conjugated ligands (to obtain cationic NPs) or without any 
modification (to obtain neutral NPs). All NPs were then coated with 
dipalmitoyl phosphatidyl choline and cholesterol. Whereas the coat-
ing of neutral NPs did not significantly improve their delivery 
through the BBB, the coating of charged NPs increased their uptake 
up to four folds [45]. The uptake of anionic lipid NPs was higher 
than neutral or cationic ones at the same concentrations [62]. These 
differences may underscore different uptake pathways: at 4°C, 
when active endocytosis was blocked and only passive diffusion 
was allowed, cationic NPs remained outside the BBB cells, neutral 
NPs were associated with cell surface, anionic NPs were detected 
on cell surface and in paracellular space; at 37°C, only neutral and 
anionic NPs had undergone endocytosis and were subjected to tran-
scytosis [63]. The use of the caveolae-interfering agent filipin 
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showed that neutral and anionic NPs used in this study followed the 
caveolae-mediated endocytotic pathway, whereas cationic NPs did 
not [63]. 
 Coating of NPs surface with hydrophilic or amphiphilic poly-
mers, such as polyethylene glycol (PEG), pluronic, poloxamer and 
poloxamine, is commonly used to increase the hydration and the 
solubility of the NP core, and to protect it from enzymatic degrada-
tion and phagocytosis by circulating mononuclear cells and re-
ticulo-endothelial cells [44, 48]. So far, pegylation is widely em-
ployed for the in vivo applications of NPs. Pegylation does not ex-
clude encasing lipophilic drugs into the NP core. Since the solubil-
ity of the drugs carried by PEG-coated NPs is related to the NP 
concentration rather than the drug concentration, also hydrophobic 
drugs, when transported by pegylated NPs can reach the BBB at 
clinically relevant concentrations after systemic administration. 
Pegylation also facilitates the passage across the BBB: 
poly(methoxy-PEG-cyanoacrylate-co-hexadecyl cyanoacrylate) 
(PEG-PHDCA) copolymers passed the BBB more easily than the 
uncoated ones [60] or poloxamine 908-coated particles [54]. 
 Beside pegylation, coating with surfactants, such as polysorbate 
80 (Tween 80) has been studied for a long time as an effective tool 
to increase NP delivery through the BBB [54, 64]. Polysorbate 80-
coated PEG-PHDCA NPs were shown to be well delivered in mice 
brain [54]. In this study polysorbate-80 was reported to increase the 
permeability to [
14
C]-sucrose [54], suggesting that the increased 
transport might be the consequence of increased paracellular, rather 
than transcellular transport. Other mechanisms, however, are possi-
ble: polysorbate 80 has been reported to enhance the phagocytosis 
of the coated NPs [64] and to reduce their efflux by Pgp [65]. As 
result of these findings, polysorbate 80-coated NPs allow drugs 
with poor CNS penetration, like doxorubicin, to be transported 
faster across the BBB. When we compare the CNS accumulation of 
doxorubicin in rats treated intravenously with free doxorubicin 
dissolved in 1% polysorbate 80, uncoated PBCA-doxorubicin or 
polysorbate 80-coated PBCA-doxorubicin, only the last formulation 
effectively increased the drug levels in all the CNS sections exam-
ined [66]. This study illustrates that an appropriate coating is crucial 
for enhanced delivery through the BBB. The presence of polysor-
bate 80 increased antitumor activity as well: PLGA NPs that carried 
doxorubicin were more cytotoxic against A172 human glioblastoma 
cells than non-coated NPs [67]. Differently from PEG, however, 
coating with polysorbate 80 did not prevent the sequestration of 
NPs by the reticulo-endothelial system [68]. 
Active Targeting by NPs Across BBB 
 The presence of adsorbed or covalently-bound ligands on NPs 
surface further improves delivery across the BBB, by receptor-
triggered endocytosis, more efficient than non-specific endocytosis 
[61, 69]. The most common receptors used for the active targeting 
by NPs on BBB cells are the insulin receptor, the transferrin (Tf) 
receptor, the low density lipoproteins receptor (LDLR), the LDLR-
related proteins (LRPs), the folic acid receptor and the diphtheria 
toxin receptor [49]. 
 Tf-conjugated NPs were delivered more effectively than uncon-
jugated ones within the CNS [70, 71], thanks to the abundance of 
Tf receptor in the BBB [61]. Tf-conjugated NPs were internalized 
by clathrin-mediated and energy-dependent endocytosis. It was 
recently shown that Tf-conjugated NP transcytosis across the mur-
ine microvascular brain endothelial cells bEnd3 involves the pas-
sage through the endosomal/lysosomal compartments and the Golgi 
apparatus [71]. Besides Tf-conjugated NPs loaded with drugs, Tf-
conjugated HA loaded with gadolinium were manufactured and 
proposed as sensitive tracers for MRI, due to more efficient deliv-
ery within the CNS parenchyma [72]. 
 Also LDLR and LRPs trigger efficient receptor-driven endocy-
tosis followed by transcytosis. They can recognize apo-lipoproteins 
as substrates, or synthetic peptides like Angiopep-2 [73], which 
were widely used in the design of targeted NPs. HA NPs covalently 
bound with apolipoprotein E (apoE) were delivered more efficiently 
than unconjugated HA NPs in brain parenchyma after intravenous 
injection into SV 129 mice [74]. The imaging analysis of apoE-HA 
uptake in mouse brain endothelial cells bEnd3 demonstrated a typi-
cal transcytotic pathway [74]. A surprising observation reported 
that PEG-PHDCA NPs not conjugated with apolipoproteins were 
internalized via a LDLR-mediated endocytosis as well, suggesting 
the existence of non-specific interactions with the receptor [75]. 
The efficiency of internalization was however increased by the 
attachment of specific ligands [74, 76, 77]. When pre-incubated 
with rat serum, PEG-PHDCA NPs spontaneously adsorbed apol-
ipoprotein B100 (apoB100) and apoE on their surface, and were 
delivered more efficiently to the CNS than apolipoprotein-free NPs 
[78]. However, adsorbing the whole protein on the NPs surface is 
neither yield- nor cost-effective. Not all the adsorbed proteins have 
the necessary conformation to bind to the receptor on the NP sur-
face. To overcome these drawbacks, NPs conjugated only with the 
receptor-binding sequences of apoE [79] and apoB100 [80] were 
synthesized. These sequences were sufficient to trigger receptor-
mediated endocytosis and subsequent delivery to brain parenchyma. 
When loaded with paclitaxel oleate, synthetic LDLs showed good 
anti-cancer activity in rats with glioblastoma [81]. Similarly, when 
a Tf-receptor targeting peptide, instead of the whole protein, was 
conjugated to gold NPs the efficiency of their passage across the 
BBB was maximized [82]. 
 Folic acid receptor is another commonly used target: folic acid-
conjugated SLNs effectively delivered docetaxel, which is other-
wise undeliverable to the CNS across the BBB [83]. When -
polyglutamic acid (-PGA) is attached on the surface of NPs, the 
length of the -PGA chain is a critical factor that determines the 
permeability across the BBB: PLGA NPs carrying the antiretroviral 
drug saquinavir conjugated with low molecular weight -PGA were 
more efficiently transported across the BBB than other PLGA NPs 
formulations [84]. This observation concurs with other evidence 
where PEG-PLGA NPs conjugated with serum bovine albumin had 
different stability and clearance rates, depending on the amount and 
density of the albumin molecules attached to the PEG-PLGA sur-
face: only specific albumin/PLGA ratios allowed a good delivery 
within CNS [85].  
 Actively targeted NPs were effective not only for drug delivery, 
but also in the context of gene therapy. Anti-sense oligonucleotides 
for nuclear factor-kB (NF-kB), conjugated with a copolymer of 
biotin-PEG/polyethyleneimine and linked to a monoclonal antibody 
anti-Tf receptor were easily uptaken in brain murine microvascular 
endothelial cells and down-regulated the NF-kB-dependent pro-
inflammatory pathways [86]. This strategy needs further discussion 
for the treatment of neuro-inflammatory diseases. DNA-carrying 
PAMAM dendrimers, conjugated with Angiopep-2 (a 19-mer pep-
tide that crosses the BBB) through bifunctional PEG, were recog-
nized by LRP1 on brain capillary endothelial cells: they were inter-
nalized through clathrin- and caveolae-mediated and energy-
dependent endocytosis, and partially through macropinocytosis. In 
vivo, they showed stronger gene delivery than unconjugated 
PAMAM dendrimers in brain parenchyma [73]. Similarly, a good 
delivery of specific siRNAs with anti-tumor activity was achieved 
in glioma-bearing rats treated with biotinylated siRNA conjugated 
to a monoclonal antibody against Tf-receptor through a streptavidin 
linker [87]. To simultaneously increase the passage across BBB and 
the docking on tumor cells, dendrimers were conjugated with more 
than one ligand, as occurred for the dual targeting PEG-PAMAM 
dendrimers conjugated with Tf and wheat germ agglutinin on their 
surface, and loaded with doxorubicin into their core [88]. 
 The major drawback in using Tf, folic acid or apolipoproteins 
as NPs ligands is that their receptors are widespread. Therefore the 
risk of NPs uptake by other tissues cannot be excluded. Only the 
design of NPs with selective tropism for brain endothelial cells 
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could switch this “unspecific” targeting into a BBB-specific one. In 
order to circumvent this problem, experiments of phage-display 
helped identify a number of short peptides that interacted more 
specifically with human cerebral microvascular endothelial cells 
(hCMEC/D3) than with human umbilical vein ones [89]. Although 
the targets of these peptides are not known, they should be investi-
gated for the future design of more BBB-selective NPs. Similarly, a 
high-throughput screening of two libraries of mono- and di-
methylated diketopiperazine-conjugated dipeptides identified a 
number of peptide shuttles with a strong ability to cross the BBB 
[90]. Further studies are necessary to verify the specific tropism of 
these peptides for the BBB endothelium and to identify their tar-
gets. 
NPs as Effective Tools to Bypass the ABC Transporter-
mediated Efflux in the BBB 
 Beside showing greater uptake by the BBB cells, NP-carried 
drugs also show less efflux by ABC transporters. The first studies 
reporting this property of NPs were done on tumors that over ex-
pressed ABC transporters and showed synchronous resistance to 
different anti-cancer drugs, a phenotype known as multidrug resis-
tance. The discovery of the role of ABC transporters in BBB cells 
gave a strong push towards the design of drug-loaded NPs less sen-
sitive to the activity of these pumps. Methotrexate, a drug which 
does not cross the BBB, became highly cytotoxic against C6 rat 
glioma cells when carried by chitosan and glycol chitosan NPs 
coated with Tween 80. This formulation of methotrexate was also 
able to cross the monolayer of MDCKII cells overexpressing Pgp, 
an in vitro model of BBB [46]. Although these results remain to be 
validated in vitro with endothelial cells from brain capillaries and in 
vivo, they suggest that NPs can rescue the therapeutic benefit of a 
drug – such as methotrexate – otherwise undeliverable across the 
BBB. Also, docetaxel, another substrate of Pgp, is poorly trans-
ported within the CNS: it was however well delivered to brain pa-
renchyma when loaded into folic acid-conjugated SLNs [83]. Of 
note, the efflux of docetaxel by Pgp increases further with the con-
current administration of other drugs interacting with Pgp, like 
ketoconazole. Since the co-administration of medications is com-
mon in medicine, drug-to-drug interactions and their potential nega-
tive effects on CNS delivery need investigation. Venishetty and 
coworkers showed that when docetaxel and ketoconazole were both 
loaded in SLNs, ketoconazole no longer increased the efflux of 
docetaxel through Pgp [83], suggesting that the SLNs formulation 
nullified any interaction of the substrates with Pgp. Also paclitaxel 
[56] and doxorubicin [66, 67, 88] were less affected by the Pgp-
mediated efflux if carried by NPs.  
 It is not clear whether the inhibition of Pgp is caused by any 
specific components of the NPs. On one hand, some NPs are less 
effluxed than others by multidrug-resistant cancer cells: pluronic-
coated NPs strongly inhibited the activity of Pgp in cancer cells as 
well as in BBB cells, with different mechanisms, such as ATP de-
pletion and changes in membrane fluidity. These events forced Pgp 
to work with lower efficacy [91]. PEG itself inhibits the activity of 
Pgp, by changing the physicochemical properties of plasma mem-
brane and altering the binding affinity of the substrates to Pgp [92]. 
PEG-NPs loaded with paclitaxel protected the drug from the Pgp-
mediated efflux [93]. Finally, surfactants – such as Cremophor EL, 
Triton X-100, Nonidet P-40, Tween 20 – may inhibit Pgp, by in-
creasing the fluidity of the lipid bilayer [91]. How polysorbate 80, 
one of the most commonly used surfactants in NP synthesis, inhib-
its Pgp remains unclear: it has been reported that polysorbate 80 
modulates Pgp activity, without causing any conformational change 
of the transporter [94]. In in vitro studies surfactants inhibit Pgp at 
micromolar/millimolar concentrations; these conditions, however, 
are hardly reproducible in vivo, because surfactants are toxic at such 
concentrations. Therefore, the biochemical mechanisms that make 
surfactant-coated NPs more effective than uncoated NPs in vivo 
remain largely unknown. In summary, the identification of the NP 
component – core compounds, PEG coating, surfactant coating – 
responsible for the Pgp inhibition will help optimize the design of 
NPs less susceptible to Pgp efflux. 
 While several works have reported that NPs-carried drugs by-
pass the efflux of Pgp, a few studies have reported the effects of 
NPs on the other ABC transporters [95, 96]. Since the BBB con-
tains many different ABC transporters and the same drug can be 
effluxed by more than one transporter, the inhibition of Pgp alone is 
not enough to guarantee the delivery of the drug to the CNS. 
Moreover, since some ABC transporters – like MRP3, MRP5 and 
MRP6 – are mainly located on the basal surface of BBB cells, their 
inhibition by NPs would result in the drug retention within the en-
dothelial cells rather than in their delivery to brain parenchyma. 
Although these issues are still largely unknown, they must com-
mend our attention if we want to improve the future design of NPs 
able to bypass specific ABC transporters and deliver their load to 
the CNS with maximum efficiency. 
 A recent interesting application of NPs is the delivery of pep-
tides, like Leu-enkephalin, after oral administration: while free 
peptides are usually degraded within the gastro-intestinal lumen, 
peptides loaded into NPs were able to enter into the portal circula-
tion, reach the systemic circulation and were delivered unaltered to 
the brain parenchyma [97]. From these findings it can be inferred 
that NPs protect peptides from the hydrolysis of proteases in the 
gastro-intestinal tract. It should be noted that enterocytes and hepa-
tocytes also carry ABC transporters, which efflux drugs taken by 
mouth back into the intestinal lumen and in the biliary tract, respec-
tively. We can speculate that the protective effects of NPs is caused 
– at least in part – by the lower efflux by ABC transporters in these 
tissues, which in turn cause increased systemic concentrations of 
the drugs to reach the BBB. 
NP Distribution and Toxicology In vivo 
 Before we try to move on to novel NP-based therapies in vivo, 
two critical issues should be examined: 1) NPs distribution in the 
CNS after crossing the BBB and 2) NPs toxicology profiles.  
 The use of capillary depletion technique, the labeling of NPs 
with radioactive, magnetic or fluorescent moieties, and the subse-
quent analysis of brain sections with PET, SPECT, MRI and fluo-
rescence microscopy was helpful to resolve whether NPs show 
uniform distribution within the brain parenchyma or are preferen-
tially concentrated in specific areas. Notably, different NPs have 
different levels of distribution within the CNS. Labeled PHDCA 
NPs were found in the epithelial cells of choroid plexus, in pia ma-
ter, in the ventricular system and – to a minor extent – in endothe-
lial cells, suggesting that the vast majority of NPs were not retained 
within BBB cells but were effectively delivered into the CNS pa-
renchyma [54]. ApoE-conjugated HA was found in brain capillary 
endothelial cells and neurons [74], likely because of the presence of 
receptors for apolipoproteins on both endothelial cells and neurons. 
Since different CNS cell types and different CNS areas may have 
different patterns of surface receptors, the choice of appropriate 
ligands may direct conjugated NPs towards selected cell popula-
tions or areas. This approach could be particularly useful in diseases 
that arise from specific cell types or areas, such as brain tumors, 
neurodegenerative diseases and epilepsy. To design effective tissue 
specific therapies, it is imperative that we know the receptor com-
position of the CNS and manufacture NPs conjugated with specific 
ligands. Studies in CNS tumor-bearing animals have shown that NP 
levels are higher in tumors than in the parenchyma surrounding 
them [68]. This EPR effect is not specific of CNS tumors as it is 
common to most tumors, where the vascular architecture is differ-
ent than normal tissues and acts as a “sink” for NPs. Nanotechnolo-
gies can further increase the distribution to CNS tumors by design-
ing dual-targeted NPs, i.e. NPs which recognize BBB and CNS 
tumor cells at the same time. Docetaxel-carrying NPs conjugated 
with the TGN peptide, selected by phage-display as a molecule 
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targeting the BBB, and with an aptamer targeting the surface of 
glioma cells, has been recently proven to reach high intratumor 
concentrations and cytotoxic efficacy [98]. 
 In recent years, the increasing exposure to NPs of environ-
mental or medical origin has shown their potential toxicity for 
mammalian tissues especially for blood-tissue interfaces, which are 
heavily exposed to NPs. Until now, the effects of NPs on BBB cells 
are poorly described. In the case of iron-oxide NPs, it has been 
shown that size, concentration, agglomeration and surface physico-
chemical properties are critical for neurotoxicity [99]. Recent work 
compared the effects of acute and repeated/chronic exposure of 
brain endothelial cells to TiO2 NPs. While acute exposure de-
creased the activity of Pgp without disrupting the integrity of BBB, 
chronic exposure decreased the expression of ABC transporters, 
impaired TJ integrity and induced the synthesis of pro-inflam-
matory cytokines, which may in turn produce a dysfunction of mi-
croglial cells [58]. This study suggests the need to consider the 
long-term toxicity of drug-loaded NPs, still largely unknown, 
mainly because long observational in vivo studies have not been 
done. From this perspective, liposomal drugs, made of cholesterol 
and endogenous phospholipids, at least theoretically appear to be 
safer and more biocompatible tools than NPs.  
LIPOSOME-BASED STRATEGIES FOR DRUG DELIVERY 
ACROSS THE BBB 
The Passive Targeting of Liposomes Across BBB: Effects of 
Size, Charge Surface and Coating 
 Liposomes, like NPs, must meet three basic requirements to 
produce therapeutic effects when administered systemically: 1) 
prolonged circulation in the bloodstream, 2) sufficient accumulation 
in the target tissue and 3) controlled drug release and uptake by the 
target cells [100]. As it occurs for NPs, size, surface charge, coating 
with PEG and surfactants are features very important for making 
stealth liposomes that can be delivered efficiently to specific com-
partments like the BBB. PEG allows a long-lasting circulation of 
liposomes [101]; of note, the length of the PEG chain influences 
delivery across the BBB [102]. Also surface charge is critical, fa-
voring or impairing liposomal uptake by the endothelial cells of 
brain capillaries. Cationic liposomes seem to be particularly well 
endocytosed by BBB cells: they can be produced as liposomes or as 
pro-liposomes, i.e. as neutral or negatively charged liposomes at pH 
7.4, that can switch into cationic ones once they reach the endoso-
mal compartment of the BBB cells [103]. Since a specific surface 
charge of liposomes may not be compatible with the encapsulation 
of charged drugs, the synthesis of pro-liposomes with a pH-
dependent surface charge may widen the spectrum of the encapsu-
lated drugs. 
 Just like NPs, liposomes can carry more than one drug. For 
instance, chemotherapeutic drugs and an inhibitors of ABC trans-
porters were co-encapsulated within the liposomal shell in the 
treatment of CNS tumors, which are rich of ABC transporters 
[104]. The synchronous delivery of conventional chemotherapeutic 
agents and gene silencing or expression vectors has been recently 
investigated [105], as an alternative approach to the classical phar-
macological therapy of CNS tumors. Also the simultaneous admini-
stration of two liposomal formulations, one containing a chemo-
therapeutic drug – like doxorubicin – and the other containing an 
adjuvant molecule – like the tumor necrosis factor-related apopto-
sis-inducing ligand (TRAIL), achieved good antitumor effect [106].  
 Pro-drugs, instead of the active drugs, have been encapsulated 
as well: this approach looks particularly useful when the drug is at 
risk of being effluxed by the BBB cells or catabolized before reach-
ing its target, as it occurs for dopamine. An interesting study pro-
posed the encapsulation of the dopamine pro-drug 2-amino-N-[2-
(3,4-dihydroxy-phenyl)-ethyl]-3-phenyl-propionamide, within 
unilamellar liposomes. When packaged this way, the drug remained 
protected from photodegradation, stable in plasma, deliverable 
across the BBB thus producing dopamine in the brain [107]. An-
other example comes from neurotensin-degrading enzyme inhibi-
tors, which have potential therapeutic benefit in neuropsychiatric 
disorders, but are highly unstable in the blood stream and cannot 
cross the BBB: liposomal encapsulation overcame these limitations 
[108]. Similarly, cytidine 5' diphosphocholine, a neuroprotective 
agent in the cerebral ischemia-reperfusion syndrome, is hydrolyzed 
in the liver and cannot reach the BBB as is. Liposomal encapsula-
tion allowed it to bypass liver catabolism and to reach the brain 
parenchyma at sufficient therapeutic concentrations [109]. 
 Because of different pharmacokinetic profiles and different 
mechanisms of extravasation, drugs encapsulated in PEG-liposomes 
are retained in ischemic areas longer than free drugs: this observa-
tion has led to the development of liposomal-based strategies to 
deliver erythropoietin in areas of cerebral ischemia, attempting to 
prevent the ischemia/reperfusion damages that occur with stroke 
[110]. Methylprednisolone is a drug with potential therapeutic 
benefit in neuroinflammatory diseases, like multiple sclerosis, that 
does not cross the BBB: its liposomal encapsulation overcame this 
obstacle and reduced clinical symptoms in experimental autoim-
mune encephalomyelitis [111].  
 By varying the lipid composition and charge, liposomes can be 
easily loaded with DNA, siRNAs or anti-sense oligonucleotides, 
which are then kept from degrading until they reach their target 
cells. For obvious ethical reasons, the studies in this field have been 
performed only in vitro or in animals, but they attained striking 
results both in experimentally-induced CNS tumors and neurode-
generative conditions, such as Parkinson disease (PD) and 
Creutzfeldt-Jakob disease [112, 113]. 
 Specific liposomes that release drugs under controlled physical 
stimuli have also been manufactured, such as temperature-sensitive 
liposomes, which release their load in a temperature-dependent 
manner. Of note, mild hyperthermia (i.e. 42°C) increased both the 
rate of delivery across the BBB and the release of doxorubicin from 
thermosensitive liposomes, reducing the growth of glioma in rats 
placed in a 42°C-bath effectively [114]. 
 Magnetic-field sensitive liposomes can be prepared by loading 
Fe3O4 into the liposomal envelope. The application of an external 
magnetic field increased the BBB passage by endocytosis and by 
monocyte-mediated transport. This strategy is currently under in-
vestigation to produce BBB-permeating formulations of the anti-
retroviral drug azidothymidine 5’-triphosphate [115]. Lastly, 
liposomes were also used in diagnostics, by incorporating specific 
isotopes for PET imaging within liposomes: for instance, 
18
F-
labelled liposomes targeted with the Ala-Pro-Arg-Pro-Gly peptide, 
which recognizes angiogenic areas, were successfully used as sensi-
tive PET tracers for the early diagnosis of glioma [116]. 
The Active Targeting of Liposomes Across BBB 
 Liposomes, like NPs, can be conjugated with specific antibod-
ies and ligands to enhance endocytosis by BBB cells; several stud-
ies using Tf, lactoferrin, insulin, GSH, apolipoproteins and peptides 
reported the successful delivery of targeted-liposomes to the brain 
parenchyma. This approach is known as “Trojan horse” strategy 
[40, 42, 112], because it allows a drug “masked” as another mole-
cule to enter into the endothelial cells of brain capillaries. Most of 
these liposomes enter the BBB cells by a mechanism of receptor-
triggered endocytosis, which is clathrin-dependent [103]. 
 Tf-conjugated PEG-liposomes were uptaken by BBB cells more 
than unconjugated liposomes and subjected to transcytosis. In co-
culture systems, Tf-conjugated PEG-liposomes effectively deliv-
ered high amounts of boron-10 into human glioma U87-MG cells, 
sufficient to exert cytotoxic effects in boron neutral capture therapy 
[117]. 
 Liposomes conjugated with monomers or tandem dimers of the 
apoE-derived peptide containing the residues 141-150 were uptaken 
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by hCMEC/D3 cells in a manner that depended on the peptide's 
density, appearing promising carriers for drug delivery within the 
CNS [118]. We recently produced an “LDL-masked” liposomal 
formulation of doxorubicin, by conjugating an LDLR-targeting 
peptide from human apoB100 to anionic pegylated liposomes [119]. 
We found that the liposomal uptake was increased by a preventive 
stimulation with statins, which per se decreased the endogenous 
synthesis of cholesterol and forced cells to increase the amount of 
LDLR on their surface. This event occurred in both epithelial tu-
mors [119] and human BBB cells [120]. Besides favoring the up-
take of the LDL-masked liposomes by hCMEC/D3 cells, this ap-
proach takes advantage of the chemosensitizing properties of stat-
ins, which increase the endogenous synthesis of nitric oxide, an 
inhibitor of ABC transporters [121]. In the case of hCMEC/D3 
cells, statins decreased the activity of Pgp and BCRP, two trans-
porters localized on the luminal surface and thus involved in the 
brain-to-blood flow of drugs. Using BBB-penetrating statins, like 
mevastatin and simvastatin, similar effects (i.e. increased surface 
LDL receptor, decreased ABC transporter activity) were achieved 
in U87-MG glioblastoma cells cultured under hCMEC/D3 mono-
layer. Thanks to the concurrent targeting of BBB and tumor cells, 
the pre-treatment with statins allowed LDL-masked liposomal 
doxorubicin to cross the BBB, to accumulate within tumor cells and 
to exert their cytotoxic effects [120]. 
 A similar “dual-targeting” approach – i.e. the dual ability to 
cross the BBB and target CNS cells – can be also achieved by con-
jugating liposomes with more than one ligand, i.e. one ligand spe-
cific for endothelial cells and the other specific for CNS cells. For 
instance, PEG-immunoliposomes conjugated with an anti-Tf recep-
tor antibody were further conjugated with an anti-A antibody: 
these dual-targeting liposomes were well delivered across the BBB 
and directed to the A peptide in the brain parenchyma [122], thus 
appearing as potential tools against Alzheimer’s disease (AD). Dual 
targeting liposomes carrying daunorubicin, conjugated with Tf and 
p-aminophenyl-alpha-D-manno-pyranoside (which recognize the 
BBB and glioma surface, respectively), were successfully used in 
glioma-bearing animals [123]. Dual targeting also increases the 
uptake of liposomes by BBB cells, because it may overcome the 
saturation limit observed when endocytosis is single receptor de-
pendent [124]. 
 The specific tropism of liposomes for BBB or CNS cells is 
problematic at the present, since most ligands (e.g. Tf, insulin, 
GSH) are not tissue-specific. Phage-display screening identified 
specific short peptides targeting the BBB [89]: disappointingly, 
when conjugated to liposomes, these peptides bound to the surface 
of hCMEC/D3 cells much less efficiently than when displayed by 
the native phage [125]. The conjugation with liposomes indeed 
altered the folding of the peptides, preventing them from binding to 
their target receptor [125]. The preservation of proper folding, as 
well as the ligand density on the liposomal surface, are two factors 
that may limit the efficiency of the BBB uptake. If these features 
are not carefully studied before we manufacture new targeted 
liposomes, then we might incorrectly judge a ligand 'ineffective', 
when in fact such 'ineffectiveness' might be caused by either wrong 
folding or wrong ligand density. Great attention must be paid to all 
the synthetic steps; subsequently careful validations of targeted 
liposomal formulations must be made, both in vitro and in vivo, to 
identify which conditions maximize delivery efficiency. 
Liposomes as Effective Tools to Bypass the ABC Transporter-
mediated Efflux in the BBB 
 After the successful treatment of unresponsive cancers with 
drug-loaded liposomes, it was hypothesized that liposomal formula-
tions might overcome the drug efflux of ABC transporters.  
 Besides sustaining prolonged release within the tumor [126], 
liposomal drugs are less potent inducers of Pgp than free drugs 
[127]. One work suggested a direct interaction between liposomes 
and Pgp, since liposomes inhibited the binding of free vincristine to 
Pgp [128]. Our group recently reported that liposomal doxorubicin 
acts as an allosteric inhibitor of Pgp, reduces ATP hydrolysis and 
competes with verapamil and colchicine for Pgp binding [129]. 
Site-directed mutagenesis suggested that the putative site of interac-
tion between the liposomal drug and Pgp is a domain centered on 
glycine 185, overlapping with a “low-affinity drug binding site” of 
Pgp [129]. It is unlikely, however, that the entire structure of a 
liposome interacts with a specific binding site on Pgp; it is more 
plausible that a specific component of the liposomal shell or a lipid-
associated form of doxorubicin be the actual modulator of Pgp, and 
that this yet unidentified compound hampers the binding and efflux 
of other substrates. Surprisingly, also empty liposomes inhibit the 
activity of Pgp, because they alter the composition of phospholipids 
and fatty acids in membrane microdomains (i.e. lipid rafts) where 
Pgp operates [129]. The increased fluidity of the plasma membrane 
observed in cells treated with liposomes may change the conforma-
tion of Pgp or force the protein to work in a non-optimal environ-
ment. 
 Only one study reported an inhibitory effect of liposomes on 
MRP transporters [127]; since MRPs are also highly embedded in 
the plasma membrane bilayer and depend on a proper lipid compo-
sition for their activity, we cannot exclude that liposomes reduce 
the activity of MRPs by impairing the architecture of the cell mem-
brane, as it occurs for Pgp.  
 Such inhibitory properties of liposomes on ABC transporters 
make liposomal drugs potentially useful not only against drug-
resistant tumors, but also for drug delivery across the BBB. The 
first few studies on the BBB focused mostly on chemotherapeutic 
drugs with poor BBB penetration, such as doxorubicin, which is 
highly effective against glioblastoma cells in vitro but highly ef-
fluxed by Pgp, MRP1 and BCRP in the BBB. Although different 
formulations of liposomal doxorubicin may have different anti-
tumor efficacy, pharmacokinetic profile and side-effects [130], 
there is a general agreement about the higher permeability of 
liposomal doxorubicin across the BBB compared with free doxoru-
bicin [131, 132]. 
 Paradoxically, liposomal formulations of doxorubicin, vincris-
tine and irinotecan in glioma-bearing rats decreased the growth rate 
of tumors but increased the BBB properties in glioma vessels [133]. 
The BBB is often disrupted within the core of a glioblastoma, 
where poorly organized vasculature develops by neo-angiogenesis. 
It has been shown that liposomes induce selective damages on im-
mature and proliferating endothelial cells of solid tumors, but spare 
mature and quiescent endothelium [134]. In glioblastoma the rescue 
of a competent BBB is usually associated with tumor regression. 
Such observation may explain the efficacy of liposomes in this 
context. From this point of view, liposomes have a dual effect, be-
ing carriers of anti-cancer drugs across a competent BBB (i.e. in the 
brain-adjacent-to-tumor area, where metastasizing tumor cells are 
present), and anti-angiogenic agents where the BBB is disrupted 
(i.e. in the tumor core). This broad spectrum of effects makes 
liposomes particularly promising as anti-glioblastoma tools. 
Liposomes Toxicology In vivo 
 Some authors have proposed that the use of liposomes is safer 
than the use of NPs [135]. This observation however may be biased, 
as studies using liposomes as carriers of drugs within the CNS are 
significantly fewer than those using NPs. On the other hand, 
liposomes may be truly less toxic that NPs, because they are made 
up of phospholipid (e.g. phosphatidylcholine, phosphatidylethano-
lamine, phosphatidylserine, phosphatidyl glycerol) and cholesterol, 
which are physiologically incorporated into the cell membrane and 
subsequently degraded. Conversely, as we have previously ob-
served in epithelial tumors, the liposomal envelop alters the compo-
sition of phospholipids and fatty acids of cell plasma membrane 
[129] and may impair the activity of integral membrane proteins, 
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such as transporters and receptors. So far, we cannot exclude that 
the prolonged exposure to liposomes may result in damages of cell 
plasma membrane and surface proteins. As there have been no toxi-
cological studies on the long-term effects of liposomes to date, this 
issue remains unclear. 
CLINICAL IMPLICATIONS OF DRUG DELIVERY 
STRATEGIES ACROSS THE BBB 
 In recent years, we have been watching the first few pioneering 
applications of NP- and liposome-based strategies for drug delivery 
across the BBB in CNS tumors, infections, neurodegenerative con-
ditions and epilepsy (Table 2). 
 Malignant gliomas are the most common brain tumors. High-
grade gliomas, such as glioblastoma multiforme, and CNS metasta-
ses of systemic tumors have high levels of ABC transporters. Their 
response to radio- and chemotherapy is poor, because most anti-
cancer drugs (doxorubicin, daunorubicin, etoposide, teniposide, 
paclitaxel, docetaxel, vincristine, vinblastine, cisplatin, methotre-
xate) do not cross the BBB or penetrate tumor cells [136]. Moreo-
ver, approximately 10% of patients with extra-CNS tumors develop 
brain metastasis, also chemoresistant and usually surrounded by a 
competent BBB [137]. 
 These new strategies for drug delivery may improve the effi-
cacy of conventional chemotherapy against primary and metastatic 
brain tumors, provided that the delivery systems are safe for normal 
CNS cells [138]. The EPR effect causes rather selective accumula-
tion of NPs and liposomes within the tumor tissue. Furthermore, 
tumor cells sometimes display antigens and surface markers that are 
not expressed or expressed at lower levels in non-transformed cells. 
These markers can be used as docking sites to increase the concen-
tration of actively targeted NPs and liposomes within tumor cells 
[139]. Human glioblastoma for instance selectively expresses dif-
ferent receptors for interleukin-13 (IL-13). IL-13-conjugated 
liposomal doxorubicin reduced the growth of glioma in mice, with-
out cytotoxic effects on BBB cells [140]. A few years ago, it was 
reported that doxorubicin-carrying NPs improved the survival of 
rats bearing the aggressive glioblastoma 101/8 and induced com-
plete histological remission at 6 months in 20-40% of the animals 
[141]. Since then, the number of studies using formulations of 
doxorubicin-carrying NPs and/or liposomes has been increasing 
steadily. Doxyl/Caelyx, the liposomal doxorubicin approved for 
breast and ovarian cancers has been used in phase I/phase II clinical 
trials in patients with glioblastoma: the drug was well tolerated and 
had few side-effects, although it did not significantly improve over-
all and progression-free survival when compared to the standard 
regimens based either on temozolomide or combination radiation 
therapy and chemotherapy [132, 142, 143]. 
 Many promising studies have been performed in animal mod-
els, that used either NPs or liposomes carrying various chemothera-
peutic agents [80, 114, 123, 133] or gene-targeting tools. PAMAM-
PEG-Angiopep-conjugated dendrimers carrying an expression vec-
tor of TRAIL were more effective than temozolomide alone in in-
ducing glioma regression [144]. PEG-SLN carrying c-Met siRNA 
effectively reduced the growth of U87-MG glioblastoma cells in 
orthotopic xenografts, without systemic toxicity [145]. 
 Viral infections, in particular cerebral infection with HIV, are 
under active investigation, because most anti-retroviral drugs are 
effluxed by Pgp at the BBB level. The administration of the antiret-
roviral drugs zidovudine, lamivudine and nelfinavir carried by NPs 
coated with pluronic 85, which reduces the activity of Pgp, im-
proved the symptoms of HIV encephalitis in mice [146]. Similarly, 
indinavir carried by solutol-coated NPs was delivered to mice brain 
significantly better than free indinavir [147]. Different drugs carried 
by the same NPs may be delivered differently, as suggested by 
work done with stavudine, delviridine and saquinavir loaded meth-
ylmethacrylate-sulfopropylmethacrylate NPs [148]. Differences in 
solubility and surface characteristics may explain different rates of 
drug uptake within the BBB cells. Differences in the affinity of 
each drug for ABC transporters may account for a different brain-
to-blood efflux. Of note, Tf-conjugated NPs carrying saquinavir not 
only crossed the BBB better than the free drug, but were also more 
effective in reducing the replication of HIV in peripheral blood 
monocytes in animals [149], suggesting that NPs may have some 
anti-retroviral activity themselves [150]. Similarly, dendrimers 
carrying specific siRNA reduced the replication of the HIV strains 
X4-HIV NL4-3 and R5-HIV BaL in infected human astrocytes 
[151]. 
 Neurodegenerative disorders, such as AD and PD, are another 
potential field of application for NP- and liposome-based strategies. 
Promising drugs and therapeutic tools for these conditions have 
Table 2. Clinical applications of nanoparticle- and liposome-based strategies in central nervous system diseases 
Disease Biological rationale for using NPs and liposomes Pre-clinical and clinical applications of NP- and liposome-based  
strategies 
Malignant gliomas Presence of surface receptors for active targeting on 
BBB cells 
Presence of ABC transporters on BBB and CNS 
cells 
Use of NPs and liposomes carrying chemotherapeutic drugs in animal 
models [76, 100, 109, 129, 136,137] 
Use of NPs for gene therapy in animal models [140,141] 
Use of liposomal doxorubicin in phase I/phase II trials [108, 138,139] 
HIV infections Overexpression of Pgp on BBB cells 
Inhibitory effects of NPs on HIV replication 
Use of NPs carrying antiretroviral drugs in animal models of HIV-induced 
encephalitis [142-144] Use of dendrimers for gene therapy [147] 
Neurodegenerative disorders 
(AD, PD) 
Changes in Pgp expression on BBB cells, associ-
ated with increased accumulation of A in CNS and 
altered drug delivery across BBB  
Use of NPs for immunotherapy and early diagnosis of AD [149] 
Use of curcumin-carrying PLGA NPs as amyloid disaggregating agents 
[150]  
 Use of L-DOPA-carrying liposomes for PD treatment [152]  
Epilepsy Increase in Pgp, MRPs and BCRP on BBB cells 
and epileptogenic foci  
Use of NPs carrying ANEP [156]  
HIV: human immunodeficiency virus; AD: Alzheimer’s disease; PD: Parkinson’s disease; BBB: blood-brain barrier; CNS: central nervous system; ABC: ATP-binding cassette; Pgp: 
P-glycoprotein; MRP: multidrug resistance related protein; BCRP: breast cancer related protein; A, amyloid ; NP: nanoparticle; PLGA: poly(lactic-co-glycolic acid); ANEP: anti-
neuroexcitation peptide. 
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little use in vivo, as they do not not easily cross the BBB [152]. 
Recent studies showed that A is an endogenous substrate of Pgp, 
that can be cleared from the brain and easily effluxed back to the 
bloodstream [16]. In the transgenic Tg2576 murine model of AD, 
which overexpresses the human amyloid precursor protein, the 
decrease in Pgp levels on BBB cells is responsible for the accumu-
lation of A and one of the first signs of AD. Conversely, the up-
regulation of Pgp through the pregnane X receptor-mediated tran-
scription of Pgp with pregnenolone-16-carbonitrile, reduced the 
accumulation of A within the CNS in the first stages of AD [26]. 
Interestingly, the role of Pgp in AD is duplicitous: on one side, it 
prevents the early damages from the abnormal accumulation of A; 
on the other , it represents an obstacle for potentially useful drugs to 
move across the BBB. For this reason, the development of NP-
based strategies has been particularly active in the last few years. 
Several immunotherapeutic strategies based on NPs have been stud-
ied: for instance anti-A antibodies, which do not cross the BBB, 
were able to do so when carried by chitosan-coated PLGA NPs 
[153]. Chitosan also increased the stability and solubility of NPs, 
making them suitable for other applications, such as the delivery of 
diagnostic antibodies to detect A in the early stages of AD [153]. 
Curcumin has the interesting property to destroy amyloid aggre-
gates and to be an anti-oxidant; unfortunately, it has low solubility 
in water and crosses the BBB poorly. These shortcomings were 
compensated by loading curcumin into PLGA NPs; the conjugation 
with the Tet-1 peptide, which has affinity for the neuron's surface 
and can trigger retrograde transport, enhanced the effective delivery 
of curcumin to the CNS, thus offering a potential strategy for AD 
treatment [154]. Several SLN and liposomes targeting A have 
been produced [155]; their efficacy has been tested in vitro. It is 
presumably only a matter of time before they get tested in animal 
models. 
 A few promising reports have been published on PD treatment: 
liposomes loaded with L-DOPA, for example, increase drug avail-
ability in nigrostriatal cells, where L-DOPA is converted into do-
pamine [156]. Moreover, liposomes containing a dopamine pro-
drug, which reliably releases dopamine in vitro, were recently syn-
thesized [107]: if their ability to prevent dopamine from peripheral 
enzymatic degradation and to deliver it to the nigrostriatal system is 
confirmed in vivo, this path might greatly improve the current 
therapeutic approach to PD. 
 Resistance to multiple antiepileptic drugs affects at least 30% of 
patients. It is not clear whether anti-epileptic drugs are effluxed by 
ABC transporters on BBB cells [157], we know, however, that Pgp 
is markedly increased in the epileptogenic foci of patients and mur-
ine models. Resistance to therapy seems to correlate directly with 
the activity of Pgp, MRPs and BCRP: the progressive increase in 
Pgp levels – first in brain capillaries and then in neurons – parallels 
the progressive loss of efficacy of antiepileptic drugs and correlates 
with the number and frequency of seizures before therapy [158]. 
Most antiepileptic drugs are highly permeable molecules and there-
fore should be well delivered across the BBB. Nonetheless, improv-
ing their delivery – through depot and slow-release oral formula-
tions, and more recently by NP and liposome systems –, and devel-
oping new anti-epileptic molecules is the object of intensive inves-
tigation [159]. Recently, the anti-neuroexcitation peptide (ANEP) 
was identified as a promising candidate for the treatment of epi-
lepsy. A novel formulation of ANEP loaded into trimethyl-chitosan 
NPs was effectively endocytosed through the BBB and delivered to 
the CNS [160], opening an alternative path to the use of conven-
tional anti-epileptic drugs for refractory epilepsy.  
CONCLUSIONS 
 Remarkable progress has been made in the field of nanomedi-
cine in the last few years. NPs and liposomes with controlled size, 
specific surface charge and surfactant coating, conjugated with 
selective ligands can be synthesized at low cost and with simple 
laboratory equipment. Therefore, the mass of new work that de-
scribes the synthesis and validation of new drug delivery systems in 
this field is growing by the day. 
 Understanding which formulations are best for a specific condi-
tion is a challenge for many reasons. First, we still do not fully un-
derstand by which mechanisms NPs and liposomes cross the BBB. 
Greater knowledge on the molecular mechanisms that increase 
endocytosis and decrease efflux by the BBB will determine better 
choices of specific formulations. From this point of view, the BBB 
model has an undisputed advantage, as it is a model where both the 
endocytotic pathways and the efflux transporters are maximally 
active and tightly controlled. The abundance of ABC transporters in 
the endothelial cells of brain capillaries of bovine, murine and hu-
man origin may help explain by which mechanisms NPs and 
liposomes protect drugs from the ABC transporters-mediated efflux 
(Fig. 2). Creating in vitro BBB models with selective knock-down 
or knock-in of proteins involved in the endocytotic pathway or the 
efflux system is the next challenge: this approach is ideal for high 
throughput screening of NPs and liposomes, and might likely help 
unveil the preferential routes of entry and efflux of specific classes 
of carriers. Besides shedding light on the biological mechanisms of 
NP and liposome delivery across the BBB, it could also translate 
into the design of new NPs and liposomes with specific physico-
chemical properties and better delivery across the BBB. The opti-
mization of nanocarriers design is the next most interesting chal-
lenge for that part of medicine focused on the BBB.  
 With that goal in mind, standardizing the assays on BBB cells 
becomes a critical point. The mechanisms of endocytosis, the pat-
terns of ABC transporters present on luminal and basal side of brain 
endothelial cells and the rate of cerebral flow are different among 
species. For this reason, results obtained in animal models will not 
necessarily be applicable to humans. These differences should be 
taken into account when we analyze the vast body of literature on 
drug delivery across the BBB. Furthermore these differences seem 
to imply that the choice of the experimental model must be rigorous 
and should strictly depend on the nature, be it animal or human, of 
the condition under study.  
 One major advantage of NP- and liposome-based strategies is 
their versatility: once a specific formulation of the carrier is synthe-
sized, its cargo can be easily manipulated to include drugs, siRNA, 
gene-delivering systems or radiotracers. Such versatility broadens 
the uses of NPs and liposomes, from therapeutics, as drug-delivery 
systems in diseases like cancer, epilepsy, infective or neurodegen-
erative disorders, to diagnostics to, eventually, theranostics [161]. 
The number of studies with a theranostic focus in CNS diseases is 
limited and in need of development. Theranostics requires not only 
the design and synthesis of appropriate nanocarriers, but also the 
parallel improvement of imaging techniques, genetics and pharma-
cogenomics. Shortening the time between diagnosis and therapy is 
critical in rapidly growing CNS tumors, such as glioblastoma. 
Therefore the development of NPs for a theranostic use should have 
very high priority, as it appears it might change the treatment and 
prognosis of such critical conditions very quickly. 
 Nanoparticle- and liposome-based strategies may in the end be 
very beneficial. Many unresolved issues however remain. First, 
there is lack of consistent information about their long term toxicity 
and lack of effective strategies for adequate tissue-specificity for 
BBB and CNS cells. The maximal efficacy of NPs and liposomes 
can be achieved by active targeting strategies, but the identification 
of surface targets selectively expressed on BBB cells is only just 
beginning. Two critical actions might help filling this knowledge 
gap: high throughput screening of the surface proteome of primary 
brain endothelial cells and high throughput screening of drug and 
peptide libraries. The combined analysis of those screenings will 
likely identify a tangible number of targets and ligands selective for 
BBB cells, and pave the way for designing NPs and liposomes 
highly specific for the BBB. At the present time, all the strategies 
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for active targeting BBB cells use unspecific targets and ligands, 
and are not reliable, with very few exceptions [89, 90]. This knowl-
edge gap, however, should not be considered as a limitation; rather, 
it should be the starting point for the next challenge, which is to 
develop new drug delivery systems, more and more selective and 
effective.  
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ABBREVIATIONS 
BBB = Blood-brain barrier 
CNS = Central nervous system 
TJ = Tight junctions 
AJ = Adherent junctions 
BCSF = Blood-cerebrospinal fluid barrier 
ABC = ATP-binding cassette 
Pgp = P-glycoprotein 
MRP = Multidrug resistance related protein 
BCRP = Breast cancer resistance protein 
A = Amyloid  
PET = Positron emission tomography 
SPECT = Single-photon emission computed tomogra-
phy 
NP = Nanoparticle 
SLN = Solid lipidic nanoparticle 
HA = Human albumin 
PLGA = poly(lactic-co-glycolic acid) 
PBCA = poly(butyl 2-cyanoacrylate) 
PAMAM = poly(amidoamine) 
GSH = Glutathione 
MRI = Magnetic resonance imaging 
EPR = Enhanced permeability and retention 
PEG = Polyethylene glycol 
PEG-PHDCA = poly(methoxy-PEG-cyanoacrylate-co-
hexadecyl cyanoacrylate 
Tf = Transferrin 
LDLR = Low density lipoproteins receptor 
LRP = Low-density lipoprotein receptor-related 
protein 
apoE = Apolipoprotein E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Nanoparticle- and liposome-loaded drugs are more easily delivered across blood-brain barrier (BBB) than free drugs with at least three mechanisms: 
1) they are favored to enter cells by simple diffusion (passive targeting); 2) they are uptaken by a receptor-triggered endocytosis, if conjugated with specific 
ligands (active targeting); 3) they are less effluxed by ABC transporters: indeed nanoparticles and liposomes can directly inhibit the catalytic cycle of ABC 
transporters and alter the optimal physicochemical properties of the plasma membrane in which the transporters work. Overall, the drugs loaded into these 
delivery systems can pass through the BBB and reach the CNS at therapeutically relevant concentrations. 
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apoB100 = Apolipoprotein B100 
-PGA = -polyglutamic acid 
NF-kB = Nuclear factor-kB 
hCMEC/D3 = Human cerebral microvascular endothelial 
cells 
TRAIL = Tumor necrosis factor-related apoptosis-
inducing ligand 
PD = Parkinson’s disease 
AD = Alzheimer’s disease 
IL-13 = Interleukin-13 
ANEP = Anti-neuroexcitation peptide. 
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FEATURE ARTICLE
The cross-talk between canonical and non-canonical
Wnt-dependent pathways regulates P-glycoprotein expression
in human blood–brain barrier cells
Martha L Pinzo´n-Daza1,2, Iris C Salaroglio1, Joanna Kopecka1, Ruth Garzo`n2, Pierre-Olivier Couraud3, Dario Ghigo1,4 and
Chiara Riganti1,4
In this work, we investigate if and how transducers of the ‘canonical’ Wnt pathway, i.e., Wnt/glycogen synthase kinase 3 (GSK3)/b-
catenin, and transducers of the ‘non-canonical’ Wnt pathway, i.e., Wnt/RhoA/RhoA kinase (RhoAK), cooperate to control the
expression of P-glycoprotein (Pgp) in blood–brain barrier (BBB) cells. By analyzing human primary brain microvascular endothelial
cells constitutively activated for RhoA, silenced for RhoA or treated with the RhoAK inhibitor Y27632, we found that RhoAK
phosphorylated and activated the protein tyrosine phosphatase 1B (PTP1B), which dephosphorylated tyrosine 216 of GSK3,
decreasing the GSK3-mediated inhibition of b-catenin. By contrast, the inhibition of RhoA/RhoAK axis prevented the activation of
PTP1B, enhanced the GSK3-induced phosphorylation and ubiquitination of b-catenin, and reduced the b-catenin-driven
transcription of Pgp. The RhoAK inhibition increased the delivery of Pgp substrates like doxorubicin across the BBB and improved
the doxorubicin efﬁcacy against glioblastoma cells co-cultured under a BBB monolayer. Our data demonstrate that in human BBB
cells the expression of Pgp is controlled by a cross-talk between canonical and non-canonical Wnt pathways. The disruption of this
cross-talk, e.g., by inhibiting RhoAK, downregulates Pgp and increases the delivery of Pgp substrates across the BBB.
Journal of Cerebral Blood Flow & Metabolism (2014) 34, 1258–1269; doi:10.1038/jcbfm.2014.100; published online 4 June 2014
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INTRODUCTION
The blood–brain barrier (BBB), a peculiar microvascular endothe-
lium in the central nervous system, limits the delivery of drugs,
xenobiotics, and toxic catabolites into the brain parenchyma,
owing to the absence of fenestrations, the abundance of tight
junctions and adherens junctions, and the presence of efﬂux
transporters belonging to the ATP binding cassette family.1
P-glycoprotein (Pgp) is one of the ATP binding cassette
transporters present on the luminal side of BBB cells: it efﬂuxes
back into the bloodstream several chemotherapeutic drugs (e.g.,
anthracyclines, taxanes, Vinca alkaloids, epipodophyllotoxins,
topotecan, methotrexate, imatinib, dasatinib, lapatinib, geﬁtinib,
sorafenib, erlotinib), analgesics, anti-epileptics, anti-retrovirals, and
antibiotics.1
The Wnt signaling has a central role in regulating the expression
of Pgp in BBB cells2,3 and relies on the simultaneous activation of
different intracellular transducers. In the so-called ‘Wnt canonical
pathway’, the soluble Wnt proteins bind to the Frizzled receptor
and the low-density lipoprotein receptor-related protein-5 and -6
co-receptors, reduces the activity of glycogen synthase kinase 3
(GSK3), allowing the release of b-catenin from the cytosolic
adenomatous polyposis coli–axin complex and its translocation
into the nucleus. Here b-catenin binds to the T-cell factor/lymphoid
enhancer factor and induces the transcription of target genes,
such as mdr1, which encodes for Pgp.4,5 We recently demon-
strated that the disruption of the Wnt3 canonical pathway
downregulates the Pgp expression in human BBB cells.6
A plethora of intracellular transducers is involved in the so-
called ‘non-canonical Wnt pathways’. By interacting with Frizzled,
Wnt recruits Disheveled, stimulates the small GTPases RhoA and
Rac, activates RhoA kinase (RhoAK), mitogen-activated protein
kinase kinases, mitogen-activated protein kinases, and Jun
N-terminal kinase.4,7 By interacting with the co-receptors ROR2
and RYK, Wnt enhances the activity of phospholipase C, increases
the intracellular calcium, activates protein kinase C and calmodulin
kinases.4 Wnt canonical and non-canonical pathways are often
reciprocally modulated, with either cooperative or antagonistic
effects.8,9
The Wnt non-canonical transducers RhoA and RhoAK regulate
the integrity of tight junctions and the paracellular transport of
substrates across BBB,10 as well as the activity of Pgp.11 It is not
known whether Wnt/RhoA/RhoAK pathway controls also the
expression of Pgp.
Aim of this work is to investigate if there are cross-talk
mechanisms between the Wnt/GSK3/b-catenin canonical pathway
and the Wnt/RhoA/RhoAK non-canonical pathway in human BBB
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cells, and how these cross-talks control the expression of Pgp and
the delivery of Pgp substrates across BBB.
MATERIALS AND METHODS
Chemicals
The plasticware for cell cultures was from Falcon (Becton Dickinson,
Franklin Lakes, NJ, USA). Wnt activators (WntA) [2-amino-4-(3,4-(methyle-
nedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine] and Y27632 were
purchased from Calbiochem (San Diego, CA, USA). Human recombinant
Dickkopf-1 (Dkk-1) was from R&D Systems (Minneapolis, MN, USA). Rho
activator II, a synthetic derivative of cytotoxic necrotizing factor from
Escherichia coli that maintains RhoA constitutively activated,12 was from
Cytoskeleton (Denver, CO, USA). The electrophoresis reagents were
obtained from Bio-Rad Laboratories (Hercules, CA, USA). The protein
content of cell lysates was assessed with the BCA kit from Sigma Chemicals
(St Louis, MO, USA). When not otherwise speciﬁed, all the other reagents
were purchased from Sigma Chemicals.
Cells
The hCMEC/D3 cells, a primary human brain microvascular endothelial cell
line that retains the BBB characteristics in vitro,13 were seeded at 50,000/
cm2 density, grown for 7 days up to conﬂuence in Petri dishes or Transwell
devices (0.4mm diameter pore size, Corning Life Sciences, Chorges, France),
and cultured as previously reported.13
The primary human glioblastoma cells (CV17, 01010627, Nov3) were
obtained from surgical samples of patients from the Neuro-Biooncology
Center, Vercelli, Italy and the DIBIT San Raffaele Scientiﬁc Institute, Milan,
Italy. The tumor diagnosis was performed according to WHO guidelines.
The U87-MG cell line was purchased from ATCC (Manassas, VA, USA). The
cells were cultured as already reported.6 The experimental protocols were
approved by the Bioethics Committee (‘Comitato di Bioetica d’Ateneo’),
University of Turin, Italy.
In co-culture experiments, 500,000 (for intracellular doxorubicin
accumulation, cytotoxicity assays and cell cycle analysis) or 1,000 (for
proliferation assay) glioblastoma cells were added in the lower chamber of
Transwell devices 4 days after seeding hCMEC/D3 cells in the Transwell
insert. After 3 days of co-culture, the medium of the upper chamber was
replaced with fresh medium or with medium containing Y27632 and
doxorubicin, alone or in combination, as detailed in the Figure legends.
Western Blot Analysis
The cells were rinsed with lysis buffer (50mmol/L Tris, 10mmol/L EDTA, 1%
v/v Triton X-100), supplemented with the protease inhibitor cocktail set III
(80mmol/L aprotinin, 5mmol/L bestatin, 1.5mmol/L leupeptin, 1mmol/L
pepstatin; Calbiochem), 2mmol/L phenylmethylsulfonyl ﬂuoride and 1mmol/
L NaVO4, then sonicated and centrifuged at 13,000 g for 10minutes at 41C.
A quantity of 20mg protein extracts were subjected to SDS–PAGE and
probed with the following antibodies: anti-GSK3 (BD Biosciences, Franklin
Lakes, NJ, USA); anti-phospho(Tyr216)GSK3 (BD Biosciences); anti-b-catenin
(BD Biosciences); anti-phospho(Ser33/Ser37/Thr41)b-catenin (Cell Signaling
Technology, Danvers, MA, USA); anti-claudin 3 (Invitrogen Life Technolo-
gies, Monza, Italy); anti-claudin 5 (Invitrogen Life Technologies); anti-
occludin (Invitrogen Life Technologies); anti-zonula occludens-1 (Invitrogen
Life Technologies); anti-protein tyrosine phosphatase 1B (PTP1B; Abcam,
Cambridge, UK); anti-phospho(Ser50)PTP1B (Abcam); anti-Pgp (clone C219,
Calbiochem); anti-multidrug resistance-related protein 1 (MRP1; Abcam);
anti-breast cancer resistance protein (BCRP; Santa Cruz Biotechnology,
Santa Cruz, CA, USA); anti-caspase-3 (C33, GeneTex, Hsinhu City, Taiwan);
anti-b-tubulin (Santa Cruz Biotechnology), followed by a peroxidase-
conjugated secondary antibody (Bio-Rad). The membranes were washed
with Tris-buffered saline-Tween 0.1% v/v, and the proteins were detected
by enhanced chemiluminescence (Bio-Rad).
To assess the presence of ubiquitinated b-catenin, 100mg of proteins
from whole-cell extracts were immunoprecipitated with the anti-b-catenin
antibody, using the PureProteome protein A and protein G Magnetic Beads
(Millipore, Billerica, MA, USA). The immunoprecipitated proteins were
separated by SDS–PAGE and probed with an anti-ubiquitin antibody (Enzo
Life Science, Farmingdale, NY, USA), followed by a peroxidase-conjugated
secondary antibody.
A quantity of 10mg of nuclear extracts, obtained with the Nuclear
Extraction Kit (Active Motif, Rixensart, Belgium), was subjected to western
blot analysis using an anti-b-catenin antibody. To check the equal control
loading in nuclear fractions, the samples were probed with an anti-TATA-
binding protein (TBP/TFIID) antibody (Santa Cruz Biotechnology). To
exclude any cytosolic contamination of nuclear extracts, we veriﬁed that
b-tubulin was undetectable in nuclear samples (not shown).
The densitometric analysis of western blots was performed with
the ImageJ software (http://rsb.info.nih.gov/ij/) and expressed as
arbitrary units, where ‘1 unit’ is the mean band density of untreated
hCMEC/D3 cells.
Chromatin Immunoprecipitation
The chromatin immunoprecipitation experiments were performed using
the Magna ChIP A/G Chromatin Immunoprecipitation Kit (Millipore). The
samples were immunoprecipitated with 5 mg of an anti-b-catenin antibody
or with no antibody. The immunoprecipitated DNA was washed and eluted
twice with 100mL of elution buffer (0.1mol/L NaHCO3, 1% w/v SDS), the
cross-linking was reversed by incubating the samples at 651C for 6 hours.
The samples were then treated with 1mL proteinase K for 1 hour at 551C.
The DNA was eluted in 50 mL of H2O and analyzed by quantitative real-time
PCR (qRT–PCR). The putative b-catenin site on mdr1 promoter was
validated by the MatInspector software (http://www.genomatix.de/); the
primers sequences were: 50-CGATCCGCCTAAGAACAAAG-30 ; 50-AGCACAAA
TTGAAGGAAGGAG-30 . As negative control, the immunoprecipitated
samples were subjected to PCR with primers matching a region
10,000bp upstream the mdr1 promoter, using the following primers: 50-
GTGGTGCCTGAGGAAGAGAG-30 ; 50-GCAACAAGTAGGCACAAGCA-30 . The
qRT–PCR was carried out using an IQ SYBR Green Supermix (Bio-Rad);
the data were analyzed with a Bio-Rad Software Gene Expression
Quantitation (Bio-Rad).
qRT–PCR
Total RNA was extracted and reverse transcribed using the QuantiTect
Reverse Transcription Kit (Qiagen, Hilden, Germany). The qRT–PCR was
performed with the IQ SYBR Green Supermix (Bio-Rad). The same cDNA
preparation was used to quantify the genes of interest and the house-
keeping gene b-actin. The primer sequences, designed with the Primer3
software (http://frodo.wi.mit.edu/primer3), were: for mdr1: 50-TGCTGGAGC
GGTTCTACG-30 ; 50-ATAGGCAATGTTCTCAGCAATG-30 ; for b-actin: 50- GCTAT
CCAGGCTGTGCTATC-30 ; 50- TGTCACGCACGATTTCC-30 . The relative quanti-
ﬁcation was performed by comparing each PCR product with the
housekeeping PCR product, using the Bio-Rad Software Gene Expression
Quantitation (Bio-Rad).
RhoA and RhoA Kinase Activity
To evaluate the RhoA activity, the RhoA-GTP-bound fraction, taken as an
index of monomeric G-proteins activation,11 was measured using the
G-LISA RhoA Activation Assay Biochem Kit (Cytoskeleton), according to the
manufacturer’s instructions. The absorbance was read at 450 nm, using a
Packard EL340 microplate reader (Bio-Tek Instruments, Winooski, VT, USA).
For each set of experiments, a titration curve was prepared, using serial
dilutions of the Rho-GTP positive control of the kit. The data were
expressed as U absorbance/mg cell proteins. The RhoAK activity was
measured using the CycLex Rho Kinase Assay Kit (CycLex, Nagano, Japan),
following the manufacturer’s instructions. For each set of experiments, a
titration curve was set, using serial dilutions of recombinant RhoAK (MBL,
Woburn, MA, USA). The data were expressed as U absorbance/mg cell
proteins.
RhoA Small Interfering RNA Transfection
A quantity of 200,000 cells were transfected with 400 nmol/L of 20 to 25
nucleotide non-targeting scrambled small interfering RNAs (Control siRNA-
A, Santa Cruz Biotechnology) or speciﬁc RhoA siRNAs (Santa Cruz
Biotechnology), as reported previously.14 To verify the silencing efﬁcacy,
48 hours after the transfection, the cells were lysed and checked for the
expression of RhoA by western blotting, using an anti-RhoA antibody
(Santa Cruz Biotechnology).
Protein Tyrosine Phosphatase 1B Activity
To measure the activity of endogenous PTB1B in cell lysates, the PTP1B
Inhibitor Screening Assay kit (Abcam) was used. Cells untreated or treated
with RhoA activator II, Y27632 or both, were washed twice in ice-cold PBS,
detached by trypsin/EDTA, rinsed with 0.5mL of PTP1B assay buffer
provided by the kit and sonicated. Cell lysate (200mL), each containing
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100mg proteins, were transferred into a 96-wells plate, in the presence of
100mmol/L PTP1B substrate from the kit. The plates were incubated for
30minutes at 371C, then 100mL of the Red Assay reagent of the kit was
added for 20minutes. The absorbance at 620 nm was read using a Packard
EL340 microplate reader.
The activity of puriﬁed PTP1B was measured in a cell-free system: 5U of
human recombinant PTP1B protein (Abcam), diluted in 100mL of reaction
buffer (10mmol/L Tris/HCl, 50mmol/L NaCl, 2mmol/L dithiothreitol,
1mmol/L MnCl2; pH 7.5), was incubated for 10minutes at 371C, with
10mg of a recombinant peptide from human GSK3 containing phosphory-
lated tyrosine 216 (Abcam). To test if RhoAK affects the dephosphorylation
of GSK3 by PTP1B, in a parallel set of experiments, PTP1B protein was
preincubated for 30minutes at 371C with 10U of human recombinant
RhoAK (MBL), diluted in 100mL of the Rho Kinase buffer (from CycLex Rho
Kinase Assay Kit) containing 25mmol/L ATP. When indicated, 10 mmol/L of
the RhoAK inhibitor Y27632 was added. After this preincubation step, a
10mL aliquot from each sample was removed and used to measure
the phosphorylation of PTP1B on serine 50 by western blot analysis.
The remaining sample was incubated for 10minutes at 371C with the
phospho(Tyr 216)-GSK3 peptide, as reported above. In all samples, the
reaction was stopped by adding 100mL of the Red Assay reagent from the
PTP1B Inhibitor Screening Assay kit; the absorbance at 620 nm was read
after 20minutes. For each set of experiments, a titration curve was
prepared, using serial dilutions of the phosphate standard from the PTP1B
Inhibitor Screening Assay kit. Data were expressed as nmol phosphate/mL.
The activity of endogenous PTP1B was then expressed as percentage of
the activity of PTP1B of each sample versus the activity of PTP1B measured
in untreated cells. The activity of puriﬁed PTP1B was expressed as
percentage of the activity of PTP1B measured after the preincubation step
with RhoAK versus the activity of PTP1B measured without the
preincubation step with RhoAK.
Permeability Assays Across Blood–Brain Barrier
The permeability to dextran–ﬂuorescein isothiocyanate (molecular weight
70 kDa), [14C]-sucrose (molecular weight: 342.30Da; 589mCi/mmol; Perki-
nElmer, Waltham, MA, USA), [14C]-inulin (molecular weight range: 5.0 to
5.5 kDa; 10mCi/mmol; PerkinElmer), sodium ﬂuorescein (molecular weight:
376.27Da) was taken as a parameter of tight junction integrity11,15 and
measured as previously reported.6,16
To measure the permeability coefﬁcient of doxorubicin across the BBB
monolayer, wild-type or RhoA-silenced hCMEC/D3 cells were grown for
7 days up to conﬂuence in 6-multiwell Transwell devices, and treated as
reported under the Results section. Doxorubicin (5mmol/L) was added in
the upper Transwell chamber for 3 hours, then the medium in the lower
chamber was collected and the amount of doxorubicin was measured
ﬂuorimetrically, using an LS-5 Spectroﬂuorimeter (PerkinElmer). The
excitation and emission wavelengths were 475 nm and 553 nm, respec-
tively. The ﬂuorescence was converted in nmol doxorubicin/cm2, using a
calibration curve prepared previously. The permeability coefﬁcients were
calculated as reported earlier.17
Intratumor Doxorubicin Accumulation in Co-Culture Models
After 3 days of co-culture, doxorubicin (5mmol/L for 3 hours) or Y27632
(10mmol/L for 3 hours) followed by doxorubicin (5mmol/L for 3 hours) were
added to the upper chamber of a Transwell insert containing an hCMEC/D3
cell monolayer. Then glioblastoma cells were collected from the lower
chamber, rinsed with PBS, re-suspended in 0.5mL ethanol/HCl 0.3N (1:1 v/v)
and sonicated. A 50 mL aliquot was used to measure the protein content;
the remaining sample was used to quantify ﬂuorimetrically the intracellular
doxorubicin content, as described above. The results were expressed as
nmol doxorubicin/mg cell proteins.
For ﬂuorescence microscope analysis, the glioblastoma cells in the lower
chamber were seeded on sterile glass coverslips and treated as reported
above. At the end of the incubation period, the cells were rinsed with PBS,
ﬁxed in 4% w/v paraformaldehyde for 15minutes, washed three times with
PBS and incubated with 40 ,6-diamidino-2-phenylindole dihydrochloride for
3minutes at room temperature in the dark. The cells were washed three
times with PBS and once with water, then the slides were mounted
with 4mL of Gel Mount Aqueous Mounting and examined with a Leica
DC100 ﬂuorescence microscope (Leica Microsystems, Wetzlar, Germany).
For each experimental point, a minimum of ﬁve microscopic ﬁelds were
examined.
Cytotoxicity, Cell Cycle Analysis and Cell Proliferation of
Glioblastoma Cells in Co-Culture Models
For cytotoxicity, apoptosis, and cell cycle analysis, after 3 days of
co-culture, doxorubicin (5 mmol/L for 24 hours) or Y27632 (10mmol/L for
3 hours) followed by doxorubicin (5 mmol/L for 24 hours) were added to
the upper chamber of Transwell inserts containing an hCMEC/D3 cell
monolayer.
The release of lactate dehydrogenase in the supernatant of glioblastoma
cells, used as an index of cell damage and necrosis, was measured
spectrophotometrically as described earlier.18 The apoptosis of gliobla-
stoma cells was assessed by analyzing the cleavage of caspase-3 by
western blotting, as described above. For cell cycle distribution, the
glioblastoma cells were washed twice with fresh PBS, incubated in 0.5mL
of ice-cold 70% v/v ethanol for 15minutes, then centrifuged at 1,200 g for
5minutes at 41C and rinsed with 0.3mL of citrate buffer (50mmol/L
Na2HPO4, 25mmol/L sodium citrate, 1% v/v Triton X-100), containing
10mg/mL propidium iodide and 1mg/mL RNAse (from bovine pancreas).
After 15-minute incubation in the dark, the intracellular ﬂuorescence was
detected by a FACSCalibur ﬂow cytometer (Becton Dickinson). For each
analysis, 10,000 events were collected and analyzed by the Cell Quest
software (Becton Dickinson).
To monitor the long-term cell proliferation, 1,000 glioblastoma cells
were seeded in the lower chamber of Transwell, containing conﬂuent
hCMEC/D3 cells in the insert. This time was considered ‘day 0’ in the
proliferation assay. After 3 days of co-culture, the upper chamber of the
Transwell insert was ﬁlled with fresh medium or medium containing
10mmol/L Y27632 for 3 hours, 5 mmol/L doxorubicin for 24 hours, 10 mmol/L
Y27632 for 3 hours followed by 5mmol/L doxorubicin for 24 hours. The
treatments were repeated every 7 days, for 4 weeks. At day 7, 14, 21, and
28 the glioblastoma cells were collected, transferred into a 96-wells plate,
ﬁxed with 4% w/v paraformaldehyde and stained with 0.5% w/v crystal
violet solution for 10minutes at room temperature. The plate was washed
three times in water, then 100mL of 0.1mmol/L sodium citrate in 50% v/v
ethanol was added to each well and the absorbance was read at 570 nm.
The absorbance units were converted into the number of cells, according
to a titration curve obtained with serial cell dilutions of each cell line. To
check if the hCMEC/D3 cells retained BBB properties, the permeability to
dextran and inulin was measured weekly in a parallel set of Transwell. No
signiﬁcant changes in the permeability coefﬁcients were detected during
the whole experiment (not shown).
Pgp ATPase Assay
The rate of ATP hydrolysis was measured spectrophotometrically on Pgp
immunoprecipitated from the membrane of hCMEC/D3 cells as described
previously.11
Statistical Analysis
All data in the text and ﬁgures are provided as means±s.d. The results
were analyzed by a one-way analysis of variance. A Po0.05 was considered
signiﬁcant.
RESULTS
Wnt Controls the GSK3/b-Catenin and RhoA/RhoA Kinase Activities
in Human Blood–Brain Barrier Cells
The hCMEC/D3 cells exhibited a GSK3 constitutively phosphory-
lated on tyrosine 216, i.e., activated, and a b-catenin constitutively
phosphorylated on serine 33, serine 37 and threonine 41
(Figure 1A), i.e., primed for ubiquitination. Notwithstanding, we
detected in the untreated hCMEC/D3 cells a basal amount of
b-catenin translocated into the nucleus (Figure 1B) and bound to
the promoter of mdr1 gene (Figure 1C), which encodes for Pgp. In
line with previous ﬁndings obtained on hCMEC/D3 cells and
primary human brain microvascular endothelial cells,6 the Wnt
activator WntA decreased the phosphorylation/activation of GSK3,
strongly reduced the phosphorylation of b-catenin (Figure 1A),
increased the nuclear translocation and the binding of b-catenin
to the mdr1 promoter (Figures 1B and 1C); the Wnt inhibitor Dkk-1
produced opposite effects (Figures 1A–C). In keeping with these
results, WntA increased and Dkk-1 decreased the mRNA level of
mdr1 in hCMEC/D3 cells (Figure 1D). In parallel, Wnt modulated
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the activity of RhoA and RhoAK: as shown in Figure 1E, WntA
increased and Dkk-1 decreased the GTP binding to RhoA and the
activity of RhoAK. These data suggest that both Wnt/GSK3
canonical pathway and Wnt/RhoA/RhoAK non-canonical pathway
are active in the hCMEC/D3 cells and vary their activity in response
to Wnt activators and inhibitors at the same time.
RhoA Modulates the GSK3/b-Catenin-Driven Transcription of Pgp
in Human Blood–Brain Barrier Cells
To investigate whether the activity of non-canonical Wnt/RhoA/
RhoAK pathway controls the activity of canonical Wnt/GSK3
pathway in hCMEC/D3 cells, we constitutively activated RhoA with
the RhoA activator II12 (Figure 2A) and silenced RhoA (Figure 2B),
respectively. The cells with active RhoA showed a reduced
phosphorylation of GSK3 and b-catenin (Figure 2C), and an
increased b-catenin nuclear translocation (Figure 2D). By contrast,
the RhoA-silenced cells exhibited a higher amount of phosphory-
lated GSK3 and b-catenin (Figure 2C), and a reduced b-catenin
nuclear translocation (Figure 2D). These data suggest that the
activity of the Wnt non-canonical transducer RhoA controls the
activation of the Wnt canonical transducers GSK3/b-catenin in our
model.
Of note for the aim of this work, the RhoA activation increased,
while the RhoA silencing decreased the binding of b-catenin to
mdr1 promoter (Figure 2E) and the levels of mdr1 mRNA
(Figure 2F) in the hCMEC/D3 cells. The increase of mdr1 expression
induced by WntA or RhoA activator II was not paralleled by an
increase in permeability to small molecules, such as sucrose and
sodium ﬂuorescein (Supplementary Figure 1), thus ruling out a
Wnt- or RhoA-mediated increase of the monolayer passive
permeability.
Figure 1. Wnt controls the b-catenin-induced transcription of P-glycoprotein (Pgp) and RhoA activity in human blood–brain barrier cells. The
hCMEC/D3 cells were grown in fresh medium (ctrl), with the Wnt activator 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-
methoxyphenyl)pyrimidine (WntA; 20 mmol/L for 24 hours) or the Wnt inhibitor Dickkopf-1 (Dkk-1) protein (Dkk; 1mg/mL for 24 hours).
(A) Western blot analysis of phospho(Tyr216)GSK3 (glycogen synthase kinase 3) (pGSK3), GSK3, phospho(Ser33/Ser37/Thr41)b-catenin (pcat),
b-catenin (cat) in whole-cell lysates. The b-tubulin expression was used as a control of equal protein loading. The figure is representative of
three experiments with similar results. The band density ratio between each protein and b-tubulin was expressed as arbitrary units. Versus ctrl
cells: *Po0.02. (B) Nuclear extracts were analyzed for the amount of b-catenin (nucl cat). The expression of TATA-binding protein (TBP) was
used as a control of equal protein loading. The figure is representative of three experiments with similar results. The band density ratio
between each protein and TBP was expressed as arbitrary units. Versus ctrl cells: *Po0.02. (C) Chromatin Immunoprecipitation assay. The
genomic DNA was extracted, immunoprecipitated with an anti-b-catenin antibody and analyzed by quantitative real-time PCR (qRT–PCR),
using primers for the b-catenin binding site on mdr1 promoter (open bars) or for an upstream region (black bars), chosen as a negative
control. Results are presented as means±s.d. (n¼ 4). Versus ctrl: *Po0.05. (D) The mdr1 expression was detected by qRT–PCR. Data are
presented as means±s.d. (n¼ 4). Versus ctrl: *Po0.02. (E) RhoA/RhoA kinase (RhoAK) activity. The samples were subjected to enzyme-linked
immunosorbent assays to measure the amount of RhoA-GTP (open bars) and the activity of RhoAK (black bars). Data are presented as
means±s.d. (n¼ 4). Versus ctrl: *Po0.05.
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The RhoA Kinase Inhibition Reduces the Pgp Transcription in
Blood–Brain Barreir Cells, by Inhibiting the Protein Tyrosine
Phosphatase 1B Activity and Increasing the Glycogen Synthase
Kinase 3-Mediated Phosphorylation and Ubiquitination of
b-Catenin
As in hCMEC/D3 cells, Wnt controls the activity of RhoA and its
downstream effector RhoAK (Figure 1E), we next investigated
whether RhoAK mediated the cross-talk between the Wnt/GSK3
canonical pathway and the Wnt/RhoA non-canonical pathway.
Time-dependence experiments with the RhoAK inhibitor Y27632
showed that at 10mmol/L, this compound effectively inhibited the
RhoAK activity at each time point considered (Supplementary
Figure 2A) and decreased the b-catenin nuclear translocation at
the time points from 3 to 24 hours (Supplementary Figure 2B).
After 3 hours, when the reduction of RhoAK activity and b-catenin
was maximal, Y27632 did not change the expression of claudin-3,
claudin-5, occludin, zonula occludens-1 (Supplementary Figure 2C)
and did not alter the permeability coefﬁcient of dextran, inulin
and sucrose (Supplementary Figure 2D), suggesting that the
RhoAK inhibition did not affect the integrity of tight junctions and
Figure 2. The RhoA activity controls the glycogen synthase kinase 3 (GSK3)/b-catenin-driven transcription of P-glycoprotein (Pgp) in human
blood–brain barrier cells. (A) The hCMEC/D3 cells were grown in fresh medium in the absence (ctrl) or in the presence of the RhoA activator II
(RhoAc; 5 mg/mL for 3 hours), then the activity of RhoA was measured by an enzyme-linked immunosorbent assay. Data are presented as
means±s.d. (n¼ 4). Versus ctrl: *Po0.005. (B) The cells were cultured for 48 hours with fresh medium (ctrl), treated with a non-targeting
scrambled small interfering RNA (siRNA) (scr) or a RhoA-targeting specific siRNA pool (siRhoA). The expression of RhoA was measured in
whole-cell lysates by western blotting. The b-tubulin expression was used as a control of equal protein loading. The figure is representative of
three experiments with similar results. The band density ratio between each protein and b-tubulin was expressed as arbitrary units. Versus ctrl
cells: *Po0.005. (C) Western blot analysis of phospho(Tyr216)GSK3 (pGSK3), GSK3, phospho(Ser33/Ser37/Thr41)b-catenin (pcat), b-catenin (cat)
in whole-cell lysates of hCMEC/D3 cells treated as described in (A and B). The b-tubulin expression was used as a control of equal protein
loading. The figure is representative of three experiments with similar results. The band density ratio between each protein and b-tubulin was
expressed as arbitrary units. Versus ctrl cells: *Po0.05. (D) Nuclear extracts from cells treated as described in (A and B) were analyzed for the
amount of b-catenin (nucl cat). The expression of TATA-binding protein (TBP) was used as a control of equal protein loading. The band density
ratio between each protein and TBP was expressed as arbitrary units. Versus ctrl cells: *Po0.005. (E) Cells were cultured as reported in (A and
B). After 3 hours (for the RhoAc II-treated cells) or 48 hours (for the scrambled- and RhoA-targeting siRNA-treated cells), the genomic DNA was
extracted, immunoprecipitated with an anti-b-catenin antibody and analyzed by quantitative real-time PCR (qRT–PCR), using primers for the
b-catenin binding site on the mdr1 promoter (open bars) or for an upstream region (black bars), chosen as a negative control. The ctrl bars in
the figure correspond to the DNA extracted after 48 hours from hCMEC/D3 cells; the results were superimposable for the DNA extracted after
3 hours (not shown in the figure). Results are expressed as means±s.d. (n¼ 4). Versus ctrl: *Po0.01. (F) The cells were treated as detailed in (A
and B). After 3 hours (for the RhoAc II-treated cells) or 48 hours (for the scrambled- and RhoA-targeting siRNA-treated cells), the mdr1
expression was detected by qRT–PCR. Data are presented as means±s.d. (n¼ 4). Versus ctrl *Po0.005.
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the paracellular transport processes. In the light of these results,
Y27632 was used at 10 mmol/L for 3 hours in all the following
experiments: in these conditions, Y27632 increased the phosphor-
ylation of GSK3 and b-catenin (Figure 3A) and reduced the
b-catenin nuclear translocation (Figure 3B), also in the presence of
a constitutively activated RhoA (Figures 3A and 3B).
The tyrosine phosphatase PTP1B reduces the activity of GSK3 by
dephosphorylating tyrosine 216, which is critical for the GSK3
activity.19 PTP1B is in its turn activated by the phosphorylation
on serine 50, operated by serine/threonine kinases.20 We thus
wondered whether RhoAK may modulate the GSK3 phosphory-
lation via PTP1B.
PTP1B was basally phosphorylated on serine 50 in the hCMEC/
D3 cells (Figure 3C). Interestingly, the cells with activated RhoA
had increased levels of phospho(Ser50)PTP1B, which was strongly
reduced in cells treated with the RhoAK inhibitor Y27632. The
latter also abolished the phosphorylation of PTP1B induced by
active RhoA (Figure 3C). The endogenous activity of PTP1B was
signiﬁcantly increased in cells with activated RhoA and signiﬁ-
cantly decreased in Y27632-treated cells (Figure 3D). To test
whether RhoAK, by phosphorylating PTP1B on serine 50, may
decrease the phosphorylation of GSK3 on tyrosine 216, we set up
a cell-free system and measured the activity of recombinant
PTP1B protein, using as a substrate a synthetic peptide derived
from GSK3, containing the phosphorylated tyrosine 216 (Figures
3E and 3F). PTP1B, when preincubated with the recombinant
RhoAK in this cell-free system, was phosphorylated on serine 50,
an effect that was prevented by Y27632 (Figure 3E). In keeping
with this observation, the preincubation with RhoAK increased the
PTP1B-mediated dephosphorylation of the recombinant phos-
pho(Tyr 216)GSK3 peptide; such a dephosphorylation was
signiﬁcantly reduced by the RhoAK inhibitor Y27632 (Figure 3F).
These data suggest that RhoAK activates PTP1B, promotes the
tyrosine dephosphorylation of GSK3 and its inhibition, whereas
the RhoAK inhibition produces opposite effects.
As an active GSK3 promotes the phosphorylation of b-catenin,
priming it for the subsequent ubiquitination and proteasomal
degradation,4,5 we next measured the b-catenin ubiquitination in
the presence of RhoA/RhoAK activators or inhibitors. The
untreated hCMEC/D3 cells showed a basal level of b-catenin
ubiquitination (Figure 4A), which was in line with the basal
phosphorylation of the protein on serine 33, serine 37, and
threonine 41 (Figure 1A). The ubiquitination of b-catenin was
reduced in cells with active RhoA and increased by the RhoA
silencing or the RhoAK inhibitor Y27632 (Figure 4A). These data
suggest that an active RhoAK prevents the ubiquitination of
b-catenin and highlight the possibility to regulate the transcrip-
tion of b-catenin-target genes by modulating the RhoAK activity.
As the silencing of RhoA did (Figures 2E and 2F), also Y27632
decreased the binding of b-catenin to the mdr1 promoter
(Figure 4B) and the levels of mdr1 mRNA (Figure 4C). Both RhoA
silencing and RhoAK inhibition reduced the Pgp protein levels,
whereas RhoA increased them; by contrast, these treatments did
not change the amount of MRP1 and BCRP, two other ATP binding
cassette transporters present on the luminal side of BBB cells1
(Figure 4D).
To verify whether the inhibition of RhoA and RhoAK increases
the delivery of Pgp substrates across the BBB, we used
doxorubicin,21 which exhibited a low permeability across the
hCMEC/D3 cell monolayer (Figure 4E), owing to the high level of
Pgp on the luminal side of these cells.22 The doxorubicin
permeability was further decreased by active RhoA, but it was
increased by RhoA silencing or Y27632 (Figure 4E). The latter,
which counteracted the effect of RhoA activator II on b-catenin
ubiquitination (Figure 4A), also prevented the effects of RhoA
activation on b-catenin binding to mdr1 promoter (Figure 4B),
mdr1 transcription (Figure 4C), Pgp protein levels (Figure 4D) and
doxorubicin permeability (Figure 4E).
The Inhibition of RhoA Kinase Increases the Doxorubicin Delivery
and Cytotoxicity in Human Glioblastoma Cells Co-Cultured with
Blood–Brain Barrier Cells
As the inhibition of RhoAK increased the doxorubicin permeability
across the hCMEC/D3 monolayer, we wondered whether priming
the BBB cells with Y27632 improves the delivery of doxorubicin to
glioblastoma cells grown under the BBB monolayer.
The doxorubicin accumulation within glioblastoma cells (CV17,
01010627, Nov3 and U87-MG) co-cultured with hCMEC/D3 cells
was low, as evaluated by ﬂuorimetric assays (Figure 5A) and
ﬂuorescence microscope analysis (Figure 5B). The pretreatment of
the hCMEC/D3 cells with Y27632 signiﬁcantly increased the
doxorubicin retention within glioblastoma cells (Figures 5A and
5B). Doxorubicin alone did not produce signiﬁcant cell damages in
terms of release of lactate dehydrogenase in the extracellular
medium of glioblastoma cells (Figure 5C), and induced weak signs
of apoptosis, as suggested by the low level of cleaved caspase-3
(Figure 5D). When effective, the drug is expected to induce a G2/
M-phase arrest, which was not observed in the 01010627
glioblastoma cells co-cultured under the hCMEC/D3 monolayer
exposed to doxorubicin alone (Figure 5E). The exposure to Y27632
followed by doxorubicin strongly increased the release of lactate
dehydrogenase (Figure 5C), the cleavage of caspase-3 (Figure 5D),
the percentage of cells arrested in G2/M phase (Figure 5E). In
parallel, such combination increased the amount of cells in pre-G1
phase, an index of apoptotic cells, and decreased the number of
cells in S phase (Figure 5E). Of note, used at 10 mmol/L for 3 hours,
Y27632 alone was not cytotoxic for glioblastoma cells (Figures 5C–
E). The repeated administration of Y27632 or doxorubicin as single
agents on the luminal side of the hCMEC/D3 monolayer did not
reduce the proliferation of 01010627 glioblastoma cells growing
under this model of BBB (Figure 5F); only the pretreatment of
hCMEC/D3 cells with Y27632 followed by doxorubicin signiﬁcantly
decreased the long-term proliferation of tumor cells (Figure 5F).
Interestingly, the pretreatment with Y27632 produced the same
effects of verapamil, a strong inhibitor of Pgp activity in the
hCMEC/D3 cells (Supplementary Figure 3A); when co-incubated
with doxorubicin, verapamil increased the drug permeability
across the BBB monolayer (Supplementary Figure 3B) and its
accumulation in co-cultured glioblastoma cells (Supplementary
Figure 3C), as well as lactate dehydrogenase release (Supplemen-
tary Figure 3D), caspase-3 activation (Supplementary Figure 3E),
G2/M-arrest (Supplementary Figure 3F) in glioblastoma cells.
DISCUSSION
In this work, we demonstrate that the expression of Pgp in human
BBB cells is controlled by a cross-talk between the Wnt/GSK3
canonical pathway and the Wnt/RhoA/RhoAK non-canonical
pathway. The activation of Wnt/GSK3/b-catenin axis is known
to increase the expression of Pgp in hCMEC/D3 cells.2,3,6 The
activation of RhoA and RhoAK is known to enhance the Pgp
activity in BBB cells.11 It is not known: (1) whether the Wnt/RhoA/
RhoAK axis controls also the Pgp expression; (2) whether the
canonical and non-canonical Wnt pathways cooperate in
regulating the Pgp levels in BBB cells.
We observed that the Wnt activation increases at the same time
the activity of GSK3 and the activity of RhoA/RhoAK in hCMEC/D3
cells, while the Wnt inhibition reduces them. The positive
cooperation between Wnt/GSK3 and Wnt/RhoA/RhoAK axis, which
we detected in BBB cells, has been described in pulmonary aortic
endothelial cells: here the bone morphogenetic protein 2
increases the activity of GSK3/b-catenin axis and at the same
time recruits the Wnt-downstream effector Disheveled, which
activates RhoA.23 As WntA activates Disheveled, and Dkk-1 inhibits
it in most mammalian cells,4 it is likely that also in our model the
changes in RhoA/RhoAK activity in response to WntA and Dkk-1
were due to the changes in Disheveled activity.
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Figure 3. The RhoA kinase (RhoAK) inhibition increases the activation of glycogen synthase kinase 3 (GSK3), by decreasing the activity of
protein tyrosine phosphatase 1B (PTP1B) in human blood–brain barrier cells. The hCMEC/D3 cells were grown in fresh medium (ctrl) or in
medium containing the RhoA activator II (RhoAc; 5 mg/mL for 3 hours) or the RhoAK inhibitor Y27632 (Y276; 10mmol/L for 3 hours), alone or co-
incubated. (A) Western blot analysis of phospho(Tyr216)GSK3 (pGSK3), GSK3, phospho(Ser33/Ser37/Thr41)b-catenin (pcat), b-catenin (cat) in
whole-cell lysates. The b-tubulin expression was used as a control of equal protein loading. The figure is representative of three experiments
with similar results. The band density ratio between each protein and b-tubulin was expressed as arbitrary units. Versus ctrl cells: *Po0.05;
versus RhoAc alone: 1Po0.001. (B) The nuclear extracts were analyzed for the amount of b-catenin (nucl cat). The expression of TATA-binding
protein (TBP) was used as a control of equal protein loading. The band density ratio between each protein and TBP was expressed as arbitrary
units. Versus ctrl cells: *Po0.002; versus RhoAc alone: 1Po0.001. (C) Western blot analysis of phospho(Ser50)PTP1B (pPTP1B) and PTP1B. The
b-tubulin expression was used as a control of equal protein loading. The figure is representative of three experiments with similar results. The
band density ratio between each protein and b-tubulin was expressed as arbitrary units. Versus ctrl cells: *Po0.005; versus RhoAc alone:
1Po0.001. (D) The activity of endogenous PTP1B was measured in cell lysates, as reported under Materials and Methods. Data are presented
as means±s.d. (n¼ 3). Versus ctrl: *Po0.002; versus RhoAc alone: 1Po0.001. (E) In vitro phosphorylation of PTP1B in the presence of RhoAK
and Y27632. 5 U of human recombinant PTP1B were incubated in the absence ( ) or in the presence of 10U of human recombinant RhoAK,
alone or in the presence of the RhoAK inhibitor Y27632 (Y276; 10 mmol/L) for 30minutes at 371C, in a reaction buffer containing 25mmol/L
ATP. At the end of this incubation time, samples were resolved by SDS–PAGE and probed with anti-phospho(Ser50)PTP1B (pPTP1B) or anti-
PTP1B antibodies. The figure is representative of three experiments with similar results. (F) The activity of purified PTP1B was measured in a
cell-free system, using a recombinant phospho(Tyr 216)GSK3 peptide as substrate. When indicated, 10U of RhoAK, alone or in the presence of
Y27632 (Y276; 10mmol/L), were added in the reaction mix 30minutes before adding the phospho(Tyr 216)GSK3 peptide. Suramin (sur;
10mmol/L), a known inhibitor of PTP1B, was added together with the phospho(Tyr 216)GSK3 peptide, as internal control. Data are presented
as means±s.d. (n¼ 3). Versus PTP1B alone ( ): *Po0.002; versus RhoAK: 1Po0.001.
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Figure 4. The RhoA kinase (RhoAK) inhibition enhances the ubiquitination of b-catenin, downregulates the b-catenin-induced transcription of
P-glycoprotein (Pgp) and increases the doxorubicin permeability in human blood–brain barrier cells. The hCMEC/D3 cells were grown in fresh
medium (ctrl), or in medium containing the RhoA activator II (RhoAc; 5 mg/mL for 3 hours) or the RhoAK inhibitor Y27632 (Y276; 10 mmol/L for
3 hours), alone or co-incubated. When indicated, the cells were treated with a non-targeting scrambled small interfering RNA (siRNA) or a
RhoA-targeting specific siRNA (siRhoA) for 48 hours (panel A) or 72 hours (panels D and E). (A) Whole-cell lysates were immunoprecipitated (IP)
with an anti-b-catenin antibody, then immunoblotted (IB) with an anti-mono/polyubiquitin antibody or with an anti-b-catenin antibody. Cells
treated with non-targeting scrambled siRNA had the same level of ubiquitination than untreated (ctrl) cells (not shown). The figure is
representative of three experiments with similar results. no Ab: samples immunoprecipitated without anti-b-catenin antibody. MW, molecular
weight markers. The 92 kDa band corresponding to the native b-catenin protein is indicated by the arrow. (B) Chromatin immunoprecipitation
assay. The genomic DNA was extracted, immunoprecipitated with an anti-b-catenin antibody and analyzed by qRT–PCR, using primers for the
b-catenin-binding site on the mdr1 promoter (open bars) or for an upstream region (black bars), chosen as a negative control. Results are
expressed as means±s.d. (n¼ 4). Versus ctrl: *Po0.05; versus RhoAc: 1Po0.01. (C) The mdr1 expression was detected by qRT–PCR. Data are
presented as means±s.d. (n¼ 4). Versus ctrl: *Po0.005; versus RhoAc: 1Po0.001. (D) Western blot analysis of Pgp, multidrug resistance-related
protein 1 (MRP1) and breast cancer resistance protein (BCRP) in the whole-cell lysates of hCMEC/D3 cells treated as described above. The b-
tubulin expression was used as a control of equal protein loading. The figure is representative of three experiments with similar results. The
band density ratio between each protein and b-tubulin was expressed as arbitrary units. Versus ctrl cells: *Po0.02; versus RhoAc: 1Po 0.005.
(E) Doxorubicin permeability. The cells were grown for 7 days up to confluence in Transwell inserts and incubated as reported above. At the
end of the incubation period, doxorubicin (5 mmol/L) was added in the upper chamber. After 3 hours the amount of drug recovered from the
lower chamber was measured fluorimetrically. The permeability coefficient was calculated as reported under Materials and Methods. In cells
treated with the non-targeting scrambled siRNA the permeability coefficient was 0.0018±0.0002 (not significant versus ctrl cells).
Measurements were performed in duplicate and data are presented as means±s.d. (n¼ 3). Versus ctrl: *Po0.05; versus RhoAc: 1Po0.02.
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It has not been clariﬁed however whether the canonical Wnt
pathway controls the activity of the non-canonical Wnt pathways
or vice versa. In gastric cancer cells, the activation of RhoA in
response to Wnt5a is dependent on the activation of the PI3K/Akt/
GSK3 axis.24 Our results demonstrated that an active RhoA
decreases the activity of GSK3, prevents the GSK3-mediated
phosphorylation of b-catenin, and favors its nuclear translocation
and the subsequent transcription of Pgp, whereas the RhoA
silencing produces opposite effects. We therefore hypothesize
that the RhoA activity controls the GSK3/b-catenin axis in hCMEC/
D3 cells. This hypothesis is in contrast with results obtained in
murine cerebrovascular endothelial cells, where the activation of
RhoA promotes the phosphorylation of b-catenin and reduces its
transcriptional activity.9 As murine and human brain microvascular
cells have often striking differences in the expression and activity
of Pgp,25 it is not surprising that they also differ in the upstream
pathways controlling Pgp expression. For instance, the mechanism
by which RhoA modulates GSK3 activity is quite different in
murine and human cerebrovascular endothelial cells: in murine
cells, RhoA controls the GSK3 activity in a PTEN- and protein kinase
Cd-dependent way and changes the phosphorylation of GSK3 on
serine 9.9 This phosphorylation has inhibitory effects on the
enzymatic activity of GSK3.26 We cannot exclude that the RhoA
activity may change the phosphorylation on serine 9 of GSK3 also
in human hCMEC/D3 cells; however, we observed that in our
model, the activation of RhoA decreases—and the silencing of
RhoA increases—the phosphorylation of GSK3 on tyrosine 216,
which is a proactivating phosphorylation.26 When phosphorylated
on tyrosine 216, GSK3 induces b-catenin phosphorylation and
degradation. To our knowledge, this is the ﬁrst work showing
that RhoA activity modulates the phosphorylation on tyrosine 216
of GSK3.
Figure 5. The RhoA kinase (RhoAK) inhibitor Y27632 increases the doxorubicin delivery and cytotoxicity in glioblastoma cells co-cultured with
blood–brain barrier cells. The hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts; CV17, 01010627, Nov3, and U87-
MG cells were seeded at day 4 in the lower chamber. After 3 days of co-culture, the supernatant in the upper chamber was replaced with fresh
medium without ( or ctrl) or with Y27632 (Y276; 10 mmol/L for 3 hours). After this incubation time, doxorubicin (dox; 5mmol/L) was added in
the upper chamber for 3 hours (panels A and B) or 24 hours (panels C–F), then the following investigations were performed. (A) Fluorimetric
quantification of intracellular doxorubicin in glioblastoma cells. Data are presented as means±s.d. (n¼ 4). Versus untreated ( ) cells:
*Po0.001. (B) The 01010627 cells were seeded on sterile glass coverslips, treated as reported above, then stained with 40,6-diamidino-2-
phenylindole dihydrochloride (DAPI) and analyzed by fluorescence microscopy to detect the intracellular accumulation of doxorubicin.
Magnification:  63 objective (1.4 numerical aperture);  10 ocular lens. The micrographs are representative of three experiments with similar
results. Scale bar, 20mm. (C) The glioblastoma cells were checked spectrophotometrically for the extracellular release of lactate dehydrogenase
(LDH) activity. Data are presented as means±s.d. (n¼ 4). Versus untreated ( ) cells: *Po0.001. (D) The whole-cell lysates from 01010627 cells
were resolved by SDS–PAGE and immunoblotted with an anti-caspase 3 antibody (recognizing both pro-caspase and cleaved active caspase).
The b-tubulin expression was used as a control of equal protein loading. The figure is representative of three experiments with similar results.
(E) Cell cycle analysis. The distribution of the 01010627 cells in sub-G1, G0/G1, S, G2/M phase was analyzed by flow cytometry, as detailed
under Materials and Methods. Data are presented as means±s.d. (n¼ 4). Versus ctrl: *Po0.005. (F). After 3 days of co-culture between hCMEC/
D3 and 01010627 cells, the medium of the upper chamber was replaced with fresh medium (open circles) or medium containing Y27632
(Y276; 10 mmol/L for 3 hours, solid circles), doxorubicin (dox; 5 mmol/L for 24 hours, open squares), Y27632 (Y276; 10 mmol/L for 3 hours)
followed by doxorubicin (doxo; 5 mmol/L for 24 hours, solid squares). Drug treatments were repeated every 7 days, as reported in the Materials
and Methods section. The proliferation of glioblastoma cells was monitored weekly by crystal violet staining. Measurements were performed
in triplicate and data are presented as means±s.d. (n¼ 4). Versus ctrl: *Po0.001.
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We next looked for putative downstream effectors of RhoA
responsible for this effect. We focused on RhoAK, whose activity
followed the same trend of RhoA activity in response to WntA and
Dkk-1 in hCMEC/D3 cells. Interestingly, the inhibition of RhoAK by
Y27632 quickly decreased the nuclear translocation of b-catenin,
with a maximal efﬁcacy after 3 hours. At longer time points,
nuclear b-catenin progressively re-accumulated in the nucleus,
although it remained lower than in untreated cells: this may be
due to the short half-life (i.e., less than 12 hours) of b-catenin,27
which produces a fast re-synthesis of new b-catenin ready to
translocate into the nucleus. After 3 hours, Y27632 effectively
increased the phosphorylation on tyrosine 216 of GSK3 and the
subsequent GSK3-induced phosphorylation of b-catenin; by acting
downstream RhoA, Y27632 was effective even in cells with a
constitutively activated RhoA. These data suggest that RhoAK
likely controls the GSK3 activity by activating a tyrosine
phosphatase, which recognizes GSK3 as substrate. PTP1B, which
is activated by the phosphorylation on serine 50,20 is one of these
phosphatases.19 Our results in hCMEC/D3 cells and in a cell-free
system demonstrate that the RhoAK phosphorylates PTP1B on
serine 50, promoting the dephosphorylation of GSK3 on tyrosine
216, an event that was fully abrogated by Y27632. These data
suggest that the RhoAK, by activating PTP1B, inhibits the GSK3
activity, prevents the ubiquitination of b-catenin, and allows its
nuclear translocation and transcriptional activity. Our results also
explain previous observations, showing that Wnt3 stimulates the
transcription of b-catenin-target genes and RhoA-target genes,
with a putative RhoAK-dependent mechanism.8
Some b-catenin-target genes encode for proteins of adherens
junctions and tight junctions; therefore, changes in RhoA/RhoAK
activity may lead to the loss of BBB integrity.10 In our experimental
conditions, no changes occurred in the protein expression and
functionality of tight junctions in the hCMEC/D3 cells treated
with Y27632. By contrast, Y27632 was sufﬁcient to reduce the
b-catenin-driven transcription of Pgp. As different promoters have
different sensitivity to the binding of b-catenin–T-cell factor
complex, we might speculate that the promoter of Pgp is more
sensitive than the promoter of other genes to the variations of
b-catenin/T-cell factor binding.
Working at proper concentrations and incubation times, the
RhoAK inhibitor increased the delivery of doxorubicin, a Pgp
substrate with a very low permeability across the BBB.13 Fasudil,
the clinically prescribed analog of Y27632, is used to prevent
vasospasms after subarachnoid hemorrhage,28 to improve tissue
perfusion during cerebral ischemia,29 to prevent the progression
of cerebral aneurisms.30 Our work suggests that Fasudil might be
used to improve the delivery of Pgp substrates through the BBB.
In the case of doxorubicin, a drug that is highly effective against
glioblastoma cells in vitro31 and ineffective in the presence of a
competent BBB,6 the pretreatment of hCMEC/D3 cells with Y27632
fully restored the doxorubicin delivery and cytotoxicity in
glioblastoma cells. Repeated pulses of Y27632 followed by
doxorubicin conﬁrmed that this approach effectively reduced
the long-term proliferation of glioblastoma cells grown under a
BBB monolayer. However, Pgp is not the only transporter present
on the luminal side of BBB that can efﬂux doxorubicin: also MRP1
and BCRP, which are detectable in the hCMEC/D3 cells,11 meet
these requisites,1 but their expression did not change in cells with
constitutively active RhoA, silenced for RhoA or treated with
Y27632. We thus hypothesize that the changes in doxorubicin
delivery after RhoA activation or inhibition were consequent to
the expression change of Pgp in hCMEC/D3 cells. To further
quantify the contribution of this transporter in doxorubicin
permeability, we treated the hCMEC/D3 cells with the Pgp
inhibitor verapamil, which produced the same effects—in terms
of doxorubicin delivery and toxicity in glioblastoma cells—of
Y27632. These results indirectly suggest that Pgp has a major role
in limiting doxorubicin delivery in the central nervous system.
Figure 6. Cross-talk between Wnt/GSK3 pathway and Wnt/RhoA/
RhoA kinase (RhoAK) pathway and effects on P-glycoprotein (Pgp)
expression in human blood–brain barrier (BBB) cells. (A) The Wnt
activators (WntA) reduce the glycogen synthase kinase 3 (GSK3)-
mediated phosphorylation and ubiquitination of b-catenin, decreas-
ing its proteasomal degradation. In these conditions, b-catenin is
released from the APC/axin complex, translocates into the nucleus,
and activates the transcription of mdr1 gene, which encodes for
Pgp. The RhoA activation reduces as well the activity of GSK3: the
active RhoA increases the activity of RhoAK, which induces the
phosphorylation on serine 50 of protein tyrosine phosphatase 1B
(PTP1B). After this phosphorylation, PTP1B dephosphorylates GSK3
on tyrosine 216 and inactivates it. Overall, the activation of the
RhoA/RhoAK axis contributes to the transcription of b-catenin target
genes, like mdr1. (B) The Wnt inhibitors (e.g., Dickkopf-1 (Dkk-1))
increase the GSK3-mediated phosphorylation and ubiquitination of
b-catenin, priming it for the proteasomal degradation. The inhibi-
tion of RhoA (e.g., by RhoA small interfering RNA (siRNA)) or RhoAK
(e.g., by Y27632) increases the GSK3 activity, by reducing the RhoAK-
mediated phosphorylation of PTP1B on serine 50 and preventing
the dephosphorylation of GSK3 on tyrosine 216. As a result, the
nuclear translocation of b-catenin and its transcriptional activity are
reduced, whereas the ubiquitination and proteasomal degradation
of b-catenin are increased. These data lead to hypothesize the
existence of a cross-talk between the Wnt/GSK3 canonical pathway
and the Wnt/RhoA/RhoAK non-canonical pathway in human BBB
cells. APC, adenomatous polyposis coli; Friz, Frizzled; LRP5/6, low
density lipoprotein receptor-related protein 5/6; Pi, phosphate; Pi(Y),
phosphotyrosine; RhoAc, RhoA activator II; RhoAK, RhoAK; Uq,
ubiquitin. Continuous arrows indicate activated pathways; dotted
arrows indicate inhibited pathways.
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Although Pgp tightly cooperates with BCRP in controlling the
delivery of several drugs across the BBB,32 doxorubicin has high
afﬁnity for Pgp, which represents the main transporter of this drug
in BBB cells.33
The downregulation of the canonical Wnt/GSK3/b-catenin
pathway is known to reduce the Pgp expression and to induce
chemosensitization in colon34 and glioblastoma17 tumor stem
cells, neuroblastoma,35 chronic myeloid leukemia,36 and cholan-
giocarcinoma.37 Also, the inhibition of the non-canonical Wnt3/
RhoA/RhoAK pathway chemosensitizes multiple myeloma cells to
doxorubicin.38 We might speculate that the same cross-talk
between canonical and non-canonical Wnt pathways, observed
in BBB cells, cooperates in regulating the Pgp expression also in
cancer cells, and may represent a critical target of therapeutic
intervention for Pgp-rich tumors.
We suggest that the expression of Pgp is controlled by a cross-
talk between canonical and non-canonical Wnt pathways in
human BBB cells. A crucial regulator of this cross-talk is RhoAK,
which inhibits the GSK3-induced phosphorylation of b-catenin by
activating PTP1B. Targeted therapies against RhoA/RhoAK can
disrupt the cross-talk and downregulate the Pgp expression
(Figure 6). Improving the BBB permeability of anticancer drugs
that are efﬂuxed by Pgp thus enhancing their delivery to brain
tumors is still an unsolved challenge.39 Moreover, the high
expression of Pgp on BBB cells decreases not only the delivery
of chemotherapeutic agents, but also the passage of drugs used
to treat infective diseases, neurodegenerative diseases, and
epilepsy.40 By unveiling a new mechanism that regulates Pgp
expression in the BBB cells, our work may pave the way to
preclinical investigations using RhoAK inhibitors as adjuvant tools
in these central nervous system diseases.
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Supplementary Figures legends 
 
Supplementary Figure 1. Effects of Pgp inducers on small molecules permeability in human 
BBB cells 
hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts, then the medium in 
the upper chamber was replaced with fresh medium (-) or medium containing Wnt activator 2-
amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine (WntA; 20 μmol/L 
for 24 h) and RhoA activator II (RhoAc; 5 μg/mL for 3 h), chosen as Pgp inducers. At the end of the 
incubation period, 2 μCi/mL [14C]-sucrose or 10 μg/mL sodium fluorescein were added in the upper 
chamber. After 3 h the amount of each compoun recovered from the lower chamber was measured 
by liquid scintillation (for sucrose) or fluorimetrically (for sodium fluorescein). Permeability 
coefficients were calculated as reported under Materials and methods. Measurements were 
performed in duplicate and data are presented as means + SD (n = 3). 
 Supplementary Figure 2. RhoA kinase inhibition decreases β-catenin translocation in human 
BBB cells 
hCMEC/D3 cells were cultured in fresh medium in the absence (0) or in the presence of 10 μmol/L 
of RhoA kinase inhibitor Y27632 (Y276) for 1, 3, 6, 9, 24 h. A. RhoA kinase activity. Samples were 
subjected to ELISA assays to measure the activity of RhoA kinase. Data are presented as means + 
SD (n = 4). Versus ctrl: * p < 0.001. B. Nuclear extracts were analyzed for the amount of β-catenin 
(nucl cat). The expression of TBP was used as control of equal protein loading. The figure is 
representative of 3 experiments with similar results. The band density ratio between each protein 
and TBP was expressed as arbitrary units. Versus ctrl cells: * p < 0.01. C. hCMEC/D3 cells were 
cultured in fresh medium (-) or in the presence (+) of 10 μmol/L of the RhoA kinase inhibitor 
Y27632 (Y276) for 3 h, then lysed and subjected to Western blot analysis for claudin-3, claudin-5, 
occludin, ZO-1. β-tubulin expression was used as control of equal protein loading. The figure is 
representative of 3 experiments with similar results. The band density ratio between each protein 
and β-tubulin was expressed as arbitrary units. D. hCMEC/D3 cells were grown for 7 days up to 
confluence in Transwell inserts, then the medium in the upper chamber was replaced with fresh 
medium (-) or medium containing (+) 10 μmol/L of the RhoA kinase inhibitor Y27632 (Y276) for 3 
h. At the end of the incubation period, 2 μmol/L dextran-FITC, 2 μCi/mL [14C]-inulin, 2 μCi/mL 
[14C]-sucrose, were added in the upper chamber. After 3 h the amount of each compound recovered 
from the lower chamber was measured fluorimetrically (for dextran-FITC) or by liquid scintillation 
(for inulin and sucrose). Permeability coefficients were calculated as reported under Materials and 
methods. Measurements were performed in duplicate and data are presented as means + SD (n = 3). 
 Supplementary Figure 3. Effects of verapamil on doxorubicin permeability and cytotoxicity in 
glioblastoma cells co-cultured with BBB cells  
hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts; CV17, 01010627, 
Nov3 and U87-MG cells were seeded at day 4 in the lower chamber. After 3 days of co-culture, 
supernatant in the upper chamber was replaced with fresh medium without (- or ctrl) or with 
verapamil (Ver; 10 μmol/L) for 3 h (panels A-C) or 24 h (panels D-F). Doxorubicin (dox; 5 µmol/L) 
was coi-incubated in the upper chamber for 3 h (panels B-C) or 24 h (panels D-F). A. ATPase 
activity was measured spectrophotometrically after immunoprecipitation of Pgp from membrane 
fractions. Measurements were performed in duplicate and data are presented as means + SD (n = 3). 
Versus ctrl: * p < 0.005. B. Doxorubicin permeability coefficient was calculated as reported under 
Materials and methods. Measurements were performed in duplicate and data are presented as means 
+ SD (n = 3). Versus ctrl: * p < 0.001. C. Fluorimetric quantification of intracellular doxorubicin in 
glioblastoma cells. Data are presented as means + SD (n = 3). Versus untreated (-) cells: * p < 0.01. 
D. Glioblastoma cells were checked spectrophotometrically for the extracellular release of LDH. 
Data are presented as means + SD (n= 4). Versus untreated (-) cells: * p < 0.001. E. Whole cell 
lysates from 01010627 cells were resolved by SDS-PAGE and immunoblotted with an anti-caspase-
3 antibody (recognizing both pro-caspase and cleaved active caspase). β-tubulin expression was 
used as control of equal protein loading. The figure is representative of 3 experiments with similar 
results. F. Cell cycle analysis. The distribution of 01010627 cells in sub-G1, G0/G1, S, G2/M phase 
was analyzed by flow cytometry, as detailed under Materials and methods. Data are presented as 
means + SD (n=4). Vs ctrl: * p < 0.01. 
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1. Introduction 
 
The microvascular endothelium surrounding central 
nervous system, known as blood brain barrier (BBB), 
represents a natural barrier that limits the delivery of drugs, 
xenobiotics and toxic catabolites into brain parenchyma. The 
peculiarity of BBB includes the absence of fenestrations, the 
high number of tight junctions and adherens junctions, the 
presence of transmembrane efflux transporters belonging to 
the ATP binding cassette (ABC) transporters family, such as 
P-glycoprotein (Pgp/ABCB1), multidrug resistance related 
proteins (MRPs/ABCCs), breast cancer resistance protein 
(BCRP/ABCG2) [1]. ABC transporters are integral membrane 
transporters that hydrolyze ATP obtaining the driving force to 
pump substrates against their concentration gradient. Pgp and 
BCRP are the main transporters present on the luminal side of 
BBB and are involved in the efflux of different substrates, e.g. 
chemotherapeutic agents (such as anthracyclines, taxanes, 
Vinca alkaloids, epipodophyllotoxins, topotecan, methotrexate, 
imatinib, dasatinib, lapatinib, gefitinib, sorafenib, erlotinib), 
analgesics, anti-retrovirals, antibiotics, anti-epileptics, back 
into the bloodstream [2]. Given the broad spectrum of drugs 
transported, Pgp represents a major obstacle for the successful 
pharmacological therapy of brain tumors, such as glioblastoma 
multiforme, neurodegenerative diseases, infections, epilepsy 
[3]. 
Hypoxia is a condition commonly present in the bulk 
of solid tumors like glioblastoma or consequent to 
cardiovascular diseases like stroke. One of the main event 
occurring during hypoxia is the stabilization of the 
transcription factor hypoxia-inducible factor-1α (HIF-1α), 
which is composed by two subunits: β subunit is constitutively 
synthesized; α subunit undergoes an O2- and iron-dependent 
degradation in normoxia, while it is stabilized in hypoxia, 
when the α-β dimer is active as transcription factor [4]. Upon 
activation, HIF-1α up-regulates several genes involved in cell 
proliferation, neo-angiogenesis, matrix remodeling and 
invasion, pH control, iron metabolism [5], glucose metabolism 
[6], lipid uptake [7], lipogenesis [8] and steroidogenesis [9,10]. 
In the last years, it has been reported that chronic 
hypoxia generates a progressive dysfunction of the neuro-
vascular unit forming the BBB; such dysfunction has been 
implicated in the pathogenesis of various central nervous 
system diseases, including Alzheimer disease and amyotrophic 
lateral sclerosis [11]. Several studies demonstrated that 
hypoxia destabilizes the tight junctions, increases the 
paracellular leakage of substrates [12-14], changes the activity 
and expression of membrane transporters, such as the Na-K-Cl 
co-transporter [15] and the glucose transporters [16]. Notably, 
the promoter of Pgp gene has an hypoxia responsive element 
[17]. Repetitive exposures to low O2 tension indeed increase 
the expression of Pgp in rat brain microvascular endothelial 
cells [18]. The increased expression of Pgp occurring in 
Abstract 
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hypoxia is expected to further limit the success of 
pharmacological therapy in diseases characterized by large 
hypoxic areas, such as glioblastoma. 
Aim of this study is to analyze how the transport of 
Pgp substrates varies in normoxic and hypoxic BBB cells, and 
to design a strategy that allows an effective delivery also in 
hypoxia. 
 
2. Experimental Details 
 
2.1. Chemicals 
Fetal bovine serum (FBS) and culture medium were 
purchased from Invitrogen Life Technologies (Carlsbad, CA). 
Plasticware for cell cultures was from Falcon (Becton 
Dickinson, Franklin Lakes, NJ). Simvastatin was purchased 
from Calbiochem (San Diego, CA). Electrophoresis reagents 
were obtained from Bio-Rad Laboratories (Hercules, CA). The 
protein content of cell lysates was assessed with the BCA kit 
from Sigma Chemical Co. (St. Louis, MO). When not 
otherwise specified, all the other reagents were purchased from 
Sigma Chemical Co. 
 
2.2. Cells 
bEND3 cells, a murine brain microvascular 
endothelial cell line, were purchased from ATCC (Manassas, 
VA) and cultured in DMEM medium, containing 10% v/v 
FBS, 1% v/v penicillin-streptomycin, 1% v/v L-glutamine. 
hCMEC/D3 cells, a primary human brain microvascular 
endothelial cell line, were a kind gift from Prof. Pierre-Olivier 
Couraud (Institut Cochin, Centre National de la Recherche 
Scientifique UMR 8104, INSERM U567, Paris, France) and 
were cultured according to [19]. Both bEND3 and hCMEC/D3 
cells retain the BBB characteristics when cultured in vitro, as 
demonstrated by the measure of permeability coefficients of 
different substrates, by the trans-epithelial electric resistance 
value and by the expression profile of tight junction proteins 
[19-22]. Cells were seeded at 50,000/cm² density, and grown 
for 7 days up to confluence in Petri dishes or Transwell 
devices (0.4 μm diameter pore-size, Corning Life Sciences, 
Chorges, France), to allow the formation of a competent BBB. 
C6 and U87-MG cells (from ATCC) were chosen as 
models of glioblastoma cells and were respectively cultured in 
HAMF12 medium and DMEM medium, with 10% v/v FBS, 
1% v/v penicillin-streptomycin, 1% v/v L-glutamine. In co-
culture experiments, 500,000 C6 cells were added in the lower 
chamber of Transwell devices, 4 days after seeding bEND3 
cells in the Transwell insert; 500,000 U87-MG cells were 
added in the lower chamber of Transwell devices, 4 days after 
seeding hCMEC/D3 cells in the Transwell insert. After 3 days 
of co-culture the medium of the upper and lower chamber was 
replaced, and cells were used for the experimental assays. 
When cultured in normoxic conditions, cells were 
maintained in a humidified atmosphere at 37°C, 5% CO2 and 
21% O2; when cultured in hypoxic conditions, cells were 
maintained in a humidified atmosphere at 37°C, 5% CO2 and 
2% O2, in a Heracell 150i incubator (Thermo Scientific, 
Waltham, MA). 
 
2.3. Permeability assays 
The permeability of doxorubicin, [
3
H]-vinblastine 
(0.25 mCi/mL, PerkinElmer, Waltham, MA), mitoxantrone, 
was taken as index of Pgp and BCRP activity [19]. bEND3 and 
hCMEC/D3 cells were seeded at 50,000/cm² and grown for 7 
days up to confluence in 6-multiwell Transwell inserts; culture 
medium was replaced with fresh one and 5 µmol/L 
doxorubicin, 2 μCi/mL [3H]-vinblastine, 10 µmol/L 
mitoxantrone were added to the upper chamber of Transwell. 
After 3 h the medium in the lower chamber was collected. The 
amount of [
3
H]-vinblastine was measured using a Tri-Carb 
Liquid Scintillation Analyzer (PerkinElmer). Radioactivity 
was converted in nmol/cm
2
, using a previously prepared 
calibration curve. The amount of doxorubicin and 
mitoxantrone was measured fluorimetrically, using a LS-5 
spectrofluorimeter (PerkinElmer). Excitation and emission 
wavelengths were: 475 nm and 553 nm (doxorubicin); 607 nm 
and 684 nm (mitoxantrone). Fluorescence was converted in 
nmol/cm
2
, using a calibration curve previously set. The 
permeability coefficients were calculated as reported [23]. 
 
2.4. Western blot 
Cells were rinsed with lysis buffer (50 mmol/L Tris, 
10 mmol/L EDTA, 1% v/v Triton-X100), supplemented with 
the protease inhibitor cocktail set III (80 μmol/L aprotinin, 5 
mmol/L bestatin, 1.5 mmol/L leupeptin, 1 mmol/L pepstatin; 
Calbiochem), 2 mmol/L phenylmethylsulfonyl fluoride and 1 
mmol/L Na3VO4, then sonicated and centrifuged at 13,000 x g 
for 10 min at 4
oC. 20 μg of protein extracts were subjected to 
SDS-PAGE and probed with the following antibodies: anti-
Pgp/ABCB1 (C219, Novus Biologicals, Cambridge, UK); anti-
MRP1/ABCC1 (Abcam, Cambridge, UK); anti-MRP2/ABCC2 
(Abcam); anti-MRP3/ABCC3 (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA); anti-MRP4/ABCC4 (Abcam); anti-
MRP5/ABCC5 (Santa Cruz Biotechnology Inc.); anti-
MRP6/ABCC6 (Santa Cruz Biotechnology Inc.); anti-
BCRP/ABCG2 (Santa Cruz Biotechnology Inc.); anti-low 
density lipoprotein receptor (LDLR; Abcam); anti-β-tubulin 
(Santa Cruz Biotechnology Inc.), followed by the peroxidase-
conjugated secondary antibody (Bio-Rad). The membranes 
were washed with Tris buffered saline (TBS)-Tween 0.1% v/v, 
and proteins were detected by enhanced chemiluminescence 
(Bio-Rad). 
10 μg of nuclear extracts, obtained with the Nuclear 
Extraction Kit (Active Motif, Rixensart, Belgium), were 
subjected to Western blot analysis using an HIF-1α (BD 
Bioscience, San Jose, CA) or an anti-sterol regulatory element 
binding protein-2 (SREBP-2, Santa Cruz Biotechnology Inc.) 
antibodies. To check the equal control loading in nuclear 
fractions, samples were probed with an anti-TATA-box 
binding protein (TBP/TFIID) antibody (Santa Cruz 
Biotechnology Inc.). To exclude any cytosolic contamination 
of nuclear extracts, we verified that β-tubulin was undetectable 
in nuclear samples (not shown). 
In co-immunoprecipitation assays, 100 μg of proteins 
from nuclear extracts were immunoprecipitated with the anti-
HIF-1α antibody, using the PureProteome protein A and 
protein G Magnetic Beads (Millipore, Billerica, MA). 
Immunoprecipitated proteins were separated by SDS-PAGE 
and probed with the anti-SREBP-2 antibody or with the anti-
HIF-1α antibody (to verify the effective immunoprecipitation), 
followed by the peroxidase-conjugated secondary antibody. 
The densitometric analysis of Western blots was 
performed with the ImageJ software (http://rsb.info.nih.gov/ij/) 
and expressed as arbitrary units, where “1 unit” (or “0 unit” in 
case of undetectable bands) is the mean band density of 
bEND3 cells grown at 21% O2. 
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2.5. HIF-1α activity 
Nuclear proteins were extracted using the Nuclear 
Extract Kit (Active Motif). The activity of HIF-1α was 
assessed on 10 μg of nuclear proteins with the TransAM™ 
HIF-1 Transcription Factor Assay Kit (Active Motif), 
following the manufacturer’s instructions. Data were 
expressed as U absorbance/mg cell proteins. For each set of 
experiments, blank (with bis-distilled water), negative control 
(with mutated oligonucleotide) and competition assay (using 
20 pmol of the wild type non-biotinylated oligonucleotide, in 
the presence of the nuclear extracts of bEND3 and hCMEC/D3 
cells grown at 2% O2 for 24 h) - were included. With mutated 
oligonucleotide, HIF-1α activity was 0.51 + 0.07 U/mg cell 
proteins for bEND3 cells and 0.63 + 0.09 U/mg cell proteins 
for hCMEC/D3 cells; in the competition assay, HIF-1α activity 
was 1.02 + 0.14 U/mg cell proteins for bEND3 cells and 2.24 
+ 0.33 U/mg cell proteins for hCMEC/D3 cells (n = 3). 
 
2.6. Quantitative Real Time PCR (qRT-PCR) 
Total RNA was extracted and reverse-transcribed 
using the QuantiTect Reverse Transcription Kit (Qiagen, 
Hilden, Germany). qRT-PCR was carried out with the IQ
TM
 
SYBR Green Supermix (Bio-Rad). The same cDNA 
preparation was used for the quantitation of Pgp, 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGCoAR) and actin, 
chosen as housekeeping gene. Primer sequences, designed 
with Primer3 software (http://frodo.wi.mit.edu/primer3), were: 
Pgp: 5’-TGCTGGAGCGGTTCTACG-3’; 5’-ATAGGCAA 
TGTTCTCAGCAATG-3’; HMGCoAR: 5’-CGCAACCTC 
TATATCCGT-3’; 5’-GTAGCCGCCTATGCTC-3’; actin: 5’-
GCTATCCAGGCTGTGCTATC-3’; 5’-TGTCACGCACGA 
TTTCC-3’. The relative quantitation of samples was 
performed by comparing each PCR product with the 
housekeeping PCR product, using the Software Gene 
Expression Quantitation (Bio-Rad). 
 
2.7. De novo cholesterol synthesis 
Cells were labeled with 1 μCi/mL [3H]acetate (3600 
mCi/mmol; Amersham Bioscience, Piscataway, NJ) and the 
synthesis of radiolabeled cholesterol was measured as 
described [24]: after 24 h cells were washed twice with 
phosphate-buffered saline (PBS) and mechanically scraped in 
200 µL of PBS. 500 µL of methanol and 1 mL of hexane were 
added to the cell suspension, which was stirred at room 
temperature for 1 h and then centrifuged at 2,000 x g for 5 
min. The upper phase was transferred into a new test tube; the 
lower phase was supplemented with 1 mL of hexane and 
stirred overnight. After a 5 min centrifugation at 2,000 x g, the 
new upper phase was added to the previous one and the 
solvent was allowed to evaporate at room temperature for 24 h. 
Cellular lipid extracts produced by this separation were re-
suspended in 30 µL of chloroform and subjected to thin layer 
chromatography, using a 1:1 (v/v) ether/hexane solution as 
mobile phase. Each sample was spotted on pre-coated LK6D 
Whatman silica gels (Merck, Darmstadt, Germany) and 
allowed to run for 30 min. A solutions of cholesterol (10 
µg/mL) was used as standard. The silica gel plates were 
exposed for 1 h to a iodine-saturated atmosphere, then the 
migrated spots were cut out and their radioactivity was 
measured by liquid scintillation, using a Tri-Carb Liquid 
Scintillation Analyzer (PerkinElmer). The results were 
expressed as pmol [
3
H]cholesterol/mg cell proteins, according 
to the relative calibration curve. 
 
2.8. “LDL-masked” liposomal doxorubicin (apo-Lipodox) 
preparation 
“LDL-masked” liposomal doxorubicin (termed apo-
Lipodox) was prepared using anionic pegylated liposomes 
(COATSOME EL-01-PA, NOF Corporation, Tokyo, Japan) as 
detailed in [25]. The size of the liposomes was evaluated by 
dynamic light scattering with an ALV-NIBS dynamic light 
scattering instrument (ALV-Laser, Langen, Germany), 
provided with a Ne-He laser and an ALV-5000 multiple tau 
digital correlator. The scattered light intensity was recorded for 
30 s on liposome suspensions at 37°C. The hydrodynamic 
radius of liposomes was evaluated by using both the cumulant 
method and the CONTIN algorithm [26]. The mean radius of 
apo-Lipodox was 72.44 + 23.17 nm; the polydispersity index 
was 0.189. 
The intraliposomal doxorubicin was measured on a 5 
µL aliquot of apo-Lipodox, diluted 1:100 into a 1:1 v/v 
solution of ethanol/HCl 0.3 N, and sonicated. The fluorescence 
of doxorubicin was detected fluorimetrically as reported 
above. The encapsulation efficiency was 86 + 7 %. Apo-
Lipodox was stocked at 4°C at a concentration of 0.5 mmol/L. 
 
2.9. Intratumor doxorubicin delivery and cytotoxicity in co-
culture models 
The intratumor doxorubicin delivery was measured as 
previously described [27]. After 3 days of co-culture, 
doxorubicin (5 μmol/L) was added to the upper chamber of 
Transwell inserts containing bEND3 or hCMEC/D3 cells 
monolayer. After 3 h, C6 and U87-MG glioblastoma cells 
were collected from the lower chamber, rinsed with PBS, re-
suspended in 0.5 mL ethanol/HCl 0.3 N (1:1 v/v), and 
sonicated. A 50 μL aliquot was used to measure the protein 
content, the remaining sample was used to quantify 
fluorimetrically the intracellular doxorubicin content, as 
described above. Results were expressed as nmol 
doxorubicin/mg cell proteins. 
For cytotoxicity assays, 5 μmol/L doxorubicin was 
added to the upper chamber of Transwell inserts. After 24 h, 
both cell culture medium and glioblastoma cells from the 
lower chamber were collected. The activity of lactate 
dehydrogenase (LDH) in cell supernatant, used as index of cell 
damage and necrosis, and the activity of LDH in cell lysates 
were measured spectrophotometrically as described earlier 
[28]. Both intracellular and extracellular enzyme activity were 
expressed in μmol NADH oxidized/min/dish, then 
extracellular LDH activity was calculated as percentage of the 
total LDH activity in the dish. 
 
2.10. Statistical analysis 
All data in text and figures are provided as means ± 
SD. The results were analyzed by a one-way Analysis of 
Variance (ANOVA). A p < 0.05 was considered significant. 
 
3. Results 
 
3.1. Hypoxia lowers the delivery of Pgp substrates across 
murine, but not human BBB cells 
To evaluate how hypoxia affects the delivery of 
substrates of Pgp and BCRP, two ABC transporters highly 
expressed  on  the  luminal side of BBB cells [2], we measured  
the permeability coefficient of doxorubicin and vinblastine 
(two Pgp substrates), and mitoxantrone (a BCRP substrate). In 
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normoxia, hCMEC/D3 cells had a lower transport of 
doxorubicin and – at lesser extent – of vinblastine, than 
bEND3 cells; no differences in the transport of mitoxantrone 
were detected between normoxic bEND3 and hCMEC/D3 
cells (Figure 1A). Hypoxia reduced the permeability of Pgp 
substrates only in murine bEND3 cells; surprisingly it did not 
further reduce the transport of doxorubicin and vinblastine in 
human hCMEC/D3 cells. In parallel, we did not detect any 
significant variations in the permeability of mitoxantrone in 
both cells lines in hypoxic conditions (Figure 1A). To explain 
such differences, we examined the ABC transporters present in 
murine and human BBB cells in normoxia and hypoxia: as 
shown in Figure 1B, normoxic human hCMEC/D3 cells were 
richer of Pgp, MRP1, MRP2 and MRP6 compared with 
normoxic murine bEND3 cells. Hypoxia did not produce 
significant differences in the expression of ABC transporters in 
both cell lines, with the exception of Pgp, which was 
significantly increased in murine bEND3 cells (Figure 1B). By 
contrast, in hCMEC/D3 cells, where the amount of Pgp in 
normoxic conditions was comparable to the amount of Pgp in 
hypoxic bEND3 cells, Pgp was not further increased by 
hypoxia (Figure 1B). 
These results suggest that species-specific differences 
occur for the transport of Pgp substrates under hypoxic 
conditions, because of the different basal levels of Pgp and the 
different modulation of Pgp in response to hypoxia. 
 
3.2. Hypoxia induces the HIF-1α-driven transcription of Pgp 
in murine, but not in human BBB cells 
HIF-1α is one of the main factor activated by hypoxia 
[4] and it is a strong inducer of Pgp [17]. We therefore 
analyzed its activation in murine and human BBB cells 
cultured in normoxia and hypoxia, by measuring the amount of 
HIF-1α in nuclear extracts and the binding of the translocated 
HIF-1α to a DNA target sequence containing an hypoxia 
responsive element (Figure 2A-B). As expected, HIF-1α was 
undetectable in the nucleus of bEND3 cells (Figure 2A) and 
the DNA binding activity was very low (Figure 2B) under 
normoxic conditions. Hypoxia increased both the nuclear 
translocation and activity of HIF-1α in bEND3 cells. The same 
results were obtained by treating cells with CoCl2 (Figure 2A-
B), used as a chemical inducer of HIF-1α [29]. Surprisingly, 
HIF-1α was constitutively translocated in the nucleus and 
bound to DNA in normoxic hCMEC/D3 cells; we did not 
detect any further increase in hCMEC/D3 cells grown in an 
hypoxic environment or treated with CoCl2 (Figure 2A-B). 
In keeping with the differential activity of HIF-1α, 
normoxic bEND3 cells had a lower expression of Pgp mRNA 
than normoxic hCMEC/D3 cells (Figure 2C); whereas hypoxia 
and CoCl2 significantly increased Pgp transcription in murine 
BBB cells, they did not change the Pgp transcription in human 
BBB cells, which had the same Pgp mRNA levels in normoxia 
and hypoxia (Figure 2C). The difference in HIF-1α 
translocation and activation may explain the differences in Pgp 
expression and in permeability of Pgp substrates, observed 
between murine and human BBB cells in normoxia and 
hypoxia. 
 
3.3. When activated, HIF-1α promotes the nuclear 
translocation and the transcriptional activity of SREBP-2 in 
both murine and human BBB cells 
Recently, we demonstrated a direct correlation 
between the expression of Pgp and the activity of mevalonate 
pathway, the metabolic cascade which produces cholesterol 
[30]. Most genes of the mevalonate pathway, including the 
pace-maker enzyme HMGCoAR, are under the transcriptional 
control of the SREBP-2 factor. The latter is activated by low 
levels of intracellular cholesterol, but also by the interaction 
with other transcription factors like HIF-1α [9]. We thus 
wonder whether the differential activation of HIF-1α between 
normoxic and hypoxic murine and human BBB cells may 
change the activity of SREBP-2 and the expression of 
HMGCoAR. 
Interestingly, when activated - i.e. in hypoxic bEND3 
cells, in normoxic and hypoxic hCMEC/D3 cells -, nuclear 
HIF-1α co-immunoprecipitated with SREBP-2 (Figure 3A). 
The interaction with HIF-1α was paralleled by a change in the 
nuclear levels of SREBP-2: normoxic bEND3 cells have a 
detectable levels of nuclear SREBP-2, which was significantly 
increased in hypoxic conditions (Figure 3B). hCMEC/D3 cells, 
which had a constitutive activation of HIF-1α in normoxia and 
hypoxia (Figure 2A-B), had a constitutively high nuclear level 
of SREBP-2 (Figure 3B). In line with the differential nuclear 
translocation of HIF-1α/SREBP-2 complex, normoxic bEND3 
cells had lower HMGCoAR mRNA levels than hypoxic cells 
(Figure 3C); by contrast, in hCMEC/D3 cells the transcription 
of HMGCoAR was unchanged in normoxia and hypoxia, and 
was similar to that measured in hypoxic bEND3 cells (Figure 
3C). 
This experimental set pointed out that the differential 
activity of HIF-1α in murine and human BBB cells not only 
explains the differences in Pgp expression, but also determines 
a different transcription of SREBP-2 target genes. 
The changes in HMGCoAR expression determined a 
different metabolic flux through the mevalonate pathway, 
measured as rate of de novo cholesterol synthesis (Figure 4A): 
compared with normoxic bEND3 cells, hypoxic bEND3 cells 
had a higher cholesterol synthesis; in hCMEC/D3 cells the 
mevalonate pathway activity was high either in normoxia or in 
hypoxia, and again was superimposable to the activity 
measured in hypoxic bEND3 cells (Figure 4A). Independently 
from the basal rate of cholesterol synthesis, in both cell lines in 
normoxia and hypoxia, the activity of the mevalonate pathway 
was significantly reduced by the HMGCoAR inhibitor 
simvastatin (Figure 4A). 
Another target gene of SREBP-2 is LDLR, whose 
expression is also increased when intracellular cholesterol 
levels decrease [31]. In our models, the expression of LDLR 
varied in accord to the activation of SREBP-2/HIF-1α 
complex: indeed normoxic bEND3 cells, which had 
undetectable nuclear translocation of HIF-1α (Figure 2A) and 
low nuclear levels of SREBP-2 (Figure 3B), had a small 
amount of LDLR (Figure 4B). Such amount was increased by 
hypoxia, which increased in parallel the nuclear levels of HIF-
1α (Figure 2A) and SREBP-2 (Figure 3B). Normoxic and 
hypoxic hCMEC/D3 cells, characterized by high amounts of 
nuclear HIF-1α (Figure 2A) and SREBP-2 (Figure 3B), were 
characterized as well by a high expression of LDLR (Figure 
4B). Of note, the expression of LDLR was sensitive to the 
intracellular variations of cholesterol: indeed simvastatin, 
which reduced the synthesis of cholesterol (Figure 4A), 
increased the expression of LDLR in all the experimental 
conditions (Figure 4B). 
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Figure 1. Hypoxia reduces the delivery of Pgp substrates and increases Pgp expression in murine, but not in human BBB cells. A. bEND3 
and hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts, in normoxic (21% O2) or hypoxic (2% O2) conditions, 
then the medium in the upper chamber was replaced with medium containing 5 μmol/L doxorubicin, 2 μCi/mL [3H]-vinblastine, 10 µmol/L 
mitoxantrone. After 3 h the amount of each compound recovered from the lower chamber was measured fluorimetrically (for doxorubicin 
and mitoxantrone) or by liquid scintillation (for vinblastine). Permeability coefficients were calculated as reported under Experimental 
Details. Measurements were performed in duplicate and data are presented as means + SD (n = 3). For each cell line, permeability at 2% O2 
versus permeability at 21% O2: * p < 0.05. B. Cells were grown for 7 days in normoxic (21% O2) or hypoxic (2% O2) conditions, then lysed 
and subjected to Western blot analysis for Pgp, MRP1, MRP2, MRP3, MRP4, MRP5, MRP6, BCRP. β-tubulin expression was used as 
control of equal protein loading. The figure is representative of 3 experiments with similar results. The band density ratio between each 
protein and β-tubulin was expressed as arbitrary units. Versus bEND3 cells at 21% O2: * p < 0.05. 
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Figure 2. Murine, but not human BBB cells are sensitive to the hypoxia induced activation of HIF-1α and transcription of Pgp. bEND3 and 
hCMEC/D3 cells were grown for 7 days up to confluence in normoxic (21% O2) or hypoxic (2% O2) conditions, then subjected to the 
following investigations. When indicated, cells grown at 21% O2 were incubated with CoCl2 (10 μmol/L for the last 24 h), chosen as a 
chemical activator of HIF-1α. A. Nuclear extracts were analyzed for the amount of HIF-1α by Western blotting. The expression of TBP was 
used as control of equal protein loading. The band density ratio between HIF-1α and TBP was expressed as arbitrary units. Versus bEND3 
cells at 21% O2: * p < 0.001. B. HIF-1α activity was measured in nuclear extracts by ELISA assay. Data are presented as means + SD (n = 
3). For each cell line, versus 21% O2: * p < 0.005. C. Pgp mRNA levels were detected in triplicate by qRT-PCR. Data are presented as 
means + SD (n = 4). For each cell line, versus 21% O2: * p < 0.02. 
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Figure 3. HIF-1α co-immunoprecipitates with SREBP-2, increases the nuclear translocation of SREBP-2 and the transcription of 
HMGCoAR in murine and human BBB cells. bEND3 and hCMEC/D3 cells were grown for 7 days up to confluence in normoxic (21% O2) 
or hypoxic (2% O2) conditions, then subjected to the following investigations. A. Nuclear extracts were immunoprecipitated (IP) with an 
anti-HIF-1α antibody, then immunoblotted (IB) with an anti-SREBP-2 antibody or with an anti-HIF-1α antibody. The figure is 
representative of 3 experiments with similar results. no Ab: hypoxic hCMEC/D3 nuclear extracts immunoprecipitated without the anti-HIF-
1α antibody. The band density ratio between HIF-1α (after IP for HIF-1α + IB for SREBP-2) and HIF-1α (after IP for HIF-1α + IB for HIF-
1α) was expressed as arbitrary units. Versus bEND3 cells at 21% O2: * p < 0.001. B. Nuclear extracts were analyzed for the amount of 
SREBP-2 by Western blotting. The expression of TBP was used as control of equal protein loading. The band density ratio between 
SREBP-2 and TBP was expressed as arbitrary units. Versus bEND3 cells at 21% O2: * p < 0.005. C. HMGCoAR mRNA levels were 
detected in triplicate by qRT-PCR. Data are presented as means + SD (n = 4). For each cell line, versus 21% O2: * p < 0.01. 
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Figure 4. BBB cells with activated HIF-1α have increased synthesis of cholesterol and expression of LDLR, two events that are modulated 
by simvastatin. bEND3 and hCMEC/D3 cells were grown for 7 days up to confluence in normoxic (21% O2) or hypoxic (2% O2) 
conditions, in fresh medium (-). When indicated, the HMGCoAR inhibitor simvastatin (10 μmol/L; SIM) was added in the last 24 h. A. 
Cells were radiolabeled 24 h with [3H]acetate, then the de novo synthesis of cholesterol was measured in duplicate as described under 
Experimental Details. Data are presented as means + SD (n=3). For each cell line, versus 21% O2: * p < 0.02; SIM-treated cells versus 
untreated (-) cells: ° p < 0.05. B. Cells were lysed and subjected to Western blot analysis for LDLR. β-tubulin expression was used as 
control of equal protein loading. The figure is representative of 3 experiments with similar results. The band density ratio between LDLR 
and β-tubulin was expressed as arbitrary units. Versus untreated bEND3 cells at 21% O2: * p < 0.05; for each cell line, SIM-treated cells 
versus untreated (-) cells: ° p < 0.05. 
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Overall, these data suggest that the activity of 
SREBP-2 is controlled by HIF-1α in BBB cells. Despite the 
different activation of HIF-1α between murine and human 
BBB cells in normoxia and hypoxia, the metabolic responses 
controlled by the HIF-1α/SREBP-2 axis - such as the synthesis 
of cholesterol and the expression of LDLR - are sensitive to 
simvastatin. 
 
3.4. The association of simvastatin plus a “LDL-masked” 
liposomal doxorubicin increases the doxorubicin delivery 
across BBB also in the presence of activated HIF-1α 
We previously showed that the association of 
simvastatin, which decreases the activity of Pgp and increases 
the exposure of LDLR in hCMEC/D3 cells, followed by a 
“LDL-masked” liposomal doxorubicin (apo-Lipodox), 
improves doxorubicin delivery across BBB cells [25]. Here, 
we tested the efficacy of this strategy in normoxic and hypoxic 
bEND3 and hCMEC/D3 cells, and we verified whether this 
strategy was effective also when HIF-1α was activated: in 
these conditions, BBB cells had indeed high levels of Pgp 
(Figure 1B), but also high levels of LDLR (Figure 4B), which 
is crucial for the LDLR-mediated endocytosis of apo-Lipodox 
[25]. 
In normoxic bEND3 cells, when Pgp expression 
(Figure 1B), HIF-1α activity (Figure 2B) and LDLR levels 
(Figure 4B) were relatively low, doxorubicin permeability was 
slightly increased by the treatment of “simvastatin plus  
apo-Lipodox” (Figure 5A). In hypoxic bEND3 cells, when Pgp 
expression (Figure 1B), HIF-1α activity (Figure 2B) and 
LDLR levels (Figure 4B) were increased, the permeability of 
free doxorubicin was lower, but doxorubicin delivery was 
significantly improved by the association of “simvastatin plus 
apo-Lipodox” (Figure 5A). hCMEC/D3 cells had high levels 
of Pgp (Figure 1B), high activity of HIF-1α (Figure 2B) and 
high expression of LDLR (Figure 4B) in normoxia and 
hypoxia; these cells had indeed a very low delivery of free 
doxorubicin, which was significantly increased by the 
sequential treatment with “simvastatin plus apo-Lipodox” in 
both normoxic and hypoxic conditions (Figure 5A). 
apo-Lipodox alone slightly improved the drug 
delivery in all the experimental conditions, but no significant 
differences with free doxorubicin were observed (Figure 5A). 
To verify whether the increased delivery of 
doxorubicin obtained with the sequential treatment 
“simvastatin plus apo-Lipodox” was sufficient to reach 
cytotoxic concentrations for tumor cells, we set-up co-culture 
models of BBB cells (bEND3 or hCMEC/D3 cells), and 
glioblastoma cells (C6 or U87-MG cells, respectively) in 
Transwell devices. Free doxorubicin, apo-Lipodox alone or 
apo-Lipodox preceded by simvastatin were applied in the 
Transwell insert, facing the luminal side of BBB cells: in both 
models, the intra-glioblastoma content of doxorubicin in 
normoxia was significantly lower with free doxorubicin and 
apo-Lipodox alone, compared with the intracellular content of 
doxorubicin obtained with “simvastatin plus apo-Lipodox” 
(Figure 5B). In hypoxia, the intratumor doxorubicin measured 
after the treatment with free doxorubicin or apo-Lipodox alone 
was even lower in C6 cells co-cultured with bEND3 cells; the 
doxorubicin content in hypoxic U87-MG cells co-cultured 
with hCMEC/D3 cells was as low as in normoxic cells. Only 
the treatment with “simvastatin plus apo-Lipodox” increased 
the intratumor drug content (Figure 5B). In line with the 
doxorubicin accumulation, free doxorubicin did not produce 
any cytotoxic effect on glioblastoma cells in normoxia and in 
hypoxia (Figure 5C). apo-Lipodox was moderately cytotoxic 
in C6 cells co-cultured with bEND3 cells in normoxic and 
hypoxic conditions, but was ineffective against U87-MG cells 
co-cultured with hCMEC/D3 cells. Simvastatin alone was not 
cytotoxic; by contrast, the scheme “simvastatin plus apo-
Lipodox” was the only effectively cytotoxic approach in both 
co-culture models, either in normoxia or hypoxia (Figure 5C). 
 
4. Discussion  
 
In this work we investigated how the delivery of Pgp 
substrates, such doxorubicin and vinblastine, varies in 
normoxic and hypoxic BBB. To our surprise, murine and 
human cells showed a widely different behavior: while in 
murine bEND3 cells the delivery of Pgp substrates was 
decreased after long term-culture (i.e. 7 days) in hypoxia, in 
human hCMEC/D3 cells the permeability of Pgp substrates 
was lower than in bEND3 cells also in normoxic conditions 
and was not further reduced by hypoxia. This trend can be 
explained by the different levels of Pgp, which was more 
expressed in normoxic human BBB cells than in normoxic 
murine BBB cells; moreover, Pgp increased in hypoxic murine 
BBB cells, but not in hypoxic human BBB cells. This is not 
the first time that murine and human brain microvascular cells 
show striking differences in the expression and activity of Pgp 
[32]; however, what emerged from our data is that there is a 
species-specific regulation of Pgp expression in BBB cells 
exposed to hypoxia. 
Other ABC transporters had a different expression 
between bEND3 and hCMEC/D3 cells: for instance, MRP2 
and MRP6 were undectable in the former and present in the 
latter. However, in this case no differences occurred in each 
cell population between normoxic and hypoxic cells, leading 
to exclude a differential hypoxia-dependent regulation of these 
transporters. 
Since HIF-1α is a strong inducer of Pgp, we analyzed 
the expression levels of nuclear HIF-1α (i.e. the activated form 
of the protein) and its DNA binding capacity, as index of its 
transcriptional activity. While murine BBB cells have HIF-1α 
active only in hypoxia (either physically induced by low O2 
tension or chemically induced by CoCl2), as it occurs in most 
mammalian cells [4], in human hCMEC/D3 cells HIF-1α was 
active in normoxia as well as in hypoxia. The activity of HIF-
1α correlated with the mRNA and protein levels of Pgp, 
suggesting that that the different expression of Pgp between 
murine and human BBB cells in normoxia and hypoxia was 
likely due to the differential activity of HIF-1α. 
Previous works on cancer cells have reported the 
constitutive activation of HIF-1α in normoxia, in consequence 
of the increased rate of its synthesis, stimulated by autocrine 
growth factors and cytokines [33]. Moreover, the 
phosphorylation on serine, e.g. by RhoA kinase [34] and MAP 
kinases [35], promotes HIF-1α stabilization, which is 
associated to its activation even in normoxic conditions [30]. 
We did not investigate the phosphorylation status of HIF-1α in 
this work; worth of note, we previously detected a basal 
activity of RhoA/RhoA kinase axis in normoxic hCMEC/D3 
cells [25]: we cannot exclude that the active RhoA kinase may 
promote the stabilization of HIF-1α in normoxic hCMEC/D3 
cells, as it occurs in solid tumors [30]. 
Our data may explain previous findings showing that 
Pgp  did not change its expression in hypoxic hCMEC/D3 cells  
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Figure 5. The combination of simvastatin plus “LDL-masked” liposomal doxorubicin effectively increases the drug delivery and 
cytotoxicity against co-cultured hypoxic glioblastoma cells. bEND3 and hCMEC/D3 cells were grown for 7 days up to confluence in 
normoxic (21% O2) or hypoxic (2% O2) conditions in Transwell inserts. A. Permeability of doxorubicin across BBB monlayer. 5 μmol/L 
doxorubicin (dox) or apo-Lipodox (apoLD) were added for 3 hour in the upper chamber. When indicated, the incubation with apo-Lipodox 
was preceded by a 24 h pre-treatment with 10 μmol/L simvastatin (apoLD+SIM). The amount of doxorubicin recovered from the lower 
chamber was measured fluorimetrically. Permeability coefficients were calculated as reported under Experimental Details. Measurements 
were performed in duplicate and data are presented as means + SD (n = 3). For each cell line, versus dox at 21% O2: * p < 0.001; versus dox 
at 2% O2: ° p < 0.002. B. bEND3 and hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts; C6 and U87-MG cells 
were seeded at day 4 in the lower chamber. After 3 days of co-culture, the medium of the upper chamber was replaced with medium 
containing 5 μmol/L doxorubicin (dox) or apo-Lipodox (apoLD); when indicated, the incubation with apo-Lipodox was preceded by a 24 h 
pre-treatment with 10 μmol/L simvastatin (apoLD+SIM). After 3 h the intraglioblastoma doxorubicin content was measured 
fluorimetrically. Data are presented as means + SD (n= 4). For each cell line, versus dox at 21% O2: * p < 0.001; versus dox at 2% O2: ° p < 
0.001. C. Cells were left untreated for 7 days (CTRL), treated with 10 μmol/L simvastatin for the last 24 h (SIM) or with doxorubicin, apo-
Lipodox, simvastatin plus apo-Lipodox, as detailed in panel B. After 24 h, the release of LDH was measured spectrophotometrically in the 
culture supernatant of glioblastoma cells, as index of doxorubicin-induced cytotoxicity. Data are presented as means + SD (n= 4). For each 
cell line, versus untreated (CTRL) cells at 21% O2: * p < 0.001; versus untreated (CTRL) cells at 2% O2: ° p < 0.001. 
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[36]: for instance, in the work of Patak and colleagues, HIF-1α 
was expressed in normoxic hCMEC/D3 cells, increased after 4 
h of hypoxia and returned to basal levels after 24 h. Another 
study reported a very small increase of HIF-1α in hypoxic 
hCMEC/D3 cells after 24 h, without appreciable changes in 
Pgp expression towards normoxic cells [37]. As many 
transcription factors, also HIF-1α is subjected to temporal 
fluctuations of its expression. In our work, we cultured 
hCMEC/D3 cells for 7 days in hypoxia and in relatively mild 
hypoxic conditions (i.e. 2% O2), in order to mimic the constant 
hypoxia present in microvascular endothelial cells within the 
bulk of glioblastoma. It is conceivable that in our experimental 
conditions, hCMEC/D3 cells became adapted to the hypoxic 
environment and HIF-1α became insensitive to the periodic 
fluctuations observed during shorter pulses of hypoxia.  
These data suggest that there are marked species-
specific differences in Pgp expression and transcription in 
cells, and that the response of BBB cells of murine and human 
origin to normoxic and hypoxic environment may widely 
differ. Given such variability, the results of permeability 
assays for Pgp substrates obtained on murine BBB cells may 
not be reproducible in human BBB models; therefore, great 
caution is needed in the comparison of permeability results 
from BBB models of different species. 
On the other hand, independently from the species 
examined, our data suggest that high levels of HIF-1α are 
associated with high levels of Pgp, and limit the delivery of 
Pgp substrate across BBB. 
We therefore investigated how to improve the drug 
delivery in BBB cells with high levels of HIF-1α and Pgp. We 
previously observed that cancer cells with a constitutive 
activation of HIF-1α have also an increased metabolic flux 
through the mevalonate pathway [30]. This pathway supplies 
cells with high levels of cholesterol, which increases activity 
[38, 39] and expression of Pgp [30]. Also in bEND3 and 
hCMEC/D3 cells, the activation of HIF-1α was associated with 
increased synthesis of cholesterol and increased transcription 
of the pace-maker enzyme HMGCoAR. 
HMGCoAR promoter has an hypoxia responsive 
element; it has been shown that in human hepatocytes HIF-1α 
up-regulates the transcription of HMGCoAR by binding to the 
gene promoter and by activating the transcription factor 
SREBP-2 [9]. We found that, when active, HIF-1α co-
immunoprecipitated with SREBP-2, favored the nuclear 
translocation of SREBP-2 and the transcription of HMGCoAR. 
These events were detected in hypoxic bEND3 cells, in 
normoxic and hypoxic hCMEC/D3 cells. By contrast, in 
normoxic bEND3 cells, where HIF-1α was undetectable, the 
nuclear levels of SREBP-2 and the mRNA levels of 
HMGCoAR were lower. The activation of HIF-1α/SREBP-2 
axis determined the rate of cholesterol synthesis. To the best of 
our knowledge, there are no other reports showing that the rate 
of cholesterol synthesis is dependent on the activity of HIF-1α 
in BBB cells. 
Note of worthy for the aim of this work, the activation 
of HIF-1α may lower the delivery of Pgp substrates across 
BBB with at least two mechanisms: 1) by increasing Pgp 
expression, because of the up-regulation of Pgp gene 
transcription [17]; 2) by increasing Pgp activity, because of the 
higher amount of cholesterol synthesized and incorporated in 
plasma membrane [38, 39]. 
Besides the increase of cholesterol synthesis, another 
consequence of HIF-1α/SREBP-2 activation was the enhanced 
expression of LDLR, which is constitutively present on BBB 
cells [40] and is further increased by the activation of SREBP-
2 or by the decrease of intracellular cholesterol exerted by 
statins [31]. Also in our models of BBB cells, higher was the 
activity of SREBP-2, higher was the expression of LDLR; on 
the other hand, when the synthesis of cholesterol was lowered 
by simvastatin, LDLR expression was further enhanced. This 
situation reflects a dysregulated cholesterol homeostasis and is 
typical of cells with activated HIF-1α, which have high levels 
of LDLR that allows the uptake of extracellular cholesterol, 
notwithstanding the high levels of intracellular cholesterol [30, 
39]. We previously observed this altered homeostasis of 
cholesterol in cancer cells overexpressing HIF-1α and Pgp [30, 
39]; this is the first time that such metabolic condition is 
described in BBB cells. HIF-1α has been reported to increase 
the expression of LDLR-related protein 1 (LRP1) and very low 
density lipoprotein receptor (VLDLR) in renal cancer cells 
[41] and in cardiomyocytes, where LDLR was concurrently 
down-regulated [42]. However, in these works, only the 
activity of HIF-1α has been considered, without analyzing 
whether SREBP-2 was also changed. In the light of our results, 
we propose that the HIF-1α-induced activation of SREBP-2 
was the actual driving force in up-regulating LDLR in BBB 
cells. 
Since the LDLR-triggered endocytosis may be 
exploited to enhance the uptake of nanoparticle sensed as 
physiological LDL [25, 39], the high level of LDLR following 
HIF-1α activation represents a paradoxical “Achille’s heel” of 
hypoxic BBB cells. We previously found that in normoxic 
hCMEC/D3 cells the administration of simvastatin, which 
increased the exposure of LDLR, followed by a LDL-masked 
liposomal doxorubicin (“apo-Lipodox”) increased the delivery 
of doxorubicin, a drug which otherwise will be effluxed by 
Pgp, and the drug cytotoxicity against glioblastoma cells 
cultured under competent BBB [25]. Here we demonstrated 
that the same strategy was effective in BBB cells with 
activated HIF-1α, i.e. hypoxic bEND3 cells, normoxic and 
hypoxic hCMEC/D3 cells. The use of classical Pgp inhibitor 
such as cyclosporine A to improve the drug delivery across 
hypoxic BBB cells was not a good strategy, because of the 
potential delivery of cyclosporine A into brain parenchyma, 
where the compound induces neurotoxicity [43]. By contrast, 
the treatment scheme “simvastatin plus apo-Lipodox” appears 
more promising: on the one hand, simvastatin alone did not 
induce any cytotoxicity; on the other hand, the association 
“simvastatin plus apo-Lipodox” was the only strategy that 
grants an effective delivery of cytotoxic amounts of 
doxorubicin into hypoxic glioblastoma cells. 
Doxorubicin is a typical substrates of Pgp and is 
effective against glioblastoma in vitro; however, the efflux via 
Pgp at BBB level strongly reduces its in vivo efficacy and 
clinical use [44]. Our work shows that doxorubicin might 
overcome such limitation, if encapsulated in a “LDL-masked” 
liposome and preceded by treatment with a statin.  
 
5. Conclusions 
 
Pgp effluxes back into the bloodstream a variety of 
drugs potentially useful for brain tumors, neurodegenerative 
diseases, infective diseases and epilepsy. Chronic hypoxia is 
involved in the pathogenesis of many of these morbidities 
[11]; moreover, the increased expression of Pgp observed in 
hypoxic conditions further reduces the success of 
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pharmacological therapies in such diseases. Our work puts 
light on the metabolic changes occurring in BBB cells during 
hypoxia and proposes an effective strategy to improve drug 
delivery across BBB cells exposed to hypoxic environment 
and/or with an activated HIF-1α. Such approach is flexible, 
since several drugs can be loaded into “LDL masked” 
liposomes, and might be advantageous in a broad spectrum of 
central nervous system diseases. 
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the promoter of Wnt3 gene, temozolomide lowers the 
endogenous synthesis of Wnt3 in BBB cells, disrupts the 
Wnt3/glycogen synthase kinase 3/β-catenin signaling, 
and reduces the binding of β-catenin on the promoter of 
mdr1 gene, which encodes for Pgp. In co-culture models 
of BBB cells and human glioblastoma cells, pre-treatment 
with temozolomide increases the delivery, cytotoxicity, and 
antiproliferative effects of doxorubicin, vinblastine, and 
topotecan, three substrates of Pgp that are usually poorly 
delivered across BBB. Our work suggests that temozolo-
mide increases the BBB permeability of drugs that are nor-
mally effluxed by Pgp back to the bloodstream. these find-
ings may pave the way to new combinatorial chemotherapy 
schemes in glioblastoma.
Keywords Blood–brain barrier · temozolomide · 
P-glycoprotein · Wnt3 · Glioblastoma multiforme
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Abstract Low delivery of many anticancer drugs across 
the blood–brain barrier (BBB) is a limitation to the success 
of chemotherapy in glioblastoma. this is because of the 
high levels of atP-binding cassette transporters like P-gly-
coprotein (Pgp/aBCB1), which effluxes drugs back to the 
bloodstream. temozolomide is one of the few agents able 
to cross the BBB; its effects on BBB cells permeability and 
Pgp activity are not known. We found that temozolomide, 
at therapeutic concentration, increased the transport of Pgp 
substrates across human brain microvascular endothelial 
cells and decreased the expression of Pgp. By methylating 
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BSa  Bovine serum albumin
FItC  Fluorescein isothiocyanate
ZO-1  Zonula occludens-1
tBP  tata-box binding protein
qRt-PCR  Quantitative real-time PCR
ChIP  Chromatin immunoprecipitation
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Introduction
Glioblastoma multiforme (GBM) accounts for 65 % of pri-
mary central nervous system (CNS) tumors in the adult 
population. adjuvant chemotherapy is, along with maximal 
surgical resection and radiation therapy, a standard therapeu-
tic approach in disseminated GBM that almost universally 
fails [1]. the failure of this approach is due to the highly 
invasive phenotype of GBM, its strong chemoresistance, 
and the low delivery of anti-neoplastic drugs across the 
blood–brain barrier (BBB) [1]. First-line therapy in GBM 
is the systemic administration of the alkylating agent temo-
zolomide (tMZ, online resource 1), one of the few drugs 
to show good permeability across the BBB [2]. In systemic 
circulation, tMZ is rapidly converted into its active metabo-
lite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MtIC, 
online resource 1) [3], the chemical entity that likely reaches 
BBB in vivo. therapeutic protocols currently in use [4] aim 
either to increase the cumulative dose of tMZ or prolong the 
duration of the treatment. Until now, however, no treatment 
protocol has been curative [1]. Since the prognosis of GBM 
is still poor, alternative approaches have been the object of 
intensive investigation [2]. the topoisomerase I inhibitors 
irinotecan and topotecan have shown excellent anti-tumor 
activity in vitro and significant efficacy in vivo when admin-
istered with tMZ or bevacizumab [5]. topotecan, however, 
does not cross the BBB and achieves maximal efficacy only 
when administered by convection-enhanced delivery [6]. 
Doxorubicin is highly effective against GBM cells in vitro, 
as well, but its clinical use is limited by low delivery across 
BBB [7].
the greatest hurdle for many promising anti-GBM drugs 
is the BBB, the peculiar brain microvascular endothelium, 
devoid of fenestrations and pinocytic vesicles, and rich in 
tight junctions, adherent junctions and drug efflux trans-
porters of the atP-binding cassette (aBC) family [8]. 
the BBB is disrupted in the core of GBM, but is intact 
in the “brain-adjacent to tumor” (Bat) area, where inva-
sive GBM cells lay scattered in the non-transformed brain 
parenchyma. Bat is a critical zone for targeting chemo-
therapy because it contains cells that will either spread to 
other areas of the CNS or cause local relapse. Since the 
Bat is surrounded by a competent BBB, the delivery of 
chemotherapeutic drugs to this area is marginal [8]. alter-
native strategies—such as the osmotic opening of tight 
junctions with mannitol [9] or ultrasound [10]—have been 
devised in vivo, to overcome the low permeability of the 
BBB, with some success. Inhibitors of the aBC transport-
ers present on the luminal side of BBB cells, such as P-gly-
coprotein (Pgp/aBCB1), multidrug resistance-related pro-
tein 1 (MRP1/aBCC1) and breast cancer resistance protein 
(BCRP/aBCG2) [8], have also been used [11]. to date, 
however, no safe or satisfactory strategies to bypass the 
aBC transporter-mediated drug efflux have been devised.
Pgp/aBCB1 transports a number of chemotherapeutic 
agents, such as anthracyclines, taxanes, vinca alkaloids, ten-
iposide/etoposide, topotecan, methotrexate, imatinib, dasat-
inib, lapatinib, gefitinib, sorafenib, erlotinib, and mediates 
the efflux of several analgesics, anti-epileptics, anti-retrovi-
rals, and antibiotics [8]. In BBB cells, Pgp/aBCB1 is up-
regulated by different stimuli, such as tumor necrosis fac-
tor α [12] and ligands of pregnane X receptor, constitutive 
androstane receptor [13], aryl hydrocarbon receptor [14].
Recent data show that the activation of the Wnt-canonical 
pathway, critical for angiogenesis in brain [15] and acquisition 
of BBB properties [16], up-regulates Pgp/aBCB1 in human 
BBB cells [17, 18]. In the Wnt-canonical pathway, the binding 
of soluble Wnt proteins on Frizzled receptor and low-density-
lipoprotein receptor related protein-5 and -6 (LRP5/lRP6) co-
receptors decreases the activity of the enzyme glycogen syn-
thase kinase 3 (GSK3). By doing so, Wnt allows β-catenin to 
move from the cytosolic aPC/axin complex into the nucleus, 
where it binds to the t-cell factor/lymphoid enhancer factor 
(tCF/leF) and induces the transcription of target genes, such 
as mdr1, which encodes for Pgp/aBCB1 [19].
While several determinants have been reported to up-
regulate Pgp/aBCB1 in BBB cells, determinants that 
down-regulate Pgp/aBCB1 are poorly known. there is 
some evidence that specific polymorphisms of Pgp/aBCB1 
change the delivery of tMZ across BBB [20], but the 
relation between tMZ and Pgp/aBCB1 is still controver-
sial. In this study, we asked the question whether a clini-
cally achievable dose of tMZ can affect the permeability 
and the activity/expression of aBC transporters in human 
BBB cells. We found that tMZ specifically down-regulates 
Pgp/aBCB1 by interfering with the Wnt/GSK3/β-catenin 
signaling.
Materials and methods
Chemicals
Plasticware for cell cultures was from Falcon (Becton–
Dickinson, Franklin Lakes, NJ, USa). tMZ, doxorubicin, 
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mitoxantrone, vinblastine, and topotecan were obtained 
by Sigma Chemical Co. (St. Louis, MO, USa). Wnta 
[2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-
methoxyphenyl)pyrimidine] was purchased from Calbio-
chem (San Diego, Ca, USa). human recombinant Dick-
kopf-1 (Dkk-1) was from R&D Systems (Minneapolis, 
MN, USa). electrophoresis reagents were obtained from 
Bio-Rad Laboratories (hercules, Ca, USa); the protein 
content of cell lysates was assessed with the BCa kit from 
Sigma Chemical Co. When not otherwise specified, all the 
other reagents were purchased from Sigma Chemical Co.
Cells
the immortalized hCMeC/D3 cells, a primary human 
brain microvascular endothelial cell line that retains the 
BBB characteristics in vitro, were cultured as reported [21]. 
Cells were seeded at 50,000/cm2 density and were grown 
for 7 days up to confluence in Petri dishes and transwell 
(0.4-μm diameter pores-size, Corning Life Sciences, 
Chorges, France). Primary human brain microvascular 
endothelial cells (hBMeCs) were purchased from PromoCell 
Gmbh (heidelberg, Germany) and cultured in the endothelial 
cell growth medium MV (PromoCell Gmbh), supplemented 
with 5 % v/v fetal calf serum (FCS), 0.4 % v/v endothelial 
cell growth supplement (PromoCell Gmbh), 10 ng/ml eGF, 
90 μg/ml heparin, and 1 μg/ml hydrocortisone.
Primary human GBM cells (CV17, 01010627) were 
obtained from surgical samples of patients from the Depart-
ment of Neuroscience, Neurosurgical Unit, University of 
turin, Italy. the pathological diagnosis was performed 
according to WhO guidelines. Cells were cultured in 
DMeM-F12 medium, supplemented with 1 mol/l hePeS, 
0.3 mg/ml glucose, 75 μg/ml NahCO3, 2 mg/ml heparin, 
2 mg/ml bovine serum albumin (BSa), 2 mmol/l progester-
one, 20 ng/ml eGF, 10 ng/ml bFGF. U87-MG cells (atCC, 
Rockville, MD) were used as GBM reference cell line and 
cultured as reported above.
In co-culture experiments, 500,000 (for intracellular 
doxorubicin accumulation, PCR and cytotoxicity assays) or 
1,000 (for proliferation assay) GBM cells were added in the 
lower chamber of transwell 4 days after seeding hCMeC/
D3 cells or hBMeCs in transwell inserts. after 3 days of 
co-culture the medium of the upper chamber was replaced 
with fresh medium with or without tMZ, doxorubicin, vin-
blastine or topotecan, alone or in combination as detailed 
below.
Permeability coefficient across the BBB cells
the permeability to dextran-fluorescein isothiocy-
anate (FItC, molecular weight 70 kDa), [14C]-sucrose 
(589 mCi/mmol; Perkinelmer, Waltham, Ma, USa), 
[14C]-inulin (10 mCi/mmol; Perkinelmer) was taken as a 
parameter of tight junction integrity [21, 22]. the permea-
bility to doxorubicin, [3h]-vinblastine (0.25 mCi/ml, Perki-
nelmer), mitoxantrone, was taken as index of aBC trans-
porters activity [21]. hCMeC/D3 cells, seeded at 50,000/cm2 
and grown for 7 days up to confluence in six-multiwell 
transwell inserts, were incubated at day 4 with or without 
tMZ (50 μmol/l for 72 h). then the culture medium was 
replaced in both chambers, 2 μmol/l dextran-FItC, 2 μ 
Ci/ml [14C]-sucrose, 2 μCi/ml [14C]-inulin, 5 μmol/l doxo-
rubicin, 2 μCi/ml [3h]-vinblastine, 10 μmol/l mitoxantrone 
were added to the upper chamber of transwell. after 3 h, 
the medium in the lower chamber was collected. the 
amount of [14C]-sucrose, [14C]-inulin or [3h]-vinblastine 
was measured using a tri-carb liquid scintillation analyzer 
(Perkinelmer). Radioactivity was converted in nmol/cm2, 
using a calibration curve previously prepared. the amount 
of dextran-FItC, doxorubicin, and mitoxantrone present in 
the lower chamber was measured fluorometrically, using 
a LS-5 spectrofluorometer (Perkinelmer). excitation and 
emission wavelengths were: 494 and 518 nm (dextran-
FItC), 475 and 553 nm (doxorubicin), 607 and 684 nm 
(mitoxantrone). Fluorescence was converted in nmol/cm2, 
using a calibration curve previously set. the permeability 
coefficients were calculated as reported [23]. In time- and 
temperature-dependence experiments, the transwell inserts 
were incubated at 4, 15, and 37 °C, and treated as reported 
above; aliquots of the medium from the lower chamber 
were collected every 30 min up to 3 h. the amount of dox-
orubicin or vinblastine in the lower chamber was quantified 
as described earlier. When indicated, a 25 % w/v solution 
of mannitol, used to increase the leakage of solutes through 
the BBB tight junctions, was co-incubated in the upper 
chamber.
For tMZ permeability, hCMeC/D3 cells seeded in 
transwell inserts as reported above were incubated for 72 h 
with 0.7 μCi/ml [3h]-tMZ (Moravek Biochemical Inc., 
Brea, Ca, USa), equivalent to 10 μmol/l tMZ, in the pres-
ence of increasing concentrations (50, 100, and 200 μM) 
of cold tMZ. after this incubation period, the amount of 
[3h]-tMZ in the lower chamber was measured by liquid 
count scintillation. the results were expressed as the per-
centage of [3h]-tMZ recovered in the lower chamber after 
72 h versus [3h]-tMZ added in the upper chamber at time 
0, taking into account the concentration of cold tMZ added 
in the upper chamber at time 0.
Rhodamine 123 and hoechst 33342 accumulation
hCMeC/D3 cells were grown up to confluence in Petri 
dishes and incubated in the absence or presence of tMZ, 
as reported above. Cells were washed with PBS, detached 
with cell dissociation solution (Sigma), centrifuged at 
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13,000 × g for 5 min and re-suspended in 0.5 ml cul-
ture medium containing 5 % v/v FCS. a 50-μl aliquot 
was taken away, sonicated and used for the measurement 
of the protein content. twenty μmol/l of rhodamine 123 
or 50 μmol/l hoechst 33342 were added to the remain-
ing sample. after 10 min at 37 °C, cells were washed 
three times with PBS and re-suspended in 1 ml PBS. the 
intracellular fluorescence of rhodamine 123 (index of 
Pgp/aBCB1 and MRP1/aBCC1 activity) and hoechst 
33342 (index of BCRP/aBCG2 activity) was measured 
fluorometrically, using a LS-5 spectrofluorometer (Perki-
nelmer). excitation and emission wavelengths were: 488 
and 520 nm for rhodamine 123, 370 and 450 nm for hoe-
chst 33342. Fluorescence was converted in nmol/mg cell 
proteins using a calibration curve previously set.
Western-blot analysis
Cells were rinsed with lysis buffer (50 mmol/l tris, 
10 mmol/l eDta, 1 % w/v triton-X100), supplemented 
with the protease inhibitor cocktail set III (80 μmol/l apro-
tinin, 5 mmol/l bestatin, 1.5 mmol/l leupeptin, 1 mmol/l 
pepstatin; Calbiochem), 2 mmol/l phenylmethylsulfonyl 
fluoride and 1 mmol/l sodium orthovanadate, then soni-
cated and centrifuged at 13,000 × g for 10 min at 4 °C. 
20 μg of protein extracts were subjected to SDS-PaGe and 
probed with the following antibodies: anti-claudin 3 (Inv-
itrogen Life technologies, Monza, Italy); anti-claudin 5 
(Invitrogen Life technologies); anti-occludin (Invitrogen 
Life technologies); anti-zonula occludens-1 (ZO-1; Invit-
rogen Life technologies); anti-Pgp/aBCB1 (clone C219, 
Cabiochem), anti-MRP1/aBCC1 (abcam, Cambridge, 
Ma, USa), anti-BCRP/aBCG2 (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, Ca, USa), anti-Wnt3 (abcam); anti-
GSK3 (BD Biosciences, Franklin Lakes, NJ, USa); anti-
phospho(tyr216)GSK3 (BD Biosciences); anti-β-catenin 
(BD Biosciences); anti-phospho(Ser33/37/thr41)β-catenin 
(Cell Signalling technology Inc., Danvers, Ma. USa); anti-
β-tubulin (Santa Cruz Biotechnology Inc). this procedure 
was followed by the exposure to a peroxidase-conjugated 
secondary antibody (Bio-Rad). the membranes were washed 
with tris buffer saline-tween 0.1 % v/v, and proteins were 
detected by enhanced chemiluminescence (Perkinelmer).
Cytosol/nucleus separation was performed as reported 
[24]. ten μg of cytosolic or nuclear extracts were sub-
jected to Western-blot analysis using the anti-β-catenin 
antibody. to check the equal control loading in cytosolic 
and nuclear fractions, samples were probed respectively 
with an anti-β-tubulin or an anti-tata-box binding protein 
(tBP/tFIID) antibody (Santa Cruz Biotechnology Inc). to 
exclude any cytosolic contamination of nuclear extracts or 
vice versa, we verified that β-tubulin was undetectable in 
nuclear samples and tBP was undetectable in cytosolic 
samples.
the densitometric analysis of Western blots was per-
formed with ImageJ software (http://rsb.info.nih.gov/ij/) 
and expressed as arbitrary units, where “1 unit” is the mean 
band density in untreated cells.
Quantitative real-time PCR (qRt-PCR)
total RNa was extracted and reverse-transcribed using 
the Quantitect Reverse transcription Kit (Qiagen, hilden, 
Germany). qRt-PCR was carried out using IQ SYBR 
Green Supermix (Bio-Rad), according to the manufactur-
er’s instructions. the same cDNa preparation was used to 
quantify the genes of interest and the housekeeping gene 
β-actin. Primer sequences, designed with the Primer3 
software (http://frodo.wi.mit.edu/primer3), are reported 
in online resource 2. the relative quantification was per-
formed by comparing each PCR product with the house-
keeping PCR product using Bio-Rad software gene expres-
sion quantitation (Bio-Rad).
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed using the Magna ChIP 
a/G chromatin immunoprecipitation kit (Millipore, Bill-
erica, Ma, USa). Samples were immunoprecipitated with 
5 μg of anti-β-catenin antibody or with no antibody. the 
immunoprecipitated DNa was washed and eluted twice 
with 100 μl of elution buffer (0.1 M NahCO3, 1 % w/v 
SDS), the cross-linking was reversed by incubating the sam-
ples at 65 °C for 6 h. Samples were then treated with 1 μl 
proteinase K for 1 h at 55 °C. the DNa was eluted in 50 μl 
of h2O and analyzed by PCR. the putative β-catenin site on 
mdr1 promoter was validated by the MatInspector software 
(http://www.genomatix.de/). Primers sequences, designed 
with the Primer3 software (http://frodo.wi.mit.edu/primer3), 
are reported in online resource 2. PCR products were visu-
alized on a 3 % agarose gel, stained with 0.05 % v/v ethid-
ium bromide. as negative control, immunoprecipitated sam-
ples were subjected to PCR with primers matching a region 
10,000 bp upstream the mdr1 promoter. In this condition, no 
PCR product was detected (not shown).
Flow cytometry analysis
Cells were washed with PBS, detached with cell dissocia-
tion solution, and re-suspended at 5 × 105 cells/ml in 1 ml 
of culture medium containing 5 % v/v FCS. Samples were 
washed with 0.25 % w/v BSa–PBS, incubated with the 
primary antibody for Frizzled (Santa Cruz Biotechnology 
Inc.) or LRP6 (abcam) for 45 min at 4 °C, then washed 
chiara.riganti@unito.it   -   January 19, 2014   -   Read articles at www.DeepDyve.com
503Temozolomide down-regulates P-glycoprotein in human blood–brain barrier
1 3
twice and incubated with secondary FItC-conjugated anti-
body for 30 min at 4 °C. after washing and fixing in para-
formaldehyde 2 % w/v, the surface amount of Frizzled or 
LRP6 was detected on 100,000 cells by a FaCSCalibur 
system, using the Cell Quest software (Becton–Dickinson). 
Control experiments included incubation of cells with 
non-immune isotypic antibody, followed by the secondary 
antibody.
Promoter methylation assay
Genomic DNa (1 μg) was subjected to bisulphite modifica-
tion using the Methyl easy Xceed kit (human Genetics Sig-
natures, Randwick, australia), following the manufacturer’s 
instructions. Wnt3 promoter sequence was obtained using 
the UCSC Genome Browser (http://genome.ucsc.edu/). the 
CpG islands localization on Wnt3 promoter and the design 
of primers for methylation-specific PCR (MSP) was per-
formed with Methprimer software (http://www.urogene.org
/methprimer). Primers specific for methylated and unmeth-
ylated Wnt3 promoter are reported in online resource 2. 
MSP was performed with amplitaq gold DNa polymerase 
(applied Biosystems, Carlsbad, Ca, USa), including uni-
versally methylated (CpGenome, Millipore) and unmethyl-
ated DNa samples (human Genetics Signatures) as control. 
PCR products were visualized on a 3 % w/v agarose gel, 
stained with 0.05 % v/v ethidium bromide.
Generation of Wnt3-silenced cells
a total of 300,000 hCMeC/D3 cells were treated with 
turbofectin 8.0 (Origene technologies Inc., Rockville, 
MD, USa) and 1 μg of 29-mer shRNa Wnt3 construct 
in pGFP-C-shLenti-vector (Origene technologies Inc.) 
or non-targeting 29-mer scrambled shRNa cassette in 
pGFP-C-shLenti Vector (Origene technologies Inc.), 
used as control. twenty-four hours after the transfection, 
the green fluorescent cells were sorted by flow cytometry 
analysis. Forty-eight hours after the transfection, the cells 
were transferred in puromycin-containing medium to select 
clones stably silenced for Wnt3. the silencing efficacy was 
controlled every two passages by qRt-PCR and Western-
blot analysis of Wnt3.
Intracellular doxorubicin accumulation in co-culture 
models
after 3 days of co-culture, 5 μmol/l doxorubicin for 24 h 
or 50 μmol/l tMZ for 72 h plus 5 μmol/l doxorubicin in 
the last 24 h were added to the upper chamber of transwell 
inserts containing hCMeC/D3 cells monolayer. then, the 
GBM cells were collected from the lower chamber, rinsed 
with PBS, re-suspended in 0.5 ml ethanol/hCl 0.3 N (1:1 
v/v) and sonicated. a 50-μl aliquot was used to measure 
the protein content and the remaining sample was used to 
quantify fluorometrically the intracellular doxorubicin con-
tent as described above. Results were expressed as nmol 
doxorubicin/mg cell proteins.
For fluorescence microscope analysis, the GBM cells in 
the lower chamber were seeded on sterile glass coverslips 
and treated as reported above. at the end of the incubation 
period, cells were rinsed with PBS, fixed in 4 % w/v para-
formaldehyde for 15 min, washed three times with PBS, 
and incubated with 4′,6-diamidino-2-phenylindole dihy-
drochloride (DaPI) for 3 min at room temperature in the 
dark. Cells were washed three times with PBS and once 
with water and then the slides were mounted with 4 μl of 
gel mount aqueous mounting and examined with a Leica 
DC100 fluorescence microscope (Leica Microsystems 
Gmbh, Wetzlar, Germany). For each experimental point, a 
minimum of five microscopic fields were examined.
Cytotoxicity assays in co-culture models
after 3 days of co-culture, the upper chamber of the tran-
swell inserts containing hCMeC/D3 cells was filled with 
fresh medium or with medium containing: 50 μmol/l tMZ 
for 72 h, 5 μmol/l doxorubicin for 24 h, 50 μmol/l tMZ for 
72 h plus 5 μmol/l doxorubicin in the last 24 h, 20 nmol/l 
vinblastine for 24 h, 50 μmol/l tMZ for 72 h plus 20 nmol/l 
vinblastine in the last 24 h, 10 μmol/l topotecan for 24 h, 
50 μmol/l tMZ for 72 h plus 10 μmol/l topotecan in the 
last 24 h. according to preliminary experiments, 50 μmol/l 
tMZ for 72 h did not produce any significant toxicity in 
GBM cells or in hCMeC/D3 cells. the concentration of 
doxorubicin, vinblastine, and topotecan was chosen on the 
basis of previous works, showing that at these concentra-
tions each drug reduced the survival of GBM cells—in the 
absence of BBB cells—to less than 20 % [25–27].
the release of lactate dehydrogenase (LDh) in cell 
supernatant, used as index of cell damage and necrosis, 
was measured spectrophotometrically as described ear-
lier [28]. Results were expressed as percentage of extra-
cellular LDh versus total (intracellular plus extracellular) 
LDh. the activation of caspase 3, as index of apoptosis, 
was assessed in cells lysates as reported [29]. the amount 
of the hydrolyzed DeVD-7-amino-4-methylcumarine, a 
substrate of caspase 3, was measured fluorometrically. 
Results were expressed as nmol/mg cell protein using 
a calibration curve prepared with standard solutions of 
amino-4-methylcumarine.
Proliferation assays in co-culture models
GBM cells (1,000) were seeded in the lower chamber of 
transwell, containing confluent hCMeC/D3 cells in the 
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insert. this time was considered “day 0” in the proliferation 
assay. after 3 days of co-culture, the upper chamber of the 
transwell inserts was filled with fresh medium or medium 
containing: 50 μmol/l tMZ for 72 h, 5 μmol/l doxorubicin 
for 24 h, 50 μmol/l tMZ for 72 h plus 5 μmol/l doxorubicin 
in the last 24 h, 20 nmol/l vinblastine for 24 h, 50 μmol/l 
tMZ for 72 h plus 20 nmol/l vinblastine in the last 24 h, 
10 μmol/l topotecan for 24 h, 50 μmol/l tMZ for 72 h plus 
10 μmol/l topotecan in the last 24 h. the treatments were 
repeated every 7 days, for 4 weeks. at day 7, 14, 21, and 
28, GBM cells were collected, transferred into a 96-well 
plate, fixed with 4 % w/v paraformaldehyde, and stained 
with 0.5 % w/v crystal violet solution for 10 min at room 
temperature. the plate was washed three times in water, 
and then 100 μl of 0.1 mmol/l sodium citrate in 50 % v/v 
ethanol was added to each well and the absorbance was read 
at 570 nm. the absorbance units were converted into cell 
number, according to a titration curve obtained with serial 
cells dilutions of each cell line. to check that hCMeC/D3 
cells retain BBB properties, the permeability to dextran and 
inulin was measured weekly in a parallel set of transwell. 
No significant changes in the permeability coefficients were 
detected during the whole experiment (data not shown).
Statistical analysis
all data in text and figures are provided as mean ± SD. the 
results were analyzed by a one-way analysis of variance 
(aNOVa). a p value <0.05 was considered significant.
Results
temozolomide increases the transport of Pgp/aBCB1 
substrates through hCMeC/D3 BBB cells monolayer
We investigated whether 50 μmol/l tMZ (equivalent to 
9.7 μg/ml, a concentration that is clinically achievable in 
blood) [30] may affect the transport of other molecules 
through hCMeC/D3 monolayer.
as shown in Fig. 1a (upper panels), the permeability of 
molecules that have a paracellular diffusion in case of tight 
junctions leakage, such as dextran, inulin, and sucrose, 
widely varied in hCMeC/D3 cells, but was compatible with 
intact tight junctions [21]. the permeability coefficients fol-
lowed this rank order: inulin >sucrose >dextran 70. tMZ 
did not affect the permeability of these compounds (Fig. 1a, 
upper panels). also the permeability of aBC transporters 
substrates displayed major differences: among the substrates 
of Pgp/aBCB1 and MRP1/aBCC1 proteins, doxorubicin 
was almost 100-fold less transported than vinblastine across 
the hCMeC/D3 monolayer. When we analyzed the trans-
port of doxorubicin and vinblastine at earlier time points, 
it increased linearly in a temperature- and time-dependent 
manner (online resource 3a). In the presence of mannitol, 
an agent that disrupts the tight junctions as shown by the 
increased permeability of inulin (online resource 3b), we 
did not detect significant changes in doxorubicin and vin-
blastine transport (online resource 3c). these results suggest 
that paracellular leakage contributed minimally to the trans-
port of doxorubicin and vinblastine across the hCMeC/D3 
monolayer. Because of their high hydrophobicity, doxoru-
bicin and vinblastine are expected to enter by passive diffu-
sion [31, 32], and then to be effluxed back by Pgp/aBCB1 
and MRP1/aBCC1. Of note, the permeability of doxoru-
bicin and vinblastine was significantly higher in hCMeC/
D3 cells pre-treated with tMZ (Fig. 1a, lower panels). By 
contrast, the permeability of mitoxantrone, a substrate of 
BCRP/aBCG2 with a permeability coefficient between 
doxorubicin and vinblastine in hCMeC/D3 cells, was unaf-
fected by tMZ (Fig. 1a, lower panels).
Congruent with these results, tMZ increased the intra-
cellular accumulation of rhodamine 123, which is effluxed 
by Pgp/aBCB1 and MRP1/aBCC1, and did not change 
the accumulation of hoechst 33342, which is effluxed by 
BCRP/aBCG2 (online resource 4).
When we analyzed the expression of typical tight junc-
tions proteins in cells exposed to tMZ we detected a small 
decrease of claudin-3. Claudin-5, occludin, and ZO-1 did not 
change (Fig. 1b). hCMeC/D3 cells constitutively expressed 
Pgp/aBCB1, MRP1/aBCC1, and BCRP/aBCG2 (Fig. 1c). 
Of note, tMZ decreased the amount of Pgp/aBCB1, with-
out affecting the other two proteins (Fig. 1c). the decrease 
of Pgp/aBCB1 exerted by tMZ was dose-dependent (online 
resource 5a). We next measured the transport of [3h]-tMZ 
across hCMeC/D3 monolayer in the presence of increasing 
concentrations of unlabeled tMZ, sufficient to significantly 
reduce Pgp/aBCB1: as shown in the online resource 5b, the 
amount of [3h]-tMZ in the lower chamber of transwell 
was about 100 % of the amount added in the upper chamber, 
independently of the decrease of Pgp/aBCB1 induced by 
tMZ itself. these results suggest that Pgp/aBCB1 played a 
minor role in the transport of tMZ across hCMeC/D3 mon-
olayer and that tMZ did not enhance its own delivery by 
decreasing Pgp/aBCB1.
Under our experimental conditions, tMZ (50 μmol/l for 
72 h) showed no toxicity on hCMeC/D3 cells, as measured 
by LDh release (as described below) and caspase-3 activity 
(not shown).
temozolomide down-regulates the transcription of mdr1 
gene by disrupting the Wnt/GSK3/β-catenin pathway in 
hCMeC/D3 BBB cells
to clarify the molecular mechanisms by which tMZ 
decreases Pgp/aBCB1 protein, we asked the questions of 
chiara.riganti@unito.it   -   January 19, 2014   -   Read articles at www.DeepDyve.com
505Temozolomide down-regulates P-glycoprotein in human blood–brain barrier
1 3
whether decreased gene transcription could be accountable 
and which transcription factors could be the targets of the 
drug. tMZ lowered the mRNa levels of mdr1 (Fig. 2a) 
and decreased the binding of β-catenin, a known inducer 
of Pgp/aBCB1 in hCMeC/D3 cells [16], to the mdr1 pro-
moter (Fig. 2b).
Fig. 1  effects of temozolomide 
on permeability coefficients, 
tight junction markers, and 
aBC transporters in blood–
brain barrier hCMeC/D3 cells. 
a hCMeC/D3 cells were grown 
for 7 days up to confluence 
in transwell inserts, without 
(CTRL) or with temozolo-
mide (TMZ; 50 μmol/l for the 
last 72 h). at the end of the 
incubation period, 2 μmol/l 
dextran-FItC, 2 μCi/ml [14C]-
inulin, 2 μCi/ml [14C]-sucrose, 
5 μmol/l doxorubicin, 2 μCi/
ml [3h]-vinblastine, 10 μmol/l 
mitoxantrone were added in the 
upper chamber. after 3 h, the 
amount of the drug recovered 
from the lower chamber was 
measured fluorometrically (for 
dextran-FItC, doxorubicin, 
and mitoxantrone) or by liquid 
scintillation (for inulin, sucrose, 
and vinblastine). Permeability 
coefficients were calculated as 
reported under the “Materials 
and methods” section. Measure-
ments were performed in dupli-
cate and data are presented as 
mean ± SD (n = 3). vs. CTRL: 
*p < 0.02. b hCMeC/D3 cells 
were incubated without (CTRL) 
or with temozolomide (TMZ; 
50 μmol/l for 72 h), then lysed 
and subjected to Western-blot 
analysis for claudin-3, clau-
din-5, occludin, ZO-1. β-tubulin 
expression was used as control 
of equal protein loading. the 
figure is representative of three 
experiments with similar results. 
the band density ratio between 
each protein and β-tubulin was 
expressed as arbitrary units. c 
hCMeC/D3 cells, treated as 
reported in b, were subjected 
to Western-blot analysis for 
Pgp/aBCB1, MRP1/aBCC1, 
and BCRP/aBCG2. β-tubulin 
expression was used as control 
of equal protein loading. the 
figure is representative of three 
experiments with similar results. 
the band density ratio between 
each protein and β-tubulin was 
expressed as arbitrary units. vs. 
CTRL: *p < 0.05
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In hCMeC/D3 cells, β-catenin was detectable in both 
cytosolic and nuclear extracts under basal conditions 
(Fig. 2c); tMZ decreased the amount of β-catenin present 
in the nucleus (Fig. 2c). In parallel the drug increased the 
active form of GSK3—i.e., phospho(tyr216)GSK3-, and 
the amount of serine 33/37/threonine 41-phosphorylated 
β-catenin (Fig. 2d). as a whole, these data suggest that 
tMZ may reduce the amount of β-catenin active as tran-
scription factor.
In hCMeC/D3 cells, the activity of GSK3 is controlled 
by the Wnt canonical pathway [17, 18]. the presence 
of Wnt proteins in endothelial cells is restricted to some 
Fig. 2  effects of temozolomide on mdr1 expression and GSK3/β-
catenin pathway in hCMeC/D3 cells hCMeC/D3 cells were grown 
in fresh medium (CTRL) or in the presence of temozolomide (TMZ; 
50 μmol/l for 48 h), then subjected to the following investigations. 
a total RNa was extracted and reverse-transcribed and the expres-
sion of mdr1 gene was detected by qRt-PCR. the expression level in 
untreated cells was considered “1”. Data are presented as mean ± SD 
(n = 3). vs. CTRL: *p < 0.002. b Chromatin immunoprecipitation of 
β-catenin on mdr1 promoter (pro) in hCMeC/D3 cells. gen PCR prod-
uct from genomic DNa. no Ab precipitated samples without anti-β-
catenin antibody. bl blank. the figure is representative of three experi-
ments with similar results. c Nuclear and cytosolic extracts were 
analyzed for the amount of β-catenin. the expression of β-tubulin 
and tBP was used as control of equal protein loading for cytosolic 
and nuclear samples, respectively, and to verify the efficacy of the 
nucleus–cytosol separation. the band density ratio between each pro-
tein and β-tubulin/tBP was expressed as arbitrary units. vs. CTRL: 
*p < 0.05. the figure is representative of three experiments with simi-
lar results. d Western-blot analysis of phospho(tyr216)GSK3, GSK3, 
phospho(Ser33/37/thr41)β-catenin, β-catenin in whole-cell lysates. 
β-tubulin expression was used as control of equal protein loading. the 
figure is representative of three experiments with similar results. the 
band density ratio between each protein and β-tubulin was expressed 
as arbitrary units. vs. CTRL: *p < 0.02
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antigens of the large Wnt family, such as Wnt2b, Wnt3, 
Wnt4, and Wnt5 [33]. the first three are associated to the 
canonical GSK3/β-catenin pathway [34–36].
We wanted to validate the hypotheses that (1) the 
Wnt/GSK3/β-catenin axis controls the expression of the 
mdr1 gene in hCMeC/D3 and (2) tMZ down-regulates 
the expression of Pgp/aBCB1 by interfering with this axis. 
We therefore treated cells with the Wnt activator Wnta, the 
Wnt antagonist Dkk-1, and the GSK3 inhibitor LiCl. as 
shown in Fig. 3a, Wnta decreased the phosphorylation of 
GSK3, whereas Dkk-1 produced the opposite effect. the 
phosphorylation of β-catenin, which was low in untreated 
hCMeC/D3 cells, was not significantly reduced by Wnta 
and was increased by Dkk-1. LiCl did not change the phos-
phorylation of GSK3 on tyrosine 216, but slightly reduced 
the phosphorylation of β-catenin on serine 33/37/threonine 
41, suggesting that it effectively inhibited the activity of 
GSK3. the nuclear translocation of β-catenin (Fig. 3b) and 
its binding on mdr1 promoter (Fig. 3c) was increased by 
Wnta and LiCl, and reduced by Dkk-1. Indeed, hCMeC/
D3 cells treated with Dkk-1 had lower levels of mdr1 
mRNa (Fig. 3d) and Pgp/aBCB1 protein (Fig. 3e). Cells 
treated with Wnta or LiCl had higher amounts of mdr1 
mRNa and Pgp/aBCB1 protein (Fig. 3d–e). Congru-
ent with this trend, Dkk-1 increased, and Wnta and LiCl 
decreased the permeability of doxorubicin, chosen as a 
Pgp/aBCB1 substrate, across the hCMeC/D3 monolayer 
(Fig. 3f). Interestingly, tMZ mimicked the effects of Dkk-1 
and counteracted the effects of Wnta and LiCl on β-catenin 
phosphorylation (Fig. 3a), nuclear translocation (Fig. 3b) 
and mdr1 promoter binding (Fig. 3c), on mdr1 mRNa 
(Fig. 3d) and Pgp/aBCB1 levels (Fig. 3e), and on doxo-
rubicin permeability (Fig. 3f). these findings suggested 
that tMZ reduced mdr1 transcription by inhibiting the 
Wnt/GSK3/β-catenin axis. 
temozolomide lowers the synthesis of Wnt3 in hCMeC/
D3 BBB cells
tMZ did not change the surface amount of the Wnt recep-
tor Frizzled and Wnt co-receptor LRP6 (online resource 6), 
leading to exclude interference with the Wnt3 signaling on 
the cell surface.
We asked the question, then, of whether tMZ down-
regulated the endogenous synthesis of one or more Wnts 
proteins. We did not detect Wnt2b and Wnt4 in hCMeC/
D3 cells (data not shown). Wnt3 was instead detectable at 
protein (Fig. 4a) and mRNa (Fig. 4b) level. Notably, tMZ 
reduced both Wnt3 protein and mRNa (Fig. 4a, b).
Since tMZ is an alkylating agent that methylates DNa 
[4], we asked the question of whether it might cause the 
methylation of the Wnt3 promoter. Wnt3 promoter has 
indeed several CpG islands (online resource 7), usually 
methylated in infrequently transcripted genes and unmeth-
ylated in highly transcripted ones. MSP PCR assays 
showed that Wnt3 promoter was fully unmethylated in 
hCMeC/D3 cells (Fig. 4c). tMZ decreased the amount of 
unmethylated promoter and induced the appearance of a 
methylated band (Fig. 4c), thus appearing to be a good can-
didate for the epigenetic down-regulation of Wnt3.
to confirm that Wnt3 was a critical controller of mdr1 
expression in our model, we permanently silenced Wnt3 
in hCMeC/D3 cells; silencing produced a 90 % reduc-
tion in Wnt3 mRNa (Fig. 5a) and made the Wnt3 protein 
undetectable by Western blotting (Fig. 5b). the depletion 
of the Wnt3 protein significantly increased the amount of 
phospho(tyr216)GSK3 and phospho(Ser33/37/thr41)β-
catenin (Fig. 5c), prevented the binding of β-catenin on 
mdr1 promoter (Fig. 5d) and markedly reduced the expres-
sion of Pgp/aBCB1 (Fig. 5e). additionally, Wnt3-depleted 
hCMeC/D3 cells showed a higher permeability to doxoru-
bicin than wild-type cells (Fig. 5f).
temozolomide increases the anti-tumor efficacy  
of Pgp/aBCB1 substrates in glioblastoma-hCMeC/D3 
co-culture models
Since tMZ decreased the amount and activity of 
Pgp/aBCB1 in BBB cells, we next asked the question 
of whether the efficacy of anti-cancer drugs commonly 
effluxed by this transporter would be improved. With this 
goal in mind, we cultured hCMeC/D3 cells, treated or 
not with tMZ, in transwell inserts, containing different 
GBM cell lines (CV17, 01010627, U87-MG) in the lower 
chamber. Without pre-treatment with tMZ, doxorubicin 
was applied in the upper chamber, facing the luminal side 
of hCMeC/D3 monolayer, which expresses high amounts 
of Pgp/aBCB1 [37]. as expected, doxorubicin was poorly 
delivered to GBM cells in the lower chamber (Fig. 6a). 
Pre-treatment of hCMeC/D3 cells with tMZ significantly 
increased the intratumor amount of doxorubicin (Fig. 6a). 
the typical nuclear red fluorescence of doxorubicin [28] 
was undetectable in 01010627 GBM cells recovered from 
the lower chamber of the co-cultures, whereas pre-treat-
ment of hCMeC/D3 cells with tMZ restored the nuclear 
accumulation of doxorubicin in GBM cells (Fig. 6b). Inter-
estingly, tMZ decreased the expression levels of mdr1 also 
in the GBM cells cultured in the lower chamber (online 
resource 8), as it did in hCMeC/D3 cells.
Under the experimental conditions used, neither tMZ 
nor doxorubicin alone induced detectable cytotoxicity, 
measured as extracellular release of LDh and activation 
of caspase 3 (Fig. 6c), in GBM cells. the tMZ-doxoru-
bicin combination produced cytotoxic effects in all the 
tumor cell lines analyzed (Fig. 6c). the rate of prolif-
eration of the three GBM cell lines was not affected by 
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the addition of doxorubicin in the upper chamber of the 
transwell (Fig. 6d). tMZ applied in the upper chamber 
reduced the proliferation rate of all tumor cell lines in a 
time-dependent way; of note, its antiproliferative effect 
was significantly enhanced when tMZ was followed by 
doxorubicin (Fig. 6d). Under these conditions tMZ and 
doxorubicin, alone or in combination, did not induce any 
significant cytotoxicity (online resource 9a) and did not 
affect cell proliferation (online resource 9b) in hCMeC/
D3 cells.
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the chemosensitizing properties of tMZ were not lim-
ited to doxorubicin. In the same co-culture models, vinblas-
tine and topotecan, two other substrates of Pgp/aBCB1, 
did not increase the extracellular LDh (online resource 
10a), did not activate the caspase 3 (online resource 10b) 
and did not decrease cell proliferation (online resource 10c) 
of GBM cells, when applied in the upper chamber of the 
transwell. Only the pre-treatment of hCMeC/D3 cells with 
tMZ followed by vinblastine and topotecan exerted signifi-
cant cytotoxicity (online resource 10a–b) and reduced the 
proliferation (online resource 10c) of GBM cells cultured 
under the BBB monolayer. the combination of tMZ plus 
vinblastine or tMZ plus topotecan (online resource 10c) 
were significantly more effective in reducing cell prolif-
eration after 21 and 28 days (p < 0.02) than tMZ alone 
(Fig. 6d).
Notably, the same permeabilizing effects induced by 
tMZ in wild-type BBB cells was obtained after Wnt3 
depletion: indeed, Wnt3-silenced hCMeC/D3 monolayer 
allowed a higher delivery (Fig. 6e) and toxicity (Fig. 6f) of 
doxorubicin in the co-cultured 01010627 GBM cells.
temozolomide downregulates the Wnt3/GSK3/β-catenin/
aBCB1 axis and increases the efficacy of doxorubicin in 
co-cultures of human primary BBB cells and glioblastoma 
cells
We then asked the question of whether the effects of tMZ 
could also occur in primary cells extracted from human 
brain microvessels, i.e., hBMeCs.
We found that the promoter of Wnt3 was fully unmethyl-
ated in hBMeCs and that tMZ induced the partial meth-
ylation of the promoter (Fig. 7a). this was followed by the 
decrease of Wnt3 mRNa (Fig. 7b) and protein (Fig. 7c), the 
increase of phospho(tyr216)GSK3 and phospho(Ser33/37-
thr41)β-catenin (Fig. 7c), the reduction of the β-catenin 
binding on mdr1 promoter (Fig. 7d), the decrease of 
Pgp/aBCB1 protein (Fig. 7e). In co-cultures of hBMeCs 
and primary GBM 01010627 cells, the intratumor delivery 
of doxorubicin was low (Fig. 7f). Neither doxorubicin nor 
tMZ induced significant cytotoxicity, measured in terms 
Fig. 3  effects of temozolomide and Wnt modulators on mdr1 expres-
sion in hCMeC/D3 cells. hCMeC/D3 cells were grown in fresh 
medium (CTRL) or with temozolomide (TMZ; 50 μmol/l for 48 h), 
Wnt activator 2-amino-4-(3,4-(methylene dioxy)benzyl amino)-6-(3-
methoxyphenyl)pyrimidine (WntA; 20 μmol/l for 24 h), Wnt inhibitor 
recombinant Dkk-1 protein (DKK; 1 μg/ml for 24 h), GSK3 inhibi-
tor LiCl (LiCl; 10 mmol/l for 24 h). When co-incubated, Wnta and 
LiCl were added to tMZ in the last 24 h. a Western-blot analysis of 
phospho(tyr216)GSK3, GSK3, phospho(Ser33/37/thr41)β-catenin, 
β-catenin in whole cell lysates. β-tubulin expression was used as 
control of equal protein loading. the figure is representative of three 
experiments with similar results. the band density ratio between each 
protein and β-tubulin was expressed as arbitrary units. vs. CTRL: 
*p < 0.02; vs. WntA or LiCl alone: °p < 0.05. b Nuclear and cyto-
solic extracts were analyzed for the amount of β-catenin. the expres-
sion of β-tubulin and tBP was used as control of equal protein load-
ing for cytosolic and nuclear samples respectively, and to verify the 
efficacy of the nucleus–cytosol separation. the band density ratio 
between each protein and β-tubulin/tBP was expressed as arbitrary 
units. vs. CTRL: *p < 0.05; vs. WntA or LiCl alone: °p < 0.005. the 
figure is representative of three experiments with similar results. c 
Chromatin immunoprecipitation of β-catenin on mdr1 promoter (pro) 
in hCMeC/D3 cells. gen PCR product from genomic DNa. no Ab 
precipitated samples without anti-β-catenin antibody. bl blank. the 
figure is representative of three experiments with similar results. d 
mdr1 expression was detected in triplicate by qRt-PCR. Data are pre-
sented as mean ± SD (n = 4). vs. CTRL: *p < 0.02; vs. WntA or LiCl: 
°p < 0.05. e Western-blot analysis of Pgp/aBCB1. β-tubulin expres-
sion was used as control of equal protein loading. the figure is repre-
sentative of three experiments with similar results. the band density 
ratio between each protein and β-tubulin was expressed as arbitrary 
units. vs. CTRL: *p < 0.01; vs. WntA or LiCl alone: °p < 0.02. f Doxo-
rubicin permeability. hCMeC/D3 cells were grown for 7 days up to 
confluence in transwell inserts and treated as reported above. at the 
end of the incubation period, 5 μmol/l doxorubicin was added in the 
upper chamber. after 3 h, the amount of the drug recovered from the 
lower chamber was measured fluorometrically. Permeability coeffi-
cient was calculated as reported under the “Materials and methods” 
section. Measurements were performed in duplicate and data are pre-
sented as mean ± SD (n = 3). vs. CTRL: *p < 0.001; vs. WntA or LiCl 
alone: °p < 0.005
◂
Fig. 4  effects of temozolomide on Wnt3 synthesis in hCMeC/D3 
cells hCMeC/D3 cells were grown in the absence (CTRL) or in the 
presence of temozolomide (TMZ; 50 μmol/l for 48 h in Western-blot 
experiments, 24 h in qRt-PCR and MSP experiments), then subjected 
to the following investigations. a Western-blot analysis of Wnt3 in 
whole cell lysates. β-tubulin expression was used as control of equal 
protein loading. the figure is representative of three experiments with 
similar results. the band density ratio between Wnt3 and β-tubulin 
was expressed as arbitrary units. vs. CTRL: *p < 0.05. b total RNa 
was extracted and reverse-transcribed, then the expression of Wnt3 
gene was detected by qRt-PCR. the expression level in untreated 
cells was considered “1”. Data are presented as mean ± SD (n = 3). 
vs. CTRL: *p < 0.05. c Methylation of Wnt3 promoter. Genomic DNa 
was subjected to bisulfite modification, followed by PCR with spe-
cific primers for methylated (M) and unmethylated (UM) Wnt3 pro-
moter. the figure is representative of three experiments with similar 
results. + positive controls with a universal methylated or unmethyl-
ated genome sequence, respectively. bl blank
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of extracellular release of LDh and activation of the cas-
pase 3, in GBM cells co-cultured with hBMeCs (Fig. 7g). 
By contrast, the addition of tMZ on the luminal side of 
hBMeCs, at a concentration that did not induce cytotoxic-
ity (online resource 11a) and did not reduce the prolifera-
tion (online resource 11b) of endothelial cells, significantly 
increased the delivery of doxorubicin and cytotoxicity in 
GBM cells (Fig. 7f, g).
Discussion
While the effect of tMZ on GBM cells is well known, no 
studies have yet investigated the effects of the drug on BBB 
cells. to explore this issue, we exposed human immortal-
ized brain microvascular endothelial cells hCMeC/D3 and 
primary brain microvascular endothelial cells hBMeCs to 
tMZ, at a concentration found in the blood of patients [30]. 
at this concentration, the drug did not induce any detect-
able cytotoxic effect on BBB cells, but was able to increase 
the permeability of substrates of Pgp/aBCB1 across the 
BBB monolayer. Unlike other permeabilizing strategies 
[9, 10], tMZ did not affect the integrity of tight junctions, 
as the permeability to dextran, inulin, and sucrose, as well 
as the expression of claudin-5, occludin and ZO-1 did not 
change. Only claudin-3 was slightly reduced by tMZ: 
since Wnt3/β-catenin has been reported to up-regulate clau-
din-3 in mouse brain microvascular endothelial cells [35], 
this effect may be caused by the decrease in Wnt3 signaling 
induced by tMZ. however, as it appears from the perme-
ability assay, the isolated decrease of claudin-3 was not suf-
ficient enough for the functional impair of the tight junc-
tions in hCMeC/D3 cells.
the reduction of Pgp/aBCB1 caused the increase in 
the permeability of doxorubicin and vinblastine elicited by 
tMZ. to the best of our knowledge, this effect of tMZ was 
not described before. this observation may have a strong 
impact on what we know about drug delivery to CNS, as 
Pgp/aBCB1 is abundantly localized on the luminal side of 
BBB cells [37] and recognizes a broad spectrum of sub-
strates. among these substrates, more specifically, is the 
majority of anticancer drugs [8], prevented from reaching 
therapeutic concentrations in CNS via this mechanism. the 
half-life of tMZ in plasma is short and the drug is chemi-
cally converted into its active metabolite MtIC [3]; it is 
conceivable that such a chemical conversion occurs also 
in our experimental system and that MtIC is the actual 
responsible for the effects on BBB cells.
the effect of tMZ was specific for Pgp/aBCB1, 
since the activity and expression of MRP1/aBCC1 
and BCRP/aBCG2, two other aBC transporters pre-
sent on BBB cells [8, 11, 37], were not affected. the 
decrease of Pgp/aBCB1 without changes in other aBC 
transporters is of particular interest. Indeed, mice knocked 
down for Pgp/aBCB1 have a compensatory increase of 
BCRP/aBCG2 in BBB, suggesting cooperation between 
these transporters [11]. Our study was performed by treat-
ing cells with a single dose of tMZ for 72 h; we did not 
investigate whether different experimental conditions (e.g., 
repetitive treatments with the drug or longer treatment peri-
ods) affect the expression of aBC transporters other than 
Pgp/aBCB1. the antitumor effects of tMZ, in terms of 
alkylating efficacy and DNa damages, are significantly 
stronger when the drug is administered repetitively within 
the same day than when the drug is administered as sin-
gle dose [4]. We cannot exclude a priori that prolonged or 
repetitive administrations of tMZ might exert a stronger 
decrease in Pgp/aBCB1, thereby triggering a progres-
sive increase in BCRP/aBCG2. When BCRP/aBCG2 
is increased in response to the decrease of Pgp/aBCB1, 
drugs that are dual substrates of these transporters are 
not more delivered through the BBB [11]. Notwithstand-
ing, the down-regulation of Pgp/aBCB1 results in the 
increased delivery of drugs, which have higher affinity for 
Pgp/aBCB1 than for BCRP/aBCG2 [11]. this is the case 
of doxorubicin and vinblastine, which are more transported 
across hCMeC/D3 monolayer upon the down-regulation of 
Pgp/aBCB1 induced by tMZ.
It has been reported that Pgp/aBCB1 is under the tran-
scriptional control of β-catenin, whose activity is regulated 
by Wnt/GSK3/β-catenin axis in hCMeC/D3 cells [17, 18]. 
In our hands, untreated hCMeC/D3 cells had β-catenin 
constitutively bound on the promoter of mdr1 gene and 
Pgp/aBCB1 constitutively expressed. In contrast, cells 
treated with tMZ showed increased activity of GSK3 and 
increased amounts of phosphorylated β-catenin. the phos-
phorylation-dependent degradation of β-catenin resulted in 
a decrease of its nuclear translocation and binding on the 
mdr1 promoter. the results with activators and inhibitors 
of the Wnt canonical pathway suggested that tMZ down-
regulated Pgp/aBCB1 acting like a Wnt-pathway inhibi-
tor. Of note, the same effect of Wnt/GSK3/β-catenin axis 
in controlling the expression of Pgp/aBCB1 and the same 
effect of tMZ occurred in primary hBMeCs. Unlike pre-
vious observations, that showed that the inhibitor of GSK3 
6-bromoindirubin-3′-oxime up-regulated the transcription 
of MRP2/aBCC2, MRP4/aBCC4 and BCRP/aBCG2, and 
the inhibitor of β-catenin quercetin produced the opposite 
effects [17], we did not find any change in the expression of 
BCRP/aBCG2 in hCMeC/D3 cells after tMZ. this discrep-
ancy could owe to the different stimuli used. Quercetin inhib-
ited the binding of tCF to its DNa target sequences [38], 
therein reducing the transcriptional activity of β-catenin/tCF 
complex. tCF is paramount in the activation of certain pro-
moters, less so in the activation of others. We hypothesized 
that the transcription of bcrp gene may be tightly dependent 
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Fig. 5  effects of Wnt3 silencing on mdr1 expression in hCMeC/
D3 cells. Wild-type hCMeC/D3 cells (CTRL), cells stably trans-
fected with a non-targeting 29-mer scrambled shRNa (scr) or stably 
silenced for Wnt3 (Wnt3-) were subjected to the following investi-
gations. a Wnt3 qRt-PCR. total RNa was extracted and reverse-
transcribed, the expression of Wnt3 gene was detected by qRt-
PCR. the expression level in untreated cells was considered “1”. 
Data are presented as mean ± SD (n = 3). vs. CTRL: *p < 0.001. 
b Western-blot analysis of Wnt3 in whole cell lysates. β-tubulin 
expression was used as control of equal protein loading. the fig-
ure is representative of three experiments with similar results. the 
band density ratio between Wnt3 and β-tubulin was expressed as 
arbitrary units. vs. CTRL: *p < 0.001. c Western-blot analysis of 
phospho(tyr216)GSK3, GSK3, phospho(Ser33/37/thr41)β-catenin, 
β-catenin in whole cell lysates. β-tubulin expression was used as 
control of equal protein loading. the figure is representative of three 
experiments with similar results. the band density ratio between each 
protein and β-tubulin was expressed as arbitrary units. vs. CTRL: 
*p < 0.01. d Chromatin immunoprecipitation of β-catenin on mdr1 
promoter (pro) in hCMeC/D3 cells. gen PCR product from genomic 
DNa. no Ab precipitated samples without anti-β-catenin antibody. bl 
blank. the figure is representative of three experiments with similar 
results. e Western-blot analysis of Pgp/aBCB1. β-tubulin expression 
was used as control of equal protein loading. the figure is represent-
ative of three experiments with similar results. the band density ratio 
between each protein and β-tubulin was expressed as arbitrary units. 
vs. CTRL: *p < 0.002. f Doxorubicin permeability. hCMeC/D3 cells 
were grown for 7 days up to confluence in transwell inserts, then 
5 μmol/l doxorubicin was added in the upper chamber. after 3 h, the 
amount of the drug recovered from the lower chamber was measured 
fluorometrically. Permeability coefficient was calculated as reported 
under the “Materials and methods” section. Measurements were per-
formed in duplicate and data are presented as mean ± SD (n = 3). 
vs. CTRL: *p < 0.001
chiara.riganti@unito.it   -   January 19, 2014   -   Read articles at www.DeepDyve.com
512 C. Riganti et al.
1 3
on the whole β-catenin/tCF complex, whereas the tran-
scription of mdr1 gene may be less so. although we did not 
measure the amount of tCF in hCMeC/D3 cells treated with 
tMZ and we cannot exclude that the drug may also inter-
fere with the formation of the β-catenin/tCF complex, our 
data strongly suggest that tMZ down-regulated β-catenin 
at an upstream level, by preventing its nuclear translocation 
and the subsequent association with tCF. alternatively, we 
may speculate that the down-regulation of bcrp gene due to 
the lower activation of β-catenin is masked by the simultane-
ous compensatory up-regulation of bcrp, consequent to the 
decrease of Pgp/aBCB1 [11]. the sum of these two events 
may leave unchanged the levels of BCRP/aBCG2 protein in 
cells treated with tMZ.
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Our results are in agreement with other reports showing 
that Wnt signaling is involved in the Pgp-mediated chem-
oresistance in tumors. the Frizzled-1 receptor of Wnt, nec-
essary for the activation of β-catenin pathway, is present at 
high levels in neuroblastoma [19] and breast cancers [39] 
overexpressing Pgp/aBCB1, where the silencing of Friz-
zled-1 down-regulated the mdr1 gene. however, we did 
not detect any change in the expression levels of Frizzled 
in hCMeC/D3 cells exposed to tMZ. We therefore moved 
our focus on the levels of Wnt ligands produced by endothe-
lial cells, which are able to bind Frizzled receptors and acti-
vate the GSK3/β-catenin axis. Wnt3 was present in both 
hCMeC/D3 and hBMeC cells; the results in Wnt3-silenced 
hCMeC/D3 cells supported the hypothesis that Wnt3 was a 
critical controller of mdr1 transcription, since its depletion 
produced a 70 % decrease in Pgp/aBC1 protein.
Interestingly, tMZ decreased Wnt3 protein and mRNa, 
leading us to hypothesize that the drug down-regulated the 
transcription of Wnt3 gene in BBB cells. as an alkylat-
ing agent, tMZ methylates guanine on O6 position and 
induces a DNa mismatch repair response that produces 
double-strand breaks, if not repaired by the O6 methyl gua-
nine methyltransferase enzyme. however, the vast major-
ity of the methylations caused by tMZ are other methyla-
tions, usually not cytotoxic [4]. the consequences of these 
non-toxic methylations have not yet been investigated. We 
found that tMZ methylates the promoter of Wnt3 gene, 
which is rich in CpG islands. Untreated hCMeC/D3 and 
hBMeC cells express a fully unmethylated promoter, 
which is consistent with the constitutive transcription of 
Wnt3: the promoter’s methylation induced by tMZ may 
explain the decrease of Wnt3, suggesting that tMZ is an 
epigenetic down-regulator of Wnt3 gene.
Of note, tMZ administered on the luminal side of 
hCMeC/D3 cells also decreased the mdr1 levels in GBM 
cells growing under hCMeC/D3 monolayer: this means 
that the drug crossed—as expected—the BBB, and acted 
on both endothelial and tumor cells, increasing at the same 
time the permeability of BBB cells and the chemosensitiv-
ity of GBM cells. experimental findings obtained in our 
laboratory suggest that tMZ down-regulates Pgp/aBCB1 
in GBM cells with a Wnt3a-dependent mechanism 
(Riganti, unpublished data).
In view of our results, we think that clinically achiev-
able doses of tMZ may facilitate the subsequent passage 
of anticancer drugs, not commonly used in the therapy of 
GBM because they are rapidly effluxed through the BBB 
by Pgp/aBCB1. Using doxorubicin as a prototype, we 
indeed observed in co-culture models of hCMeC/D3 or 
hBMeC with GBM cells that the pre-treatment of BBB 
cells with tMZ significantly increased the delivery of 
doxorubicin, induced marked cytotoxicity, and reduced the 
proliferation of GBM cells. the increased permeability of 
doxorubicin induced by tMZ was likely triggered by the 
down-regulation of the Wnt3/GSK3/β-catenin/Pgp axis in 
BBB cells, since the same effect was achieved by depleting 
Wnt3 in hCMeC/D3 cells.
Several strategies that increase the delivery of doxo-
rubicin to GBMs, such as encapsulating the drug in 
PeGylated liposomes [7, 40] or loading it in BBB-tar-
geting nanoparticles [41, 42], are under intensive inves-
tigations. Our approach is different as we studied a drug 
already commonly used in GBM therapy, like tMZ. the 
pharmacokinetics, the pharmacodynamic effects and the 
side effects of tMZ and doxorubicin are well known. the 
combination of tMZ and doxorubicin is new and requires 
appropriate studies of pharmacokinetics and safety 
Fig. 6  effects of temozolomide on doxorubicin delivery and cyto-
toxicity in glioblastoma cells co-cultured with hCMeC/D3 cells. 
hCMeC/D3 cells were grown for 7 days up to confluence in transwell 
inserts; CV17, 01010627, and U87-MG cells were seeded at day 4 
in the lower chamber. after 3 days of co-culture, supernatant in the 
upper chamber was replaced with fresh medium without (−) or with 
temozolomide (50 μmol/l for 72 h; TMZ or T). 5 μmol/l doxorubicin 
(dox) was added in the upper chamber in the last 24 h, then the fol-
lowing investigations were performed. a Fluorimetric quantification 
of intracellular doxorubicin in GBM cells. Measurements were per-
formed in duplicate and data are presented as mean ± SD (n = 4). vs. 
untreated cells: *p < 0.05. b 01010627 cells were seeded on sterile 
glass coverslips, treated as reported above, then stained with DaPI and 
analyzed by fluorescence microscopy to detect the intracellular accu-
mulation of doxorubicin. Magnification: 63× objective (1.4 numeri-
cal aperture); 10× ocular lens. the micrographs are representative of 
three experiments with similar results. c the culture supernatant of 
GBM cells was checked spectrophotometrically for the extracellular 
activity of LDh (open bars), the cell lysates were analyzed fluoro-
metrically for the activity of caspase 3 (hatched bars). Measurements 
were performed in duplicate and data are presented as mean ± SD 
(n = 4). vs. untreated cells: *p < 0.05. d after 3 days of co-culture, 
the medium of the upper chamber was replaced with fresh medium 
(open circles) or medium containing 50 μmol/l temozolomide for 72 h 
(solid circles, T), 5 μmol/l doxorubicin for 24 h (open squares, dox), 
50 μmol/l temozolomide for 72 h plus 5 μmol/l doxorubicin in the last 
24 h (solid squares, T + dox). Drug treatments were repeated every 
7 days, as reported in the “Materials and methods” section. the prolif-
eration of GBM cells was monitored weekly by crystal violet staining. 
Measurements were performed in triplicate and data are presented as 
mean ± SD (n = 4). vs. untreated cells (CTRL): *p < 0.01. T + dox 
vs. T alone: °p < 0.05. e–f Wild-type hCMeC/D3 cells (CTRL), cells 
stably transfected with a non-targeting 29-mer scrambled shRNa 
(scr) or stably silenced for Wnt3 (Wnt3-) were grown for 7 days up 
to confluence in transwell inserts; 01010627 GBM cells were seeded 
at day 4 in the lower chamber. after 3 days of co-culture, superna-
tant in the upper chamber was replaced with fresh medium without 
(−dox) or with 5 μmol/l doxorubicin (+dox) for 24 h. the intracel-
lular doxorubicin in GBM cells was measured fluorometrically (e). 
Measurements were performed in duplicate and data are presented as 
mean ± SD (n = 3). vs. untreated cells: *p < 0.001. the culture super-
natant of GBM cells was checked spectrophotometrically for the extra-
cellular activity of LDh (open bars, f), the cell lysates were analyzed 
fluorometrically for the activity of caspase 3 (hatched bars, panel f). 
Measurements were performed in duplicate and data are presented as 
mean ± SD (n = 3). vs. untreated cells: *p < 0.001
◂
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pharmacology. the results of the present study are pav-
ing the way to other studies on the antitumor efficacy of 
this new drug combination in orthotopic animal models of 
human glioblastoma.
the same chemosensitizing effects of tMZ that we 
describe here were obtained with two other substrates 
of Pgp/aBCB1, vinblastine, and topotecan. While the 
former is not currently used in GBM therapy, the latter 
has received a great deal of interest in the last few years. 
although topotecan does not cross the BBB [6], it has a 
very low IC50 against GBM cells in vitro [27, 43] and has 
been proposed as an effective agent when administered by 
convection-enhanced delivery [6]. If the results obtained in 
our co-culture models will be confirmed in vivo, this might 
open the door for new therapeutic protocols based on the 
pre-treatment with tMZ followed by systemic administra-
tion of topotecan. Our findings may also explain the clini-
cal observation that the topoisomerase I inhibitors produce 
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significant benefits in patients with recurrent gliomas when 
used in combination with tMZ [5].
In conclusion, we describe a novel role of tMZ in BBB 
cells, as a down-regulator of the expression of Pgp/aBCB1 
at clinically achievable concentrations. Beside opening the 
door for new treatment protocols, our results might have 
important implications for the eradication of GBM cells in 
the Bat area, where tumor cells lay surrounded by intact 
BBB [8], cannot be completely removed by surgery or effi-
ciently radiated and almost never are reached by effective 
concentrations of chemotherapeutic drugs. the use of tMZ 
in association with doxorubicin, topotecan, or vinblastine 
may become a successful strategy for eradicating GBM 
cells from Bat area and preventing recurrence.
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Fig. 7  effects of temozolomide in primary human brain microvas-
cular endothelial cells co-cultured with primary human glioblastoma 
cells. a Methylation of Wnt3 promoter. hBMeCs were grown in the 
absence (CTRL) or in the presence of temozolomide (TMZ; 50 μmol/l, 
for 24 h), then genomic DNa was subjected to bisulfite modifica-
tion, followed by PCR with specific primers for methylated (M) and 
unmethylated (UM) Wnt3 promoter. the figure is representative of 
three experiments with similar results. + positive controls with a uni-
versal methylated or unmethylated genome sequence, respectively. 
bl blank. b Wnt3 mRNa levels. Cells were incubated in the absence 
(CTRL) or in the presence of temozolomide (TMZ; 50 μmol/l, for 
48 h). total RNa was extracted and reverse-transcribed, the expres-
sion of Wnt3 gene was detected by qRt-PCR. the expression level in 
untreated cells was considered “1”. Data are presented as mean ± SD 
(n = 3). vs. CTRL: *p < 0.02. c Western-blot analysis of Wnt3 signal-
ing. Cells were incubated as reported in b, then lysed and subjected 
to the Western-blot analysis of Wnt3, phospho(tyr216)GSK3, GSK3, 
phospho(Ser33/37/thr41)β-catenin, β-catenin in whole-cell lysates. 
β-tubulin expression was used as control of equal protein loading. the 
figure is representative of three experiments with similar results. the 
band density ratio between each protein and β-tubulin was expressed 
as arbitrary units. vs. CTRL: *p < 0.05. d Chromatin immunopre-
cipitation of β-catenin on mdr1 promoter (pro) in cells incubated as 
reported in b gen PCR product from genomic DNa. no Ab precipi-
tated samples without anti-β-catenin antibody. bl blank. the figure 
is representative of three experiments with similar results. e Cells 
were incubated for 72 h without (CTRL) or with temozolomide 
(TMZ; 50 μmol/l), then lysed and subjected to Western-blot analysis 
for Pgp/aBCB1. β-tubulin expression was used as control of equal 
protein loading. the figure is representative of three experiments 
with similar results. the band density ratio between each protein 
and β-tubulin was expressed as arbitrary units. vs. CTRL: *p < 0.01. 
f hBMeCs were grown for 7 days up to confluence in transwell 
inserts; 01010627 GBM cells were seeded at day 4 in the lower cham-
ber. after 3 days of co-culture, supernatant in the upper chamber was 
replaced with fresh medium without (CTRL) or with temozolomide 
(50 μmol/l for 72 h; TMZ); 5 μmol/l doxorubicin (dox) was added in 
the upper chamber in the last 24 h. GBM cells were then collected and 
analyzed for the intracellular amount of doxorubicin by a fluorimetric 
assay. Measurements were performed in duplicate and data are pre-
sented as mean ± SD (n = 3). vs. untreated cells (CTRL): *p < 0.001. 
g Co-cultures of hBMeCs and 01010627 cells were set up as detailed 
in f. at the end of the incubation period, the culture supernatant of 
GBM cells was checked spectrophotometrically for the extracellular 
activity of LDh (open bars), the cell lysates were analyzed fluoro-
metrically for the activity of caspase 3 (hatched bars). Measurements 
were performed in duplicate and data are presented as mean ± SD 
(n = 3). vs. untreated cells: *p < 0.005
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Online Resource 1 
 
 
Online Resource 1. Chemical structure of temozolomide (TMZ) and its metabolite 3-methyl-(triazen-1-
yl)imidazole-4-carboxamide (MTIC). 
Online Resource 2 
 
Primers sequences of quantitative Real Time-PCR (qRT-PCR), chromatin immunoprecipitation (ChIP) and 
methylation specific PCR (MSP). 
 
Gene Assay Forward primer (5'-3') Reverse primer (5'-3') 
mdr1 qRT-PCR TGCTGGAGCGGTTCTACG ATAGGCAATGTTCTCAGCAATG 
Wnt2b qRT-PCR GTGTCCTGGCTGGTTCCTTA GAAGCTGGTGCAAAGGAAAG 
Wnt3 qRT-PCR ACGAGAACTCCCCCAACTTT GATGCAGTGGCATTTTTCCT 
Wnt4 qRT-PCR GCTGTGACAGGACAGTGCAT GCCTCATTGTTGTGGAGGTT 
β-actin qRT-PCR GCTATCCAGGCTGTGCTATC TGTCACGCACGATTTCC 
mdr1 (promoter) ChIP CGATCCGCCTAAGAACAAAG AGCACAAATTGAAGGAAGGAG 
mdr1 (upstream sequence) ChIP GTGGTGCCTGAGGAAGAGAG GCAACAAGTAGGCACAAGCA 
mdr1 (genomic) ChIP GACCAAGCTCTCCTTGCATC AGGGAAGTCTGGCAGCTGTA 
Wnt3 promoter (methylated) MSP GAATTTTATTGAGGTTGTGGGTTAC TTATCAAAAATCAAATCGATATCGA
Wnt3 promoter (unmethylated) MSP ATTTTATTGAGGTTGTGGGTTATGT TATCAAAAATCAAATCAATATCAAA
 
 
Online Resource 3 
 
Online Resource 3. Time- and temperature-dependence in the transport of doxorubicin and vinblastine across 
hCMEC/D3 monolayer. 
a. hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts, then 5 μmol/L doxorubicin or 2 
μCi/mL [3H]-vinblastine (equivalent to 10.8 μmol/L) were added in the upper chamber. Plates were incubated at 4°C, 
15°C and 37°C. From each plate, aliquots of 100 μL form the lower chamber medium were collected at fixed time point 
up to 3 h. The amount of the drug was measured fluorimetrically (for doxorubicin) or by liquid scintillation (for 
vinblastine). Measurements were performed in duplicate and data are presented as means + SD (n = 3). b. hCMEC/D3 
cells were grown for 7 days up to e confluence in Transwell inserts, then 2 μCi/mL [14C]-inulin was added in the upper 
chamber, in the absence (CTRL) or presence of 25% w/v mannitol (MAN), chosen as tight junctions-disrupting agent. 
After 3 h the amount of inulin in the lower chamber was quantified by liquid scintillation. Measurements were 
performed in duplicate and data are presented as means + SD (n = 2). Vs CTRL: * p < 0.02. c. hCMEC/D3 cells were 
treated as reported in a, in the presence of 25% w/v mannitol (MAN) in the upper chamber. The amount of the drug was 
measured fluorimetrically (for doxorubicin) or by liquid scintillation (for vinblastine). Measurements were performed in 
duplicate and data are presented as means + SD (n = 3). 
Online Resource 4 
 
Online Resource 4. Intracellular accumulation of rhodamine 123 and Hoechst 33342 by hCMEC/D3 cells. 
hCMEC/D3 cells were grown in fresh medium (CTRL) or with 50 μmol/L temozolomide (TMZ) for 72 h, then 
incubated with the Pgp/ABCB1 substrate rhodamine 123 (panel a) or the BCRP/ABCG2 substrate Hoechst 33342 
(panel b). The intracellular retention of rhodamine 123 and Hoechst 33342 was measured in duplicate fluorimetrically, 
as reported under Materials and methods. Data are presented as means + SD (n=4). Vs CTRL: * p < 0.005. 
Online Resource 5 
 
 
Online Resource 5. Effect of temozolomide on its own transport across hCMEC/D3 monolayer. 
a. hCMEC/D3 cells were grown in fresh medium (0) or with 50, 100 or 200 μmol/L temozolomide (TMZ) for 72 h, then 
subjected to the Western blot analysis of Pgp/ABCB1, MRP1/ABCC1, BCRP/ABCG2. β-tubulin expression was used 
as control of equal protein loading. The figure is representative of 3 experiments with similar results. The band density 
ratio between each protein and β-tubulin was expressed as arbitrary units. Vs untreated cells (0): * p < 0.05. b. 
hCMEC/D3 cells were cultured in Transwell device for 7 days up to confluence, then incubated as reported in a, in the 
presence of 0.7 μC/mL (equivalent to 10 μmol/L) [3H]-temozolomide. After this incubation period, the amount of [3H]-
temozolomide in the lower chamber was measured by liquid count scintillation. Results were expressed as percentage of 
[3H]-temozolomide recovered in the lower chamber versus [3H]-temozolomide added in the upper chamber at time 0. 
Data are presented as means + SD (n=3).  
Online Resource 6 
 
 
 
 
Online Resource 6. Effects of temozolomide on the expression of Frizzled and LRP6 in hCMEC/D3 cells. 
hCMEC/D3 cells were incubated for 72 h in fresh medium (CTRL) or with 50 μmol/L temozolomide (TMZ). Flow 
cytometry analysis of surface Frizzled (left panel) and LRP6 (right panel) in cells untreated (continuous line) or treated 
with temozolomide (dotted line). Grey peak: cells treated with anti-isotypic antibody. The figures shown here are 
representative of 3 similar experiments, performed in triplicate. 
Online Resource 7 
 
 
Online Resource 7. Localization of CpG islands on the promoter of Wnt3 gene. 
CpG islands localization on Wnt3 promoter, according to Methprimer software (http://www.urogene.org/methprimer). 
As input the promoter sequence (from -5,000 bps to 0 bps) obtained by the UCSC Genome Browser 
(http://genome.ucsc.edu/) was used. 
Online Resource 8 
 
 
 
Online Resource 8. Effects of temozolomide on mdr1 expression in glioblastoma cells co-cultured with 
hCMEC/D3 cells. 
hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts; CV17, 01010627 and U87-MG cells 
were seeded at day 4 in the lower chamber. After 3 days of co-culture, the supernatant in the upper chamber was 
replaced with fresh medium without (-) or with temozolomide (50 µmol/L for 48 h; TMZ). Total RNA was extracted 
and reverse-transcribed, the expression of mdr1 gene was detected by qRT-PCR. The expression level in untreated 
CV17 cells was considered “1”. Data are presented as means + SD (n = 3). Vs untreated cells: * p < 0.02. 
Online Resource 9 
 
Online Resource 9. Effects of temozolomide and doxorubicin on cell survival of hCMEC/D3 cells. 
a. hCMEC/D3 were cultured 7 days up to confluence, then incubated in fresh medium (CTRL), or medium containing 
50 µmol/L temozolomide for 72 h (TMZ), 5 µmol/L doxorubicin for 24 h (dox), or 50 µmol/L temozolomide for 72 h 
plus 5 µmol/L doxorubicin in the last 24 h. The culture supernatant of cells was checked spectrophotometrically for the 
extracellular activity of LDH, taken as an index of cytotoxicity. Measurements were performed in duplicate and data are 
presented as means + SD (n= 3). b. 1,000 hCMEC/D3 were seeded at day 0 in 96-wells plates. After 4 days, the 
medium was replaced with fresh medium (open circles, CTRL) or medium containing 50 µmol/L temozolomide for 72 h 
(solid circles, TMZ), 5 µmol/L doxorubicin for 24 h (open squares, dox), 50 µmol/L temozolomide for 72 h plus 5 
µmol/L doxorubicin in the last 24 h (solid squares, TMZ + dox). Drug treatments were repeated every 7 days. Cell 
proliferation was monitored on day 7, 14, 21 and 28 by crystal violet staining. Measurements were performed in 
triplicate and data are presented as means + SD (n= 3). 
Online Resource 10 
 
 
Online Resource 10. Effective cytotoxicity of the combination temozolomide plus vinblastine and topotecan on 
glioblastoma cells co-cultured with hCMEC/D3 cells. 
hCMEC/D3 cells were grown for 7 days up to confluence in Transwell inserts; CV17, 01010627 and U87-MG cells 
were seeded at day 4 in the lower chamber. After 3 days of co-culture, the supernatant in the upper chamber was 
replaced with fresh medium without (-) or with temozolomide (50 µmol/L for 72 h; T). 20 nmol/L vinblastine (VBL) or 
10 µmol/L topotecan (TOP) was added in the upper chamber of Transwell in the last 24 h, then the following 
investigations were performed. a. The culture supernatant of glioblastoma cells was checked for the extracellular 
activity of LDH. Measurements were performed in duplicate and data are presented as means + SD (n= 4). Vs untreated 
cells: * p < 0.02. b. The activation of caspase-3 was measured fluorimetrically in glioblastoma cells lysates. 
Measurements were performed in duplicate and data are presented as means + SD (n = 4). Vs untreated cells: * p < 
0.01. c. After 3 days of co-culture, the medium of the upper chamber was replaced with fresh medium (dashed line) or 
medium containing 20 nmol/L vinblastine for 24 h (open circles, VBL), 10 µmol/L topotecan for 24 h (open squares, 
TOP), 50 µmol/L temozolomide for 72 h plus 20 nmol/L vinblastine in the last 24 h (solid circles, T + VBL), 50 µmol/L 
temozolomide for 72 h plus 10 µmol/L topotecan in the last 24 h (solid squares, T + TOP). Drug treatments were 
repeated every 7 days, as reported in the Materials and methods section. The proliferation of glioblastoma cells was 
monitored weekly by crystal violet staining. Measurements were performed in triplicate and data are presented as means 
+ SD (n= 4). Vs untreated cells (CTRL): * p < 0.02. 
Online Resource 11 
 
Online Resource 11. Effects of temozolomide and doxorubicin on cell survival of primary human brain 
microvascular endothelial cells. 
a. HBMECs were cultured 7 days up to confluence, then incubated in fresh medium (CTRL), or medium containing 50 
µmol/L temozolomide for 72 h (TMZ), 5 µmol/L doxorubicin for 24 h (dox), or 50 µmol/L temozolomide for 72 h plus 
5 µmol/L doxorubicin in the last 24 h. The culture supernatant of cells was checked spectrophotometrically for the 
extracellular activity of LDH, taken as an index of cytotoxicity. Measurements were performed in duplicate and data are 
presented as means + SD (n= 3). b. 1,000 HBMECs were seeded at day 0 in 96-wells plates. After 4 days, the medium 
was replaced with fresh medium (open circles, CTRL) or medium containing 50 µmol/L temozolomide for 72 h (solid 
circles, TMZ), 5 µmol/L doxorubicin for 24 h (open squares, dox), 50 µmol/L temozolomide for 72 h plus 5 µmol/L 
doxorubicin in the last 24 h (solid squares, TMZ + dox). Drug treatments were repeated every 7 days. Cell proliferation 
was monitored on day 7, 14, 21 and 28 by crystal violet staining. Measurements were performed in triplicate and data 
are presented as means + SD (n= 3). 
